import type { ChecklistEntry } from "./services/ChecklistService"

export const CTD_CHECKLISTS: ChecklistEntry[] = [
	{
		number: "1.1",
		title: "Comprehensive Table of Contents for all Modules.",
		input: [
			"Gather Integrated Summary of Safety and Integrated Summary of Efficacy documents or equivalent CTD Module 2 summaries to ensure correct referencing and placement in the TOC.",
			"Gather Appendix F (facility and component guidance) to determine when to provide separate documents per facility or per component for TOC entries (3.2.A.1 and 3.2.A.2).",
			"Gather information on all manufacturing facilities and excipients to determine whether separate documents are required per facility or per excipient for TOC entries.",
			"Gather regional-specific requirements for TOC presentation if applicable.",
			"Ensure access to the CTD/eCTD hierarchy tables that define where documents/files should be located and whether single or multiple documents are appropriate at each point.",
			"Gather the CTD/eCTD granularity guidance (Annex) to understand document/file placement and hierarchy for accurate TOC compilation.",
			"Gather data and analyses for Section 2.7.3.4 (Analysis of Clinical Information Relevant to Recommended Dose) providing integrated dose-response or blood concentration-response relationships of effectiveness.",
			"Collect microbiology data from both in vitro and in vivo studies for inclusion under efficacy information (Module 2.7 and Module 5.3.5.4) to ensure proper TOC entries.",
			"Collect the table presenting the overall extent of drug exposure in all phases of clinical development, including all subjects (patients and healthy volunteers) exposed to at least one dose.",
			"Collect the table presenting the overall extent of drug exposure in all phases of clinical development, including all subjects exposed to at least one dose.",
			"Ensure access to the final pagination and organization of all modules to accurately reflect in the comprehensive TOC.",
			"Gather definitions and terminology for 'Common Adverse Events' as per ICH E3 Guideline for consistent usage in TOC-linked sections.",
			"Obtain any separate reports of analyses from more than one study (e.g., large statistical outputs) that are too extensive for inclusion in Module 2 summaries, for placement in Module 5.3.5.3 and corresponding TOC entries.",
			"Obtain the complete list of all sections, subsections, and headings for Modules 1 through 5 as per CTD structure.",
			"Obtain unique short identifiers for each clinical study report in Module 5 to be used consistently throughout the application.",
			"Collect the official CTD module structure and numbering scheme as defined in the CTD guideline (Modules 1\u00035) to ensure correct hierarchy representation in the comprehensive TOC.",
			"Collect tabulated summaries of noteworthy toxicology findings (statistically significant or otherwise noteworthy) for inclusion in relevant TOC-linked sections.",
			"Gather finalized titles of all documents, reports, and datasets included in Modules 1 through 5.",
			"Gather list of references for nonclinical summaries (sections 2.6.8, 2.6.2.8, 2.6.4.11, 2.6.6.11) for inclusion in TOC-linked sections.",
			"Gather any correspondence or clarifications from the reviewing division regarding placement of integrated analyses or microbiology data to ensure TOC accuracy.",
			"Obtain regional guidance related to the submission of amendments and variations in CTD format to determine applicability and TOC implications.",
			"Gather list of all nonclinical study categories conducted and not conducted, with justifications for omissions, to ensure headings are retained in TOC with explanations.",
			"Collect any available impurity-specification test results for test articles used in early-stage toxicology studies, noting whether analyses were conducted for non-GLP studies.",
			"Obtain FDA\u0019s Guideline for the Format and Content of Clinical and Statistical Sections of Applications to understand integration of clinical and statistical data for TOC-linked sections.",
			"Gather Appendix E (container closure system guidance) to determine how to organize TOC entries for products with multiple container closure systems.",
			"Obtain list of all pivotal repeat-dose toxicity studies as defined by ICH M3, including study durations and relevance, for inclusion in TOC entries.",
			"Compile any abbreviations or shortened identifiers for lengthy document titles to be used in headers/footers.",
			"Gather list of references for nonclinical summaries for inclusion in TOC-linked sections.",
			"Gather data and analyses for Section 2.7.3.4 providing integrated dose-response or blood concentration-response relationships of effectiveness.",
			"Collect definitions and rules for document granularity and pagination (from the Annex) to ensure consistency between paper and electronic submissions.",
			"Gather list of all nonclinical study categories (e.g., carcinogenicity, repeat-dose toxicity) conducted and not conducted, with justifications for omissions, to ensure headings are retained in TOC with explanations.",
			"Obtain any separate reports of analyses from more than one study that are too extensive for inclusion in Module 2 summaries, for placement in Module 5.3.5.3 and corresponding TOC entries.",
			"Gather Appendix C (stability data organization guidance) for reference when structuring TOC entries related to stability studies (3.2.P.8 and 3.2.P.8.3).",
			"Gather data and analyses for Section 2.7.3.3 summarizing efficacy across all studies.",
			"Collect volume numbers, module numbers, and tab identifiers for all dossier components.",
			"Obtain templates or preferred formats for nonclinical tabulated summaries (Module 2.6) to guide TOC-linked content structure.",
			"Obtain bookmarks list for electronic submissions to ensure alignment with TOC entries.",
			"Gather regional guidance on the use of section 3.2.R or its sub-sections for inclusion in the TOC, as applicable.",
			"Gather Appendix A (granularity and placement guidance) to ensure correct document-level organization for sections 3.2.P.2 through 3.2.P.8 and 3.2.A.",
			"Collect the official CTD module structure and numbering scheme as defined in the CTD guideline (Modules 1\u00135) to ensure correct hierarchy representation in the comprehensive TOC.",
			"Collect any available impurity-specification test results for test articles used in early-stage toxicology studies.",
			"Obtain the full titles of all clinical studies for inclusion in the Tabular Listing of All Clinical Studies (Section 5.2).",
			"Collect microbiology data from both in vitro and in vivo studies for inclusion under efficacy information to ensure proper TOC entries.",
			"Obtain FDA’s Guideline for the Format and Content of Clinical and Statistical Sections of Applications to understand integration of clinical and statistical data for TOC-linked sections.",
			"Collect the official CTD module structure and numbering scheme as defined in the CTD guideline (Modules 1–5) to ensure correct hierarchy representation in the comprehensive TOC.",
			"Obtain the latest regional guidance documents specifying the content and format of Module 1 to ensure alignment with local regulatory expectations.",
			"Gather Integrated Summary of Safety (ISS) and Integrated Summary of Efficacy (ISE) documents or equivalent CTD Module 2 summaries to ensure correct referencing and placement in the TOC.",
			"Gather 'Drug Substance' impurity data tables for nonclinical safety sections, including footnotes identifying batches relevant to impurity qualification.",
			"Collect tabulated summaries of noteworthy toxicology findings for inclusion in relevant TOC-linked sections.",
			"Gather information on all container closure systems, manufacturers, strengths, and stability study protocols to determine appropriate TOC structure for 3.2.P.7 and 3.2.P.8 sections.",
			"Gather Appendix D (excipient guidance) to determine when to use 3.2.P.4 and/or 3.2.P.4.x levels for TOC entries.",
			"Gather data and analyses for Section 2.7.3.3 (Comparisons and Analyses of Results Across Studies) summarizing efficacy across all studies.",
		],
		output: [
			"Ensure each document has a distinct identifier in header/footer.",
			"If Module 2 summary fulfills 21 CFR 314.50, avoid duplicating ISS/ISE entries.",
			"Use standard CTD structure for amendments and variations.",
			"Do not incorporate attachments or appendices as separate entries in the comprehensive TOC unless they are standalone documents under a multi\u0001document section.",
			"Exclude lower-level Tables of Contents that are internal to documents (e.g., those created for pagination/segregation) from the comprehensive Table of Contents.",
			"Ensure identifiers in headers/footers remain distinct; abbreviations acceptable.",
			"For clinical summaries, plan length proportional to indications (50\u0013400 pages per indication).",
			"For Clinical Summary (Section 2.7), plan for an estimated length of 50\u0013400 pages for a single indication; increase proportionally for multiple indications with multiple efficacy sections.",
			"Ensure that the comprehensive Table of Contents for all modules follows the official CTD organization and numbering as defined in the CTD guideline (Modules 1–5).",
			"Cross-references in paper submissions should include only section numbers.",
			"Use section 3.2.R or its sub-sections if applicable, following regional guidance.",
			"When analytical methods change for impurity data, use footnotes in the 'Drug Substance' table to identify batches relevant to impurity qualification in TOC-linked sections.",
			"If the CTD Module 2 summary fulfills the requirements of 21 CFR 314.50, ensure that the TOC reflects this by not duplicating ISS/ISE entries unnecessarily.",
			"Use nonclinical summary templates (Module 2.6) as basis for TOC-linked content.",
			"Apply consistent pagination and segregation principles across all modules so that the TOC accurately represents document boundaries.",
			"Lower-level section numbers may be used for navigation within documents but should be included only as PDF bookmarks, not in the overall TOC.",
			"Maintain consistent granularity throughout the dossier lifecycle.",
			"Ensure that identifiers in headers/footers remain distinct and may use abbreviations when full document titles are too long, as long as clarity is maintained.",
			"Ensure that the comprehensive TOC reflects the correct hierarchy and placement of documents/files as defined in the CTD/eCTD granularity tables.",
			"Differentiate content between Section 2.7.3.3 (summarizing efficacy across all studies) and Section 2.7.3.4 (integrated dose-response or blood concentration-response analysis) in TOC-linked sections.",
			"Include module numbers, volume numbers, and tab dividers in all TOCs.",
			"Ensure that cross-references (cross-strings) in paper submissions include only the section number, not the section name, to maintain brevity while ensuring clarity through contextual text.",
			"Assign each clinical study report a unique identifier and use consistently.",
			"Exclude lower-level tables of contents internal to documents from the comprehensive TOC.",
			"If impurity-specification test results exist for non-GLP study test articles, include them in the 'Drug Substance' table in TOC-linked sections; absence of such data does not require analysis.",
			"Include references for nonclinical summaries in TOC-linked sections.",
			"For section 3.2.A.2, typically only one document is provided, but if there is more than one component (e.g., multiple component vaccines or combination products), documents may be provided per component, as per Appendix F.",
			"Ensure the 'Overall Extent of Exposure' table in Section 2.7 includes all subjects (patients and healthy volunteers) exposed to at least one dose of the drug product.",
			"Ensure the TOC covers all modules comprehensively and reflects the final structure and content of the dossier.",
			"Do not include document-specific or section-specific TOCs in the comprehensive TOC.",
			"Ensure that TOC title entries correspond only to heading names and section numbering defined in CTD guidelines or tab identifiers (paper submissions).",
			"Ensure each document in the dossier has a distinct identifier in the header/footer on every page; abbreviations are acceptable instead of full titles.",
			"Ensure that the TOC follows the official CTD organization and numbering for Modules 1–5.",
			"Ensure that any document‑specific or section‑specific Tables of Contents (e.g., for literature references) are not included in the comprehensive Table of Contents for all modules.",
			"List microbiology data appropriately in TOC: summaries in 2.7, reports in 5.3.5.4.",
			"Include only noteworthy toxicology findings in tabulated summaries linked from the TOC.",
			"Use the recommended nonclinical tabulated summary templates for Module 2.6 as a starting point, modifying as needed for clarity and comprehension in TOC-linked sections.",
			"Ensure that the comprehensive Table of Contents for all modules follows the official CTD organization and numbering as defined in the CTD guideline (Modules 1\u00035).",
			"Do not incorporate attachments or appendices as separate entries in the comprehensive TOC unless they are standalone documents under a multi\u0011document section.",
			"Ensure that the TOC follows the official CTD organization and numbering for Modules 1\u00135.",
			"Ensure that any document\u0001specific or section\u0001specific Tables of Contents (e.g., for literature references) are not included in the comprehensive Table of Contents for all modules.",
			"Refer to the ICH Granularity document for rules on whether to assign section numbers to individual clinical study reports in Module 5 TOC entries.",
			"Ensure that any appendices or detailed analyses referenced in Module 2 summaries are properly cross-linked and listed in the TOC under the appropriate Module 5 sections.",
			"Include a list of references for nonclinical summaries (sections 2.6.8, 2.6.2.8, 2.6.4.11, 2.6.6.11) in TOC-linked sections, even though not explicitly covered in guidance.",
			"Include module numbers, volume numbers, and tab dividers in all Tables of Contents.",
			"If a Control Strategy Summary is included, it may be placed at 3.2.P.2.",
			"For section 3.2.P.7, if the drug product has more than one container closure system, information may be provided in its entirety or per system or per distinguishing information, as per Appendix E.",
			"For clinical summaries, plan length proportional to indications (50–400 pages per indication).",
			"Do not include headings in the TOC below the numbering specified in the CTD guideline.",
			"For Clinical Summary (Section 2.7), plan for an estimated length of 50–400 pages for a single indication; increase proportionally for multiple indications with multiple efficacy sections.",
			"For amendments and variations submitted in CTD format, use the standard CTD structure without modification.",
			"Do not include modules that are not used for an amendment or variation; omit rather than mark headings as 'not applicable'.",
			"Maintain consistent inclusion of identifiers in headers/footers across all documents while allowing layout differences between report types (e.g., clinical vs. quality sections).",
			"For section 3.2.A.1, if more than one facility is provided, documents may be provided per facility, as per Appendix F.",
			"Maintain identifier consistency across headers/footers.",
			"Ensure that the 'Overall Extent of Exposure' table includes all subjects exposed at least once.",
			"Assign each clinical study report a unique short identifier and use it consistently throughout all modules; the applicant may select the identifier.",
			"Ensure that the comprehensive Table of Contents for all modules follows the official CTD organization and numbering as defined in the CTD guideline (Modules 1\u00135).",
			"Follow ICH E3 Guideline for the definition and consistent use of the term 'Common Adverse Events' in TOC-linked sections.",
			"When integrated analyses (e.g., ISE or ISS) generate extensive statistical outputs, include only summary-level references in Module 2 and list the detailed reports separately in Module 5.3.5.3 within the TOC.",
			"Retain all CTD section headings in the TOC even if certain studies were not conducted, and include a brief explanation in the relevant section for the omission.",
			"Ensure appendices referenced in Module 2 summaries are cross-linked and listed in Module 5.",
			"Maintain consistency in document granularity between paper and electronic submissions; a new file in eCTD should correspond to a tab-separated document in paper format.",
			"Follow ICH E3 definition for 'Common Adverse Events' in TOC-linked sections.",
			"Ensure referenced impurity-specification test results appear where applicable.",
			"Ensure the full title of each clinical study is provided in the Tabular Listing of All Clinical Studies (Section 5.2) and not necessarily in the TOC.",
			"Do not include headings in the overall TOC that go below the numbering specified in the CTD guideline; lower-level numbering can be used within documents but should not appear in the overall TOC.",
			"Exclude lower\u0011level Tables of Contents that are internal to documents (e.g., those created for pagination/segregation) from the comprehensive Table of Contents.",
			"For paper submissions, do not include page numbers in the comprehensive TOC.",
			"Ensure the TOC covers all modules and reflects final dossier structure.",
			"For section 3.2.P.2, use either the 3.2.P.2 (roll-up of P.2.1 to P.2.6) or 3.2.P.2.x level; a single 3.2.P.2 document is not recommended for Quality by Design or large molecule applications.",
			"Use footnotes in impurity tables to identify batches relevant to impurity qualification when analytical methods change.",
			"Ensure that any document-specific or section-specific Tables of Contents (e.g., for literature references) are not included in the comprehensive Table of Contents for all modules.",
			"Follow ICH granularity rules for numbering clinical study reports in Module 5 TOC.",
			"Apply consistent pagination rules across all modules so TOC accurately reflects document boundaries.",
			"Ensure the 'Overall Extent of Exposure' table includes all subjects exposed at least once.",
			"Differentiate content between Sections 2.7.3.3 and 2.7.3.4 in TOC-linked summaries.",
			"Retain all CTD section headings in the TOC even if certain studies were not conducted, with explanations in the corresponding sections.",
			"Only include noteworthy toxicology findings in tabulated summaries linked from the TOC; these may be statistically significant or otherwise noteworthy.",
			"For section 3.3 (literature references), provide one file per reference.",
			"Exclude lower‑level Tables of Contents that are internal to documents (e.g., those created for pagination/segregation) from the comprehensive Table of Contents.",
			"For paper CTD submissions, the comprehensive Table of Contents in Module 1 should not include page numbers.",
			"Do not specify page numbers anywhere in the comprehensive Table of Contents.",
			"Ensure TOC title entries correspond only to heading names and section numbering defined in CTD guidelines or tab identifiers (paper submissions).",
			"When citing a section in cross-strings or text, ensure the surrounding narrative clearly indicates the section content so the reader can easily locate the referenced material.",
			"No page-number rules for TOCs beyond Module 1 unless regional guidance applies.",
			"For section 3.2.P.8 and 3.2.P.8.3, stability information may be provided in its entirety or per container closure system, manufacturer, strength, stability study protocol, or other distinguishing information, as per Appendix C.",
			"Ensure TOC reflects correct hierarchy and document placement according to granularity guidance.",
			"Place detailed integrated analysis reports in Module 5.3.5.3 when summaries are in Module 2.",
			"Do not include additional headers or subsection numbering created within documents in the comprehensive TOC.",
			"Lower-level section numbers may be used within documents but appear only as PDF bookmarks, not in the TOC.",
			"Abbreviations are acceptable on printed tab dividers.",
			"Ensure pivotal repeat-dose toxicity studies, as defined by ICH M3, are clearly identified in the TOC-linked sections and tabulated appropriately.",
			"For section 3.2.A.3, if more than one excipient is provided, documents may be provided per excipient.",
			"Ensure that microbiology data (both in vitro and in vivo) are listed under efficacy information in the TOC, with summary information in Module 2.7 and reports in Module 5.3.5.4.",
			"Ensure the full title of each clinical study is provided in Section 5.2 and not necessarily in the TOC.",
			"Exclude lower\u0001level Tables of Contents that are internal to documents (e.g., those created for pagination/segregation) from the comprehensive Table of Contents.",
			"Ensure that any document\u0011specific or section\u0011specific Tables of Contents (e.g., for literature references) are not included in the comprehensive Table of Contents for all modules.",
			"Do not include additional headers or subsection numbering created within individual documents in the comprehensive Table of Contents.",
			"Use only CTD-defined headings and numbering in TOC title entries.",
			"Do not incorporate attachments or appendices as separate entries in the comprehensive TOC unless they are standalone documents under a multi‑document section.",
			"For paper submissions, tabs must be printed.",
			"For cross-strings in paper submissions, include only the section number to avoid overly long references while maintaining clarity.",
			"Do not incorporate attachments or appendices as separate entries in the comprehensive TOC unless they are standalone documents under a multi-document section.",
			"Omit modules not applicable to amendments/variations rather than marking 'not applicable'.",
			"Verify the TOC includes only applicable sections while maintaining numbering.",
			"For Module 4, include a Table of Contents only for paper submissions; no TOC entry is needed for eCTD submissions.",
			"Verify that the comprehensive TOC includes only applicable sections for the specific submission while maintaining the overall CTD numbering structure.",
			"Lower-level section numbers (e.g., 3.2.P.3.3.1) may be used for navigation within documents but should be included only as PDF bookmarks, not in the overall TOC.",
			"Ensure that once a granularity approach (single or multiple documents per section) is adopted, it is maintained consistently throughout the dossier lifecycle.",
			"Identify pivotal repeat-dose toxicity studies clearly in TOC-linked sections.",
			"There are no specific guidelines for page numbers in TOCs for other modules; follow regional requirements if applicable.",
		],
	},
	{
		number: "1.2",
		title: "Cover letter",
		input: [
			"Prepare the official cover letter document to accompany the CTD submission.",
			"Compile a list of all documents and modules included in the CTD submission to reference in the cover letter.",
			"Gather contact information for the responsible regulatory and technical representatives.",
			"Ensure that all literature references cited in the submission are compiled and listed in the table of contents, as required by CTD conventions.",
			"Obtain references to previous regulatory correspondence or commitments relevant to the submission.",
			"Identify which CTD modules are applicable for the specific submission type (including amendments or variations) so that only relevant modules are referenced in the cover letter.",
			"Collect any legal authorizations or power of attorney documents if the submission is made by an authorized representative.",
			"Collect any specific instructions or requests from the regulatory authority that must be addressed in the cover letter.",
			"Gather regulatory identifiers and submission details (e.g., application number, product name, applicant name, submission type).",
		],
		output: [
			"Maintain a logical structure: introduction, purpose of submission, list of contents, contact information, and closing statement.",
			"Verify that the cover letter is signed by an authorized company representative.",
			"For paper submissions, ensure that tabs are printed and may use abbreviated titles for section identification.",
			"Ensure the cover letter is written in the language required by the target regulatory authority (e.g., English for FDA, national language for EU member states).",
			"Ensure the cover letter is brief and focused, typically limited to one or two pages.",
			"Format the document according to regulatory submission standards (e.g., PDF for eCTD, appropriate margins, pagination, and headers).",
			"Use a consistent and legible font style such as Arial or Times New Roman, ensuring alignment with corporate identity and regulatory readability expectations.",
			"Use clear, formal, and professional language consistent with regulatory correspondence standards.",
			"Include a distinct identifier in the header or footer on every page of the cover letter; this can be an abbreviation rather than the full title.",
			"Ensure cross-references to CTD sections are accurate and use section numbers for clarity.",
			"Reference all relevant CTD modules and sections included in the submission.",
			"Include proper page numbering and headers on all pages of the cover letter, consistent with CTD formatting conventions.",
			"Verify that document granularity and file organization follow CTD conventions, ensuring that each document or file corresponds to the appropriate CTD section and that replacements of complete documents/files can be managed efficiently during lifecycle updates.",
			"Ensure that any cross-references in the cover letter include at least the CTD section number, and write the surrounding text so the reader understands the section content without requiring the full section name.",
			"Include a concise summary of the purpose of the submission (e.g., new application, amendment, response to deficiency).",
			"Follow CTD granularity and numbering conventions for section headers and identifiers, ensuring consistency between electronic and paper formats.",
			"Ensure the cover letter clearly identifies the submission type, product name, applicant, and date.",
			"Check that the cover letter complies with regional regulatory requirements (e.g., FDA, EMA, etc.) for submission cover letters.",
			"Confirm that while the CTD format is harmonized internationally, region-specific content expectations may apply; ensure the cover letter reflects any required regional adaptations.",
			"Ensure that literature references are properly listed in the table of contents, in accordance with CTD formatting and indexing requirements.",
			"When preparing a cover letter for amendments or variations, use the standard CTD structure without creating a separate format, and omit any modules that are not applicable rather than including 'not applicable' pages.",
		],
	},
	{
		number: "1.3",
		title: "Comprehensive Table of Content",
		input: [
			"Gather module numbers, volume numbers, and tab divider identifiers for all dossier components to be included in the Table of Contents.",
			"Gather facility information for sections where multiple manufacturing or testing facilities are involved to determine if separate documents per facility are required (per Note 11).",
			"Collect full heading names and section numbering as defined in the M4Q guideline to ensure TOC entries correspond exactly to official titles.",
			"Gather information on document granularity and replacement policy for lifecycle changes to ensure complete document/file replacements are prepared when relevant information changes.",
			"Obtain any applicable regional requirements for Table of Contents presentation (e.g., EU, US, Japan) to ensure compliance.",
			"Collect component information for combination products or multi-component vaccines to determine if separate documents per component are needed (per Note 12).",
			"Gather individual study reports for each non-clinical or clinical study included in Module 4, ensuring each is prepared as a single document unless large size warrants splitting.",
			"Collect study narratives that include both efficacy and safety information for studies contributing to both domains, ensuring they are referenced appropriately in the TOC.",
			"Gather excipient information to determine if separate documents per excipient are required (per Note 13).",
			"Collect the finalized structure and numbering of all CTD sections and subsections as per the CTD guideline.",
			"Collect report titles and report numbers for all documents (e.g., clinical reports, study reports) to determine appropriate TOC title entries and header/footer identifiers.",
			"For large study reports (e.g., carcinogenicity studies), prepare the text portion as one document and appendices as one or more separate documents.",
			"Obtain guidance references from Appendices C, D, E, and F to ensure correct document segmentation and TOC structure for sections 3.2.P.4, 3.2.P.7, 3.2.P.8, and 3.2.A.",
			"Compile internal numbering schemes for sub-sections within documents (e.g., 3.2.P.3.3.1, 3.2.P.3.3.2) for internal navigation, even if not included in the overall TOC.",
			"For applications supporting more than one indication, prepare a separate Comprehensive Table of Contents for each indication.",
			"Gather section numbers and section names for all CTD sections to ensure accurate cross-referencing and cross-string creation in paper submissions.",
			"Gather references to appendices containing case report forms (Appendix 16.3), individual patient data listings (Appendix 16.4), and literature references (Appendices 16.1.11 and 16.1.12) to ensure correct placement in Module 5.3.7 and 5.4.",
			"Identify sections containing multiple documents and compile the chronology and titles of those documents for inclusion in section-specific Tables of Contents.",
			"Collect literature references and their original source pagination for inclusion in the TOC where applicable.",
			"Collect unique identifiers (abbreviations of section number and title) for use in headers/footers and on physical tabs for paper submissions.",
			"Obtain the complete list of all documents included in the CTD submission across Modules 1 to 5, including their official titles and identifiers.",
			"Gather information on container closure systems for the drug product to determine whether information should be presented per system or in aggregate (per Note 9).",
			"Collect stability study information organized by container closure system, manufacturer, strength, or protocol to determine appropriate document segmentation (per Note 10).",
			"Gather document identifiers or abbreviations for each dossier document to be used in headers/footers.",
			"Gather indication-specific section identifiers and titles (e.g., 2.7.3.UTI, 2.7.3.Pneumonia) for inclusion in the Comprehensive Table of Contents when multiple indications are presented.",
		],
		output: [
			"Lower-level Tables of Contents described under Document Pagination and Segregation should be excluded from the 3.1 Table of Contents.",
			"Additional headers or subsection numbering beyond M4Q definitions should only be included within a document, not as separate documents or new subsections.",
			"For sections 3.2.P.7 and 3.2.P.8, allow flexibility to organize information either in aggregate or per container closure system, manufacturer, strength, or other distinguishing factor, as referenced in Appendices C and E.",
			"In Module 4, include a Table of Contents only for paper submissions; no TOC entry is required for eCTD submissions.",
			"Additional subsections beyond the fifth level defined in M4Q should be used within the dossier but excluded from the 3.1 Table of Contents.",
			"List literature references in the Tables of Contents.",
			"Ensure that each document in the dossier has a distinct identifier in the header or footer on every page; this can be an abbreviation rather than the full title.",
			"Repeat the Comprehensive Table of Contents for each indication in multi-indication applications.",
			"When creating cross-references or cross-strings in paper submissions, include at least the section number; including the section name is optional but improves clarity.",
			"For paper CTD submissions, do not include page numbers in the comprehensive Table of Contents in Module 1.",
			"Write cross-references so that the reader can infer the section content even if only the section number is provided (e.g., '...as seen in the population PK study 101 (5.3.3.5)').",
			"Number each document starting at page one, except for individual literature references where original journal pagination is retained.",
			"For studies contributing both efficacy and safety data, ensure that the TOC reflects inclusion of narratives in section 2.7.3.2 and cross-references to section 2.7.4.1.1 as appropriate.",
			"Do not include headings in the overall TOC that go below the numbering level specified in the CTD guideline; lower-level numbering can be used within documents for navigation but should not appear in the overall TOC.",
			"It is acceptable to use different page layouts for different document types (e.g., reports vs. quality sections) as long as each page includes a distinct identifier.",
			"In electronic submissions, lower-level section numbers can be included as PDF bookmarks for navigation.",
			"Exclude lower-level Tables of Contents (such as those created for individual documents or described under Document Pagination and Segregation) from the overall CTD Module 1.3 Comprehensive Table of Contents.",
			"Ensure that all TOC title entries correspond exactly to official heading names and section numbering as defined in the M4Q guideline, or to tab identifiers in paper submissions.",
			"An abbreviation of the full section number and title may be used in headers/footers and on tabs.",
			"To avoid excessive subheading levels within a document, use shortened numbering strings in the document body and include the document number and name in headers/footers; full numbering strings are also acceptable.",
			"If literature references are included, ensure they are placed in a TOC specific to their section rather than the overall Comprehensive Table of Contents.",
			"For Module 3, the Table of Contents under 3.1 should include high-level section numbering, associated section heading, and volume number in dossier order, going down to the fifth level only (e.g., 3.2.P.2.1).",
			"If a section contains multiple documents, include a section-specific Table of Contents listing the chronology and titles of the documents.",
			"Do not use '1 of n' page numbering format; simple sequential numbering is sufficient.",
			"Apply the same indication-specific numbering structure consistently across all relevant sections (e.g., 2.7.3, 5.3.5) to maintain clarity in the Comprehensive Table of Contents.",
			"Maintain all CTD section headings in the Comprehensive Table of Contents even when a study category is not conducted; include the heading without removing or renumbering sections.",
			"There are no specific guidelines for page numbers in TOCs beyond the instruction for Module 1; follow regional requirements if applicable.",
			"Include a distinct identifier (e.g., report number or abbreviation) in the header or footer of each document; the full title is not required if it is excessively long.",
			"For section 3.2.P.4, follow Appendix D guidance to determine whether to use the 3.2.P.4 or 3.2.P.4.x level in the TOC.",
			"Ensure that appendices containing case report forms, individual patient data listings, and literature references are correctly referenced in the TOC under Modules 5.3.7 and 5.4 according to ICH E3 and CTD organization.",
			"The Comprehensive Table of Contents should not specify any page numbers.",
			"If a section contains only a single document, precede it only with a tab identified by its section number and title.",
			"Retain the current CTD numbering when identifying multiple indications, appending the indication name to the section number (e.g., 2.7.3.UTI, 2.7.3.Pneumonia).",
			"For section 3.2.R, include it or its sub-sections as applicable, following regional guidance (per Note 14).",
			"Do not incorporate attachments or appendices into the Comprehensive Table of Contents format except when they constitute standalone documents within a multi-document section.",
			"For Module 4 study reports, provide a single document per study unless the report is large, in which case the text portion should be one document and appendices one or more separate documents.",
			"Maintain consistent inclusion of identifiers in headers/footers throughout the dossier, even if page layouts differ between sections (e.g., reports vs. quality sections).",
			"For Module 2, the CTD Table of Contents should go down to the third (e.g., 2.3.S) or fourth (e.g., 2.3.S.1) level depending on document definition for the Quality Overall Summary.",
			"When splitting large study reports into multiple documents, ensure that the chosen granularity supports complete document/file replacement when relevant information changes.",
			"For literature references, use the original source pagination (journal, abstract, etc.) rather than renumbering.",
			"For sections 3.2.A.1 to 3.2.A.3, allow multiple documents when multiple facilities, components, or excipients are involved, ensuring each is clearly identified in the TOC.",
			"Include module numbers, volume numbers, and tab divider identifiers in all Tables of Contents across Modules 1 to 5.",
			"Ensure that indication-specific subsections (e.g., 2.7.3.1.UTI Background, 2.7.3.1.Pneumonia Background) are clearly reflected in the TOC to distinguish data by indication.",
			"When relevant information changes during the product lifecycle, replace complete documents/files rather than partial updates.",
			"If additional headers or subsection numbering are introduced beyond M4Q requirements, include them only within documents and do not list them in the Comprehensive Table of Contents.",
			"Include a unique header or footer on all pages of a document briefly identifying its subject matter; in paper submissions, use a similar identifier on the preceding tab.",
			"Section-specific Tables of Contents for multiple-document sections may be included at the applicant's discretion to identify chronology and subject matter.",
		],
	},
	{
		number: "1.4",
		title: "Quality Information Summary (QIS)",
		input: [
			"Collect information on historical analytical procedures used to generate stability data for inclusion in 3.2.P.8.3.",
			"Collect information on potential cross-contamination with adventitious agents and related data from 3.2.A.1 and 3.2.A.2.",
			"Gather justifications for exclusion of impurities from specifications from 3.2.P.5.6.",
			"Gather information on all other reference standards not cited in 3.2.S.5 for inclusion in 3.2.P.6.",
			"Collect data on source and starting materials, raw materials of biological origin, and critical manufacturing steps as described in 3.2.S.2.3 and 3.2.S.2.4.",
			"Obtain design and justification data for reduced stability designs (e.g., bracketing, matrixing) for inclusion in 3.2.P.8.3.",
			"Gather detailed information on critical steps and all intermediates that are controlled from 3.2.P.3.4, including those identified in 3.2.P.3.3.",
			"Collect certificates of analysis or batch data for excipients for inclusion in 3.2.P.4.4.",
			"Obtain the applicable regional guidance documents for Module 2 structure and granularity to ensure alignment with QIS preparation.",
			"Gather results from any tests performed that are not included in the specifications (for inclusion in batch analyses summaries).",
			"Obtain detailed statistical analysis reports of stability data for inclusion in 3.2.P.8.3 and summaries/conclusions for inclusion in 3.2.P.8.1.",
			"Compile relevant tables, figures, and flow diagrams from Module 3 for direct import into the QIS.",
			"Collect summaries or cross-referenced data that support specification justifications without repeating information.",
			"Collect characterization data from 3.2.S.3, including evidence of structure, isomerism, and stereoisomer information for chiral substances.",
			"Gather stress study data for inclusion in 3.2.P.8.3, with potential cross-reference to analytical procedure validation.",
			"Gather summaries of data from other sections that support specification justifications, ensuring cross-references to detailed information are available.",
			"Collect information on analytical procedures unique to the stability program for inclusion in 3.2.P.8.3.",
			"Gather cross-references to non-clinical and clinical studies that used batches affected by manufacturing changes (from CTD-S and CTD-E modules).",
			"Collect critical process control values from relevant batches to support numeric ranges and limits for critical process controls from 3.2.P.3.4.",
			"Collect shelf-life specifications for inclusion in 3.2.P.8.1.",
			"Collect results from all relevant batches (clinical, nonclinical, stability) from 3.2.S.4.4, including those used to justify acceptance criteria.",
			"Acquire collated data sets for batch analysis tests if available and applicable.",
			"Collect data from constitution or dilution studies performed as part of formal stability studies to confirm product quality through shelf-life from 3.2.P.8.3.",
			"Gather data on compatibility of reconstitution diluents to support label claims from 3.2.P.2.6.",
			"Obtain region-specific certifications relating to TSE/BSE for excipients of human or animal origin.",
			"Obtain justification data for skip testing from 3.2.P.5.6.",
			"Collect information on all reference standards or materials used (active moiety and impurities) from 3.2.S.5.",
			"Collect results from all relevant batch analyses (clinical, nonclinical, stability) from 3.2.P.5.4, including batch descriptions (batch number, site, and use).",
			"Gather data from supporting stability studies for inclusion in 3.2.P.8.3, if appropriate.",
			"Gather manufacturing information from section 3.2.S.2, including manufacturer details, manufacturing process description, flow diagrams, and process validation summaries.",
			"Gather specification details from 3.2.P.5.1 for any process test that replaces an end-product test, ensuring it is specified as a process test.",
			"Collect justification for skip testing from 3.2.S.4.5, including any supporting data or cross-references.",
			"Gather all relevant data and summaries from Module 3 (Quality) to ensure consistency with the Quality Overall Summary (QOS) and the Quality Information Summary (QIS).",
			"Collect manufacturing process descriptions including reprocessing steps, over-fill identification, and statements regarding manipulation of ruminant-derived materials from 3.2.P.3.3.",
			"Gather details of all process controls identified in 3.2.P.3.3 and critical controls from 3.2.P.3.4.",
			"Collect information on incompatible diluents for inclusion in 3.2.P.2.6.",
			"Collect complete lists of all observed impurities from 3.2.P.5.5, regardless of specification inclusion.",
			"Obtain analytical methods from both 3.2.S and 3.2.P when they are identical but differ in sample preparation requirements.",
			"Gather any expert opinions or literature references used to justify deviations from guidelines or critical quality attributes.",
			"Ensure access to all supporting technical documents such as analytical data, validation reports, and stability data summaries from Module 3.",
			"Gather results from tests not listed in the specifications from 3.2.S.4 for inclusion in the QIS summary.",
			"Gather information on compatibility with co-administered drugs for inclusion in 3.2.P.2.6.",
			"Obtain validation information related to reprocessing operations from 3.2.P.3.5, if warranted.",
			"Gather batch formula information including any overages from 3.2.P.3.2.",
			"Collect the complete Quality Information Summary (QIS) document template or structure as required for CTD section 1.4.",
			"Collect company name, dosage form(s), strength(s), route(s) of administration, and proposed indication(s).",
			"Obtain characterization data for reference standards from 3.2.S.5, including cross-references to 3.2.S.3.2 where applicable.",
			"Gather both release and shelf-life specifications from 3.2.P.5.1, including acceptance criteria and all analytical procedures used to control the drug product.",
			"Obtain collated data from multiple batch analyses (if warranted) from 3.2.S.4.4 for inclusion in the QIS summary.",
			"Gather information on excipients of human or animal origin for inclusion in 3.2.P.4.5, and obtain adventitious agent safety evaluation data from 3.2.A.2.",
			"Obtain analytical procedures and method validation information for any in-process material test performed in lieu of a finished product test from 3.2.P.3.4.",
			"Obtain information on the proprietary name, non-proprietary name, or common name of the drug substance.",
			"Obtain summaries of major manufacturing changes made throughout development and conclusions from assessments evaluating product consistency (3.2.S.2.6).",
			"Collect all analytical procedures from 3.2.P.5.2, including historical analytical procedures used for batch analyses and analytical procedures used only for stability studies.",
		],
		output: [
			"Include design and justification for reduced stability designs (e.g., bracketing, matrixing) in 3.2.P.8.3.",
			"Follow standard CTD formatting conventions for headings, numbering, and section labeling.",
			"Ensure that compatibility data summarized in the QIS reflect information from 3.2.P.2.6, including compatibility with reconstitution diluents, co-administered drugs, and incompatible diluents, with cross-references to supporting data.",
			"Use clear, concise, and scientifically accurate language consistent with regulatory terminology.",
			"Maintain a logical and consistent structure aligned with the CTD format (e.g., 2.3.S, 2.3.P subsections).",
			"Provide sufficient information from each section to give reviewers an overview of Module 3, emphasizing critical key parameters.",
			"Ensure that summaries of process controls in the QIS distinguish between general process controls (3.2.P.3.3) and critical controls (3.2.P.3.4), with validation information referenced from 3.2.P.3.5 where applicable.",
			"When including reference standards in the QIS, cross-reference those cited in 3.2.S.5 in 3.2.P.6 where appropriate, and include information on all other reference standards in 3.2.P.6.",
			"For paper CTD submissions, include a Table of Contents for Module 2; for eCTD submissions, no TOC entry is required for Module 2.",
			"Ensure that shelf-life specifications are indicated in 3.2.P.8.1.",
			"Ensure that the QIS granularity level is chosen appropriately based on product complexity, in line with Note 1 guidance on QOS granularity.",
			"Place stress study data in 3.2.P.8.3, with cross-references to analytical procedure validation where appropriate.",
			"Do not include new information, data, or justifications not already present in Module 3 or other CTD parts.",
			"Ensure consistency between QIS, QOS, and Module 3 data to maintain regulatory compliance.",
			"Include justification for skip testing in the QIS summary, referencing 3.2.S.4.5, and ensure that supporting data are summarized with cross-references to detailed sections.",
			"When summarizing justification of specifications for excipients, provide summaries with cross-references to detailed data in other sections rather than repeating full data sets.",
			"When presenting information in appendices (3.2.A), list drug substance information first, followed by drug product information within each section.",
			"When collated data from multiple batch analyses are warranted, summarize them in the QIS with clear cross-references to 3.2.S.4.4.",
			"Limit the QIS to a maximum of 40 pages of text (excluding tables and figures); for biotech or complex products, it may extend up to 80 pages.",
			"Use the updated ICH title 'Excipients' for 3.2.A.3 to include noncompendial, nonnovel excipients.",
			"Highlight and justify any deviations from guidelines within the summary.",
			"Ensure that summaries of batch analyses in the QIS include results from all relevant batches (clinical, nonclinical, stability) and any tests not listed in specifications, referencing 3.2.S.4.4 and 3.2.S.4 as appropriate.",
			"Ensure that impurity summaries include all observed impurities and indicate where justification for non-inclusion in specifications is located.",
			"Ensure the QIS follows the same scope and outline as the Body of Data in Module 3.",
			"Follow eCTD v3.2.2 submission rules regarding document placement and granularity for Module 2 content, ensuring documents are submitted at the correct level.",
			"Include information on reference standards and materials (active moiety and impurities) in the QIS summary, referencing 3.2.S.5 and cross-referencing characterization data from 3.2.S.3.2 where applicable.",
			"Import tables, figures, and other items directly from Module 3 where indicated (italicized text).",
			"Place detailed statistical analysis reports of stability data in 3.2.P.8.3 and summaries/conclusions in 3.2.P.8.1.",
			"Include cross-references to volume and page numbers in other Modules where applicable.",
			"Ensure the introduction includes proprietary name, non-proprietary name, company name, dosage form(s), strength(s), route(s) of administration, and proposed indication(s).",
			"Include data from supporting stability studies in 3.2.P.8.3 if appropriate.",
			"Integrate discussions of key issues across Quality, Nonclinical, and Clinical Modules where relevant.",
			"When summarizing manufacturing information in the QIS, include references to reprocessing steps, overages, over-fill identification, and statements on ruminant-derived materials as described in 3.2.P.3.2 and 3.2.P.3.3.",
			"Verify that all cross-references and data summaries are accurate and traceable to Module 3 content.",
			"Include information on historical analytical procedures used to generate stability data in 3.2.P.8.3.",
			"Summaries of batch analyses in the QIS must include all relevant batch types and highlight critical attributes, referencing Module 3 for full details.",
			"Ensure that summaries of specifications in the QIS reflect both release and shelf-life specifications and include mention of all analytical procedures used to control the product.",
			"When summarizing specification justifications, provide concise summaries supported by cross-references rather than repeating full data sets.",
			"Ensure that analytical procedure summaries in the QIS correctly differentiate between routine, historical, and stability-only procedures and reference their placement in Module 3.",
			"Include information on analytical procedures unique to the stability program in 3.2.P.8.3.",
		],
	},
	{
		number: "1.5.1",
		title: "Prescribing Information (Summary of Product Characteristics)",
		input: [
			"Obtain stability study data, either in its entirety or organized per manufacturer, stability study protocol, or other distinguishing criteria.",
			"Gather the table summarizing the overall extent of drug exposure (from Module 2.7) including all subjects exposed to at least one dose of the drug product, for use in summarizing safety and exposure information in the prescribing information.",
			"Obtain the current approved Summary of Product Characteristics (SmPC) or prescribing information if the drug substance is already approved, as per health authority guidance.",
			"Gather complete 'P' (drug product) information for the finished product, including for any reconstitution diluent(s) as separate drug products if applicable.",
			"Collect the Tabular Listing of All Clinical Studies (Section 5.2) to ensure accurate cross-referencing of study identifiers used in the prescribing information.",
			"Gather a description and composition of the drug product, including list of all components, their quantities, functions, and quality standards, as per ICH Q6A and Q6B.",
			"Collect pharmaceutical development data demonstrating that the dosage form, formulation, manufacturing process, container closure system, microbiological attributes, and usage instructions are appropriate for the intended purpose.",
			"Collect analytical procedures and validation data used to generate stability data, as per ICH Q1A, Q1B, Q2A, Q2B, and Q5C.",
			"Gather stability study data for the drug substance, including forced degradation and stress condition results, protocols, and conclusions on storage conditions and retest period, as per ICH Q1A, Q1B, and Q5C.",
			"Obtain reference standards and comparator product information if referenced in the prescribing information.",
			"Obtain documentation of GCP compliance statements and assessments of study design quality from the Clinical Overview.",
			"Obtain post-approval stability protocol and stability commitment documentation, as per ICH Q1A and Q5C.",
			"Collect detailed descriptions and specifications of the container closure system for the drug substance, including materials of construction, drawings, and validation of non-compendial methods, as per ICH Q6A and Q6B.",
			"Gather analytical data, test results, and specifications relevant to the product’s composition, quality, and stability.",
			"Compile literature references and expert opinions that support the clinical use, safety, and efficacy statements in the prescribing information.",
			"Gather individual clinical study reports (ICH E3) and comprehensive clinical data from Module 5, including efficacy, safety, pharmacokinetic, and pharmacodynamic studies that substantiate prescribing information claims.",
			"Gather analytical data, test results, and specifications relevant to the product\u0004s composition, quality, and stability.",
			"Gather information on reference standards or reference materials used for testing of the drug substance, including source, characterization, and qualification data, as per ICH Q6A and Q6B.",
			"Collect synopses of individual studies from Module 2.7.6 for reference when summarizing clinical evidence in the prescribing information.",
			"Gather microbiology data (in vitro and in vivo) when relevant to the product\u0004s prescribing information, including summary-level data for use in clinical sections and detailed reports located in Module 5.",
			"Gather data from Module 2.7 subsections such as dosing recommendations, persistence of efficacy/tolerance, safety in special groups, drug interactions, use in pregnancy/lactation, overdose, drug abuse, withdrawal, and effects on driving or mental ability for inclusion in relevant prescribing information sections.",
			"Gather analytical validation information, including experimental data for analytical procedures used for testing the drug substance, in accordance with ICH Q2A, Q2B, and Q6B.",
			"Gather all relevant regulatory correspondence and approvals related to the product’s prescribing information.",
			"Collect clinical and non-clinical study summaries and results that support the indications, dosing, contraindications, and safety information in the prescribing information.",
			"Collect detailed summaries from the Clinical Summary (Module 2.7) including biopharmaceutical studies, clinical pharmacology studies, clinical efficacy summaries, and clinical safety summaries to support prescribing information content.",
			"Obtain post-marketing safety data from Module 2.7.4.6 to support safety-related statements in the prescribing information.",
			"Refer to Appendix A for specific content requirements and templates for prescribing information.",
			"Collect complete technical and quality information for each drug substance in the product, including for combination products (full 'S' information for each active substance).",
			"Collect batch analysis descriptions and results for the drug substance, including batch numbers, manufacturing sites, and analytical results, as per ICH Q3A, Q3C, Q6A, and Q6B.",
			"Obtain justification for the drug substance specification, including rationale for test parameters, limits, and acceptance criteria, referencing ICH Q3A, Q3C, Q6A, and Q6B.",
			"Obtain information on accompanying reconstitution diluents, including composition and container closure details, if applicable.",
			"Gather all relevant regulatory correspondence and approvals related to the product\u0004s prescribing information.",
			"Collect the Clinical Overview (Module 2.5) and Clinical Summary documents to extract conclusions and interpretations that support the prescribing information.",
			"Gather microbiology data (in vitro and in vivo) when relevant to the product’s prescribing information, including summary-level data for use in clinical sections and detailed reports located in Module 5.",
			"Obtain and review Appendix C for stability information requirements relevant to content included in the prescribing information.",
			"Collect benefit–risk evaluations and analyses from the Clinical Overview that explain how efficacy and safety findings support the proposed dose and indication.",
			"Gather information on unresolved clinical issues, risk management plans, and explanations for unusual aspects of the prescribing information as described in the Clinical Overview.",
			"Collect benefit\u0013risk evaluations and analyses from the Clinical Overview that explain how efficacy and safety findings support the proposed dose and indication.",
		],
		output: [
			"Ensure that exposure data presented in the prescribing information reflects all subjects exposed to at least one dose of the drug product, consistent with the overall exposure table in Module 2.7.",
			"Maintain clarity, conciseness, and accuracy to facilitate regulatory review and healthcare professional use.",
			"Ensure that prescribing information content is informed by and consistent with the structure and data presentation in Module 2.7 subsections, including biopharmaceutical, pharmacology, efficacy, and safety summaries.",
			"Ensure that the prescribing information reflects the conclusions and interpretations presented in the Clinical Overview, particularly regarding benefit–risk evaluation, dose justification, and indication support.",
			"Describe the container closure system with clear identification of materials, specifications, and critical dimensions, including drawings where appropriate, and discuss suitability with respect to protection, compatibility, and safety.",
			"Use consistent terminology and language in line with regulatory standards and medical terminology conventions.",
			"Ensure the prescribing information follows the structure and headings required by the health authority for the Summary of Product Characteristics (SmPC).",
			"Ensure compliance with any formatting, heading hierarchy, and content requirements specified in Appendix A and applicable health authority guidelines.",
			"Include a distinct identifier (e.g., report number or abbreviation) in the header or footer on every page of the prescribing information; the full title is not required if it is too long.",
			"Ensure that cross-references in the prescribing information include only the section number in the cross string, but write the surrounding text so the reader can understand the section content without the full section name.",
			"Use unique short identifiers for each clinical study consistently throughout the prescribing information and across all CTD modules to ensure traceability and consistency.",
			"Verify that all clinical claims in the prescribing information are traceable to data and analyses summarized in the Clinical Overview and detailed in Module 5.",
			"Ensure that the prescribing information aligns with the Clinical Overview’s discussion of efficacy, safety, and risk management to maintain internal consistency across CTD modules.",
			"Ensure cross-references (cross strings) use section numbers (without full section names) to maintain clarity while minimizing text length.",
			"Ensure that dosing recommendations and special population considerations in the prescribing information are consistent with analyses in Module 2.7.3.4 and 2.7.4.5 subsections.",
			"Ensure that reference standards or materials are described with sufficient detail to demonstrate suitability and traceability, following ICH Q6A and Q6B.",
			"For combination products, present complete 'S' information for each active substance in a clear and organized manner.",
			"Follow Note 4 guidance by avoiding inclusion of unnecessary individual documents or files within lower-level headings where they are not expected.",
			"Include all mandatory sections such as therapeutic indications, dosage and administration, contraindications, warnings and precautions, adverse reactions, pharmacological properties, and pharmaceutical particulars.",
			"Include post-approval stability protocol and commitment information in a clearly labeled subsection, referencing ICH Q1A and Q5C.",
			"Cross-reference relevant sections of the CTD where supporting data is located (e.g., clinical, non-clinical, quality modules).",
			"Ensure that the prescribing information aligns with the Clinical Overview\u0019s discussion of efficacy, safety, and risk management to maintain internal consistency across CTD modules.",
			"Ensure that terminology for adverse events and related safety terms aligns with definitions provided in ICH E3.",
			"Ensure that stability information is organized in accordance with Appendix C when presenting relevant data within the prescribing information.",
			"Present justification of specifications in a structured narrative that explains rationale for each test and acceptance criterion, consistent with ICH Q3A, Q3C, Q6A, and Q6B.",
			"Ensure that the prescribing information reflects the conclusions and interpretations presented in the Clinical Overview, particularly regarding benefit\u0013risk evaluation, dose justification, and indication support.",
			"Summarize stability studies in tabular, graphical, or narrative format, including forced degradation and stress condition results, and provide conclusions on storage conditions and retest period, consistent with ICH Q1A, Q1B, and Q5C.",
			"Incorporate safety information in the prescribing information in alignment with Module 2.7.4 structure, ensuring coverage of exposure, adverse events, laboratory evaluations, vital signs, safety in special groups, drug interactions, and post-marketing data.",
			"Ensure that cross-references to efficacy and dose-related analyses are consistent with the distinctions between Sections 2.7.3.3 (efficacy summaries) and 2.7.3.4 (dose-response analyses) to maintain clarity in dose justification within the prescribing information.",
			"For products with reconstitution diluents, present 'P' information for the diluent(s) as separate drug products in the document.",
			"Clearly explain the basis for important or unusual aspects of the prescribing information, consistent with the rationale provided in the Clinical Overview.",
			"Ensure that analytical procedures used for stability testing are described and validated, referencing ICH Q2A and Q2B.",
			"Ensure that analytical validation data and batch analysis results are summarized clearly and traceably, referencing ICH Q2A, Q2B, and Q6B for format and content expectations.",
			"When describing the drug product composition, list all components, their quantities, functions, and quality standards, and include information on reconstitution diluents and container closure systems, as per ICH Q6A and Q6B.",
			"Maintain a logical flow that reflects the clinical development rationale and study design considerations as described in the Clinical Overview.",
			"Ensure that pharmaceutical development information is presented to demonstrate that formulation, process, and packaging are appropriate for the intended use, distinguishing development studies from routine control tests.",
			"Present stability information in a consistent format, either as a complete dataset or organized per manufacturer/protocol, ensuring clarity and traceability.",
			"When summarizing clinical evidence in the prescribing information, ensure alignment with the synopses of individual studies in Module 2.7.6 to maintain accuracy and consistency.",
			"Ensure that the prescribing information remains concise and proportionate to the scope of indications, avoiding unnecessary expansion beyond what is supported by the data.",
			"Ensure that the prescribing information aligns with the Clinical Overview\u0004s discussion of efficacy, safety, and risk management to maintain internal consistency across CTD modules.",
			"Verify that all claims and statements in the prescribing information are supported by data in the submission dossier.",
			"When referencing detailed statistical or integrated analyses that are too extensive for prescribing information, direct readers to the appropriate Module 5 section (e.g., 5.3.5.3) rather than including excessive detail in the prescribing information.",
		],
	},
	{
		number: "1.5.2",
		title: "Container Labelling",
		input: [
			"Obtain specifications for container closure systems including description, identification, and critical dimensions, and include non-compendial methods with validation where appropriate.",
			"Retrieve data from constitution or dilution studies performed as part of formal stability studies to confirm product quality through shelf-life, as these support labelling statements on reconstitution and use period.",
			"Obtain legal documents such as trademark authorization letters or proof of proprietary name ownership, if applicable.",
			"Obtain finalized container and carton labelling mock‑ups for all proposed packaging configurations (primary, secondary, and any special packs).",
			"Gather drug substance storage conditions and shelf-life (or retest period for chemicals) from stability summary and conclusions to support label claims.",
			"Gather detailed descriptions, manufacturer information, and specifications for each container closure system type (e.g., blister packs, HDPE bottles) to support differentiated labelling content.",
			"Obtain finalized container and carton labelling mock-ups for all proposed packaging configurations (primary, secondary, and any special packs).",
			"Obtain translations or language versions of labelling text if multiple markets or languages are required.",
			"Obtain compatibility data for co-administered drugs to support labelling statements related to concomitant administration or mixing instructions.",
			"Collect brief descriptions for non-functional secondary packaging components and detailed information for functional secondary packaging components.",
			"Obtain post-approval stability protocol and stability commitment documentation.",
			"Obtain finalized container and carton labelling mock\u0011ups for all proposed packaging configurations (primary, secondary, and any special packs).",
			"Collect stability data in appropriate formats (tabular, graphical, narrative) including analytical procedures used and their validation.",
			"Collect applicable regulatory labelling templates or format requirements from the target health authority (e.g., EU, FDA, Health Canada).",
			"Gather stability summary and conclusions including types of studies conducted, protocols used, results, and conclusions regarding storage conditions, shelf-life, and in-use storage/shelf-life if applicable.",
			"Gather comparator product labelling or reference product labelling (for generics or biosimilars) to ensure consistency with reference standards.",
			"Gather any expert opinions or internal reviews confirming compliance with local labelling regulations and readability standards.",
			"Gather regulatory documents such as previously approved labelling, regulatory correspondence, and any commitments related to labelling changes.",
			"Obtain stability study data supporting storage conditions and shelf-life statements to be included on the label.",
			"Collect technical specifications of the container closure system to ensure label compatibility (e.g., material type, size, shape).",
			"Collect packaging component information (e.g., aluminium lidding, PVC laminate) relevant to each container closure system for accurate labelling statements.",
			"Gather compatibility data of reconstitution diluents that support label claims regarding preparation and administration instructions.",
			"Collect microbiological and physicochemical data relevant to labelling statements such as sterility, preservative content, or handling precautions.",
			"Collect approved product name, dosage form, strength, route of administration, and storage conditions for inclusion on labels.",
			"Obtain material of construction and specification details for the container closure system to ensure accurate and compliant labelling statements.",
			"Gather data on container closure system performance, including light protection characteristics, leachables and extractables, and cleaning validation (if relevant to labelling statements).",
			"Gather description of each container closure system including identity of materials of construction for each primary packaging component and its specification, including critical dimensions and drawings where appropriate.",
			"Collect information on incompatible diluents to ensure appropriate cautionary statements are included on the label.",
		],
		output: [
			"Ensure that the labelling mock-ups are provided in the required file format (e.g., PDF, high-resolution image) and are clearly legible.",
			"Include a distinct identifier (e.g., abbreviated title or document code) in headers or footers on every page of the container labelling document to support traceability and consistency.",
			"Include cautionary or contraindication statements on the label for any identified incompatible diluents or co-administered drugs, ensuring consistency with supporting data.",
			"If the product has more than one container closure system, ensure that labelling information is organized per system when required by regional guidance (based on Note 9).",
			"Include version control and date of preparation on the labelling document for traceability.",
			"Confirm that the label content matches the physical container and packaging configuration described in the dossier.",
			"Include additional packaging component details in document titles or labelling content to differentiate similar container types when relevant (e.g., aluminium lidding, PVC laminate).",
			"Verify that all mandatory regulatory statements, cautionary phrases, and controlled substance symbols are included as per jurisdictional requirements.",
			"When describing container closure systems in the labelling section, include identity of materials of construction, specifications, and critical dimensions, and reference any non-compendial methods with validation where applicable.",
			"Ensure that no page numbers are added in the Module 1 comprehensive Table of Contents when referencing container labelling materials.",
			"Ensure that the chosen granularity for container closure system documentation (single vs. multiple documents) supports clarity in labelling and aligns with business and regulatory needs.",
			"When multiple container closure systems are described, use clear and informative document titles (e.g., 'Description - Blister', 'HDPE Bottle - 50 mL - Specification') to differentiate them in the dossier and ensure labelling reflects these distinctions.",
			"Perform a compliance check against applicable labelling regulations and guidance documents (e.g., EU QRD templates, FDA 21 CFR 201).",
			"Ensure that the labelling text is consistent with the approved Product Information (SmPC, PI, or equivalent) and other CTD sections (e.g., 1.3 Product Information, 3.2.P.7 Stability).",
			"Ensure that translations, if applicable, are accurate and consistent across all language versions.",
			"Ensure that the labelling complies with readability and comprehension standards (e.g., clear language, avoidance of abbreviations, use of standard terminology).",
			"Ensure that container labelling statements regarding storage conditions and shelf-life are directly supported by stability summary and conclusions data from section 3.2.S.7.1.",
			"Include cross-references to relevant sections where supporting data are provided (e.g., stability data in 3.2.P.8.3 for storage conditions, container closure details in 3.2.P.2.4).",
			"Maintain consistent inclusion of module numbers, volume numbers, and tab identifiers when container labelling content appears in any TOC.",
			"Follow the format and layout requirements specified by the target regulatory authority (e.g., font size, legibility, contrast, and placement of mandatory information).",
			"Follow CTD rules stating that sub-heading numbering below the official CTD levels may be used within the container labelling document for navigation but must not appear in the overall TOC.",
			"Ensure that storage condition and shelf-life statements in labelling are consistent with conclusions from stability summary (3.2.P.8.1) and supported by stability data (3.2.P.8.3).",
			"Check that all information is presented in the correct sequence and that no required elements are omitted.",
			"Cross-reference compatibility and reconstitution information appropriately within the CTD to maintain traceability between labelling claims and supporting data sources.",
			"If multiple documents are included under the container labelling section, assign priority numbers to control the order of appearance and ensure logical sequencing for reviewers.",
			"Ensure the container labelling section includes all required information: product name, strength, dosage form, route of administration, storage conditions, batch number, expiry date, manufacturer, and any cautionary statements.",
			"When storage conditions differ per container closure system (referencing Note 10), ensure that the corresponding labelling statements and supporting references are clearly structured and differentiated.",
			"For non-functional secondary packaging components, provide only a brief description in labelling; for functional secondary packaging components, ensure additional details are included as required.",
			"Ensure that any labelling statements regarding reconstitution, dilution, or co-administration are supported by compatibility data from section 3.2.P.2.6 and stability data from 3.2.P.8.3.",
			"Ensure that TOC formatting for the container labelling document follows CTD expectations, including use of module numbers and appropriate structuring.",
		],
	},
	{
		number: "1.5.3",
		title: "Patient Information leaflet (PIL)",
		input: [
			"Collect information on particular efficacy or safety issues encountered during development and how they were addressed",
			"Collect any other relevant reports that may have clinical implications, such as pertinent animal data or product quality reports",
			"Gather unique short identifiers for each clinical study report to ensure consistent citation throughout the dossier",
			"Refer to Appendix A or equivalent national guidance documents for specific regulatory instructions applicable to the Patient Information Leaflet (PIL)",
			"Gather analytical procedure details and method validation information for any in-process material test performed in lieu of a finished product test",
			"Obtain the comprehensive Clinical Summary from Module 2.7 for reference in interpreting and summarising clinical data",
			"Gather information on the overall clinical development program, including rationale for critical study design decisions",
			"Gather information on container closure systems, pack sizes, and appearance of the product for inclusion in the PIL",
			"Obtain results from user testing or readability testing of the PIL, if required by the regulatory authority",
			"Collect summaries of clinical findings, including limitations such as missing comparator data, absent patient population data, or missing endpoint information",
			"Obtain certifications relating to TSE/BSE for excipients of human or animal origin, following region-specific guidance",
			"Gather all individual clinical study reports (ICH E3) relevant to the product, including efficacy, safety, pharmacokinetic, and pharmacodynamic studies",
			"Collect the overall extent of exposure data (covering all subjects exposed to at least one dose of the drug product) to support patient safety information in the PIL",
			"Collect patient-friendly descriptions of clinical study results or benefit-risk information, if required",
			"Gather benefit-risk evaluation data, including efficacy and safety findings supporting proposed dose and indication",
			"Obtain statements or documentation regarding Good Clinical Practice (GCP) compliance for all relevant studies",
			"Obtain any applicable national or regional template or guidance documents for PIL content and format",
			"Obtain detailed information on critical steps and all intermediates that are controlled, as identified in 3.2.P.3.3",
			"Gather information on excipients of human or animal origin for inclusion in 3.2.P.4.5",
			"Consult the relevant health authority for guidance if the drug substance or product is already approved, to ensure consistency of the PIL content with existing approvals",
			"Obtain definitions and terminology for adverse events as per ICH E3 guideline to ensure consistent use in patient-friendly language within the PIL",
			"Obtain information on adventitious agent safety evaluation for excipients of human or animal origin for inclusion in 3.2.A.2",
			"Obtain the latest approved Patient Information Leaflet (PIL) text from previous regulatory submissions or approvals, if available",
			"Obtain any relevant literature references or expert opinions used to support patient-friendly explanations in the PIL",
			"Collect critical process control values from relevant batches to support numeric ranges, limits, and other parameters for critical process controls",
			"Gather product-specific information: dosage form, strength, route of administration, indications, contraindications, warnings, precautions, side effects, storage conditions",
			"Obtain the proposed prescribing information to ensure alignment with clinical conclusions",
			"Collect the Tabular Listing of All Clinical Studies (Section 5.2) to ensure consistent referencing of study identifiers across documents",
			"Collect the Summary of Product Characteristics (SmPC) or Product Information to ensure alignment of content with the PIL",
			"Collect certificates of analysis or batch data for excipients for inclusion in 3.2.P.4.4",
			"Obtain specification details from 3.2.P.5.1 for any process test replacing an end-product test, ensuring it is specified as a process test",
			"Gather details of unresolved clinical issues and plans for their resolution",
			"Collect translations of the PIL into required local languages, if applicable",
			"Gather any regulatory authority feedback or correspondence related to the PIL from previous submissions",
			"Collect information on excipients, especially those with known effects, for inclusion in the PIL",
			"Gather the most recent draft PIL text from the medical writing or product team for the current submission",
		],
		output: [
			"If a process test replaces an end-product test, ensure it is listed in the specification (3.2.P.5.1) and clearly identified as a process test in accordance with ICH Q6A",
			"Present strengths and limitations of the clinical development program and study results",
			"Verify that the PIL meets readability and comprehension standards as per regulatory guidance (e.g., user testing requirements)",
			"Ensure consistent page layout throughout the PIL, while allowing for minor layout differences if justified (e.g., readability or section type)",
			"Assess the quality of study design and performance, and include a statement on GCP compliance",
			"Include appropriate bookmarks in the electronic (PDF) version for any sub-sections created within the PIL document",
			"Include any required pictograms, diagrams, or tables to aid patient understanding",
			"Ensure correct spelling, grammar, and terminology in the target language(s)",
			"Ensure that the PIL is paginated correctly and that page numbers are clear and sequential",
			"For justification of specifications, a summary of data from other sections with cross-references to detailed information may be provided instead of repeating the full data",
			"Ensure the Clinical Overview integrates relevant information from other modules (e.g., animal data, product quality) where they have clinical implications",
			"Verify that the PIL file format complies with submission requirements (e.g., PDF with bookmarks for eCTD submissions)",
			"Ensure the PIL is written in clear, patient-friendly language, avoiding technical jargon",
			"Explain the basis for important or unusual aspects of the prescribing information",
			"Discuss unresolved issues, justify why they are not barriers to approval, and outline plans for resolution",
			"Ensure that literature references are paginated according to the original source (journal, abstract, etc.)",
			"Use sub-numbering within the document (e.g., 1.5.3.1, 1.5.3.2) if needed for navigation, but do not include these lower-level headings in the overall CTD table of contents",
			"Ensure cross-references within the PIL are accurate and functional",
			"Check that the PIL includes up-to-date safety information, including recent changes from pharmacovigilance updates",
			"Include all mandatory sections such as: What the medicine is and what it is used for, Before you take/use the medicine, How to take/use the medicine, Possible side effects, How to store the medicine, Contents of the pack and other information",
			"Verify that any references to clinical exposure data in the PIL reflect total subjects exposed to at least one dose of the drug product",
			"Include module numbers, volume numbers, and tab dividers in all tables of contents for paper submissions",
			"Ensure that the PIL complies with any additional structural or content requirements referenced in Appendix A or equivalent national appendices",
			"Follow the structure and headings required by the applicable national or regional regulatory authority for PILs",
			"Address particular efficacy or safety issues encountered and how they were resolved",
			"Provide a brief overview of clinical findings, highlighting important limitations such as missing comparator data or absent patient population information",
			"Ensure consistency in study naming and referencing between the PIL, Clinical Overview, and Clinical Summary to maintain traceability",
			"Format the PIL according to regulatory specifications, including font size, spacing, and layout requirements for legibility",
			"In the Clinical Overview, provide a succinct discussion and interpretation of clinical findings rather than repeating detailed data",
			"Ensure that the dossier follows CTD format requirements, recognizing that content may vary by region due to local regulatory preferences",
			"When including in-process material tests in lieu of finished product tests, provide the same level of detail as for finished product tests, including analytical procedures and method validation information",
			"Describe and explain the overall approach to clinical development, including rationale for critical study design decisions",
			"Ensure terminology for adverse events and safety information aligns with ICH E3 definitions and is translated into patient-friendly language",
			"Include a distinct identifier (e.g., abbreviated title or document number) in the header or footer of each page of the PIL",
			"Evaluate benefits and risks, interpreting how efficacy and safety findings support the proposed dose and indication",
			"Ensure the PIL content is consistent with the approved Summary of Product Characteristics (SmPC) or Product Information",
			"Ensure consistent use of unique short identifiers for each clinical study across all modules and references within the PIL",
		],
	},
	{
		number: "1.5.4",
		title: "Mock-ups and Specimens",
		input: [
			"Gather results from tests not listed in the specifications, if applicable.",
			"Collect a complete list of all observed impurities in the drug product, including those not in the specification.",
			"Collect information on batch definition and batch size or range for CM processes if relevant to labeling or packaging claims.",
			"Collect stability study summaries, protocols, and results relevant to packaging and labeling claims, including storage conditions and shelf-life.",
			"Obtain post-approval stability protocol and stability commitment documents if they impact packaging or labeling.",
			"Obtain mock-ups and specimens for any reconstitution diluent(s) supplied with the drug product, treated as separate drug product packaging components.",
			"If the drug product contains more than one drug substance, gather complete 'S' information for each drug substance, even if one or more are already approved, and consult the health authority for guidance on approved substances.",
			"Compile collated data from multiple batch analyses for specific tests, if warranted.",
			"Gather complete 'P' information for any reconstitution diluent(s) supplied with the drug product, treating each diluent as a separate drug product for documentation purposes.",
			"Gather release specifications and shelf-life specifications for the drug product, including acceptance criteria.",
			"Gather regional validation data for high-impact process models and continuous process verification schemes if they affect packaging or labeling claims.",
			"Gather justification for any proposed skip testing in the specifications.",
			"Collect information on critical process parameters, in-process testing, and contingency plans for process models that may affect labeling or packaging specifications.",
			"Gather stability data in tabular, graphical, or narrative format, including analytical procedures and validation reports used to generate the data.",
			"Obtain specifications and validation data for any non-compendial test methods used for packaging components.",
			"Obtain results from all relevant batch analyses (clinical, nonclinical, stability batches), including batch descriptions (batch number, manufacturing site, intended use).",
			"Gather approved labeling text and artwork from the labeling department to ensure consistency between mock-ups/specimens and the proposed labeling.",
			"Gather any legal or trademark documentation related to product name, logo, or branding elements appearing on the packaging.",
			"Collect container closure system descriptions, including identity of materials of construction for each primary packaging component, specifications, and critical dimensions with drawings where appropriate.",
			"Obtain regulatory correspondence or prior approvals related to labeling or packaging design, if applicable.",
			"Collect contingency testing and monitoring plans for analytical models used in release testing, if applicable to labeling or packaging.",
			"Obtain justification documents for any observed impurities not included in the specification.",
			"Gather brief descriptions for non-functional secondary packaging components and detailed information for functional secondary packaging components.",
			"Collect details of any alternative analytical procedures used to control the drug product, along with associated acceptance criteria.",
			"Gather all specifications applicable to the drug substance manufacturer and/or applicant when multiple specifications exist, ensuring consistency with labeling and packaging claims.",
			"Obtain analytical model validation information if models are used for release testing or real-time release that influence labeling or packaging claims.",
			"Collect reference samples or comparator product packaging for alignment with market standards and regulatory expectations.",
			"Collect any continuous manufacturing (CM)-specific information relevant to packaging or labeling presentation if applicable to the product.",
			"Obtain summaries and justifications of control strategies related to CM that may influence packaging or labeling (e.g., system start-up, shutdown, pause, disturbance management).",
			"Collect final or representative specimens of printed packaging materials that will be used for marketing authorization submission.",
			"Prepare summaries of supporting data from other sections with cross-references to detailed information for specification justification.",
			"Gather ICH guideline references relevant to mock-ups and specimens to ensure alignment with applicable quality and safety standards (e.g., Q2A, Q2B, Q6B).",
			"Gather narrative descriptions of manufacturing processes and flow diagrams that identify continuous manufacturing portions, if these impact packaging or labeling presentation.",
			"Collect internal quality assurance approvals or sign-offs for the packaging artwork and labeling content prior to submission.",
			"Collect information on any alternative analytical procedures used to control the drug substance, including associated acceptance criteria, if relevant to packaging or labeling claims.",
			"Gather integrated flow diagrams for continuous manufacturing processes if packaging or labeling is affected by integrated drug substance and drug product processes.",
			"Obtain mock-ups of all proposed packaging components, including outer carton, container labels, blister packs, and any other immediate or secondary packaging.",
			"Obtain any relevant national or regional packaging and labeling requirements (e.g., language, Braille, safety symbols) applicable to the submission region.",
			"Ensure availability of product-specific information such as dosage form, strength, route of administration, and storage conditions to be reflected accurately on mock-ups.",
			"For stability data relevant to mock-ups/specimens, collect information either in its entirety or organized per manufacturer, per stability study protocol, or by other distinguishing criteria as appropriate.",
		],
		output: [
			"Modify or adapt the presentation format of mock-ups and specimens if needed to provide the clearest possible understanding for regulatory reviewers.",
			"Include both outer and inner packaging representations, clearly labeled and legible.",
			"Ensure that any alternative analytical procedures used to control the drug product are included in the specifications with corresponding acceptance criteria.",
			"When including specifications, ensure both release and shelf-life specifications are presented together in the appropriate section, with all analytical procedures and acceptance criteria clearly listed.",
			"If the drug product contains more than one drug substance, ensure that the 'S' information is presented in its entirety for each drug substance, with clear organization and cross-references, even if one or more substances are already approved.",
			"Cross-reference the mock-ups/specimens with the corresponding labeling text and packaging components described elsewhere in the dossier.",
			"List all observed impurities in the relevant section, regardless of whether they are included in the specification, and cross-reference to justification for exclusion if applicable.",
			"Ensure that any analytical procedure used to control the drug substance or product, along with its acceptance criteria, is clearly listed in the relevant specification section and cross-referenced where applicable.",
			"Include results from all relevant batches in a clear, tabulated format, along with batch descriptions (batch number, manufacturing site, intended use).",
			"If multiple specifications exist for the drug substance manufacturer and/or applicant, ensure all are clearly presented and appropriately referenced to maintain consistency with labeling and packaging claims.",
			"Confirm that all symbols, pictograms, and safety warnings comply with applicable regulatory and pharmacovigilance labeling standards.",
			"Provide only a brief description for non-functional secondary packaging components, and detailed information for functional secondary packaging components, as per guidance.",
			"Ensure that any integrated flow diagrams or process descriptions relevant to CM are referenced appropriately if they influence packaging or labeling presentation.",
			"If the drug product is supplied with reconstitution diluent(s), present mock-ups/specimens for the diluent(s) as separate drug product packaging, clearly labeled and organized to distinguish them from the primary drug product.",
			"Include Braille text or other accessibility features if required by regional legislation.",
			"If continuous manufacturing (CM) information is relevant to packaging or labeling, ensure cross-references to CM-related sections (e.g., 3.2.S, 3.2.P) are clearly indicated.",
			"Ensure that mock-ups and specimens are presented in the format required by the regulatory authority (e.g., color printed copies or electronic PDF files).",
			"If stability information relevant to packaging is organized by container closure system in other sections, ensure consistent cross-referencing and alignment in this section.",
			"Present stability data in an appropriate format (tabular, graphical, narrative) ensuring analytical procedures and validation details are included and clearly linked to the data.",
			"When describing container closure systems, include identity of materials, specifications, and critical dimensions, with drawings where appropriate, ensuring clarity and completeness.",
			"Organize the section to include a list or table of submitted mock-ups/specimens, followed by the actual images or attachments.",
			"Ensure pagination, labeling, and file naming conventions follow the CTD Module 1 formatting requirements.",
			"Present results from tests not listed in the specifications in the same section as batch analyses, clearly identified as such.",
			"Verify that all mandatory information (product name, strength, dosage form, route of administration, storage conditions, batch number, expiry date, manufacturer details) is present and correctly formatted.",
			"Ensure that the layout, font size, and color contrast meet readability and accessibility standards as per local labeling regulations.",
			"Include summaries and justifications of control strategies related to CM only if they impact packaging or labeling, maintaining consistency with other CTD sections.",
			"Verify that any batch definition or batch size information relevant to CM aligns with labeling claims (e.g., batch number representation on packaging).",
			"If more than one container closure system exists for the drug product, organize mock-ups and specimens per system or per distinguishing feature to ensure clarity for reviewers.",
			"For stability data included in this section, choose an organizational approach (entirety, per manufacturer, per stability study protocol, or other distinguishing criteria) that maximizes clarity and aligns with Appendix C guidance.",
			"For non-compendial test methods related to packaging components, include method descriptions and validation data in the appropriate format.",
			"Include justification for skip testing in the specification justification section, supported by summarized data and cross-references to detailed information elsewhere in the dossier.",
			"Maintain consistency between regional CM-related validation data and the packaging or labeling information presented in this section.",
			"When including stability information relevant to packaging claims, summarize types of studies, protocols, results, and conclusions on storage conditions and shelf-life in a clear, concise format.",
			"Perform a compliance check to ensure that the submitted mock-ups/specimens correspond exactly to the proposed marketed presentation.",
			"Use the official language(s) required by the target regulatory authority for all text appearing on the packaging.",
			"If collated data from multiple batch analyses is provided, organize it in a way that facilitates reviewer understanding (e.g., summary tables).",
			"If analytical models or PAT-based release testing are referenced in labeling or packaging claims, ensure model validation and contingency plans are clearly summarized and cross-referenced.",
			"Ensure that all labeling text on mock-ups/specimens matches the approved labeling content in section 1.3 (Product Information).",
		],
	},
	{
		number: "1.6",
		title: "Information about the Experts",
		input: [
			"If expert statements reference drug products containing more than one drug substance, gather full S\u000011section information for each drug substance, even if one or more drug substances are already approved.",
			"If expert statements reference multiple facilities, gather facility-specific documentation as applicable, in alignment with Appendix F.",
			"If expert statements reference drug products supplied with reconstitution diluents, gather complete P\u000011section information for each diluent as separate drug product(s), in alignment with Note 6.",
			"Obtain signed statements or declarations from each expert confirming their role and responsibility for the content they reviewed or authored.",
			"If expert statements reference container closure systems, gather detailed information for each system (or per distinguishing information such as manufacturer, strength) as applicable, in alignment with Appendix E.",
			"Collect the names, qualifications, and professional titles of each expert contributing to the dossier (quality, non-clinical, clinical).",
			"Collect publications and literature references relevant to the studies, ensuring they are available for placement in the correct CTD module location (Module 5.4).",
			"Gather up-to-date CVs or résumés for each expert, including education, training, and relevant experience.",
			"Collect contact information for each expert (address, phone, email) as required by the regional authority.",
			"If expert statements reference multiple components (e.g., in combination products or multi-component vaccines), gather component-specific documentation as applicable, in alignment with Appendix F.",
			"Collect the contact information for the designated Medical Expert (as identified by the sponsor) or identify the location in the dossier where this information can be found, ensuring it aligns with the controlled terminology definition (CNEW).",
			"Gather case report forms (CRFs) for relevant studies, ensuring they are available for placement in the correct CTD module location (Module 5.3.7).",
			"If expert statements reference drug products supplied with reconstitution diluents, gather complete P‑section information for each diluent as separate drug product(s), in alignment with Note 6.",
			"If applicable, gather stability study protocols and related data when expert statements reference stability aspects of the product, ensuring alignment with Appendix C or other referenced appendices.",
			"Gather any professional licenses, registrations, or certifications relevant to the expert’s field.",
			"Refer to Appendix A for any additional regulatory or procedural requirements related to expert information or cross-referenced sections.",
			"Gather any professional licenses, registrations, or certifications relevant to the expert\u0000e2\u000080\u000099s field.",
			"If expert statements reference drug products containing more than one drug substance, gather full S‑section information for each drug substance, even if one or more drug substances are already approved.",
			"Ensure availability of any legal authorizations or letters of appointment designating the expert for the submission.",
			"Obtain any required expert signature pages in accordance with regional requirements (e.g., EU-specific signature requirements from the European Commission).",
			"Gather any amendment details or written messages describing protocol amendments relevant to expert information, including whether the protocol has been amended previously.",
			"Gather up-to-date CVs or r\u0000e9sum\u0000e9s for each expert, including education, training, and relevant experience.",
			"Gather up-to-date CVs or resumes for each expert, including education, training, and relevant experience.",
			"If expert statements reference stability data, gather stability information organized per container closure system, manufacturer, strength, stability study protocol, or other distinguishing information, in alignment with Appendix C.",
			"Consult the relevant health authority for guidance if the drug substance is already approved, to determine whether expert information or justification is still required.",
			"If expert statements reference excipients, gather excipient-specific documentation as applicable.",
			"Gather individual patient data listings for relevant studies, ensuring they are available for placement in the correct CTD module location (Module 5.3.7).",
			"Collect narrative descriptions of studies that contributed both efficacy and safety data, including details on extent of exposure of study subjects to the test drug and how safety data were collected, for inclusion in the appropriate CTD sections.",
		],
		output: [
			"Maintain all required CTD section headings even if certain expert categories (e.g., non-clinical, clinical) are not applicable, and provide a brief explanation for their absence rather than deleting the heading.",
			"For sections with multiple indications, organize subsections under each indication consistently (e.g., Background, Summary of Results of Individual Studies, Comparison and Analysis).",
			"Ensure compliance with CTD Module 1 structure \u0014 place Information about the Experts in section 1.6 without adding subheadings beyond those allowed by the CTD guideline.",
			"Ensure compliance with CTD Module 1 structure — place Information about the Experts in section 1.6 without adding subheadings beyond those allowed by the CTD guideline.",
			"When expert information references stability data, structure the content so that information is clearly organized either in its entirety or per container closure system, manufacturer, strength, stability study protocol, or other distinguishing information, in accordance with Appendix C.",
			"If expert information references products containing more than one drug substance, ensure that content is structured so that S\u0011section information is clearly organized per drug substance, consistent with Note 3.",
			"When expert information references multiple excipients, structure the content so that documents are organized per excipient.",
			"Ensure consistency with CTD formatting conventions by retaining section numbering and structure even when certain expert roles are not represented.",
			"Retain headings 11 and 11.1 as required elements when referenced in expert-related content cross-referencing protocols, ensuring they appear exactly as prescribed (heading only for section 11, with no text).",
			"Ensure the section clearly identifies each expert by name, area of expertise (quality, non-clinical, clinical), and role in the submission.",
			"Ensure that heading-only sections (such as section 11) contain no narrative text and comply with the 'heading only' rule specified in the guideline.",
			"Ensure compliance with CTD Module 1 structure \u0000e2\u000080\u000094 place Information about the Experts in section 1.6 without adding subheadings beyond those allowed by the CTD guideline.",
			"When referencing appendices (e.g., Appendix A or Appendix C), ensure that cross-references are accurate and clearly labeled in the dossier.",
			"Retain current CTD numbering when multiple indications are presented, appending the indication name to the section number (e.g., 2.7.3.UTI Summary of Clinical Efficacy, 2.7.3.Pneumonia Summary of Clinical Efficacy) and apply the same approach consistently across applicable sections.",
			"When preparing narratives for studies contributing both efficacy and safety data, include in section 2.7.3.2 a reasonably complete description with details on subject exposure and safety data collection methods, while discussing safety results in section 2.7.4.",
			"Do not repeat or reuse the 'Amendment Details' heading or Medical Expert contact information fields; each should appear only once per applicable protocol or expert record.",
			"Ensure that lower-level CTD headings (as noted in CTD-Q) are retained for structural consistency, even if they do not contain individual documents or files, and include a note explaining their absence if applicable.",
			"If the drug substance is already approved, include a statement or note in the expert section referring to the health authority guidance and justification for any omitted or summarized expert information.",
			"Present expert information in a consistent order (e.g., Quality Expert, Non-clinical Expert, Clinical Expert).",
			"If expert information references reconstitution diluents, clearly structure P\u0011section information for each diluent as separate drug product(s), in alignment with Note 6.",
			"When expert information references container closure systems, structure the content so that information is clearly organized either in its entirety or per system or per other distinguishing information, in accordance with Appendix E.",
			"Include the Medical Expert contact information as a text data field or indicate the location where it can be found, ensuring it conforms to the controlled terminology definition (CNEW) and is linked one-to-one with the sponsor protocol identifier.",
			"Ensure that the 'Amendment Details' heading is included as a required heading (non-repeating, one-to-one cardinality) and that any amendment information is presented as a valid value under this heading, describing whether the protocol has been amended previously.",
			"Verify that all expert information is accurate, complete, and matches supporting documents (CVs, declarations).",
			"When expert information references multiple facilities, structure the content so that documents are organized per facility, in accordance with Appendix F.",
			"When expert information references multiple components (e.g., in combination products or multi-component vaccines), structure the content so that documents are organized per component, in accordance with Appendix F.",
			"If expert information references reconstitution diluents, clearly structure P‑section information for each diluent as separate drug product(s), in alignment with Note 6.",
			"If required by the region, include original signatures or certified copies of signed statements from experts.",
			"Include qualifications and relevant experience in a concise, structured format.",
			"If expert information references products containing more than one drug substance, ensure that content is structured so that S‑section information is clearly organized per drug substance, consistent with Note 3.",
			"Follow regional formatting requirements for expert information (e.g., EU-specific signature placement and format).",
			"Ensure that any abbreviations or shortened identifiers used for experts are clear and consistent throughout the dossier.",
			"Ensure placement of case report forms in Module 5.3.7, individual patient data listings in Module 5.3.7, and literature references in Module 5.4, in accordance with CTD organization requirements.",
		],
	},
	{
		number: "1.7",
		title: "APIMFs and certificates of suitability to the monographs of the European Pharmacopoeia",
		input: [
			"Gather all relevant batch analysis data for the API and drug product, including results from clinical, nonclinical, and stability batches used to justify acceptance criteria.",
			"For a drug product containing more than one drug substance, gather complete 'S' information for each drug substance, including APIMF or CEP and all supporting data.",
			"Gather a Letter of Access or Letter of Authorization from the API manufacturer permitting the regulatory authority to reference the APIMF.",
			"Obtain the Active Pharmaceutical Ingredient Master File (APIMF) from the API manufacturer, including both the open (applicant’s) and restricted (confidential) parts.",
			"Gather details of analytical procedures used exclusively for stability studies.",
			"Obtain information on any historical analytical procedures used to generate batch analysis data.",
			"Collect collated data summaries from multiple batch analyses if these are referenced or required to support the APIMF or CEP.",
			"Gather information on all observed impurities in the API, including those not included in the specification, if referenced in the APIMF or CEP.",
			"Gather all applicable drug substance specifications from both the API manufacturer and the applicant, if they differ.",
			"Collect technical data supporting the API quality, including manufacturing process description, specifications, analytical methods, and validation data (if referenced in the APIMF).",
			"Obtain the current version of the relevant European Pharmacopoeia monograph(s) applicable to the API(s).",
			"Ensure availability of cross-references to relevant sections of Module 3 (e.g., 3.2.S) where the API information is detailed.",
			"Collect a copy of the EDQM approval letter or correspondence confirming the validity and current status of the CEP.",
			"Collect details of all analytical procedures used to control the drug substance, including acceptance criteria.",
			"Collect any expert statements or summaries provided by the API manufacturer that explain the content of the APIMF or CEP.",
			"Gather information on the API manufacturer’s GMP compliance status (e.g., GMP certificate, inspection reports).",
			"If the drug substance is already approved, obtain guidance or confirmation from the relevant health authority on submission requirements.",
			"Gather results from any tests performed that are not listed in the specification, if they are referenced in the APIMF or CEP documentation.",
			"Gather any previous regulatory correspondence or commitments related to the APIMF or CEP submissions.",
			"Collect detailed batch descriptions (batch number, manufacturing site, intended use) for all batches included in the APIMF or CEP submission.",
			"Collect validation data for all analytical procedures, including relevant chromatograms.",
			"Obtain the Active Pharmaceutical Ingredient Master File (APIMF) from the API manufacturer, including both the open (applicant\u0000s) and restricted (confidential) parts.",
			"Gather information on the API manufacturer\u0000s GMP compliance status (e.g., GMP certificate, inspection reports).",
			"Collect the European Directorate for the Quality of Medicines (EDQM) Certificate(s) of Suitability (CEP) to the monographs of the European Pharmacopoeia for each API used in the product.",
			"Gather information on the API manufacturer\u0019s GMP compliance status (e.g., GMP certificate, inspection reports).",
			"For a drug product supplied with reconstitution diluent(s), gather complete 'P' information for the diluent(s) as separate drug product(s), including all relevant quality data.",
			"Obtain stability data and impurity profiles if these are referenced or required to support the APIMF or CEP.",
			"Obtain the most recent version of the ICH M4 guideline and its Questions & Answers (R3) document to ensure alignment with the latest codification and structural requirements for CTD submissions.",
			"Obtain the Active Pharmaceutical Ingredient Master File (APIMF) from the API manufacturer, including both the open (applicant\u0019s) and restricted (confidential) parts.",
			"For stability data, gather information either in its entirety or organized per manufacturer, stability study protocol, and/or other distinguishing factors, as applicable.",
			"If no CEP is available, ensure that the full APIMF dossier is provided, including all supporting data and documentation.",
		],
		output: [
			"Include analytical procedures used only for stability studies in the designated stability section (3.2.S.7.3).",
			"Ensure that the APIMF or CEP documents are current and valid at the time of submission; expired or superseded versions must not be included.",
			"When summarizing data from other sections to support justification of specifications, include appropriate cross-references to the detailed information rather than duplicating content.",
			"For stability information in section 1.7, organize data either in its entirety or grouped per manufacturer, stability study protocol, or other distinguishing criteria, ensuring consistency with Appendix C guidance.",
			"If the drug substance is already approved, include a statement or documentation indicating consultation with the relevant health authority and any agreed submission approach.",
			"Ensure that the CTD section 1.7 follows the latest ICH M4 codification and revision numbering (e.g., M4(R3)) to maintain consistency with current regulatory standards.",
			"When multiple specifications exist for the drug substance (e.g., from manufacturer and applicant), ensure all are included in the relevant specification section and clearly identified.",
			"Ensure that sub-numbering within documents does not appear in the overall CTD Table of Contents but may be used internally (e.g., 3.2.P.3.3.1).",
			"Confirm that the CTD format used for section 1.7 aligns with the harmonized structure across ICH regions, while allowing for regional differences in content as permitted by M4 Q&As.",
			"If collated data from multiple batch analyses are presented, ensure they are clearly organized and placed in the batch analysis section (3.2.P.5.4).",
			"For a drug product supplied with reconstitution diluent(s), present the 'P' information for the diluent(s) in its entirety as separate drug product(s) within the CTD structure, as appropriate.",
			"Ensure that any references to ICH guidelines within section 1.7 use the updated codification system adopted in November 2005.",
			"Do not include modules or sections that are not used; omit them entirely rather than inserting 'not applicable' pages.",
			"Ensure that section 1.7 clearly identifies whether the API information is provided via an APIMF or a Certificate of Suitability (CEP).",
			"Include internal navigation bookmarks in PDFs for subsections that do not appear in the overall CTD TOC.",
			"Use a distinct identifier in headers or footers of every document; abbreviations are acceptable and the full report title is not required.",
			"Clearly indicate cross-references to the relevant sections of Module 3 (e.g., 3.2.S) where detailed API information is provided.",
			"Use consistent terminology and nomenclature for the API across all sections of the dossier.",
			"Include relevant chromatograms in the analytical procedure validation section (3.2.S.4.3).",
			"List any alternative analytical procedures used to control the drug product, along with their acceptance criteria, in the specification section (3.2.P.5.1).",
			"Ensure that results from all relevant batches (clinical, nonclinical, stability) are included in the batch analysis section (3.2.P.5.4) with full batch descriptions.",
			"Verify that all referenced documents (APIMF, CEP, Letters of Access) are legible, signed, and dated.",
			"Follow the CTD Module 1 structure and numbering conventions; section 1.7 should be a standalone subsection titled 'APIMFs and Certificates of Suitability to the Monographs of the European Pharmacopoeia'.",
			"Place information on historical analytical procedures used for batch analyses in the designated section (3.2.S.4.4) and not in the current specification section.",
			"Ensure that all documents are in the required electronic format (e.g., PDF) and comply with eCTD technical specifications for file naming and hyperlinking.",
			"Include results from tests not listed in the specification in the batch analysis section (3.2.P.5.4) if they are relevant to the justification of specifications.",
			"Ensure that confidential information from the restricted part of the APIMF is not included in the applicant\u0019s submission; only the open part should be attached.",
			"For a drug product containing more than one drug substance, ensure that the 'S' information is provided in its entirety for each drug substance in section 1.7, with appropriate cross-references to Module 3.",
			"If skip testing is applied, include a clear justification in the justification of specifications section (3.2.P.5.6).",
			"Ensure that analytical methods for the drug substance and drug product are described in both relevant sections (3.2.S and 3.2.P) even if they are identical, due to differences in sample preparation.",
			"Ensure that all Tables of Contents include module numbers, volume numbers, and tab identifiers, as required for CTD structure.",
			"List all analytical procedures used to control the drug substance in the specification, along with their acceptance criteria.",
			"Check that the presentation and formatting (pagination, headers, footers, section numbering) comply with regional CTD formatting standards.",
			"Attach copies of the relevant certificates (CEP) or Letters of Access (for APIMF) as appendices or annexes, as per regional submission requirements.",
			"For paper CTD submissions, paginate literature references using the original source pagination.",
			"Ensure that confidential information from the restricted part of the APIMF is not included in the applicant’s submission; only the open part should be attached.",
			"Provide the APIMF reference number, version/date, and Letter of Access details, or the CEP number, version/date, and issuing authority.",
			"For amendments or variations submitted in CTD format, follow the same CTD structure as for initial submissions, in accordance with regional guidance.",
			"List all observed impurities in the impurity characterization section (3.2.P.5.5), even if they are not included in the specification, and provide justification for their exclusion in the justification section (3.2.P.5.6).",
			"Ensure that both release and shelf-life specifications are clearly identified and included in the appropriate specification section (3.2.P.5.1).",
			"Ensure that confidential information from the restricted part of the APIMF is not included in the applicant\u0000s submission; only the open part should be attached.",
			"Include the name, address, and contact details of the API manufacturer and the holder of the APIMF or CEP.",
			"Verify that the dossier structure and numbering conform to the latest M4 guideline and its annexes, including the Granularity Document revisions.",
		],
	},
	{
		number: "1.8",
		title: "Good Manufacturing Practice (GMP)",
		input: [
			"Container closure system suitability studies including compatibility, sorption, leaching, moisture/light protection, material safety, and dose delivery performance",
			"Batch analysis data including batch descriptions, analytical results, and testing summaries for representative production and pilot batches",
			"Table of contents for Module 3 (Quality) to ensure correct placement of GMP documentation under section 1.8",
			"Data from constitution or dilution studies performed as part of formal stability studies to confirm product quality through shelf-life",
			"Proposals for reprocessing of materials with supporting justification and data",
			"Specifications, analytical procedures, validation data, and justification for excipients (including novel excipients)",
			"Full details of manufacture, characterisation, and controls for novel excipients with cross-references to supporting safety data (nonclinical and/or clinical)",
			"Cross-references to sections 3.2.S (Drug Substance) and 3.2.P (Drug Product) for manufacturing and control information relevant to GMP compliance",
			"Records of material rejection, reprocessing, reworking, recovery, and returns",
			"Traceability records for agents, brokers, traders, distributors, repackers, and relabellers",
			"Information on quality and control of intermediates isolated during the process",
			"Data supporting formulation development, including differences between clinical and commercial formulations",
			"Container closure system specifications including material identity, description, identification tests, and critical dimensions (with drawings where appropriate)",
			"Information on incompatible diluents",
			"Container closure integrity data for sterile products",
			"Justification data for proposed drug product specifications, including rationale for test selection, limits, and acceptance criteria",
			"List of all manufacturers, including contractors, with name, address, and description of responsibilities for manufacturing and testing",
			"Production operation records including time limits, in-process sampling plans, and in-process control data",
			"Post-approval stability protocol and stability commitment documentation",
			"Documentation of blending operations for intermediates or APIs, including rationale and control measures",
			"Justification data for numeric ranges for critical steps (to be cross-referenced with 3.2.P.3.4)",
			"Adventitious agent safety evaluation data from section 2.3.A.2 for inclusion or cross-reference in GMP documentation",
			"Facility and equipment diagrams showing material, personnel, and waste flow, including adjacent area relationships for contamination control",
			"Stability data and commitments from section 3.2.S.7 and 3.2.P.8 to confirm GMP-related stability practices",
			"Information on over-fill amounts in the manufacturing process",
			"Warehousing and distribution procedures for APIs and intermediates",
			"Data on compatibility of reconstitution diluents to support label claims",
			"Label issuance and control records for API and intermediate packaging",
			"Facility design and contamination control procedures (e.g., area classification, production scheduling, cleaning validation)",
			"Supporting information for justification of excipient specifications",
			"Details of each proposed production site or facility involved in manufacturing and testing",
			"Microbiological attribute data including preservative effectiveness and rationale for omission of microbial limits where applicable",
			"References to applicable pharmacopoeial monographs for excipients",
			"Narrative description of the manufacturing process including packaging, sequence of steps, scale of production, and details of novel processes or technologies",
			"Data supporting justification of any overages in the formulation",
			"Test methods, acceptance criteria, and supporting experimental data for critical steps in the manufacturing process",
			"Specifications and quality documentation for packaging materials used for APIs and intermediates",
			"Statement and supporting information regarding manipulation of ruminant-derived materials in the drug product manufacturing facility",
			"Manufacturing, quality, and validation records for APIs intended for use in clinical trials",
			"Development studies demonstrating the appropriateness of the dosage form, formulation, manufacturing process, container closure system, microbiological attributes, and usage instructions",
			"Validation and evaluation study reports for critical manufacturing steps or assays (e.g., sterilisation, aseptic processing, filling)",
			"Compatibility studies between drug substance and excipients, and between drug substances for combination products",
			"Equipment cleaning, sterilisation, and storage procedures and records",
			"Laboratory control records including testing of intermediates and APIs, certificates of analysis, stability monitoring data, expiry/retest dating, and reserve sample records",
			"Data on compatibility with co-administered drugs",
			"Description, documentation, and results of process validation and/or evaluation studies for critical steps or assays (e.g., sterilisation, aseptic processing, filling)",
			"Source information and control documentation for excipients of human or animal origin",
			"Reference standards or materials information from section 3.2.S.5 and 3.2.P.6 to support GMP traceability",
			"Stability study protocols, reports, and data (real-time, accelerated, in-use) including analytical methods and validation data",
			"Environmental condition requirements for specific products (e.g., low humidity for effervescent products)",
			"List of process parameters for each step (e.g., time, temperature, pH) with expected numeric ranges",
			"Rationale and data supporting choice and concentration of excipients",
			"Viral safety evaluation data if applicable (cross-reference to 3.2.A.2)",
			"Impurity characterization data for the drug product, including identification, quantification, and structural elucidation of impurities not covered in 3.2.S.3.2",
			"Validation data for non-compendial analytical methods used for container closure testing",
			"Comparative in vitro studies (e.g., dissolution) and comparative in vivo studies (e.g., bioequivalence), if conducted",
			"Drug product specifications, analytical procedures, validation data, batch analysis data, impurity characterisation data, and justification of specifications",
			"Complaint and recall records for APIs and intermediates",
			"Any regulatory correspondence or previous GMP inspection reports relevant to manufacturing sites",
			"Specifications for all excipients used in the dosage form",
			"Validation policy documents, validation protocols, qualification records, process validation program documentation, cleaning validation records, and analytical method validation reports",
			"Drug substance physicochemical characterization data (water content, solubility, particle size distribution, polymorphic/solid-state form)",
			"Identification of equipment by type and working capacity where relevant",
			"Specifications for excipients including tests, analytical procedures, and acceptance criteria for each quality attribute",
			"Contracts and quality agreements with contract manufacturers and laboratories",
			"Flow diagram of the manufacturing process showing process steps, material entry points, critical steps, and points of process/intermediate/final product controls",
			"Contamination control procedures and records for production areas and equipment",
			"Manufacturing process optimisation data and rationale for process selection",
			"Supporting information for validation of analytical procedures for excipients",
			"Adventitious agent risk assessment data and supporting documentation",
			"Cell bank maintenance records, cell culture/fermentation records, harvesting/isolation/purification records, and viral removal/inactivation validation data for APIs manufactured by cell culture/fermentation",
			"Relevant ICH guidelines (Q2A, Q2B, Q6A, Q6B) for reference during preparation",
			"Full qualitative and quantitative drug product batch formula as required under established conditions",
			"Reference standards or materials used for drug product testing, including certificates of analysis and validation data if not previously provided",
			"Information on other products manufactured or manipulated in the same facility areas",
			"Complete batch formula including all components of the dosage form, amounts per batch (including overages), and references to quality standards",
			"Data on differences between clinical batch manufacturing and commercial manufacturing relevant to performance",
			"Facility and equipment information from section 2.3.A.1 to support GMP compliance statements",
			"Physicochemical and biological performance data (pH, ionic strength, dissolution, reconstitution, particle size, aggregation, rheology, potency, immunological activity)",
			"Certificates of GMP compliance for manufacturing and testing facilities",
			"Information on excipients of human or animal origin including source, specifications, testing, and viral safety data",
			"Manufacturing process descriptions and process control data from section 3.2.S.2 and 3.2.P.3 for consistency verification in GMP section",
			"Analytical procedures for excipients when pharmacopoeial monographs do not exist (as referenced in ICH Q12 Chapter 3, section 3.2.3.2)",
			"Information on sterilisation methods where applicable",
			"Change control records for manufacturing and testing processes",
		],
		output: [
			"Provide batch analysis descriptions and results in section 3.2.P.5.4 referencing ICH Q3B, Q3C, Q6A, and Q6B",
			"Provide full details of manufacture, characterisation, and controls for novel excipients in section 3.2.P.4.6 with cross-references to safety data in 3.2.A.3",
			"Include information on facility design and contamination control measures (e.g., area classification, cleaning, production scheduling) in section 3.2.A.1",
			"Ensure that all GMP-related data (e.g., stability, reference standards, adventitious agent safety) are properly linked to their corresponding CTD sections",
			"For sterile products, address container closure integrity against microbial contamination",
			"Include procedures for rejection, reprocessing, reworking, recovery, and returns of materials",
			"Include analytical procedures for drug product testing in section 3.2.P.5.2 referencing ICH Q2A and Q6B",
			"Describe traceability, quality management, repackaging/relabelling/holding, stability, transfer of information, complaint/recall handling, and returns for agents, brokers, traders, distributors, repackers, and relabellers",
			"Ensure supportive information for analytical validation and specification justification is included and clearly cross‑referenced",
			"Ensure compliance with relevant ICH guidelines (Q2A, Q2B, Q6A, Q6B)",
			"Provide detailed description, documentation, and results of process validation and/or evaluation studies for critical steps or assays in section 3.2.P.3.5",
			"Ensure supportive information for analytical validation and specification justification is included and clearly cross\u0011referenced",
			"Provide drug product specifications in section 3.2.P.5.1 referencing ICH Q3B, Q6A, and Q6B",
			"Discuss compatibility of drug substance with excipients and with other drug substances (if combination products)",
			"Describe source and control measures for excipients of human or animal origin in compliance with applicable regulatory expectations",
			"Discuss comparative in vitro and in vivo study results where applicable",
			"Include overages in the batch formula in section 3.2.P.3.2 and identify over-fill in the manufacturing process description (3.2.P.3.3)",
			"Include analytical validation data for excipient testing methods in section 3.2.P.4.3 referencing ICH Q2A, Q2B, and Q6B",
			"Describe suitability of container closure system considering materials, protection, compatibility, safety, and performance",
			"Provide only brief descriptions for non-functional secondary packaging components and detailed information for functional ones",
			"Maintain consistency between GMP documentation and the Module 3 Table of Contents to ensure traceability of manufacturing and control information",
			"Cross-reference facility and equipment information from section 2.3.A.1 and manufacturing process descriptions from 3.2.S.2 and 3.2.P.3 to demonstrate GMP compliance",
			"Use clear, precise technical language consistent with GMP terminology",
			"Describe packaging and labelling operations for APIs and intermediates, including packaging material specifications, label issuance/control, and operational controls",
			"Include a statement on manipulation of ruminant-derived materials in the manufacturing facility in 3.2.P.3.3, and provide additional information in 3.2.A.1 and 3.2.A.2 if cross-contamination risk exists",
			"Follow CTD numbering and titling conventions when referencing or compiling GMP documentation to maintain regulatory consistency",
			"Include specific GMP guidance for APIs manufactured by cell culture/fermentation, covering cell bank maintenance, cell culture/fermentation, harvesting/isolation/purification, and viral removal/inactivation steps",
			"Maintain logical sequencing of manufacturing information from manufacturer details through process validation",
			"Include compatibility of reconstitution diluents, co-administered drugs, and incompatible diluents in the relevant section (3.2.P.2.6) with clear linkage to label claims",
			"Provide adventitious agent safety evaluation in section 3.2.A.2, assessing potential contamination risks",
			"Describe change control procedures for manufacturing and testing processes",
			"Include a clear flow diagram of the manufacturing process showing all steps, material entry points, and control points",
			"Include process validation/evaluation descriptions, documentation, and results for critical steps or assays",
			"Present post-approval stability protocol and stability commitment in section 3.2.P.8.2",
			"Identify all process controls in 3.2.P.3.3, with critical controls detailed in 3.2.P.3.4",
			"Include validation policy, documentation, qualification, process validation approaches/programs, periodic review of validated systems, cleaning validation, and analytical method validation",
			"Include storage and distribution procedures for APIs and intermediates, covering warehousing and distribution controls",
			"Include analytical validation data for drug product testing in section 3.2.P.5.3 referencing ICH Q2A, Q2B, and Q6B",
			"Discuss physicochemical and biological properties relevant to drug product performance",
			"Describe complaint handling and recall procedures for APIs and intermediates",
			"Include impurity characterisation information in section 3.2.P.5.5 referencing ICH Q3B, Q5C, Q6A, and Q6B",
			"Verify that all required data and justifications are included before finalizing the section",
			"Clearly describe and justify any reprocessing proposals, referencing supporting data",
			"Include analytical procedures for excipients in section 3.2.P.4.2 referencing ICH Q2A and Q6B",
			"Provide justification for excipient specifications in section 3.2.P.4.4 referencing ICH Q3C and Q6B",
			"Provide a description of batches and results of batch analyses in section 3.2.P.5.4, ensuring inclusion of representative production and pilot batches",
			"Include information on reference standards or materials used for testing in section 3.2.P.6, cross-referencing 3.2.S.5 if applicable",
			"Describe container closure systems in section 3.2.P.7, including material identity, specifications, and critical dimensions with drawings where appropriate",
			"Include requirements for contract manufacturers and laboratories, including quality agreements and oversight",
			"Discuss development studies clearly and distinguish them from routine control testing",
			"Discuss differences between clinical trial manufacturing and commercial manufacturing where relevant",
			"Document analytical procedures for excipients that lack pharmacopoeial monographs, ensuring alignment with ICH Q12 Chapter 3 section 3.2.3.2",
			"Summarize stability studies in section 3.2.P.8.1, including study types, protocols, results, and conclusions on storage conditions and shelf-life",
			"Explain and justify selection and optimisation of the manufacturing process",
			"List process parameters with numeric ranges; justify ranges for critical steps in section 3.2.P.3.4",
			"Provide excipient specifications in section 3.2.P.4.1 following ICH Q6A and Q6B",
			"State environmental conditions where relevant to product quality",
			"List excipient specifications in a clear, organized format",
			"Report constitution or dilution study data from formal stability studies in section 3.2.P.8.3, not in GMP section, but ensure cross-reference if relevant to GMP compliance",
			"Cross-reference viral safety evaluation to section 3.2.A.2 when applicable",
			"Cross-reference viral safety evaluation to section 3.2.A.2 if applicable",
			"Provide manufacturer information in a structured format including name, address, and responsibilities",
			"Discuss formulation and process attributes (critical parameters) impacting product performance and batch reproducibility",
			"Provide a detailed narrative description of the manufacturing process, including packaging, sequence, scale, and novel processes",
			"Ensure that established conditions (ECs) for manufacturing sites, batch formula, unit operations, controls of critical steps, and process validation are clearly identified and aligned with ICH Q12 expectations",
			"Ensure production operations are described including time limits, in-process sampling and controls, blending of intermediates/APIs, and contamination control measures",
			"Include GMP requirements for APIs intended for use in clinical trials, covering quality, equipment/facilities, raw material control, production, validation, changes, laboratory controls, and documentation",
			"For critical steps, provide tests, acceptance criteria, and justification with experimental data",
			"Present excipient specifications with test methods and acceptance criteria per quality attribute in a structured format",
			"Describe laboratory controls for intermediates and APIs, including testing, certificates of analysis, stability monitoring, expiry/retest dating, and reserve sample management",
			"Present batch formula in tabular form with all components, amounts per batch, overages, and quality standard references",
			"Provide a brief but complete summary of formulation development including differences between clinical and commercial formulations",
			"Identify equipment by type and working capacity where relevant",
			"For intermediates, describe quality and control measures",
			"Ensure all diagrams, tables, and descriptions are consistent and cross-referenced correctly",
			"Provide summary descriptions of product-contact equipment, including use (dedicated or multi-use), cleaning, sterilisation, and storage procedures",
			"Justify any overages included in the formulation",
			"Include facility and equipment diagrams in section 3.2.A.1 showing material, personnel, and waste flow, and adjacent area relationships",
			"Discuss microbiological attributes including rationale for microbial limits testing decisions and preservative effectiveness",
			"Provide justification for proposed drug product specifications in section 3.2.P.5.6, referencing relevant ICH guidelines (Q3B, Q6A, Q6B)",
			"Ensure the GMP section (1.8) aligns structurally with the CTD Module 3 organization, referencing relevant subsections (3.2.S, 3.2.P, 2.3.A) where applicable",
			"Include validation data for non-compendial analytical methods used for container closure testing",
			"Provide justification for drug product specifications in section 3.2.P.5.6 referencing ICH Q3B, Q6A, and Q6B",
			"Describe reprocessing within the manufacturing process description (3.2.P.3.3), include critical controls in 3.2.P.3.4, and validation information in 3.2.P.3.5 if warranted",
			"Include impurity characterization information in section 3.2.P.5.5 if not already provided in 3.2.S.3.2, clearly identifying impurity sources and analytical methods",
			"Include information on excipients of human or animal origin in section 3.2.P.4.5 referencing ICH Q5A, Q5D, and Q6B",
			"Ensure all sections reference applicable ICH guidelines (Q1A, Q1B, Q2A, Q2B, Q3B, Q3C, Q5C, Q6A, Q6B) as appropriate",
			"Reference pharmacopoeial monographs clearly where applicable for excipient specifications and analytical procedures",
			"Present stability data in section 3.2.P.8.3 in tabular, graphical, or narrative format, including analytical procedures and validation information",
			"Ensure supportive information for analytical validation and specification justification is included and clearly cross-referenced",
			"Include information on other products manufactured or manipulated in the same areas to assess cross-contamination risk",
			"Explain choice, concentration, and functional attributes of excipients",
		],
	},
	{
		number: "1.9.1",
		title: "List of Countries in EAC and Countries With SRAs In Which A Similar Application has been Submitted",
		input: [
			"Collect internal policy documents or SOPs that describe the sponsor's approach to regulatory and ethical compliance in clinical trials.",
			"If no similar applications have been submitted, confirm and document that the section will be marked as 'Not applicable'.",
			"Collect ISO 3166 Alpha-2 country codes for all listed countries to ensure standardized identification.",
			"Obtain submission details or confirmation letters from affiliates or partners confirming submission in each listed country.",
			"Gather descriptions or summaries of country/region-specific requirements that are not tied to specific protocol items.",
			"Collect a complete list of East African Community (EAC) countries where the same or similar application has been submitted.",
			"Collect ISO 3166 region codes (Alpha-2 and Alpha-3) if regional identifiers are used instead of country identifiers.",
			"Collect the Local Sponsor Name for each country or region where the sponsor has a legal representative or local affiliate.",
			"Gather descriptions or summaries of country/region-specific protocol clarifications related to specific protocol items.",
			"Review supportive data from Section 2.7.2 (Summary of Clinical Efficacy) if relevant to confirm consistency of country listings and submission scope.",
			"Gather applicable prevailing ethical guidelines, legal frameworks, and regulatory standards that will be applied throughout the trial for inclusion in the high-level statement.",
			"Check that all listed countries correspond to actual submissions and that supporting documentation is available for verification.",
			"Gather regulatory correspondence or acknowledgement letters from EAC or SRA authorities confirming receipt or status of similar applications.",
			"Gather internal records or agreements identifying local affiliates or designees acting as the sponsor in specific countries.",
			"Collect ISO 3166 Alpha-3 country codes for all listed countries, as these may also be acceptable identifiers per controlled terminology.",
			"Retrieve internal regulatory tracking data or submission logs showing submission dates, dossier versions, and reference numbers for each country.",
			"Collect the Local Sponsor Address corresponding to each Local Sponsor Name, ensuring it reflects the legally registered address of the local representative.",
			"Obtain documentation confirming the legal status of the local sponsor or representative in each country where the sponsor has no legal presence.",
			"If applicable, gather documentation or explanations of country/region-specific differences in requirements (e.g., document retention, contraception requirements).",
			"Collect a list of countries with Stringent Regulatory Authorities (SRAs) where a similar application has been submitted.",
		],
		output: [
			"Applicants may modify the format of the section if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation by regulatory reviewers.",
			"Maintain one-to-many cardinality: multiple countries or regions may be listed under this section.",
			"Ensure alignment with controlled terminology concept CNEW when describing region-specific requirements or clarifications.",
			"Include a heading titled 'List of Countries in EAC and Countries With SRAs In Which A Similar Application has been Submitted'.",
			"Ensure consistency with controlled terminology (C20108, CNEW) and ISO 3166 country/region identifiers.",
			"Follow repeatability rules: content may be repeated for each country/region as needed.",
			"Verify that the section conforms to the CTD structure and hierarchy (linked to section 12.2 Country/Region-Specific Differences).",
			"Include country/region-specific protocol clarifications when applicable, written in text format and referencing relevant protocol sections.",
			"Refer to regional guidance to determine when one or multiple documents should be provided under this section.",
			"Ensure compliance with business rules linking section 1.9.1 content to protocol hierarchy section 12.2 when differences are described.",
			"Ensure that the 'Regulatory and Ethical Considerations' subheading is included exactly as specified, with no modifications.",
			"Do not repeat or reuse content from other sections; this section should be unique to the list of countries.",
			"Verify that the section complies with business rules: Value Allowed = Yes for Local Sponsor Name and Address fields, and that relationships to Sponsor Name, Address, and Country are correctly represented.",
			"Ensure that the Local Sponsor Name and Local Sponsor Address fields are completed when applicable, particularly when the sponsor has no legal presence in the country.",
			"Ensure that any repeated or separate sections maintain the complete structure and required subsections of the original section format.",
			"Repeat the Local Sponsor Name field for each applicable local sponsor, as it is repeatable per country or region.",
			"Follow regional guidance when determining whether to combine or separate information for different product presentations or manufacturing schemes.",
			"Ensure that the section is optional only if there are no country/region-specific differences or no similar applications submitted.",
			"Ensure that the Local Sponsor Name and Address information is aligned with the Title Page hierarchy and correctly linked to the Sponsor Name and Country fields.",
			"Provide a high-level statement under 'Regulatory and Ethical Considerations' summarizing the prevailing ethical, legal, and regulatory guidelines applied throughout the trial.",
			"If country/region-specific differences exist, include a reference to the relevant section of the protocol where the differing requirement applies.",
			"Verify that identifiers correspond to the correct data type (valid value) and meet the relationship rules defined under the Title Page hierarchy.",
			"Do not include additional attachments in this CTD section unless explicitly required by regional guidance.",
			"Ensure that the Local Sponsor Name and Address fields are optional but included when a local affiliate or designee acts as the sponsor in a specific country.",
			"Ensure that the 'TRIAL OVERSIGHT AND OTHER GENERAL CONSIDERATIONS' heading is included exactly as specified, with no additional text in the heading itself.",
			"Ensure that any supportive data referenced from Section 2.7.2 is cited appropriately and that cross-references are accurate and traceable.",
			"Ensure that the content under 'Regulatory and Ethical Considerations' aligns with controlled terminology concept CNEW and is presented as text.",
			"List each country or region using the ISO 3166 Alpha-2 country or region code format.",
			"Follow granularity document guidance regarding document hierarchy, location, and pagination to ensure proper CTD structure.",
			"If regional identifiers are used instead of country identifiers, ensure that ISO 3166 region codes (Alpha-2 or Alpha-3) are applied correctly.",
			"When repeating a section for clarity, add a distinguishing title in parentheses following the CTD heading to indicate the specific scope or context.",
			"If country/region-specific clarifications are not applicable, retain the heading and enter 'Not applicable'.",
			"Ensure that headings are marked as non-repeatable and conform to the CTD Table of Contents structure.",
			"Check that all listed countries correspond to actual submissions and that supporting documentation is available for verification.",
			"Allow the use of ISO 3166 Alpha-3 country codes in addition to Alpha-2 codes when identifying countries, consistent with controlled terminology C20108.",
			"Ensure that Local Sponsor Name and Address entries conform to controlled terminology concept CNEW and are presented as text values.",
			"Ensure that the section is optional only if there are no similar applications submitted.",
			"Use clear, concise, and standardized language when listing countries or regions.",
			"Follow one-to-one cardinality for the 'TRIAL OVERSIGHT AND OTHER GENERAL CONSIDERATIONS' heading and its subheading 'Regulatory and Ethical Considerations' as per protocol hierarchy.",
			"Ensure conformance with the allowed identifier values (country, region, or site) and confirm they align with controlled terminologies C20108 and CNEW.",
			"Avoid unnecessary duplication of identical information; present common data once and separate only the differing information under the appropriate subsections.",
			"If no similar applications exist, retain the heading and enter 'Not applicable'.",
			"Do not include extraneous or unrelated information under the 'Regulatory and Ethical Considerations' section; focus on ethical, legal, and regulatory aspects only.",
			"Applicant logos may be placed on top of the CTD but must not be added to CTD section titles, which must remain harmonized and unmodified.",
			"Ensure that the data type for each country/region identifier is a valid value conforming to ISO 3166 Alpha-2 standards.",
			"Follow one-to-one cardinality between Local Sponsor Name and Local Sponsor Address; each Local Sponsor Name must have a corresponding address.",
			"Do not repeat or reuse the Local Sponsor Address field; it is non-repeatable and must correspond uniquely to each Local Sponsor Name.",
			"Ensure that repeated sections are only created when justified by differences in content that cannot be clearly presented within a single section.",
			"Consult the CTD Granularity Document Annex for rules on when multiple documents per heading may be provided.",
			"Include country/region-specific requirement descriptions when applicable, ensuring they are written in text format.",
			"Do not include 'not applicable' pages for unused CTD headings when preparing amendments or variations, as the CTD structure itself is sufficient without placeholder pages.",
		],
	},
	{
		number: "1.9.2",
		title: "Evaluation Reports from EAC-NMRA",
		input: [
			"Assemble patient data listings required by the evaluation report, including discontinued patients, protocol deviations, patients excluded from efficacy analysis, demographic data, compliance/drug concentration data, individual efficacy response data, adverse event listings, and individual laboratory measurements by patient.",
			"Obtain any pertinent animal data or product quality information that may have clinical implications and are referenced in the evaluation report.",
			"Ensure availability of the final approved product information (SmPC, PIL, labelling) if referenced in the evaluation report.",
			"Gather literature references cited in the Clinical Overview that support clinical conclusions or contextualize findings.",
			"Gather any individual patient data listings required for archival purposes (e.g., US archival listings) if referenced in the evaluation report.",
			"Gather all relevant data tables, datasets, statistical analyses, and test results cited in the EAC-NMRA evaluation report.",
			"Collect copies of previous submissions or dossiers reviewed by EAC-NMRA that are referenced in the evaluation report.",
			"Assemble supporting technical documents referenced in the evaluation report, such as clinical study reports, non-clinical study reports, bioequivalence study reports, and stability study reports.",
			"Obtain the official evaluation report(s) issued by the EAC-NMRA for the product under registration or variation.",
			"Obtain all tables, figures, and graphs referred to in the evaluation report but not included in the main text, including demographic, efficacy, and safety data.",
			"Gather detailed safety data displays, including adverse event tables, listings of deaths and other serious/significant adverse events, narratives of such events, and abnormal laboratory value listings for each patient.",
			"Collect all clinical study reports from Module 5, including biopharmaceutical studies, pharmacokinetic (PK), pharmacodynamic (PD), efficacy, and safety studies relevant to the evaluation report.",
			"Gather the comprehensive Clinical Summary (Module 2.7) and individual clinical study reports (ICH E3) referenced in the Clinical Overview.",
			"Collect all appendices referenced in the evaluation report, including study protocols and amendments, sample case report forms, IEC/IRB lists and chair names, patient information sheets, consent forms, investigator lists and CVs, investigator or sponsor medical officer signatures, batch-to-patient listings, randomisation schemes and codes, audit certificates, documentation of statistical methods, inter-laboratory standardisation and quality assurance procedures, and relevant publications.",
			"Obtain any annexes referenced in the evaluation report, such as synopsis, investigator signatures, study design and schedule of assessments, patient disposition listings, and guidance documents for statistical/analytical issues.",
			"Obtain any legal documents required to share or reproduce the EAC-NMRA evaluation report, such as authorization letters or confidentiality agreements.",
			"Assemble data from post-marketing experience reports, if referenced in the evaluation report.",
			"Collect literature references or expert opinions cited in the evaluation report.",
			"Gather any regulatory correspondence from EAC-NMRA related to the evaluation process, including queries, responses, and meeting minutes.",
			"Collect any separate integrated analysis reports (e.g., ISE or ISS) when statistical output is too extensive for inclusion in the summary document, ensuring placement in Module 5.3.5.3.",
			"Gather microbiology data from both in vitro and in vivo studies if referenced in the evaluation report, ensuring summary information is available for Module 2.7 Clinical Summary and detailed reports for Module 5.3.5.4 Other Study Reports.",
			"Collect case report forms for deaths, other serious adverse events, and withdrawals due to adverse events, as well as any other CRFs submitted.",
		],
		output: [
			"Include a discussion of the overall clinical development approach, including rationale for key study design decisions.",
			"Verify that the evaluation report file naming and placement comply with eCTD granularity and submission-level rules (documents written at this level must be submitted at the higher level if required).",
			"If the evaluation report is in a non-English language, provide a certified translation alongside the original document.",
			"Ensure the document is legible, with all tables, figures, and appendices from the original report included and clearly reproduced.",
			"For eCTD submissions, confirm that the evaluation report is submitted at the correct granularity level as per eCTD v3.2.2 specifications (i.e., one document may be submitted at this level).",
			"When including patient data listings, CRFs, and annexes, ensure they are complete, legible, and formatted consistently with the rest of the evaluation report.",
			"Include a structured evaluation of benefits and risks, explaining how efficacy and safety findings support the proposed dose and indication.",
			"Maintain consistency between the evaluation report and the Clinical Overview in terms of conclusions, benefit-risk assessment, and data interpretation.",
			"Ensure that the evaluation report or Clinical Overview section provides a critical analysis of clinical data rather than a repetition of detailed results.",
			"Ensure the evaluation report is presented in full, without alteration of EAC-NMRA content, maintaining original wording and conclusions.",
			"Ensure that all referenced tables, figures, graphs, and appendices in the evaluation report are included in the submission, properly labeled, and placed in the correct sequence as per the original report.",
			"Ensure that the evaluation report is placed correctly within the CTD structure according to Module 1.9.2 requirements and consistent with the overall CTD table of contents.",
			"Provide a concise overview of clinical findings, highlighting important limitations such as missing populations, endpoints, or comparator data.",
			"For paper submissions, when using cross strings, include only the section number in the cross string and write the text so the reader understands the section content without the full section name.",
			"Clearly identify the source, date, and reference number of the EAC-NMRA evaluation report on the cover page or in the header.",
			"Ensure that the Clinical Overview or evaluation summary is succinct, interpretive, and aligned with the comprehensive Clinical Summary and individual study reports.",
			"For paper CTD submissions, include module numbers, volume numbers, and tab dividers in all tables of contents, including Module 1 and subsequent modules.",
			"When sub-numbering within the evaluation report is needed for navigation, use lower-level numbering (e.g., 1.9.2.1, 1.9.2.2) within the document but do not include these in the overall CTD table of contents; they may be included as bookmarks in the PDF.",
			"When microbiology data are included, ensure summary information is placed in Module 2.7 Clinical Summary and detailed reports in Module 5.3.5.4, with cross-references to relevant nonclinical sections if applicable.",
			"Discuss unresolved issues, justify why they are not barriers to approval, and outline plans for resolution.",
			"Present conclusions and implications of the data clearly, focusing on interpretation rather than data recapitulation.",
			"Maintain pagination consistent with the original EAC-NMRA document; if re-paginated, provide a concordance table.",
			"Ensure that literature references included in the evaluation report are paginated according to the original source (journal, abstract, etc.) rather than restarting page numbering.",
			"If the evaluation report is provided as a scanned document, ensure high-resolution, searchable PDF format is used.",
			"Verify that all subsections within the evaluation report (including signal-related assessments such as actions taken or planned) are complete and accurately reflected in the reproduced document.",
			"Address specific efficacy or safety issues encountered during development and describe how they were evaluated and resolved.",
			"Include a distinct identifier (e.g., abbreviated title or report number) in the header or footer of each page of the evaluation report for traceability; the full title is not required.",
			"Assess and document the quality of study design and performance, including a statement on GCP compliance.",
			"Ensure that the evaluation report document is formatted consistently with other Module 1 documents, following EAC-NMRA and regional guidance on structure and presentation.",
			"Cross-reference the evaluation report appropriately within the CTD, ensuring consistency with related sections (e.g., clinical, non-clinical summaries).",
			"If integrated analyses (ISE/ISS) contain extensive statistical output unsuitable for Module 2.7, prepare a separate report for Module 5.3.5.3 and summarize appropriately in Module 2.7.",
			"For paper submissions, ensure that the evaluation report is listed in the Module 1 table of contents, as the TOC is required only for paper CTDs.",
			"Maintain the numbering and titles of appendices, patient data listings, and annexes exactly as in the original evaluation report to preserve traceability.",
			"Explain the basis for any unusual or critical aspects of the prescribing information derived from the evaluation report.",
			"Ensure that the layout and page design of the evaluation report are consistent across the dossier, allowing for minor differences between report types (e.g., clinical vs. quality sections) as long as identifiers are clear.",
			"If the evaluation report includes summaries of key data or rationales for further evaluation, reproduce them exactly as issued, ensuring no modifications are made.",
			"Verify that confidential information is handled according to applicable regulations and agreements before submission.",
			"Include the complete document structure as issued by EAC-NMRA, preserving headings, subheadings, and numbering.",
			"If the evaluation report references ICH E3 clinical study report structure, ensure that any included appendices or data listings follow the ICH E3 format and numbering conventions.",
			"Ensure that the included evaluation report contains the required sections such as 'Reason for Evaluation' and 'Actions Taken or Planned', as these are expected components of the EAC-NMRA evaluation format.",
		],
	},
	{
		number: "1.9.3",
		title: "Evaluation Reports from SRAs",
		input: [
			"Gather nonclinical study data (e.g., repeat-dose toxicity, carcinogenicity, Segment 2 reproductive toxicity studies) referenced in SRA evaluation reports to verify consistency with CTD nonclinical summaries.",
			"Gather copies of marketing authorization approvals, assessment reports, or summary basis of approval documents from SRAs.",
			"Gather the Clinical Overview (Module 2.5) and Clinical Summary documents referenced in the CTD to ensure consistency with SRA evaluation conclusions.",
			"Collect impurity data tables and related analytical information for drug substance batches used in toxicology studies if referenced in SRA evaluation reports.",
			"Gather tabulated summaries of nonclinical studies (e.g., toxicity, pharmacology) that may have been included or referenced in SRA evaluation reports for cross-verification.",
			"Obtain any footnotes or annotations used in impurity data tables to identify batches relevant to impurity qualification, if included in SRA evaluation documentation.",
			"Ensure appendices for study reports are organized in accordance with the ICH E3 guideline, including synopsis, main body, and appropriate appendices.",
			"Collect translations of SRA evaluation reports if they are not in English, ensuring certified translation accuracy.",
			"Compile a list of all literature references cited in the SRA evaluation reports for inclusion in the table of contents.",
			"Gather complete study reports for any studies referenced in the SRA evaluation reports, ensuring each study report is available as a single document unless large size requires splitting.",
			"Gather final summary study reports associated with CAD submissions when they are part of the documentation reviewed by SRAs.",
			"If large study reports are split, ensure the text portion is one document and appendices are in one or more separate documents.",
			"Collect supporting regulatory documents such as Certificates of Pharmaceutical Product (CPP), Good Manufacturing Practice (GMP) certificates, and other SRA-issued certifications if referenced in the evaluation reports.",
			"Gather any expert opinions or summaries prepared by SRAs or recognized experts that were part of the evaluation process.",
			"Obtain the complete list of clinical studies included in Module 5, including bioavailability, bioequivalence, pharmacokinetic, pharmacodynamic, efficacy, and safety studies, for cross-reference with SRA evaluation reports.",
			"Ensure that all referenced documents (e.g., study reports, clinical summaries, non-clinical summaries) cited in the SRA evaluation reports are available for verification.",
			"Obtain evaluation reports issued by Stringent Regulatory Authorities (SRAs) such as FDA, EMA, MHRA, PMDA, Health Canada, or other recognized agencies.",
			"Compile literature references listed in the CAD-related section of regulatory guidance, if they are cited or relevant to the SRA evaluation reports being included.",
			"Gather complete study reports for any non-clinical studies referenced in the SRA evaluation reports, including carcinogenicity studies, ensuring each is available as a single document unless large size requires splitting.",
			"Collect all correspondence and official communications between the applicant and SRAs related to the product evaluation.",
			"Ensure availability of the same product dossier or submission package that was reviewed by the SRA for cross-reference.",
			"Gather Carcinogenicity Assessment Documents (CADs) referenced in SRA evaluation reports or required for cross-verification.",
			"Ensure availability of any post-marketing experience reports or pharmacovigilance data referenced in the SRA evaluation reports.",
			"Collect all individual clinical study reports (ICH E3 format) that were part of the SRA evaluation to verify alignment with the evaluation findings.",
			"Collect 2-year rat carcinogenicity study full reports or executive summaries when applicable, especially if referenced in SRA evaluation reports.",
			"Gather any relevant literature references cited in the Clinical Overview or Clinical Summary that may have been considered by SRAs during evaluation.",
			"Compile any inspection reports, deficiency letters, or responses exchanged with SRAs relevant to the product evaluation.",
		],
		output: [
			"Cross-reference the SRA evaluation reports to relevant CTD sections (e.g., clinical, non-clinical, quality) where applicable.",
			"If multiple SRA reports exist, organize them by authority and date of approval in a logical sequence.",
			"For large non-clinical study reports (e.g., carcinogenicity studies), follow the same splitting rule as for clinical studies: one text document and one or more appendix documents.",
			"Verify that the Clinical Overview (Module 2.5) and Clinical Summary are consistent with the conclusions presented in the SRA evaluation reports, particularly regarding benefit-risk assessment and clinical interpretation.",
			"Ensure that all documents are legible, complete, and formatted consistently with CTD Module 1 presentation standards (pagination, margins, and section numbering).",
			"For study reports referenced in SRA evaluation reports, provide them as a single document per study unless the report is large, in which case split into one text document and one or more appendix documents.",
			"Clearly identify the indication or product version evaluated by each SRA, ensuring traceability to the corresponding CTD sections.",
			"Follow the recommended CTD tabulated summary templates for nonclinical data presentation but modify the format as needed to best facilitate understanding and evaluation of results.",
			"Ensure literature references are listed in the tables of contents for the section, in compliance with Note 2 requirements.",
			"When providing study reports, ordinarily structure them as multiple documents: a synopsis, a main body, and appropriate appendices, with appendices organized per ICH E3 guideline.",
			"Include a brief introductory note or cover page summarizing the source, date, and scope of each SRA evaluation report.",
			"Ensure that the organization of SRA evaluation reports aligns with the CTD Module 5 structure, facilitating traceability between evaluation conclusions and underlying clinical study reports.",
			"Maintain the current CTD numbering and structure when including evaluation reports from SRAs under section 1.9.3.",
			"Confirm that the inclusion of SRA evaluation reports complies with local regulatory authority requirements for acceptance of foreign assessments.",
			"Follow CTD general expectations that module numbers, volume numbers, and tab identifiers should be included in any tables of contents associated with the section, if applicable.",
			"Confirm that the presentation of SRA evaluation reports supports regulatory reviewers in linking the evaluation findings to the CTD’s clinical data structure.",
			"For paper CTD submissions, include a table of contents for Module 5; for eCTD submissions, no Module 5 TOC entry is required.",
			"For paper CTD submissions, a table of contents for Module 4 is required; for eCTD submissions, no Module 4 TOC entry is needed.",
			"Ensure that for paper submissions, literature references included or cited in SRA evaluation reports retain the original page numbering of the published source.",
			"Include a list of references for nonclinical summaries if referenced in SRA evaluation reports, even though not explicitly required by CTD guidance, to maintain traceability and completeness.",
			"When including cross-references to other CTD sections within 1.9.3, use section numbers (without long section titles) in alignment with CTD cross-string recommendations to maintain clarity and avoid overly long references.",
			"When including impurity data tables, use footnotes to identify batches relevant to impurity qualification if analytical methods have changed during development.",
			"When splitting large study reports, ensure that the separation between text and appendices is clear and consistent.",
			"Ensure that any references to clinical data in the SRA evaluation reports correspond accurately to the relevant sections of Module 5 (e.g., 5.3.1–5.3.7).",
			"Ensure that all translations, if applicable, are certified and clearly labeled as translations of official SRA documents.",
			"Ensure that any sub-numbering used within the SRA evaluation report documents (e.g., 3.2.P.3.3.1, 3.2.P.3.3.2) does not appear in the overall CTD table of contents but may be used internally for navigation.",
			"Maintain section headings for any nonclinical study categories not conducted (e.g., carcinogenicity) and provide a brief explanation for their omission rather than deleting the heading or renumbering subsequent sections.",
			"Ensure that the evaluation reports are presented in their entirety or as officially authorized summaries without modification of content.",
			"Maintain consistency in terminology and study identifiers between the SRA evaluation reports and the CTD clinical study listings.",
			"If impurity data from non-GLP studies are available, include them in the relevant tables even though such analyses are not mandatory.",
			"Verify that confidential or proprietary information is redacted in accordance with SRA disclosure policies and local regulatory requirements.",
			"Consider document granularity carefully, as any relevant lifecycle changes will require replacement of complete documents/files.",
			"Include distinct identifiers in headers or footers of all SRA evaluation report pages; abbreviations may be used instead of full report titles to maintain readability.",
			"Ensure that tabulated summaries of nonclinical data include only noteworthy or toxicologically significant findings, including statistically significant differences or other relevant observations.",
			"Ensure that literature references cited in SRA evaluation reports are listed in the table of contents.",
		],
	},
	{
		number: "1.9.4",
		title: "Manufacturing and Marketing Authorization",
		input: [
			"Gather excipient specifications, including test methods, acceptance criteria, and references to pharmacopoeial monographs where applicable.",
			"Obtain the Recommended International Nonproprietary Name (INN) for the drug substance.",
			"Refer to Appendix A for additional regulatory or procedural guidance relevant to manufacturing and marketing authorization.",
			"For biotech products, prepare a flow diagram illustrating the manufacturing route from original inoculum to last harvesting operation, including all steps, intermediates, and relevant parameters (population doubling levels, cell concentration, volumes, pH, cultivation times, holding times, temperature).",
			"Compile a list of physicochemical and other relevant properties of the drug substance, including biological activity for biotech products.",
			"Collect regulatory approvals or certificates from competent authorities confirming manufacturing and marketing authorization status.",
			"Consult the health authority for guidance if the drug substance is already approved, to determine if additional manufacturing or marketing authorization documentation is required.",
			"Identify and justify any reprocessing steps, with supporting data referenced or filed in section 3.2.S.2.5.",
			"Collect other non-proprietary names such as national names, USAN, JAN, BAN.",
			"Gather the structural formula, including relative and absolute stereochemistry, molecular formula, and relative molecular mass for NCEs.",
			"Prepare a flow diagram of the synthetic process(es) for NCEs, including molecular formulae, weights, yield ranges, chemical structures of starting materials, intermediates, reagents, stereochemistry, operating conditions, and solvents.",
			"Obtain the Chemical Abstracts Service (CAS) registry number for the drug substance.",
			"For biotech products, obtain the schematic amino acid sequence indicating glycosylation sites or other posttranslational modifications and relative molecular mass.",
			"Gather supportive information for validation of analytical procedures and justification of specifications.",
			"For biotech products, gather detailed information on the manufacturing process from cell bank vial(s) through cell culture, harvest, purification, modification reactions, filling, storage, and shipping conditions.",
			"Gather the drug product batch formula, including qualitative and quantitative composition.",
			"Collect detailed descriptions of any alternate manufacturing processes with the same level of detail as the primary process.",
			"Collect evidence of compliance with local and international regulatory requirements for manufacturing and marketing.",
			"Gather technical documentation describing the manufacturing process, process controls, and quality systems in place at authorized sites.",
			"Gather the chemical name(s) of the drug substance.",
			"Gather specifications, analytical procedures, and acceptance criteria for critical steps and intermediates, including storage conditions of critical intermediates.",
			"Obtain copies of GMP (Good Manufacturing Practice) certificates for each manufacturing site.",
			"Collect information on excipients of human or animal origin, including source and control measures.",
			"Collect references to pharmacopoeial monographs or, if none exist, analytical procedures as per ICH Q12 Chapter 3, section 3.2.3.2.",
			"Collect any relevant compendial name(s) for the drug substance.",
			"Obtain copies of the current manufacturing authorization/licence for each manufacturing site involved in the product lifecycle.",
			"Collect detailed descriptions of individual unit operations and their sequence in the manufacturing process.",
			"Collect information on drug product manufacturing sites, including those for testing, primary and secondary packaging, and device assembly for combination products.",
			"Gather details of all manufacturing sites, including names, addresses, and scope of authorized activities.",
			"Collect any previous regulatory correspondence related to manufacturing or marketing authorization.",
			"Obtain the company or laboratory code for the drug substance.",
			"Prepare an explanation of the batch numbering system, including pooling of harvests or intermediates and batch size or scale.",
			"Prepare a sequential procedural narrative of the manufacturing process for NCEs, including quantities of raw materials, solvents, catalysts, reagents, representative batch scale, critical steps, process controls, equipment, and operating conditions.",
			"Obtain copies of agreements or contracts with contract manufacturing organizations (CMOs) or marketing partners.",
			"Obtain copies of the current marketing authorization/licence for the product in relevant jurisdictions.",
			"Collect supportive information for process validation and/or evaluation.",
			"Gather the name, address, and responsibility of each manufacturer, including contractors, and each proposed production site or facility involved in manufacturing and testing.",
			"Gather legal documents such as letters of authorization or power of attorney if manufacturing or marketing rights are delegated to third parties.",
		],
		output: [
			"Ensure that the information provided aligns with applicable ICH guidelines where available.",
			"For nomenclature, present all required names and identifiers in a clear, standardized format.",
			"Ensure that manufacturing site information includes testing, packaging, and device assembly sites for combination products, consistent with ICH Q12 guidance.",
			"Clearly identify the section as 'Manufacturing and Marketing Authorization' in the CTD structure under 1.9.4.",
			"Maintain consistent terminology for site names, product names, and authorization numbers throughout the dossier.",
			"Include specifications for critical steps and intermediates, including analytical procedures, acceptance criteria, and storage conditions, formatted in tabular or structured form.",
			"Confirm that the structure and content of this section align with the CTD module hierarchy and numbering conventions.",
			"For structure information, present diagrams and molecular or amino acid sequences clearly, with appropriate annotations for stereochemistry or modifications.",
			"Present documents in the format required by the regulatory authority (e.g., PDF, scanned copies with certification if applicable).",
			"Verify that all manufacturing sites listed have valid GMP certification and that the scope matches the activities described.",
			"If more than one facility is involved, provide documents per facility as per Note 11 guidance and reference Appendix F.",
			"Include a clear and complete Table of Contents for Module 3 in the dossier.",
			"List all marketing authorizations with jurisdiction, authorization number, date of issue, and scope of authorization.",
			"Ensure that all marketing authorizations listed are current and correspond to the product and dosage forms described in the dossier.",
			"If applicable, reference Appendix C or other appendices cited in the CTD for cross-referenced information, ensuring proper linkage and consistency.",
			"Ensure that the section follows the CTD-Q structure and that lower-level headings do not contain unnecessary or individual files, as per Note 4 guidance.",
			"For manufacturer information, clearly state the name, address, and responsibilities of each manufacturer, including contractors, in a consistent format.",
			"Describe alternate processes with the same level of detail as the primary process and clearly identify and justify any reprocessing steps.",
			"For general properties, list physicochemical and other relevant properties in a structured and concise manner, referencing ICH Q6A and Q6B as applicable.",
			"List all manufacturing sites with their full legal names, physical addresses, and the specific manufacturing activities they are authorized to perform.",
			"If no pharmacopoeial monograph exists for an excipient, reference the analytical procedure as per ICH Q12 Chapter 3, section 3.2.3.2.",
			"Ensure that lower-level CTD-Q headings under section 1.9.4 do not contain individual documents or files, as per Note 4 guidance.",
			"For stability-related information in this section, organize data either in its entirety or per manufacturer, stability study protocol, or other distinguishing information, referencing Appendix C as applicable.",
			"Ensure that where multiple container closure systems are involved, information is organized either in its entirety or per system or other distinguishing information, as per Note 9 guidance and Appendix E.",
			"For manufacturing process descriptions, include both flow diagrams and detailed procedural narratives, ensuring completeness and clarity.",
			"Provide supportive information for process validation and/or evaluation in a concise and referenced manner.",
			"Clearly explain the batch numbering system, including pooling and scale information, in a way that is understandable and traceable.",
			"Describe the manufacturing process by listing individual unit operations in sequence, ensuring clarity and traceability.",
			"If the product includes a reconstitution diluent, ensure that information related to the diluent is provided in its entirety as a separate drug product, as appropriate, following Note 6 guidance.",
			"Clearly identify excipients of human or animal origin and describe their source and control measures in compliance with applicable regulatory standards.",
			"Organize manufacturing authorizations and marketing authorizations separately, with clear headings and subheadings.",
			"For excipient specifications, list each quality attribute with corresponding test methods and acceptance criteria, referencing pharmacopoeial monographs where applicable.",
			"If the product has multiple components (e.g., combination products), provide documents per component as per Note 12 guidance and reference Appendix F.",
			"Present the drug product batch formula in both qualitative and quantitative terms, clearly labeled and consistent with manufacturing documentation.",
			"Include supportive information for validation of analytical procedures and justification of specifications, ensuring traceability to source data.",
			"Follow relevant regional guidelines for the content of this section, as harmonised content is not available for all regions.",
			"For biotech manufacturing descriptions, include all relevant stages from cell bank to final harvest, with diagrams and parameters clearly presented.",
			"For stability-related authorizations or data, organize information either in its entirety or per container closure system, manufacturer, strength, stability study protocol, or other distinguishing information, as per Note 10 guidance and Appendix C.",
			"If multiple excipients are involved, provide documents per excipient as per Note 13 guidance.",
			"Cross-reference manufacturing sites listed here with those described in Module 3 (Quality) to ensure consistency.",
			"If the product contains more than one drug substance, ensure that manufacturing and marketing authorization information is provided in its entirety for each drug substance, referencing Appendix A and consulting the health authority if any substance is already approved.",
			"Ensure that copies of manufacturing and marketing authorizations are legible, current, and issued by the relevant competent authority.",
		],
	},
	{
		number: "1.10",
		title: "Paediatric Development Program",
		input: [
			"Collect informed consent templates and procedures for transitioning from child assent to legal informed consent once the participant reaches the age of consent.",
			"Collect microbiological attribute data for paediatric dosage forms, including rationale for microbial limits testing, preservative system selection and effectiveness, and container closure integrity for sterile products.",
			"Collect non-clinical study data supporting paediatric use, including juvenile animal studies if applicable.",
			"Gather summaries of formulation development for paediatric products, including differences between clinical and proposed commercial formulations.",
			"Gather documentation on child assent procedures, including assent forms, age\u0011appropriate informational materials, and institutional policies.",
			"Gather collection procedures and identification data related to adverse events, product complaints, and pregnancy/postpartum information as part of paediatric clinical program documentation.",
			"If the paediatric drug product is supplied with reconstitution diluent(s), gather complete 'P' information for each diluent as if it were a separate drug product, including all relevant quality, manufacturing, and control data.",
			"Gather data on formulation and process attributes (critical parameters) influencing batch reproducibility, product performance, and drug product quality for paediatric formulations.",
			"Obtain clinical study reports for paediatric studies, including completed, ongoing, or planned trials.",
			"Collect all documents related to the Paediatric Development Program, including paediatric investigation plans (PIPs) or equivalent regional paediatric study plans.",
			"Obtain manufacturing process development data for paediatric products, including selection, optimisation, and critical aspects, and justification for sterilisation methods if applicable.",
			"For paediatric combination products, gather compatibility data between drug substances.",
			"Gather regulatory correspondence and approvals related to paediatric development, such as PIP opinions, waivers, or deferrals from relevant authorities.",
			"Collect any expert opinions or advisory committee recommendations related to paediatric development.",
			"Obtain results from comparative in vitro studies (e.g., dissolution) and comparative in vivo studies (e.g., bioequivalence) relevant to paediatric formulations.",
			"Gather data on suitability of container closure systems for paediatric products, including material choice, protection from environmental factors, compatibility, safety, and performance (e.g., dose delivery reproducibility).",
			"Obtain proof of registration of paediatric clinical trials on publicly accessible recognized registries (e.g., ClinicalTrials.gov, regional equivalents).",
			"Collect information on differences between manufacturing processes for pivotal paediatric clinical batches and proposed commercial processes.",
			"Obtain compatibility studies of the paediatric drug substance with excipients, including physicochemical characteristics such as water content, solubility, particle size distribution, and polymorphic form.",
			"Gather evidence or stakeholder inputs (clinicians, patients, academic experts) supporting the scientific basis for the paediatric development approach.",
			"Collect justification and data for choice and concentration of excipients in paediatric formulations, including their functional roles.",
			"Assemble summaries of adult data used to justify paediatric extrapolation.",
			"Gather documentation related to confidentiality and privacy requirements for paediatric participants, including compliance with local regulations.",
			"Assemble rationale and supporting data for selection of paediatric subpopulations and age groups included in studies.",
			"Gather documentation on prevailing ethical, legal, and regulatory guidelines applicable to paediatric clinical trials, including institutional review board (IRB) or ethics committee approvals, and compliance statements with international standards (e.g., ICH E6, Declaration of Helsinki).",
			"Gather documentation on child assent procedures, including assent forms, age-appropriate informational materials, and institutional policies.",
			"Collect development study reports establishing suitability of dosage form, formulation, manufacturing process, container closure system, microbiological attributes, and usage instructions for paediatric use.",
			"Gather data on physicochemical and biological properties relevant to paediatric product performance (e.g., pH, ionic strength, dissolution, particle size, aggregation, polymorphism, rheology, potency, immunological activity).",
			"Collect data and documentation on serious adverse events (SAEs), product complaints (including medical device product complaints if applicable), and pregnancy and postpartum information relevant to paediatric studies.",
			"Gather documentation on child assent procedures, including assent forms, age‑appropriate informational materials, and institutional policies.",
			"Collect justification for any overages in paediatric formulations.",
			"Gather relevant literature references supporting paediatric dosing, safety, and efficacy.",
			"Include any regional legal or regulatory documents required for paediatric submissions (e.g., cover letters, declarations, or commitments).",
			"Collect public clinical trial results summaries or links required for transparency compliance.",
			"Collect information on potential need for distinct formulations, dosage forms, or delivery devices for specific paediatric subgroups.",
		],
		output: [
			"Maintain conformance with required CTD heading structure and one-to-one cardinality for each heading and subheading within section 1.10.",
			"Provide a concise, high-level statement summarizing the prevailing ethical, legal, and regulatory guidelines applied throughout the paediatric trials.",
			"Provide a brief summary of paediatric formulation development, including differences between clinical and proposed commercial formulations.",
			"Ensure the discussion reflects alignment with relevant ICH guidances referenced in E11 (e.g., E2, E3, E4, E5, E6, E8, E9, E10, M3, Q1, Q2, Q3) where applicable to paediatric development.",
			"Demonstrate compliance with local confidentiality and privacy protections for paediatric participants.",
			"Discuss whether inclusion of paediatric subpopulations in adult trials (or adult subpopulations in paediatric trials) was scientifically justified.",
			"If the paediatric drug product is supplied with reconstitution diluent(s), present the complete 'P' information for each diluent as a separate drug product within the CTD, ensuring full compliance with quality and manufacturing data requirements.",
			"Provide rationale for selection of paediatric populations and subgroups, including scientific justification beyond chronological age when appropriate.",
			"Discuss compatibility of paediatric drug substance with excipients and, for combination products, compatibility between drug substances.",
			"Address physicochemical and biological properties relevant to paediatric product performance.",
			"Applicants may modify the format of section 1.10 if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation of the results, provided CTD structural integrity is maintained.",
			"Ensure headings such as 'Collection Procedures' and 'Identification' are used consistently and correctly when describing data collection or identification processes relevant to paediatric safety information.",
			"Discuss choice, concentration, and functional characteristics of excipients in relation to paediatric product performance.",
			"Include supportive data and results from specific studies or published literature within or attached to the section, with cross-references to relevant nonclinical or clinical sections as needed.",
			"Ensure the document is complete, accurate, and compliant with regional regulatory requirements for paediatric development documentation.",
			"Discuss results from comparative in vitro and in vivo studies relevant to paediatric formulations when appropriate.",
			"Include a heading for 'Trial Oversight and Other General Considerations' (section 11) and its subheading 'Regulatory and Ethical Considerations' (section 11.1) as required by CTD structure, even if only a high-level statement is provided.",
			"Explain the procedure for transitioning from child assent to informed consent once the participant reaches legal age, including compliance with local regulatory expectations.",
			"Use the standard CTD structure for section 1.10 without creating a separate or modified format for amendments or variations.",
			"Verify that all included information is consistent with the overall CTD structure and cross-referenced appropriately within the dossier.",
			"Discuss differences between manufacturing processes for pivotal paediatric clinical batches and proposed commercial processes that could influence performance.",
			"Ensure that any data or discussion related to serious adverse events (SAEs), product complaints, and pregnancy/postpartum information are clearly identified and appropriately referenced within the paediatric development context.",
			"Address microbiological attributes of paediatric dosage forms, including rationale for microbial limits testing, preservative system selection and effectiveness, and container closure integrity for sterile products.",
			"Ensure the section addresses ICH E11 core topic areas, including initiation considerations for paediatric programs, timing of paediatric studies within development, types of paediatric studies (PK, PK/PD, efficacy, safety), age category definitions, and ethical considerations.",
			"Ensure conformance with one-to-one cardinality for headings 11 and 11.1, and that no additional or missing headings are introduced.",
			"Do not include any value text under the main heading 'Trial Oversight and Other General Considerations'—it serves as a heading only.",
			"Follow regional guidance for applicability and content expectations of the paediatric development section.",
			"Ensure the section is clearly labeled as '1.10 Paediatric Development Program' and organized according to CTD conventions.",
			"Ensure that the 'Regulatory and Ethical Considerations' subsection text is clearly identified as data content (D) and not as a heading (H).",
			"Identify and describe formulation and process attributes (critical parameters) that influence batch reproducibility, product performance, and quality in paediatric products.",
			"Discuss suitability of container closure systems for paediatric products, considering material choice, environmental protection, compatibility, safety, and performance.",
			"Include a description of transparency measures taken, including clinical trial registration and public availability of paediatric study results.",
			"Clearly distinguish development studies from routine control tests when describing paediatric pharmaceutical development.",
			"Do not include any value text under the main heading 'Trial Oversight and Other General Considerations'\u0001it serves as a heading only.",
			"Justify any overages in paediatric formulations.",
			"Explain and justify selection and optimisation of manufacturing process for paediatric products, including sterilisation methods if applicable.",
			"Describe stakeholder input (e.g., clinicians, patients, academic experts) used to inform the paediatric development strategy.",
			"Describe child assent requirements and how they were operationalized in the paediatric clinical program, ensuring respect for refusal or withdrawal of assent.",
			"Incorporate explanation of the common scientific approach applied to the paediatric development plan, including how regional differences were managed.",
			"Address considerations for different formulations, dosage forms, or delivery devices needed to accommodate paediatric subgroups.",
			"Do not include unused CTD modules or sections; omit 'not applicable' pages for headings that do not apply.",
			"Confirm that the section aligns with controlled terminology definitions for 'Regulatory and Ethical Considerations' and that the content reflects careful deliberation of ethical and regulatory aspects of the trial.",
			"Explain consideration of developmental physiology, disease pathophysiology, treatment options, and pharmacology in defining paediatric subgroups.",
		],
	},
	{
		number: "1.11",
		title: "Product Samples",
		input: [
			"Gather supportive information justifying excipient specifications for the product samples.",
			"Ensure availability of batch manufacturing records for the specific batches from which the product samples are taken.",
			"Gather information on any overages or over-fills used in the manufacturing batches from which product samples are drawn.",
			"Gather certificates of analysis or batch data for excipients for inclusion in the relevant section.",
			"If the drug product is supplied with reconstitution diluent(s), gather complete 'P' information for the diluent(s) as separate drug product(s), including all relevant technical and regulatory data.",
			"Collect information on excipients of human or animal origin, including source, processing, and any associated certifications (e.g., TSE/BSE certificates) as per regional requirements.",
			"Collect specifications, analytical procedures, and acceptance criteria for critical steps and intermediates relevant to the product samples, including storage conditions of critical intermediates.",
			"Obtain stability data and expiry dating information for the product samples, if required by the authority.",
			"Obtain any covering letter or transmittal form required to accompany the product samples submission.",
			"Gather detailed information on critical manufacturing steps and all intermediates that are controlled, as identified in section 3.2.P.3.3, including descriptions and control parameters.",
			"Collect any additional written consent forms or documentation describing the consent process for optional exploratory research using remaining samples, if applicable.",
			"Gather data from constitution or dilution studies performed as part of formal stability studies to confirm product quality through shelf-life, if relevant to the product samples provided.",
			"Gather import/export permits or customs documentation if product samples are being shipped internationally to the regulatory authority.",
			"Ensure reference standards or comparator products are available if required for evaluation alongside the product samples.",
			"Gather detailed descriptions of individual unit operations and their sequence in the manufacturing process for the product samples.",
			"If exploratory research using remaining mandatory samples is applicable, gather documentation describing consent requirements for such use, including any text from the original consent forms addressing use of remaining samples.",
			"Gather excipient specifications for the product samples, including test methods, acceptance criteria, and references to pharmacopoeial monographs where applicable.",
			"Obtain physical product samples of the drug product in the final commercial presentation (including packaging, labeling, and container closure system) as required by the regulatory authority.",
			"Collect critical process control values from relevant batches to support numeric ranges, limits, and acceptance criteria for critical process controls.",
			"Obtain supportive information related to process validation or evaluation for the product samples, if applicable.",
			"Collect information on excipient sources and controls, particularly for excipients of human or animal origin, relevant to the product samples.",
			"Collect statements or documentation regarding manipulation of ruminant-derived materials in the drug product manufacturing facility, if applicable to the product samples.",
			"Collect any special handling or storage instructions for the product samples (e.g., temperature requirements, hazardous material handling).",
			"Collect Certificates of Analysis (CoA) for the product samples to be submitted.",
			"Collect information on compatibility of reconstitution diluents, co-administered drugs, and incompatible diluents if applicable to the product samples submitted.",
			"Collect references to pharmacopoeial monographs or analytical procedures for excipients used in the product samples, and validation data if non-pharmacopoeial methods are used.",
			"Gather information on the manufacturing sites involved in production, testing, packaging, and device assembly for the product samples, including site names and addresses.",
			"Gather any regulatory instructions or correspondence from the health authority specifying the type, quantity, and presentation of product samples to be submitted for section 1.11.",
			"Obtain analytical procedures and method validation information for any in-process material test performed in lieu of a finished product test.",
			"Prepare a list of batch numbers, manufacturing sites, and manufacturing dates for the product samples provided.",
			"Collect the qualitative and quantitative batch formula for the product samples, including all components and their quantities.",
		],
		output: [
			"For excipient specifications, list each quality attribute along with the corresponding test method and acceptance criteria, or reference the applicable pharmacopoeial monograph.",
			"Ensure that any accompanying documentation (e.g., CoA, batch details) is cross-referenced to the corresponding product sample.",
			"Present the batch formula for the product samples in both qualitative and quantitative terms, ensuring consistency with manufacturing records.",
			"Include justification of excipient specifications as supportive information, ensuring consistency with analytical data and pharmacopoeial references.",
			"If the drug product is supplied with reconstitution diluent(s), present the complete 'P' information for the diluent(s) in its entirety as a separate drug product section, ensuring full compliance with CTD-Q structure.",
			"Provide supportive information for process validation or evaluation related to the product samples, ensuring alignment with the manufacturing process description.",
			"In 3.2.P.4.5, include information on excipients of human or animal origin, and ensure adventitious agent safety evaluation is addressed in 3.2.A.2, with TSE/BSE certifications located per regional guidance.",
			"For in-process material tests performed in lieu of finished product tests, present the same level of detail in 3.2.P.3.4 as for finished product tests, including analytical procedures and method validation information.",
			"If multiple strengths or presentations are submitted, organize and present them in a logical sequence (e.g., by strength, dosage form).",
			"If constitution or dilution studies are referenced, ensure that data supporting product quality through shelf-life are cross-referenced to the appropriate stability section (3.2.P.8.3).",
			"Follow any specific format or packaging requirements provided by the regulatory authority for submission of product samples.",
			"Confirm that inclusion of consent information for exploratory research is conditional\u0001include only if applicable to the product samples submitted.",
			"If no pharmacopoeial monograph exists for an excipient, reference the appropriate analytical procedure and validation information as per ICH Q12 Chapter 3, section 3.2.3.2.",
			"If optional exploratory research is planned, describe the consent process for obtaining additional written consent for use of remaining samples.",
			"Confirm that inclusion of consent information for exploratory research is conditional—include only if applicable to the product samples submitted.",
			"Describe individual unit operations and their sequence in the manufacturing process clearly, referencing established conditions for process parameters and material attributes where applicable.",
			"Confirm that inclusion of consent information for exploratory research is conditional\u0014include only if applicable to the product samples submitted.",
			"Ensure compliance with any special transport, storage, or temperature control requirements during shipment to the authority.",
			"Include specifications, analytical procedures, and acceptance criteria for critical steps and intermediates, and specify storage conditions for critical intermediates if relevant.",
			"Include a detailed inventory list of all product samples submitted, specifying quantity, batch number, and presentation for each.",
			"If overages or over-fills are relevant to the product samples, ensure they are identified and described consistently with the batch formula and manufacturing process description.",
			"Ensure packaging and labeling of product samples match the proposed commercial presentation unless otherwise instructed by the authority.",
			"If a process test replaces an end-product test, ensure it is listed in the specification (3.2.P.5.1) and clearly identified as a process test in accordance with ICH Q6A.",
			"Ensure that manufacturing site information for the product samples includes all relevant facilities (production, testing, packaging, and device assembly) and is presented in a clear tabular format.",
			"In section 3.2.P.3.4, include detailed descriptions of all critical steps and intermediates that are controlled, ensuring alignment with information in 3.2.P.3.3.",
			"Clearly identify excipient sources and controls, particularly for excipients of human or animal origin, and ensure traceability and compliance with regional requirements.",
			"Ensure that the section describing consent for exploratory research is presented as text and follows the one-to-one cardinality rule (only one entry per applicable study).",
			"Include critical process control values from relevant batches in 3.2.P.3.4 to justify numeric ranges and limits for critical process controls.",
			"If applicable, include a description of consent requirements for exploratory research using remaining mandatory samples, ensuring the text aligns with the original consent documentation.",
			"Document chain of custody for product samples from manufacturing site to submission to the authority.",
			"In 3.2.P.4.4, include certificates of analysis or batch data for excipients and, where appropriate, provide a summary with cross-references to detailed data in other sections.",
			"Ensure that compatibility information for reconstitution diluents, co-administered drugs, and incompatible diluents is clearly presented and aligned with labeling claims, if applicable to the product samples.",
			"Clearly label each product sample with product name, strength, dosage form, batch number, manufacturing date, and expiry date.",
			"Verify that product samples are within their shelf-life at the time of submission.",
			"If ruminant-derived materials are used in the manufacturing facility, include a statement regarding their manipulation and cross-reference to adventitious agent safety information in 3.2.A.1 and 3.2.A.2.",
			"Provide clear instructions for handling and storage of the product samples in the submission package.",
		],
	},
	{
		number: "1.12",
		title: "Requirement for Submission of a Risk Mitigation Plan",
		input: [
			"Collect technical documentation describing system start-up, shutdown, and pause strategies for CM processes.",
			"Gather real-time data (RTD) and material traceability information relevant to CM process control and risk mitigation.",
			"Obtain regional validation data for high-impact process models, if used, and continuous process verification schemes, if applicable.",
			"Gather expert opinions or internal quality management assessments used to define critical-to-quality factors and mitigation strategies.",
			"Collect supporting data or analyses used to identify and evaluate risks (e.g., risk matrices, risk evaluation tables).",
			"Collect analytical model validation information for models associated with release testing (e.g., NIR or dissolution models).",
			"Obtain development and justification reports for models used in the control strategy (e.g., process models, PAT analytical models).",
			"Gather summaries or cross-references to supporting data from other sections or documents that substantiate risk mitigation strategies, ensuring no duplication of detailed data.",
			"Obtain summaries of overall process development and justification of the control strategy, including links or references to CTD sections containing detailed control strategy information.",
			"Obtain detailed descriptions of trial-specific intervention risks and corresponding mitigation strategies.",
			"Collect process control documentation describing feedforward and feedback control systems based on measured attributes, if used.",
			"Gather information on controls of critical steps and intermediates, including critical process parameters and in-process testing details (sampling frequency, sample size, analytical methods).",
			"Gather relevant sections of the clinical trial protocol that describe risk management or quality oversight procedures.",
			"Collect information and data outlined in ICH M4Q relevant to continuous manufacturing (CM) processes, if applicable to the product under review.",
			"Gather information on equipment design and system integration aspects shown to be critical to output material quality.",
			"Collect documentation or reports describing risk mitigation strategies and control measures implemented in the trial.",
			"Gather integrated flow diagrams for integrated drug substance and drug product CM processes, ensuring cross-references between CTD sections 3.2.P and 3.2.S.",
			"Obtain contingency plans for when process models or PAT systems are unavailable.",
			"Obtain narrative descriptions and flow diagrams of the commercial manufacturing process, clearly indicating continuous process portions.",
			"Gather justification for the range of batch sizes claimed, including supporting data.",
			"Gather nonclinical study data and prior clinical trial data that form the basis for identifying participant risks.",
			"Gather any protocol sections or supporting technical documents that describe risks related to trial-specific treatments and interventions.",
			"Gather protocol sections describing trial procedures associated with unique or high\u0011risk elements (e.g., biopsies, placebo designs, challenge agents, imaging agents, medical devices, special population considerations).",
			"Gather protocol sections describing trial procedures associated with unique or high‑risk elements (e.g., biopsies, placebo designs, challenge agents, imaging agents, medical devices, special population considerations).",
			"Collect any certificates of analysis or batch data that support the justification of specifications for materials or excipients relevant to the trial, if referenced in the Risk Mitigation Plan.",
			"Obtain risk assessment reports identifying potential risks associated with the trial design, conduct, and data integrity.",
			"Obtain regulatory correspondence or guidance specifying requirements for submission of a Risk Mitigation Plan, if applicable.",
			"Gather contingency testing and monitoring plans for analytical models when data gaps or equipment failures occur.",
			"Obtain any region-specific certifications or safety evaluations (e.g., TSE/BSE certificates) if referenced as part of risk mitigation for biological or animal-derived materials used in the trial.",
			"Gather documentation describing identified critical-to-quality factors for the trial.",
			"Collect batch definition documentation describing batch size or range and the approach to achieving the intended batch size or range.",
			"Collect the Risk Mitigation Plan document or equivalent plan describing risk management strategies for the clinical trial.",
			"Gather information on CM-related process parameters, controls, and criteria (e.g., input rates, feeder operating ranges, control points).",
			"Retrieve any referenced documents or separate reports where risk-based quality management or risk mitigation strategies are described.",
			"Collect sampling strategy documentation, including sampling frequency and rationale for CM processes.",
			"Obtain documentation on disturbance management strategies, including material diversion and collection strategies.",
			"Collect documentation describing known and potential risks and benefits to individual trial participants, including their scientific basis.",
			"Collect criteria for product collection, including diversion strategies and control points.",
		],
		output: [
			"Applicants may modify the format of the section if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation by regulatory reviewers.",
			"Verify that the section aligns with the controlled terminology definition for risk-based quality management (CNEW concept).",
			"When describing trial-specific risks, ensure these are linked to the protocol hierarchy section 2.2.1 (Risk Summary and Mitigation Strategy) where applicable.",
			"When submitting amendments or variations involving Section 1.12 content, do not include unused CTD modules or 'not applicable' pages, consistent with CTD general guidance.",
			"Provide a concise textual description of how potential risks and critical-to-quality factors associated with the trial will be identified and managed.",
			"Confirm that the content is presented as text (Value: Text) and does not include repeating or reused content (Repeating/Reuse Rules: No).",
			"Maintain consistency in terminology and structure between the Risk Mitigation Plan and referenced CTD manufacturing sections (3.2.S, 3.2.P, 3.2.R).",
			"Ensure the section is properly linked or cross-referenced within the CTD hierarchy under 'Trial Oversight and Other General Considerations'.",
			"Ensure any discussion of known or potential risks is supported by referenced nonclinical or prior clinical data where applicable.",
			"Ensure that any discussion of process models, PAT systems, or analytical models includes justification, validation summary, and contingency planning information.",
			"If including content related to trial-specific intervention risks, ensure the description focuses on key risks relevant to THIS trial.",
			"Check that the section complies with applicable regulatory requirements for submission of a Risk Mitigation Plan, including completeness and accuracy of described strategies.",
			"Focus descriptions on unique trial-specific risks rather than providing an exhaustive list, consistent with user guidance.",
			"If continuous manufacturing (CM) processes are relevant to the trial or product, ensure cross-references to CTD sections 3.2.P and 3.2.S are accurate and clearly indicated.",
			"Avoid using headings or structural elements from other CTD sections (e.g., Section 2.2 headings), maintaining consistency with Section 1.12 requirements.",
			"Confirm that all cross-references to supporting documents (e.g., analytical data, certificates, or validation reports) are accurate and consistent with CTD structure and numbering conventions.",
			"When including CM-related risk mitigation content, describe system start-up, shutdown, and pause strategies in a clear, structured manner.",
			"Ensure that summaries of process development and control strategy justification are concise and reference the appropriate CTD sections containing detailed data.",
			"For 'Trial-specific Procedure Risks and Mitigations' and 'Trial-specific Other Risks and Mitigations', present content as text, do not reuse content, and ensure each appears once if included (Optional, One-to-one cardinality).",
			"Ensure the section includes a clear description of identified critical-to-quality factors, associated risks, and corresponding mitigation strategies.",
			"Verify that all CM-related risk mitigation descriptions align with the control strategy and process verification schemes described elsewhere in the dossier.",
			"When describing integrated drug substance and drug product CM processes, include a clear cross-reference between the relevant CTD sections and ensure the integrated flow diagram is properly cited.",
			"Ensure descriptions of other trial-specific risks (e.g., challenge agents, imaging agents, medical devices, special populations) include either brief mitigation descriptions or clear cross-references to protocol sections.",
			"Ensure that any CM-related information referenced in the Risk Mitigation Plan is consistent with ICH M4Q structure and terminology.",
			"For optional subcomponents describing trial-specific procedure risks, provide brief, focused descriptions of unique or less common procedural risks and associated mitigation strategies.",
			"Ensure that any referenced supporting data or certificates are appropriately cited and traceable to their source sections or appendices.",
			"Ensure conformance with the requirement that this section is mandatory (Conformance: Required) and appears once (Cardinality: One to one).",
			"If risk mitigation strategies are described in a separate document, include a reference to that document within this section.",
			"Ensure that any regional information (e.g., validation data for high-impact process models) is clearly identified and appropriately referenced within the section.",
			"Use clear, concise, and factual language consistent with regulatory terminology for risk management and quality assurance.",
			"When referencing supporting data or certificates (e.g., certificates of analysis, batch data), provide a summary and cross-reference to the detailed information rather than duplicating content.",
			"Include a brief description of mitigation strategies for trial-specific intervention risks or provide appropriate cross-references within the protocol.",
			"Follow the required structure: include a heading titled 'Risk-Based Quality Management' and a corresponding text section describing the risk mitigation approach.",
		],
	},
	{
		number: "1.13",
		title: "Submission of Risk Management (RMP)",
		input: [
			"Gather epidemiological data and literature references supporting the safety profile and risk assessment.",
			"Consult Appendix A and any referenced appendices for additional guidance or templates applicable to RMP submission.",
			"Ensure access to reference product information (SmPC, labeling) to align safety concerns and risk minimization measures.",
			"Collect data and analyses describing known and potential risks and benefits from nonclinical and prior clinical trials relevant to the product\u0003s safety profile.",
			"Collect information on ongoing or planned safety studies (e.g., PASS \u0003 Post-Authorisation Safety Studies) referenced in the RMP.",
			"Compile risk minimization measures and their implementation plans, including educational materials, controlled distribution programs, or other interventions.",
			"Collect data and analyses describing known and potential risks and benefits from nonclinical and prior clinical trials relevant to the product\u0019s safety profile.",
			"Gather trial-specific intervention risk information and corresponding mitigation strategies from clinical protocols or safety management plans.",
			"Collect information on ongoing or planned safety studies (e.g., PASS – Post-Authorisation Safety Studies) referenced in the RMP.",
			"Collect information on ongoing or planned safety studies (e.g., PASS \u0013 Post-Authorisation Safety Studies) referenced in the RMP.",
			"If the drug substance is already approved, obtain relevant health authority guidance or documentation confirming the approval status and any associated RMP requirements.",
			"Collect data and analyses describing known and potential risks and benefits from nonclinical and prior clinical trials relevant to the product’s safety profile.",
			"Obtain documentation or summaries describing the basis of identified risks (e.g., nonclinical studies, prior clinical trials, or literature sources).",
			"Obtain regulatory correspondence or approvals related to previous RMP submissions or updates.",
			"Obtain the current, approved Risk Management Plan (RMP) document in the format required by the regional authority.",
			"Gather any regional-specific RMP annexes or modules required by the target regulatory authority.",
			"Gather certificates of analysis or batch data for excipients for inclusion in section 3.2.P.4.4.",
			"Gather detailed information on all critical steps and intermediates identified in section 3.2.P.3.3 that are controlled.",
			"Obtain details of the product\u0019s benefit\u0013risk evaluation from internal safety review committees or expert opinions.",
			"Collect critical process control values from relevant manufacturing batches to support numeric ranges and limits for critical process controls.",
			"Gather all supporting safety data from clinical studies, non-clinical studies, and post-marketing surveillance relevant to the RMP.",
			"Collect summaries and full reports of identified and potential risks, including safety concerns and pharmacovigilance findings.",
			"Obtain details of the product\u0003s benefit\u0003risk evaluation from internal safety review committees or expert opinions.",
			"Obtain analytical procedures and method validation information for any in-process material test performed in lieu of a finished product test.",
			"Collect information on excipients of human or animal origin, including adventitious agent safety evaluation data and relevant TSE/BSE certifications as per regional guidance.",
			"Obtain details of the product’s benefit–risk evaluation from internal safety review committees or expert opinions.",
		],
		output: [
			"For eCTD submissions, do not include a separate Table of Contents (TOC) for Module 2; the TOC is only required for paper submissions.",
			"In section 3.2.P.4.4, include certificates of analysis or batch data for excipients, and it is acceptable to provide a summary with cross-references to detailed data in other sections to avoid duplication.",
			"Perform a final compliance check against the applicable regional RMP template or guidance before submission.",
			"Provide concise descriptions of mitigation strategies or cross-references to relevant protocol sections where detailed strategies are described.",
			"Maintain consistency with the SmPC and other labeling documents regarding identified and potential risks.",
			"Ensure that the 'Risk Summary and Mitigation Strategy' subsection describes trial-specific intervention risks and corresponding mitigation strategies.",
			"If the product has an already approved drug substance, ensure the RMP submission aligns with the health authority’s specific guidance for such cases.",
			"Ensure that documents are submitted at the correct granularity level according to the eCTD structure; documents written at a lower level must be submitted at the higher level as specified.",
			"Apply the optionality of granularity for the Quality Overall Summary (QOS) based on the product’s complexity, ensuring the chosen level is consistent throughout the submission.",
			"Refer to relevant appendices (e.g., Appendix A) and regional authority instructions for any additional formatting or submission requirements applicable to RMPs.",
			"If a process test replaces an end-product test, list it in the specification (3.2.P.5.1) and clearly identify it as a process test in accordance with ICH Q6A.",
			"Verify that the RMP and associated summaries are properly linked and referenced within the eCTD structure, maintaining traceability between Module 1.13 and relevant Module 2 sections.",
			"Follow the key for document granularity: one document per level where indicated, or multiple documents where permitted, ensuring consistency with eCTD v3.2.2 specifications.",
			"Do not include unused CTD modules or 'not applicable' placeholder pages for headings that are not relevant to the amendment or variation.",
			"Verify that all tables, figures, and annexes are correctly numbered, titled, and referenced in the text.",
			"In section 3.2.P.3.4, include detailed information for all controlled critical steps and intermediates, including critical process control values from relevant batches to justify numeric ranges and limits.",
			"When creating cross-references within the RMP section, include only the section number in cross strings to improve clarity while maintaining brevity.",
			"For amendments or variations to the RMP, use the same CTD structure as for initial submissions, following regional guidance on applicability.",
			"Ensure conformance with required headings and hierarchy (2.2, 2.2.1, etc.) as per the CTD protocol structure.",
			"If applicable, structure the section under one heading 'Assessment of Risks and Benefits' or under three subheadings: 'Risk Summary and Mitigation Strategy', 'Benefit Assessment', and 'Overall Risk-Benefit Assessment'.",
			"When an in-process material test is performed in lieu of a finished product test, present the same level of detail as for a finished product test, including analytical procedures and method validation information, within section 3.2.P.3.4.",
			"Use clear, concise, and consistent terminology aligned with regulatory definitions for risks, safety concerns, and minimization measures.",
			"If the product has an already approved drug substance, ensure the RMP submission aligns with the health authority\u0019s specific guidance for such cases.",
			"Ensure the RMP is structured according to the regional guidance for CTD section 1.13, using the prescribed headings and subheadings.",
			"If the product has an already approved drug substance, ensure the RMP submission aligns with the health authority\u0003s specific guidance for such cases.",
			"Ensure information on excipients of human or animal origin is placed in section 3.2.P.4.5, with adventitious agent safety evaluation in 3.2.A.2, and TSE/BSE certifications located per regional guidance.",
			"Include all mandatory sections: product overview, safety specification, pharmacovigilance plan, risk minimization plan, and summary tables.",
			"Ensure compliance with any page or section length restrictions specified by the regional authority.",
			"Check that the RMP version number, date, and status (initial submission or update) are clearly indicated.",
			"Follow the required file format for submission (eCTD or paper CTD as applicable) and place the RMP in the correct location in Module 1.13.",
			"Include an assessment of known and potential risks and benefits from the perspective of an individual participant, clearly describing the basis of each risk.",
			"Verify that all headings and subheadings follow the controlled terminology and hierarchy rules (e.g., 2.2 Assessment of Risks and Benefits, 2.2.1 Risk Summary and Mitigation Strategy).",
			"Ensure that the section is complete and compliant with the required conformance level ('Required' for 2.2, 'Optional' for 2.2.1) and cardinality rules ('One to many' or 'One to one' as applicable).",
			"Ensure cross-references to supporting data in Modules 2, 4, and 5 are accurate and functional.",
		],
	},
	{
		number: "2.1",
		title: "Table of Contents of Module 2",
		input: [
			"Obtain the list of all nonclinical study categories relevant to the product, including those not conducted, to ensure headings are retained with explanations.",
			"Collect impurity-specification test results for test articles used in early-stage toxicology studies if available, noting whether studies were GLP or non-GLP.",
			"Obtain the finalized structure and numbering scheme of the CTD as per ICH M4 guidelines to align the TOC with the standardized format.",
			"Collect the complete list of all documents included in Module 2 to accurately populate the Table of Contents.",
			"Obtain the official CTD section sequence for Modules 2‑5 as per ICH guidelines to ensure correct ordering in the TOC.",
			"Gather finalized titles and numbering of all Module 2 subsections and documents (e.g., 2.1, 2.2, 2.3, etc.) to ensure correct referencing.",
			"Obtain the latest version of the ICH eCTD v3.2.2 specification and associated granularity table to confirm which sections require or omit TOC entries.",
			"Obtain the official CTD section sequence for Modules 2–5 as per ICH guidelines to ensure correct ordering in the TOC.",
			"Collect information on reagents manufactured via recombinant DNA technology for inclusion in 3.2.S.2.3.",
			"Obtain analytical procedures for intermediates or critical steps for inclusion in 3.2.S.4.2.",
			"Obtain the finalized structure and numbering of Module 5 (Clinical Study Reports) to ensure cross-referencing accuracy in the Module 2 Table of Contents.",
			"Gather analytical procedures for control of materials (starting materials, reagents, raw materials, solvents) for inclusion in 3.2.S.2.3.",
			"Gather justification for reprocessing (if required by regional authority) for inclusion in 3.2.S.2.2.",
			"Obtain the official CTD section sequence for Modules 2\u00135 as per ICH guidelines to ensure correct ordering in the TOC.",
			"Collect complete manufacturing process descriptions and process control information for inclusion in 3.2.S.2.2, ensuring all process controls are identified.",
			"Gather the applicable granularity guidance for CTD/eCTD submissions to determine the appropriate document/file level listings in the TOC.",
			"Gather process validation or evaluation information for inclusion in 3.2.S.2.5.",
			"Obtain document identifiers or abbreviations for each report or section to be used in headers/footers and TOC entries.",
			"Obtain the recommended templates for nonclinical tabulated summaries (Module 2.6) as outlined in ICH M4S, for potential adaptation.",
			"Collect information on module numbers, volume numbers, and tab identifiers for inclusion in the Table of Contents.",
			"Collect the full list of literature references if applicable, so they can be included in a section\u0011specific Table of Contents.",
			"Obtain analytical procedures related to adventitious agent safety evaluation for materials of biological origin for inclusion in 3.2.A.2.",
			"Gather brief justifications for any nonclinical study categories (e.g., carcinogenicity) that were not conducted, for inclusion under the retained headings.",
			"Gather detailed information on the properties of the drug substance, including possible alternative forms, for inclusion in 3.2.S.3.1.",
			"Collect critical controls associated with reprocessing operations for inclusion in 3.2.S.2.4.",
			"Identify which drug substance batches are relevant for impurity qualification and prepare footnotes for the 'Drug Substance' table to indicate relevance.",
			"Gather impurity data for drug substance batches relevant to qualification of impurities, including identification of analytical methods used and any changes over development.",
			"Gather detailed information on critical process controls for inclusion in 3.2.S.2.4.",
			"Gather batch data, analytical procedures, and acceptance criteria for intermediates or critical steps for inclusion in 3.2.S.2.4.",
			"Gather any regional or agency-specific formatting examples of Module 2 TOCs that include detailed clinical subsections for reference.",
			"Collect all repeat-dose toxicity study reports specified by ICH M3, including any other repeat-dose studies considered pivotal, for accurate tabulation and TOC listing.",
			"Gather the detailed list of all subsections under 2.5 (Clinical Overview) and 2.7 (Clinical Summary), including all subheadings (e.g., 2.5.1\u00132.5.7, 2.7.1\u00132.7.6) for accurate inclusion in the Table of Contents.",
			"Collect the full list of literature references if applicable, so they can be included in a section‑specific Table of Contents.",
			"Obtain acceptance criteria for intermediates or critical steps for inclusion in 3.2.S.4.1.",
			"Collect definitions and rules for what constitutes a 'document' in both paper and electronic submissions to ensure consistent TOC entries.",
			"Obtain document identifiers or abbreviations for each report or section to be used in headers or footers and TOC entries.",
			"Gather any regional requirements or preferences for TOC presentation (e.g., EU, US, Japan) since CTD format allows regional variation.",
			"Obtain tabulated summaries of noteworthy toxicology findings, including statistically significant differences from controls and other noteworthy but non-significant findings.",
			"Ensure access to the finalized electronic or paper dossier layout to confirm pagination and volume organization.",
			"Obtain the official CTD section sequence for Modules 2\u00115 as per ICH guidelines to ensure correct ordering in the TOC.",
			"Gather the detailed list of all subsections under 2.5 (Clinical Overview) and 2.7 (Clinical Summary), including all subheadings (e.g., 2.5.1–2.5.7, 2.7.1–2.7.6) for accurate inclusion in the Table of Contents.",
			"Gather the key or legend defining document submission levels (e.g., levels where one or multiple documents can be submitted, or where documents are not appropriate) to ensure correct TOC representation for paper submissions.",
			"Collect discussion and justification of starting materials for inclusion in 3.2.S.2.3.",
			"Collect the official CTD numbering and titles for all subsections within 2.7 (e.g., 2.7.1.1–2.7.4.7) to ensure consistency in TOC entries.",
			"Collect the official CTD numbering and titles for all subsections within 2.7 (e.g., 2.7.1.1\u00132.7.4.7) to ensure consistency in TOC entries.",
		],
		output: [
			"If impurity-specification test results exist for test articles used in early-stage toxicology studies, include them in the relevant tables; note in the TOC-referenced section whether studies were GLP or non-GLP.",
			"Ensure that the TOC clearly distinguishes between main sections (e.g., 2.5, 2.7) and their subcomponents (e.g., 2.7.1–2.7.6) through formatting or indentation.",
			"For paper submissions, understand that a document is a set of sequentially numbered pages separated by a tab; for electronic submissions, a document equates to a file starting at the same point as a paper tab divider.",
			"List the seven Module 2 sections in the correct order as per ICH guidance: 2.1 CTD Table of Contents (Modules 2–5), 2.2 CTD Introduction, 2.3 Quality Overall Summary, 2.4 Nonclinical Overview, 2.5 Clinical Overview, 2.6 Nonclinical Written and Tabulated Summaries, 2.7 Clinical Summary.",
			"The TOC must not specify any page numbers.",
			"Ensure that pivotal repeat-dose toxicity studies, as defined by ICH M3 and any others considered pivotal, are clearly identified and tabulated in the appropriate section, with corresponding TOC entries.",
			"Ensure uniform layout and presentation across all TOC entries, maintaining consistent terminology and numbering.",
			"Ensure that the TOC reflects the agreed granularity and document definitions, and that it is compatible with lifecycle management requirements.",
			"For electronic submissions, include bookmarks for lower-level sections within PDF files, but do not list them in the overall TOC.",
			"If multiple documents exist within a section, an optional section\u0011specific TOC may be included to show chronology and subject matter, but these entries must not appear in the main CTD TOC.",
			"Apply the granularity key correctly: indicate where one document, multiple documents, or no documents are appropriate at each level, and ensure that rolled-up levels are not used inappropriately.",
			"Verify that the TOC accurately reflects the structure and sequence of Module 2 documents and sections.",
			"Do not include page numbers or internal pagination references in the Module 2 Table of Contents; only section titles and numbering should appear.",
			"Any additional headers or subsection numbering beyond M4Q guidelines must only appear within a document and must not be treated as separate documents or new subsections in the TOC.",
			"Ensure that the TOC lists subsections in hierarchical order (e.g., 2.7.1.1, 2.7.1.2, etc.) and maintains consistent indentation or formatting to indicate hierarchy.",
			"If multiple documents exist within a section, an optional section‑specific TOC may be included to show chronology and subject matter, but these entries must not appear in the main CTD TOC.",
			"Verify that the TOC includes cross-references to Module 5 (Clinical Study Reports) only as section titles, not as detailed listings of individual reports.",
			"Only include noteworthy toxicology findings in tabulated summaries referenced in the TOC, including statistically significant differences from controls and other noteworthy non-significant findings.",
			"Ensure that the TOC for paper submissions reflects the hierarchy and numbering shown in the official Module 2 table, including subsections such as 2.3.S.1–2.3.S.7, 2.3.P.1–2.3.P.8, and 2.3.A.1–2.3.A.3.",
			"Include module numbers, volume numbers, and tab dividers in the Table of Contents for Module 2.",
			"Exclude lower‑level Tables of Contents intended for pagination or segregation from the main CTD Table of Contents.",
			"Maintain all CTD section headings in the TOC even if certain studies were not conducted, and include a brief explanation under the heading rather than deleting it or renumbering subsequent sections.",
			"Ensure that the TOC presentation aligns with regional guidance where applicable, as noted in the Module 2 table.",
			"List the seven Module 2 sections in the correct order as per ICH guidance: 2.1 CTD Table of Contents (Modules 2\u00115), 2.2 CTD Introduction, 2.3 Quality Overall Summary, 2.4 Nonclinical Overview, 2.5 Clinical Overview, 2.6 Nonclinical Written and Tabulated Summaries, 2.7 Clinical Summary.",
			"Ensure that sub-numbering within documents (e.g., 2.3.S.1.1.1) does not appear in the overall Table of Contents; only CTD-specified heading levels should be listed.",
			"Exclude lower\u0011level Tables of Contents intended for pagination or segregation from the main CTD Table of Contents.",
			"Ensure that for eCTD submissions, documents written at lower levels but submitted at higher levels are not listed separately in the TOC.",
			"For eCTD submissions (v3.2.2), no entry for the Table of Contents (2.1) is required; the TOC is only applicable to paper submissions.",
			"Ensure that the TOC for paper submissions reflects the hierarchy and numbering shown in the official Module 2 table, including subsections such as 2.3.S.1\u00132.3.S.7, 2.3.P.1\u00132.3.P.8, and 2.3.A.1\u00132.3.A.3.",
			"Ensure that in the TOC-referenced sections, information on process controls is presented in 3.2.S.2.2, with additional details on critical controls in 3.2.S.2.4, in accordance with CTD-Q guidance.",
			"Maintain consistent formatting for all section titles, including capitalization and numbering, as shown in the official CTD structure.",
			"Ensure that in the TOC-referenced sections, justification for reprocessing (if required) is included in 3.2.S.2.2, critical controls for reprocessing in 3.2.S.2.4, and validation information in 3.2.S.2.5.",
			"All TOC title entries must match M4Q‑defined heading names and section numbering or correspond to tab identifiers (paper submissions only).",
			"List the seven Module 2 sections in the correct order as per ICH guidance: 2.1 CTD Table of Contents (Modules 2‑5), 2.2 CTD Introduction, 2.3 Quality Overall Summary, 2.4 Nonclinical Overview, 2.5 Clinical Overview, 2.6 Nonclinical Written and Tabulated Summaries, 2.7 Clinical Summary.",
			"Ensure that once a granularity approach (single or multiple documents at a given section) is adopted, it is applied consistently throughout the life of the dossier.",
			"When impurity data tables are included in the TOC-referenced sections, use footnotes to indicate which batches are relevant for impurity qualification, especially if analytical methods have changed over development.",
			"Ensure that in the TOC-referenced sections, discussion and justification of starting materials, and analytical procedures for control of materials, are presented in 3.2.S.2.3, with adventitious agent safety evaluation procedures for materials of biological origin in 3.2.A.2.",
			"Confirm that the TOC is formatted according to CTD Module 2 specifications and aligns with the overall dossier organization.",
			"Literature references must be listed in a TOC specific to their section and not in the main CTD TOC.",
			"When using nonclinical tabulated summary templates in TOC-referenced sections, follow the recommended format outlined in ICH M4S but adapt as needed for clarity and understanding.",
			"Ensure that the TOC clearly distinguishes between main sections (e.g., 2.5, 2.7) and their subcomponents (e.g., 2.7.1\u00132.7.6) through formatting or indentation.",
			"Ensure that each document listed in the TOC has a distinct identifier in headers or footers; abbreviations may be used instead of full titles.",
			"All TOC title entries must match M4Q\u0011defined heading names and section numbering or correspond to tab identifiers (paper submissions only).",
			"Maintain consistency with CTD guideline numbering; lower-level subheadings may be used within documents but should not appear in the TOC.",
			"Follow the CTD/eCTD granularity principles when determining which documents/files to list in the TOC, ensuring consistency between paper and electronic submissions.",
			"When preparing the paper TOC, clearly indicate the section numbering and titles consistent with the Module 2 structure table, omitting any sections not applicable to the product type.",
			"If additional information is appended to a section containing multiple documents, reference it within the relevant section; if the section contains only one document, the additional information must be incorporated into that document and not listed separately in the TOC.",
			"Verify that the TOC presentation aligns with regional guidance where applicable, as noted in the Module 2 table.",
			"Do not include page numbers in the comprehensive Table of Contents for Module 1; for Module 2, page numbering is not specifically regulated but should be consistent and clear.",
			"Include all subsection titles under 2.5 (Clinical Overview) and 2.7 (Clinical Summary) in the Table of Contents to reflect the full structure of these sections.",
			"Ensure that in the TOC-referenced sections, batch data, analytical procedures, and acceptance criteria for intermediates or critical steps are presented in 3.2.S.2.4, with acceptance criteria in 3.2.S.4.1 and analytical procedures in 3.2.S.4.2.",
			"Ensure that the Table of Contents includes preambles and appendices where applicable, reflecting their placement within the CTD structure.",
		],
	},
	{
		number: "2.2",
		title: "CTD Introduction",
		input: [
			"Gather a clear description of the purpose and scope of the CTD submission to be summarized in the Introduction.",
			"Obtain a summary of the regulatory history of the product, including key approvals, submissions, and correspondence relevant to the application.",
			"Collect references to appendices or supporting documents that will be cited in the Introduction.",
			"Gather an overview of the development program, including types of studies conducted (non-clinical, clinical, bioequivalence, stability) and their general outcomes.",
			"Collect high-level background information on the product, including product name(s), active ingredient(s), dosage form(s), strength(s), and route(s) of administration.",
			"If the drug product is supplied with reconstitution diluent(s), gather complete 'P' (drug product) information for each diluent as separate drug product(s) for potential reference in the Introduction.",
			"For stability information referenced in the Introduction, gather data either in its entirety or organized per manufacturer, stability study protocol, and/or other distinguishing factors, as appropriate, and refer to Appendix C.",
			"If the drug substance is already approved, consult the relevant health authority for guidance on how to reference or summarize that approval in the Introduction.",
			"Gather information on any special considerations for the submission, such as multiple container closure systems, multiple manufacturing sites, or multiple product components, if relevant to the overall context.",
			"Obtain any institutional review board (IRB) or ethics committee approvals or statements relevant to the trial oversight and ethical considerations to be summarized.",
			"Obtain any regional or national regulatory requirements that influence the structure or content of the CTD Introduction.",
			"Collect information on the overall organization of the CTD, including which modules and sections are included and any deviations from standard CTD structure.",
			"If the drug product contains more than one drug substance, gather complete 'S' (drug substance) information for each drug substance for potential reference in the Introduction.",
			"Collect any internal company policies or standard operating procedures (SOPs) governing ethical conduct and regulatory compliance of clinical trials for reference in the section.",
			"Gather documentation of the prevailing ethical, legal, and regulatory guidelines applicable to the clinical trial(s) referenced in the CTD Introduction (e.g., ICH GCP, Declaration of Helsinki, local regulatory frameworks).",
			"Refer to Appendix A for any additional guidance or templates relevant to the CTD Introduction.",
		],
		output: [
			"Ensure that the section conforms to the required one-to-one cardinality rule—each heading appears once and only once.",
			"If the product contains more than one drug substance, ensure the Introduction notes that complete 'S' information is provided for each.",
			"Lower-level headings used for navigation may be included as internal PDF bookmarks in electronic submissions.",
			"For cross\u0011references in paper submissions, use only the section number in cross-strings while ensuring the accompanying text makes the referenced content clear.",
			"If referencing appendices (e.g., Appendix A or C), ensure they are correctly cited and aligned with the CTD structure.",
			"Ensure that the content under 'Regulatory and Ethical Considerations' reflects careful thought or deliberation on ethical and regulatory aspects, consistent with controlled terminology definitions.",
			"Use consistent terminology and naming conventions for the product, active ingredient(s), and sections throughout the document.",
			"Write in clear, formal, regulatory-appropriate language.",
			"Ensure cross-references to other CTD sections or appendices are accurate and correctly labeled.",
			"Clearly state the purpose of the CTD Introduction as an overview of the submission and its organization.",
			"If templates or tabulated formats are referenced or used in the Introduction, follow the recommended CTD format but adapt as needed to best present the information and facilitate understanding.",
			"For paper CTD submissions, include the Introduction (2.2) in the Module 2 Table of Contents; for eCTD submissions, no TOC entry is required for the Introduction.",
			"Organize the Introduction to include: product identification, regulatory history, development program overview, and CTD structure summary.",
			"If supplied with reconstitution diluent(s), ensure the Introduction notes that complete 'P' information is provided for each as a separate drug product.",
			"If the product is supplied with reconstitution diluent(s), ensure the Introduction notes that complete 'P' information is provided for each diluent as a separate drug product, as appropriate.",
			"Maintain the hierarchical relationship between headings (11 and 11.1) in the Table of Contents and document structure.",
			"Do not include modules or sections that are not used for the amendment or variation, and do not insert 'not applicable' pages for unused CTD headings.",
			"Include the heading '11 TRIAL OVERSIGHT AND OTHER GENERAL CONSIDERATIONS' exactly as specified; no text should be inserted under this heading.",
			"Write in clear, formal, and regulatory-appropriate language.",
			"Maintain compliance with regional guidance on the placement and content of introductory material.",
			"Under '11.1 Regulatory and Ethical Considerations', provide a concise, high-level statement describing the ethical, legal, and regulatory frameworks governing the trial.",
			"If templates or tabulated formats are used in the Introduction, follow the recommended CTD format but adapt as needed to facilitate understanding.",
			"Include the subheading '11.1 Regulatory and Ethical Considerations' exactly as specified; this heading is required and must appear once.",
			"Maintain all standard CTD section headings and provide brief explanations for omissions.",
			"For amendments or variations submitted in CTD format, use the standard CTD structure unless regional guidance specifies otherwise.",
			"Ensure every page contains a distinct identifier in headers or footers; a shortened or abbreviated title is acceptable.",
			"Ensure that Module numbers, volume numbers, and tab dividers are included in all Tables of Contents for paper CTD submissions.",
			"Do not modify or replace controlled terminology or heading values; use them exactly as defined in the guideline.",
			"Internal sub-numbering below CTD-specified levels (e.g., 3.2.P.3.3.1, 3.2.P.3.3.2) may be used for additional navigation within the document, but these lower-level headings must not appear in the overall Table of Contents.",
			"Follow all formatting requirements for Module 2 documents.",
			"If applicable, briefly note the presence of multiple container closure systems, manufacturing sites, or product components, without detailed data.",
			"When summarizing stability information, indicate whether it is presented in its entirety or organized by manufacturer or protocol, and reference Appendix C.",
			"For paper CTD submissions, include the Introduction (2.2) in the Module 2 Table of Contents; for eCTD submissions, no TOC entry is required.",
			"If referencing appendices, ensure they are correctly cited and aligned with the CTD structure.",
			"Ensure every page contains a distinct identifier in headers or footers; a shortened or abbreviated title is acceptable rather than the full report title.",
			"Do not include modules or sections that are not used; do not insert 'not applicable' pages for unused CTD headings.",
			"Organize the Introduction to include product identification, regulatory history, development program overview, and CTD structure summary.",
			"Ensure the Introduction explains any deviations from the standard CTD format or special organizational features.",
			"Ensure that any summarized data referenced in the Introduction includes only noteworthy or significant findings.",
			"For amendments or variations, use the standard CTD structure unless regional guidance specifies otherwise.",
			"If applicable, briefly note the presence of multiple container closure systems, manufacturing sites, or product components, without going into detailed data.",
			"Internal sub-numbering below CTD-specified levels may be used for navigation but must not appear in the overall Table of Contents.",
			"Ensure that any tabulated or summarized data referenced in the Introduction (if applicable) include only noteworthy or significant findings, consistent with CTD presentation principles.",
			"If the product contains more than one drug substance, ensure the Introduction notes that complete 'S' information is provided for each drug substance, in line with Appendix A and health authority guidance.",
			"Use source-based pagination for literature references.",
			"When summarizing stability information in the Introduction, indicate whether it is presented in its entirety or organized per manufacturer, stability study protocol, or other distinguishing factors, and reference Appendix C as applicable.",
			"Ensure that the section complies with the business rules: headings are non-repeating, values are not allowed to be altered, and the section is linked to the Table of Contents hierarchy.",
			"Maintain compliance with regional guidance on placement and content of introductory material.",
			"For cross-references in paper submissions, use only the section number in cross-strings while ensuring the accompanying text makes the referenced content clear.",
			"Present information in a concise, high-level manner without duplicating detailed data from later sections.",
			"Ensure that the Introduction (2.2) is submitted as a standalone document at the correct CTD granularity level in both paper and eCTD formats, in compliance with the granularity key and regional guidance.",
			"When referring to approved drug substances, clearly indicate that guidance from the relevant health authority has been followed and that the reference is compliant with regional expectations.",
			"Ensure that the Introduction (2.2) is submitted as a standalone document at the correct CTD granularity level.",
			"Use source-based pagination for literature references, retaining the page numbering of the originating journal, abstract, or other source.",
			"Follow any applicable formatting requirements for Module 2 documents, including file format (eCTD or paper CTD), pagination, and section numbering.",
			"For cross‑references in paper submissions, use only the section number in cross-strings while ensuring the accompanying text makes the referenced content clear.",
			"When referring to approved drug substances, clearly indicate compliance with relevant health authority guidance.",
			"Maintain all standard CTD section headings even if certain study categories (e.g., carcinogenicity or other toxicology studies) are not applicable, and provide a brief explanation for their omission rather than deleting the heading.",
			"If supplied with reconstitution diluent(s), ensure the Introduction notes that complete 'P' information is provided for each diluent as a separate drug product, as appropriate.",
		],
	},
	{
		number: "2.3",
		title: "Quality Overall Summary - Product Dossiers (QOS-PD)",
		input: [
			"Collect stability study data, conditions, batches, analytical procedures, results, and conclusions from 3.2.S.7.1.",
			"Collect excipient quality information from 3.2.P.4.",
			"Obtain manufacturing information from 3.2.P.3, including manufacturer details, manufacturing process description, controls, flow diagram (3.2.P.3.3), and process validation summaries (3.2.P.3.5).",
			"Collect compatibility data for reconstitution diluents to support label claims from 3.2.P.2.6.",
			"Collect compatibility data with co-administered drugs from 3.2.P.2.6.",
			"Gather characterization data for biotech products from 3.2.S.3.1, including product-related substances, structure, and biological activity.",
			"Obtain regional information from 3.2.R, as applicable, based on regional guidance.",
			"Collect data on critical manufacturing steps, process controls, and acceptance criteria from 3.2.S.2.4.",
			"Obtain information for any novel or noncompendial nonnovel excipients that require a complete 3.2.A.3 Excipients section.",
			"Collect drug product description and composition data from 3.2.P.1.",
			"Obtain justification for skip testing from 3.2.P.5.6.",
			"Gather information on major manufacturing changes made throughout development and conclusions from assessments of product consistency from 3.2.S.2.6.",
			"Gather all relevant information from 3.2.S.1 (General Information) for inclusion in 2.3.S.1.",
			"Obtain facility and equipment information for biotech products from 3.2.A.1.",
			"Collect specifications from 3.2.S.4.1.",
			"Gather information on source and starting materials and raw materials of biological origin from 3.2.S.2.3.",
			"Gather data on stereoisomerism, including which stereoisomers were used in nonclinical and clinical studies and which will be used in the marketed product.",
			"Collect analytical procedures for control of materials (starting materials, reagents, raw materials, solvents) from 3.2.S.2.3.",
			"Obtain the flow diagram from 3.2.S.2.2 for inclusion in the summary.",
			"Gather pharmaceutical development data from 3.2.P.2, including formulation compositions for clinical batches and dissolution profile data.",
			"Collect information on incompatible diluents from 3.2.P.2.6.",
			"Collect batch formula information including overages from 3.2.P.3.2.",
			"Ensure access to supporting information from other CTD modules (e.g., toxicological studies for impurity qualification from CTD-S).",
			"Collect validation information for reprocessing operations if warranted from 3.2.P.3.5.",
			"Collect critical controls associated with reprocessing from 3.2.S.2.4.",
			"Obtain the post-approval stability protocol from 3.2.S.7.2.",
			"Gather container closure system information from 3.2.S.6.",
			"Gather information for each drug product presentation (e.g., different strengths, container closure types, formulations, or manufacturing schemes) to ensure all variations are represented in the QOS.",
			"Collect manufacturing process description including reprocessing steps from 3.2.P.3.3.",
			"Obtain process validation and/or evaluation summaries from 3.2.S.2.5.",
			"Collect complete list of all process controls from 3.2.S.2.2, and for critical controls, gather additional detailed information from 3.2.S.2.4.",
			"Obtain tabulated impurity data and any graphical representations from 3.2.S.3.2.",
			"Collect tabulated summary of formulation compositions used in clinical trials and dissolution profiles, where relevant, from 3.2.P.2.",
			"Gather information on stereoisomerism, including which stereoisomers were used in nonclinical and clinical studies and which will be used in the marketed product.",
			"Obtain validation data for analytical procedures from 3.2.P.5.3.",
			"Collect tabulated summary of viral clearance reduction factors from 3.2.A.2.",
			"Collect information from 3.2.S.2 (Manufacture), including manufacturer details, manufacturing process description, starting materials, critical steps, process controls, and acceptance criteria.",
			"Collect reference standards and materials information from 3.2.S.5, including any required tabulated format.",
			"Collect data from constitution or dilution studies performed as part of formal stability studies to confirm product quality through shelf-life from 3.2.P.8.3.",
			"Collect analytical procedures related to adventitious agent safety evaluation for materials of biological origin from 3.2.A.2.",
			"Collect information for each manufacturing site if a single drug substance is produced at multiple sites with different manufacturing processes or specifications.",
			"Collect cross-references to non-clinical and clinical studies that used batches affected by manufacturing changes (from CTD-S and CTD-E modules).",
			"Collect impurity profiles, impurity qualification information, and impurity limits from 3.2.S.3.2.",
			"Gather data on measures implemented to control endogenous and adventitious agents in production from 3.2.A.2.",
			"Gather analytical procedure information from 3.2.P.5.2, including current procedures, historical procedures used to generate batch analysis data (from 3.2.P.5.4), and procedures used only for stability studies (from 3.2.P.8.3).",
			"Collect statement regarding manipulation of ruminant-derived materials in the drug product manufacturing facility from 3.2.P.3.3.",
			"Collect more detailed information on the properties of the drug substance, including possible alternative forms, from 3.2.S.3.1.",
			"Gather complete list of all observed impurities from 3.2.P.5.5, even if not included in the drug product specification.",
			"Collect data for any reconstitution diluent if the product is supplied with one, ensuring separate documentation for the drug product and the diluent.",
			"Collect discussion and justification of starting materials from 3.2.S.2.3.",
			"Obtain the complete Module 3 (Quality) data package, as the QOS must summarize information from each section of Module 3.",
			"Gather summaries of data from other sections with cross-references to detailed information to support justification of specifications from 3.2.P.5.6.",
			"Collect justification for reprocessing (if warranted) from 3.2.S.2.2.",
			"Collect validation information for reprocessing (if warranted) from 3.2.S.2.5.",
			"Collect batch data, analytical procedures, and acceptance criteria for intermediates or critical steps from 3.2.S.2.4.",
			"Gather information on multiple drug substances if applicable, including separate data packages for each substance when more than one is used in the product.",
			"Gather information for each manufacturing facility if multiple facilities are registered for biotech drug manufacture, including repeated appendices as needed.",
			"Gather analytical procedure and validation information from 3.2.S.4.",
			"Prepare tables, figures, and other items that can be imported directly from Module 3 for inclusion in the QOS.",
			"Collect proprietary name, non-proprietary name or common name of the drug substance, company name, dosage form(s), strength(s), route of administration, and proposed indication(s) for the introduction section.",
			"Collect additional information on potential cross-contamination with adventitious agents from 3.2.A.1 and 3.2.A.2.",
			"Obtain justification for not including certain observed impurities in the specification from 3.2.P.5.6.",
			"Collect information on critical controls associated with reprocessing from 3.2.P.3.4.",
			"Collect drug product release and shelf-life specifications from 3.2.P.5.1, including any alternative analytical procedures used to control the drug product and associated acceptance criteria.",
			"Collect information on over-fill from 3.2.P.3.3.",
			"Collect acceptance criteria for intermediates or critical steps from 3.2.S.4.1 and analytical procedures from 3.2.S.4.2.",
			"Obtain batch analysis data from 3.2.S.4.4, including tables and any required graphical representations.",
			"Collect information on critical steps and intermediates from 3.2.P.3.3.",
			"Obtain data from 3.2.S.3.1 for characterization, including evidence of structure and isomerism for new chemical entities (NCEs).",
			"Gather tabulated stability study results and any graphical representations from 3.2.S.7.3.",
			"Collect batch analysis results from all relevant batches (clinical, nonclinical, stability) from 3.2.P.5.4, including batch descriptions (batch number, manufacturing site, use) and results from tests not listed in the specifications, as well as any collated data for specific tests.",
		],
		output: [
			"Include tabulated summary of viral clearance reduction factors from 3.2.A.2.",
			"Summarize compatibility data for reconstitution diluents, co-administered drugs, and incompatible diluents in the pharmaceutical development section (3.2.P.2.6) as applicable.",
			"Include summary of stability studies (conditions, batches, analytical procedures), results, conclusions, and analysis of data from 3.2.P.8.",
			"Include summary of facility information for biotech products as described under 3.2.A.1.",
			"If a single drug substance is produced at multiple manufacturing sites with different processes or specifications, create separate Drug Substance sections as appropriate.",
			"Provide summaries of structure, isomerism, and characterization data as required for NCE and biotech substances.",
			"When justifying specifications, provide summaries of supporting data with cross-references to detailed sections rather than duplicating information.",
			"Emphasize critical key parameters of the product and provide justification where guidelines were not followed.",
			"Summarize batch data, analytical procedures, and acceptance criteria for intermediates or critical steps in 3.2.S.2.4, with acceptance criteria referred to in 3.2.S.4.1 and analytical procedures in 3.2.S.4.2.",
			"For materials of biological origin, summarize analytical procedures related to adventitious agent safety evaluation from 3.2.A.2.",
			"Ensure that repeated or separate sections are clearly titled and distinguished to avoid confusion.",
			"Include tabulated and graphical summaries where appropriate for impurities, batch analyses, stability studies, and other relevant data.",
			"Ensure that all critical manufacturing steps, process controls, and validation summaries are clearly and accurately represented.",
			"Ensure that the QOS-PD content aligns with the explanatory and illustrative intent of the guideline and references existing ICH guidelines for detailed content.",
			"Ensure that repeated or separate sections are logically organized and clearly labeled to reflect differences in manufacturing sites, specifications, or product presentations.",
			"Ensure composition and description of the drug product are clearly summarized from 3.2.P.1.",
			"Summarize batch analysis results from all relevant batches, including batch descriptions, results from tests not in specifications, and any collated data, ensuring clarity and completeness.",
			"Include overages in the batch formula summary (3.2.P.3.2).",
			"Summarize analytical procedures for the drug product, including current, historical (used for batch analyses), and stability-only methods, ensuring correct placement and cross-referencing to relevant sections.",
			"Ensure both release and shelf-life specifications for the drug product are summarized, including any alternative analytical procedures and associated acceptance criteria.",
			"Provide a brief summary of justification of specifications, analytical procedures, validation, and impurity characterization as per 3.2.P.5.",
			"Do not include any new information, data, or justification not already included in Module 3 or other CTD parts.",
			"Provide a brief summary of specifications, analytical procedures, and validation for the drug substance.",
			"Include tabulated summary of batch analyses with graphical representation where appropriate from 3.2.P.5.4.",
			"Ensure consistency with CTD-Q guideline (Modules 2 and 3) and follow regional guidance for content and location of information.",
			"When multiple drug substances are used, present each as a separate complete Drug Substance section, clearly distinguished by title (e.g., 2.3.S Drug Substance [Name, Manufacturer A]).",
			"In the Introduction, include proprietary name, non-proprietary/common name, company name, dosage form(s), strength(s), route of administration, and proposed indication(s).",
			"Include summarized stability study conditions, results, conclusions, storage conditions, retest period or shelf-life, and post-approval stability protocol.",
			"Provide a brief summary of manufacturing information including manufacturer, process description, controls, flow diagram, and validation summary as per 3.2.P.3.",
			"In the manufacturing process description (3.2.P.3.3), include reprocessing steps, identification of critical steps and intermediates, over-fill, and statement on manipulation of ruminant-derived materials.",
			"Include post-approval stability protocol as described in 3.2.P.8.2.",
			"Include tabulated summary of stability results with graphical representation where appropriate from 3.2.P.8.3.",
			"Provide a brief description and discussion of the container closure system.",
			"Include specification(s) from 3.2.P.5.1.",
			"Include discussion of key issues integrating information from Quality Module sections and supporting information from other Modules.",
			"Include summary and justification of impurity levels, impurity limits, and impurity qualification.",
			"Use italicized text to indicate where tables, figures, or other items are imported directly from Module 3.",
			"List all observed impurities in the summary, even if not included in the specification, and include justification for their exclusion in the appropriate section.",
			"Summarize validation of analytical procedures for the drug product.",
			"Include brief description of regional information as provided under 3.2.R, where appropriate.",
			"Include tabulated presentation of reference standards or materials information from 3.2.P.6.",
			"If a product includes a reconstitution diluent, prepare separate Drug Product sections for the drug product and the diluent (e.g., 3.2.P [Drug Product] and 3.2.P [Diluent]).",
			"Confirm that all critical manufacturing steps, process controls, and validation summaries are clearly and accurately represented.",
			"If justification for reprocessing is warranted, summarize it in the manufacturing process description (3.2.S.2.2), include critical controls in 3.2.S.2.4, and validation information in 3.2.S.2.5.",
			"Ensure consistency of terminology and data presentation with Module 3.",
			"Ensure that more detailed information on the properties of the drug substance, including possible alternative forms, is summarized from 3.2.S.3.1.",
			"Provide summarized information for reference standards and materials, using tabulated format where appropriate.",
			"Ensure that critical controls associated with reprocessing are summarized in the process controls section (3.2.P.3.4) and any validation information is included in the validation section (3.2.P.3.5).",
			"Ensure stereoisomer information is clearly stated for chiral substances, including which isomer(s) were used in studies and which will be marketed.",
			"If multiple manufacturing facilities are registered for biotech drug manufacture, repeat Appendix 3.2.A.1 as appropriate.",
			"Include a brief summary of excipient quality data.",
			"For multiple drug product presentations (e.g., strengths, container types, formulations), combine common information in one Drug Product section and present differing information separately under relevant subsections (e.g., 3.2.P.7, 3.2.P.8).",
			"Ensure that data from constitution or dilution studies performed as part of formal stability studies are summarized in the stability section (3.2.P.8.3) and cross-referenced appropriately.",
			"When novel or noncompendial nonnovel excipients are included, ensure a complete 3.2.A.3 Excipients section is prepared for each, following the same format and subsections as the Drug Substance section.",
			"Summarize discussion and justification of starting materials in 3.2.S.2.3, including analytical procedures for control of materials.",
			"If potential for cross-contamination with adventitious agents exists, summarize additional information from 3.2.A.1 and 3.2.A.2.",
			"Verify that all cross-references are accurate and correspond to correct volume and page numbers.",
			"Include discussion on measures implemented to control endogenous and adventitious agents in production as per 3.2.A.2.",
			"Ensure the QOS follows the scope and outline of the Body of Data in Module 3.",
			"Include cross-references to volume and page numbers in other Modules where applicable.",
			"Maintain a maximum length of 40 pages of text (excluding tables and figures); for biotech or complex products, the QOS may extend up to 80 pages (excluding tables and figures).",
			"Ensure clarity and conciseness in summarizing technical data.",
			"Follow the prescribed structure: Introduction, 2.3.S Drug Substance (with subsections 2.3.S.1 General Information, 2.3.S.2 Manufacture, 2.3.S.3 Characterisation, etc.).",
			"Ensure that all process controls are identified in 3.2.S.2.2, with additional detail for critical controls provided in 3.2.S.2.4.",
			"Ensure that any repeated sections (e.g., for multiple drug substances or manufacturing sites) are clearly titled and distinguished to avoid confusion.",
			"Include justification for skip testing in the summary where applicable.",
			"Include a summarized discussion of pharmaceutical development with required tables (formulation composition, dissolution data).",
			"Include tabulated summary of formulation compositions used in clinical trials and dissolution profiles, where relevant.",
			"Provide a brief description and discussion of container closure system information from 3.2.P.7.",
			"Provide sufficient information from each section to give the Quality reviewer an overview of Module 3.",
			"Include a brief summary on the quality of excipients as described in 3.2.P.4.",
			"Include conclusions on storage conditions, shelf-life, and in-use storage conditions and shelf-life, where applicable.",
			"Summarize drug product manufacturing information, including manufacturer details, process description, controls, flow diagram, and validation.",
		],
	},
	{
		number: "2.4",
		title: "Nonclinical Overview for New Chemical Entities",
		input: [
			"Genotoxicity study reports: in vitro non-mammalian cell system, in vitro mammalian cell system, in vivo mammalian system (including supportive toxicokinetics), and other systems",
			"Non-pivotal toxicology study reports for inclusion in summaries (less detail required than pivotal studies)",
			"Analytical method validation data for biological sample analysis, including detection and quantification limits and sample stability data",
			"Data on impurities and degradants in the drug substance and product (except for biotechnology-derived products), including their potential pharmacologic and toxicologic effects",
			"Information on alternatives to whole-animal experiments used, including scientific validity assessments",
			"Reproductive and developmental toxicity study reports (including range-finding and supportive toxicokinetics): fertility and early embryonic development, embryo-fetal development, prenatal and postnatal development (including maternal function), juvenile animal studies",
			"Structure diagram of the pharmaceutical for inclusion in the Introduction section",
			"Templates from Appendix B for Nonclinical Tabulated Summaries and example tables from Appendix C, adapted as needed",
			"Consistent units for all reported data and, if applicable, a unit conversion table",
			"Quality documentation cross-references for impurity assessments and impurity limit justifications",
			"Information on differences in chirality, chemical form, and impurity profile between nonclinical study material and the marketed product",
			"Tables and figures summarizing toxicology data for inclusion in the section",
			"GLP compliance statements for submitted studies",
			"All nonclinical study reports covering pharmacology, pharmacokinetics, and toxicology evaluations of the pharmaceutical",
			"Pharmacokinetic study reports covering absorption, distribution, metabolism, excretion, and pharmacokinetic drug interactions",
			"Carcinogenicity study reports (including supportive toxicokinetics): long-term studies by species, short-/medium-term studies, and other studies, with rationale for study selection and high-dose selection",
			"Impurity-specification test results for test articles used in early-stage toxicology studies, if such analyses were conducted",
			"Identification of pivotal repeat-dose toxicity studies as defined by ICH M3 for inclusion in Tabulated Summaries",
			"Information on compliance with relevant guidelines for nonclinical studies, including any deviations and justifications",
			"Relevant findings with stereoisomers and/or metabolites from nonclinical studies",
			"Safety assessment data for any novel excipient included in the drug product",
			"Relevant scientific literature on the pharmaceutical and related products",
			"Local tolerance study reports, organized by species, route, and duration",
			"Pharmacodynamic study data, including mode of action and potential side effects",
			"Toxicology study data covering onset, severity, duration, dose-dependency, reversibility, and species/gender differences",
			"For biotechnology-derived products: comparability data for materials used in nonclinical studies, clinical studies, and proposed marketed product",
			"Other toxicity study reports (if available): antigenicity, immunotoxicity, mechanistic studies, dependence, studies on metabolites, studies on impurities, and other relevant studies",
			"Juvenile animal study data for tabulation using appropriate template",
			"Pharmacokinetic, toxicokinetic, and metabolism study data, including analytical methods, PK models, derived parameters, and interspecies comparisons (AUC, Cmax, etc.)",
			"Data on animal-to-human extrapolation factors: species used, numbers of animals, routes of administration, dosages, duration of treatment/study, systemic exposures at NOAEL and toxic doses in relation to human exposures at MRHD, and observed effects in animals vs. expected/observed in humans",
			"List of references for the Nonclinical Overview, including all cited literature, study reports, and supporting documents",
			"Epidemiologic data relevant to carcinogenic risk assessment, if available",
			"Information on quality of batches of drug substance used in referenced literature studies",
			"Age- and gender-related effects data from nonclinical studies",
			"Microbiology data from both in vitro and in vivo studies, if relevant to the nonclinical assessment, for inclusion or cross-reference in the Nonclinical Overview",
			"Identification of batches relevant to impurity qualification for inclusion or annotation in impurity-related tables (via footnotes)",
			"Information on the pharmaceutical’s proposed clinical indication, dose, and duration of use",
			"Tabulated Summaries of nonclinical data with study/report numbers for citation",
			"Details of the nonclinical testing strategy, including rationale and justification",
			"Specific toxicology endpoints data: toxic signs, causes of death, pathologic findings, genotoxicity, carcinogenicity, fertility, embryofetal development, pre- and post-natal toxicity, juvenile animal studies, pregnancy/lactation/pediatric use, local tolerance, and other special toxicity studies",
			"Pharmacology study reports covering primary pharmacodynamics, secondary pharmacodynamics, safety pharmacology, and pharmacodynamic drug interactions",
			"Justifications and critical reviews for use of published literature in place of applicant-conducted studies, including study design evaluation and deviations from guidelines",
		],
		output: [
			"Introduction section should introduce the reviewer to the pharmaceutical and its proposed clinical use",
			"Evaluate toxicology data in logical order, grouping all relevant data elucidating a certain effect/phenomenon together",
			"When the same nonclinical pharmacokinetic study is relevant to multiple subsections, include the full report in the first applicable section and cross-reference it in subsequent sections rather than duplicating files",
			"Total length of the three Nonclinical Written Summaries should generally not exceed 100\u00150 pages",
			"Assess pharmacokinetic, toxicokinetic, and metabolism data, addressing analytical methods, PK models, derived parameters, and cross-references to pharmacology/toxicology studies as needed",
			"Nonclinical Overview should be an integrated and critical assessment of pharmacologic, pharmacokinetic, and toxicologic data",
			"In Pharmacokinetics Brief Summary, summarize principal findings in approximately 2–3 pages, describing scope of evaluation, species/strains used, and formulation comparability",
			"Include appropriate references to Modules 4 and 5 for relevant nonclinical and clinical studies",
			"Consider epidemiologic data in carcinogenic risk assessment, if available",
			"Juvenile animal studies should be tabulated using the appropriate template for the study type",
			"In the Pharmacology Written Summary, follow the sequence: Brief Summary; Primary Pharmacodynamics; Secondary Pharmacodynamics; Safety Pharmacology; Pharmacodynamic Drug Interactions; Discussion and Conclusions; Tables and Figures",
			"Document should not exceed approximately 30 pages",
			"Evaluate pharmacodynamic effects, mode of action, and potential side effects, and discuss significance of any issues",
			"Ensure that pivotal repeat-dose toxicity studies (as defined by ICH M3) are tabulated in the appropriate CTD tables",
			"Applicants may modify the format of the Nonclinical Overview to provide the best possible presentation and facilitate understanding and evaluation of results",
			"Maintain section headings for any category of toxicology studies not conducted and provide a brief explanation for non-conduct",
			"Use Appendix B templates and Appendix C examples for Tabulated Summaries, deleting italicized guidance text before submission",
			"For other toxicity studies, summarize if available and provide rationale when appropriate; include antigenicity, immunotoxicity, mechanistic studies, dependence, studies on metabolites, studies on impurities, and other studies",
			"Ensure consistent use of units throughout summaries; include a unit conversion table if useful",
			"Include relevant findings with stereoisomers and/or metabolites",
			"In Pharmacology Discussion and Conclusions, discuss pharmacologic evaluation and significance of any issues",
			"Order routes of administration as: intended human route, oral, intravenous, intramuscular, intraperitoneal, subcutaneous, inhalation, topical, other",
			"For local tolerance, summarize in order by species, route, and duration, with brief methodology and important findings",
			"In Secondary Pharmacodynamics, summarize studies by organ system where appropriate and evaluate them",
			"Use footnotes in impurity tables to identify batches relevant to impurity qualification when analytical methods have changed",
			"Indicate associations between nonclinical findings and quality characteristics, clinical trial results, or related products",
			"If using published literature in place of applicant studies, provide justification reviewing study design and deviations from guidelines, and discuss quality of batches used",
			"Tabulate only noteworthy findings, including statistically significant changes and notable non-significant findings",
			"If microbiology data are relevant to the nonclinical assessment, describe them appropriately within the Nonclinical Overview and cross-reference to the Clinical Summary or Module 5 as needed",
			"In the Introduction section, include brief information on the pharmaceutical’s structure (preferably with a structure diagram) and pharmacologic properties, as well as proposed clinical indication, dose, and duration of use",
			"Provide safety assessment for any novel excipient",
			"If pharmacodynamic drug interaction studies were performed, briefly summarize them in the appropriate section",
			"When extrapolating animal data to humans, address species used, numbers of animals, routes of administration, dosages, study duration, systemic exposures at NOAEL and toxic doses vs. human exposures at MRHD, and observed effects in animals vs. expected/observed in humans; present in tables or figures where possible",
			"In Integrated Overview and Conclusions, clearly define characteristics of the human pharmaceutical as demonstrated by nonclinical studies and provide logical, well-argued conclusions supporting safety for intended clinical use",
			"For reproductive and developmental toxicity, summarize in order: fertility and early embryonic development; embryo-fetal development; prenatal and postnatal development (including maternal function); juvenile animal studies; modify subheadings if study designs differ",
			"Within Pharmacokinetics and Toxicology sections, order multiple studies by species, then by route, then by duration (shortest first)",
			"In Discussion and Conclusion sections, integrate information across studies and species, relating animal exposure to human exposure at maximum intended doses",
			"Take into account relevant scientific literature and properties of related products",
			"In Primary Pharmacodynamics, summarize and evaluate studies, relating pharmacology to available data on other drugs in the class (selectivity, safety, potency, etc.)",
			"Use recommended templates for nonclinical Tabulated Summaries but modify them as needed to facilitate clarity and understanding",
			"In Methods of Analysis, briefly summarize analytical methods for biological samples, including detection/quantification limits, validation data, and sample stability; discuss potential impact of analytical methods on interpretation of results",
			"Include tables/figures within text where possible, or group at end of each Written Summary if preferred",
			"Follow the order of presentation from the Nonclinical Written Summaries when preparing Nonclinical Tabulated Summaries",
			"Include appropriate reference citations to Tabulated Summaries in the format: (Table X.X, Study/Report Number)",
			"Discuss and justify the nonclinical testing strategy",
			"Tables and figures may be placed within the text at appropriate points or at the end of the summary",
			"Comment on GLP status of submitted studies",
			"For biotechnology-derived products, assess comparability of materials used in nonclinical, clinical, and marketed product",
			"For carcinogenicity, provide a brief rationale for study selection and high-dose selection; summarize in order: long-term studies by species (including range-finding not in repeat-dose or PK), short-/medium-term studies (including range-finding not in repeat-dose or PK), other studies",
			"Discuss inconsistencies in data and interspecies comparisons of metabolism and systemic exposure, highlighting limitations and utility for human risk prediction",
			"Whenever appropriate, discuss age- and gender-related effects",
			"For eCTD submissions, provide references to a single file rather than submitting multiple copies of the same study report",
			"Include a list of references in the most appropriate location within the Nonclinical Overview, creating new subsection numbers if needed to improve clarity for reviewers",
			"Include tables and figures either within the text or at the end of each summary, ensuring clarity and readability",
			"Discuss toxicology endpoints: toxic signs, causes of death, pathologic findings, genotoxicity, carcinogenicity, fertility, embryofetal development, pre- and post-natal toxicity, juvenile animal studies, pregnancy/lactation/pediatric use, local tolerance, and other special toxicity studies",
			"In Written Summaries, present in vitro studies before in vivo studies",
			"When cross-referencing sections in paper or electronic submissions, include the section number in the cross string and write the text so the reader understands the section content without needing the full section name",
			"In Pharmacokinetics Written Summary, follow the sequence: Brief Summary; Methods of Analysis; Absorption; Distribution; Metabolism; Excretion; Pharmacokinetic Drug Interactions; Other Pharmacokinetic Studies; Discussion and Conclusions; Tables and Figures",
			"Order species as: Mouse, Rat, Hamster, Other rodent, Rabbit, Dog, Non-human primate, Other non-rodent mammal, Non-mammals",
			"In Safety Pharmacology, summarize and evaluate studies, and include relevant secondary pharmacodynamic studies that contribute to safety evaluation",
			"Include assessment of impurities and degradants (except for biotechnology-derived products) and cross-reference to quality documentation",
			"In Discussion and Conclusions, discuss toxicologic evaluation and significance of issues; include tables or figures summarizing information",
			"Ensure sufficient detail in Tabulated Summaries for primary review in some regions, while providing concise overviews",
			"Discuss and justify any deviations from relevant guidelines",
			"Follow recommended sequence: Introduction; Written Summary of Pharmacology; Tabulated Summary of Pharmacology; Written Summary of Pharmacokinetics; Tabulated Summary of Pharmacokinetics; Written Summary of Toxicology; Tabulated Summary of Toxicology",
			"Summarize non-pivotal studies in less detail than pivotal studies",
			"Total length of the three Nonclinical Written Summaries should generally not exceed 100–150 pages",
			"Discuss implications of nonclinical findings for safe human use, including applicability to labeling",
			"For genotoxicity, summarize studies in the order: in vitro non-mammalian cell system; in vitro mammalian cell system; in vivo mammalian system (including supportive toxicokinetics); other systems",
			"Discuss implications of differences in chirality, chemical form, and impurity profile between nonclinical and marketed product material",
			"Follow required sequence: Overview of the nonclinical testing strategy; Pharmacology; Pharmacokinetics; Toxicology; Integrated overview and conclusions; List of literature references",
			"If alternatives to whole-animal experiments are used, discuss their scientific validity",
			"In the Pharmacology Brief Summary, summarize principal findings from pharmacology studies in approximately 2–3 pages, including description of the pharmacologic data package and any notable inclusions/exclusions",
			"One tabular format may contain results from several studies, or data from one study may be cited in several tabular formats as appropriate",
		],
	},
	{
		number: "2.5.1",
		title: "Product Development Rationale",
		input: [
			"Obtain container closure system data, including material specifications, compatibility studies, leachables/sorption data, and performance testing (e.g., dose delivery reproducibility).",
			"Obtain description and composition details of the drug product, including dosage form description, list of all components with amounts per unit (including overages), function of components, reference to quality standards, description of reconstitution diluents, and type of container and closure used.",
			"Obtain data on physicochemical and biological properties relevant to product performance (e.g., pH, ionic strength, dissolution, redispersion, reconstitution, particle size, aggregation, polymorphism, rheological properties, biological or immunological activity).",
			"Obtain information on reference standards or reference materials used for testing the drug substance, including source, characterization, and specifications.",
			"Collect scientific background information supporting investigation of the product for the proposed indication(s).",
			"Obtain summaries of benefit\u0003risk evaluations and any internal or external expert assessments supporting clinical conclusions.",
			"Obtain plans and supporting documents for the use of foreign clinical data (per ICH E5).",
			"Gather copies of formal regulatory advice documents, including meeting minutes, official guidance, and regulatory authority letters.",
			"Confirm cross-references to Module 2.7 (Clinical Summary) and Module 5 (Clinical Study Reports) are available for consistency and traceability.",
			"Collect detailed description and specifications of the container closure system for the drug substance, including identity of materials of construction, critical dimensions, drawings (if appropriate), and validation of non-compendial methods.",
			"Obtain information on materials of biological origin, including analytical procedures related to adventitious agent safety evaluation, from section 3.2.A.2.",
			"Collect justification for reprocessing operations, including associated critical controls and validation information, from sections 3.2.S.2.2, 3.2.S.2.4, and 3.2.S.2.5.",
			"Obtain summaries of benefit–risk evaluations and any internal or external expert assessments supporting clinical conclusions.",
			"Obtain stability study reports for the drug substance, including protocols, results from forced degradation and stress studies, and conclusions on storage conditions and retest period/shelf-life, in accordance with ICH Q1A, Q1B, and Q5C.",
			"Gather information on all analytical procedures used to control the drug product, including those used historically for batch analyses and those used only for stability studies.",
			"Obtain an overview of currently used major therapies in the intended patient population.",
			"Collect post-approval stability protocol and stability commitment documentation for the drug substance.",
			"Gather data on suitability of the container closure system for the drug substance, including protection from environmental factors, compatibility, sorption, leaching, and safety of materials.",
			"Obtain justification documents for not including certain observed impurities in the specification.",
			"Gather documentation describing the clinical development program, including ongoing and planned clinical studies, and justification for timing of submission.",
			"Collect documentation describing the overall clinical development strategy, including rationale for study design, patient population selection, and dose justification.",
			"Gather detailed information on possible alternative forms of the drug substance from section 3.2.S.3.1 for consideration in the development rationale.",
			"Reference applicable ICH guidelines (Q6A and Q6B) for quality and specification standards.",
			"Collect compatibility studies between drug substance and excipients, and between multiple drug substances for combination products.",
			"Collect information describing the clinical or pathophysiological condition targeted by the medicinal product, including indication rationale.",
			"Obtain acceptance criteria for intermediates or critical steps from section 3.2.S.4.1 and analytical procedures from section 3.2.S.4.2.",
			"Collect pertinent published literature discussing standard research approaches relevant to clinical development of the medicinal product.",
			"Ensure access to the CTD Module 2 Table of Contents to confirm correct section numbering and placement of 2.5.1 Product Development Rationale within the Clinical Overview.",
			"Obtain summaries of benefit\u0000risk evaluations and any internal or external expert assessments supporting clinical conclusions.",
			"Collect comprehensive clinical data from the Clinical Summary (Module 2.7) and individual clinical study reports (Module 5) for reference and interpretation.",
			"Collect justification documents for any overages in formulation.",
			"Gather statements of Good Clinical Practice (GCP) compliance for all clinical studies included in the development program.",
			"Obtain results from comparative in vitro studies (e.g., dissolution) and comparative in vivo studies (e.g., bioequivalence) if applicable.",
			"Gather stability data in tabular, graphical, or narrative format, including analytical procedures used and their validation, in accordance with ICH Q1A, Q1B, Q2A, Q2B, and Q5C.",
			"Obtain analytical validation reports and experimental data for analytical procedures used for testing the drug substance, in accordance with ICH Q2A, Q2B, and Q6B.",
			"Gather information on unresolved clinical issues, risk management plans, and post-marketing commitments relevant to the product’s clinical use.",
			"Gather justification documents for any skip testing applied to the drug product specifications.",
			"Gather data and reports on formulation development, including differences between clinical and proposed commercial formulations.",
			"Collect a complete list of all observed impurities in the drug product, including those not included in the specification.",
			"Collect all pharmaceutical development study reports demonstrating the rationale for formulation, manufacturing process, container closure system, microbiological attributes, and usage instructions.",
			"Collect release and shelf-life specifications for the drug product, including any alternative analytical procedures and associated acceptance criteria.",
			"Gather microbiological data, including preservative effectiveness studies, microbial limits testing rationale, and container closure integrity data for sterile products.",
			"Gather manufacturing process development reports, including process optimization studies and identification of critical process parameters.",
			"Gather information on unresolved clinical issues, risk management plans, and post-marketing commitments relevant to the product\u0000s clinical use.",
			"Gather physicochemical characterization data of the drug substance (e.g., water content, solubility, particle size distribution, polymorphic form).",
			"Collect results from all relevant batch analyses (clinical, nonclinical, stability), including batch descriptions (batch number, manufacturing site, intended use) and results from tests not listed in the specifications.",
			"Collect discussion and justification of starting materials, including analytical procedures for their control, from section 3.2.S.2.3.",
			"Gather collated data from multiple batch analyses where applicable.",
			"Collect documentation explaining differences between manufacturing processes used for pivotal clinical batches and the proposed commercial process.",
			"Obtain cross-references to related sections (e.g., 3.2.P.1, 3.2.P.3.3, 3.2.P.7) for consistency and traceability.",
			"Collect regulatory guidance and advice received from health authorities relevant to development of the product.",
			"Gather documentation identifying the pharmacological class of the medicinal product.",
			"Collect batch descriptions and results of batch analyses for the drug substance, in accordance with ICH Q3A, Q3C, Q6A, and Q6B.",
			"Gather justification documents for the drug substance specification, referencing relevant ICH guidelines (Q3A, Q3C, Q6A, Q6B).",
			"Gather batch data, analytical procedures, and acceptance criteria for intermediates or critical steps from section 3.2.S.2.4.",
			"Collect relevant literature references supporting formulation or process development decisions.",
		],
		output: [
			"Ensure the Clinical Overview provides a critical analysis and interpretation of clinical data rather than a repetition of detailed results.",
			"Ensure the section numbering and title match the CTD Table of Contents (2.5.1 Product Development Rationale) and are consistent with the overall Module 2 structure.",
			"Provide a concise overview of clinical findings, highlighting important limitations such as missing populations, endpoints, or comparators.",
			"Discuss how prescribing information and risk management measures will optimize benefits and mitigate risks.",
			"Ensure that release and shelf-life specifications, including any alternative analytical procedures and associated acceptance criteria, are clearly presented and consistent with data discussed in the rationale.",
			"Describe formulation development considering route of administration and usage, and discuss differences between clinical and proposed commercial formulations.",
			"Discuss compatibility of drug substance(s) with excipients and, for combination products, compatibility between drug substances.",
			"Include a concise description of the clinical or pathophysiological condition targeted by the product and the proposed indication(s).",
			"Explain concordance or lack of concordance with current standard research approaches in study design, conduct, and analysis.",
			"If historical analytical procedures are discussed to support development decisions, clearly identify them and reference their location in the CTD.",
			"Ensure that any discussion of drug substance properties in the rationale is consistent with and cross-referenced to section 3.2.S.3.1, including possible alternative forms.",
			"Provide a brief overview of major existing therapies for the intended patient population.",
			"If impurities are discussed in the rationale, ensure all observed impurities are listed and provide justification for any not included in the specification, with cross-reference to the justification section.",
			"Describe and justify the overall clinical development approach, including rationale for study design and key decisions.",
			"Maintain clear structure and logical flow, aligning with CTD Module 2.5 format and linking to supporting data in Module 5.",
			"Identify and describe formulation and process attributes (critical parameters) that can influence batch reproducibility, product performance, and drug product quality.",
			"When referencing analytical procedures in the rationale, ensure they are aligned with those listed in the specification and appropriately cross-referenced to relevant CTD sections.",
			"Maintain logical flow and organization, grouping related topics (formulation, process, container, microbiology) under appropriate subheadings.",
			"Ensure that the section distinguishes development studies from routine control tests conducted according to specifications.",
			"Cite formal regulatory advice documents and ensure that copies are included in Module 5 references.",
			"Identify unresolved clinical issues, justify why they are not barriers to approval, and outline plans for resolution.",
			"Describe plans for the use of foreign clinical data in accordance with ICH E5.",
			"Explain selection and optimization of the manufacturing process, highlighting critical aspects and differences from clinical batch processes.",
			"Highlight strengths and limitations of the clinical development program and study results.",
			"Present conclusions and implications of clinical findings, integrating data from the Clinical Summary, individual study reports, and other relevant sources.",
			"Address physicochemical and biological properties relevant to product performance, such as pH, dissolution, particle size, and biological activity.",
			"Identify regulatory guidance and advice received and describe how the advice was implemented.",
			"Use clear, scientific, and consistent terminology throughout the section.",
			"Assess the quality of study design and performance, and include a statement confirming GCP compliance.",
			"Ensure consistency between the Clinical Overview, Clinical Summary, and other CTD modules.",
			"Cross-reference supporting data and studies to relevant CTD sections (e.g., nonclinical, clinical, 3.2.P.1, 3.2.P.3.3, 3.2.P.7).",
			"Verify that all data and discussions support the overall product development rationale and demonstrate suitability for intended use.",
			"Provide concise summaries of development studies, referencing detailed data in other CTD sections where appropriate.",
			"If starting materials are discussed in the rationale, ensure justification and analytical control information are consistent with section 3.2.S.2.3 and, for biological origin materials, with section 3.2.A.2.",
			"Address microbiological attributes, including rationale for microbial testing, preservative system selection, and container closure integrity for sterile products.",
			"Address specific efficacy or safety issues encountered during development and describe how they were evaluated and resolved.",
			"Explain the basis for any unusual or critical aspects of the proposed prescribing information.",
			"Briefly summarise the scientific background supporting investigation of the medicinal product.",
			"Provide a brief summary of the clinical development program, including ongoing and planned studies, and rationale for timing of submission.",
			"When presenting batch analysis data in support of development rationale, include descriptions of batches and results from all relevant tests, including those not in the specification, and collated data where applicable.",
			"Ensure the section identifies the pharmacological class of the medicinal product.",
			"If skip testing is part of the development rationale, include justification and reference to supporting data from other CTD sections.",
			"Ensure compliance with ICH Q6A and Q6B guidelines for quality and specification standards.",
			"Ensure the Clinical Overview is succinct, interpretive, and focused on regulatory relevance rather than exhaustive data presentation.",
			"Reference pertinent published literature supporting clinical rationale.",
			"Explain the choice and function of excipients relative to their influence on product performance.",
			"Include a clear heading and subheading structure consistent with the CTD Table of Contents to facilitate navigation and cross-referencing.",
			"Verify that the section is properly placed within the Clinical Overview (Module 2.5) and appropriately linked to subsequent sections (2.5.2–2.5.7).",
			"If intermediates or critical steps are referenced in the rationale, ensure batch data, analytical procedures, and acceptance criteria are consistent with sections 3.2.S.2.4, 3.2.S.4.1, and 3.2.S.4.2.",
			"Ensure that summaries of development studies clearly distinguish them from routine control tests, as per CTD guidance.",
			"Evaluate benefits and risks of the medicinal product, explaining how efficacy and safety findings support the proposed dose and indication.",
			"Include justification for any formulation overages.",
			"Structure the section to clearly present the rationale for product development, covering formulation, manufacturing process, container closure system, and microbiological attributes.",
			"Include discussions of critical formulation and process parameters that influence batch reproducibility, product performance, and quality.",
			"Discuss suitability of the container closure system, including material choice, protection from environmental factors, compatibility, safety, and performance.",
			"If reprocessing operations are relevant to the development rationale, ensure justification, critical controls, and validation information are consistent with sections 3.2.S.2.2, 3.2.S.2.4, and 3.2.S.2.5.",
		],
	},
	{
		number: "2.5.2",
		title: "Overview of Bio-pharmaceutics",
		input: [
			"Compile in vitro–in vivo correlation (IVIVC) data, if available.",
			"Collect data from formulation development studies that impact bioavailability, including formulation composition and manufacturing process parameters.",
			"Compile data on inter- and intrasubject variability observed in comparative bioavailability studies.",
			"Gather summaries and full reports of comparative bioavailability/bioequivalence studies against reference/comparator products.",
			"Gather references or electronic links to the full reports of each bio-pharmaceutics study for inclusion in the narratives.",
			"Collect data on formulation and manufacturing changes and their effects on in vitro dissolution and bioavailability, including any PK studies comparing pre- and post-change products.",
			"Refer to Appendix A for any additional guidance or templates relevant to the preparation of the Overview of Bio-pharmaceutics section.",
			"Obtain analytical method validation reports for assays used in bio-pharmaceutics studies (e.g., dissolution, assay of active ingredient in plasma).",
			"Gather relevant literature references supporting bio-pharmaceutic properties of the drug substance and drug product.",
			"If large volumes of statistical output or detailed analyses from bio-pharmaceutics studies exist that are too extensive for inclusion in the overview, prepare these as separate detailed reports for placement in the appropriate Module 5 section, with summaries in Module 2.",
			"Consult the health authority for guidance if the drug substance is already approved, to determine whether abbreviated or cross-referenced bio-pharmaceutics information is acceptable.",
			"Prepare tabular datasets summarizing bioavailability and in vitro dissolution results, including mean ratios (test/reference) for Cmax and AUC and their 90% confidence intervals or other recommended bioequivalence metrics.",
			"If the drug product includes a reconstitution diluent, gather complete bio-pharmaceutic and stability information for the diluent as a separate drug product, as appropriate.",
			"If applicable, collect pharmacodynamic (PD) or clinical trial data and antigenicity data when required to support conclusions about product similarity following formulation or manufacturing changes.",
			"Gather information on reference standards and comparator products used in bio-pharmaceutics studies, including certificates of analysis.",
			"Collect comparative bioavailability data for different dosage form strengths and for clinical versus marketed formulations.",
			"Collect any expert opinions or advisory board recommendations on bioavailability/bioequivalence strategy.",
			"Obtain pharmacokinetic (PK) study data, including single-dose and multiple-dose PK studies, food-effect studies, and dose proportionality studies.",
			"If multiple manufacturers or stability study protocols exist, collect stability data organized per manufacturer or per protocol, ensuring traceability and differentiation.",
			"Obtain data on food-effect studies assessing the impact of meal type and timing on bioavailability and bioequivalence conclusions.",
			"Collect narrative summaries or abstracts of each bio-pharmaceutics study, including critical design features and critical results, which may be adapted from the ICH E3 synopsis.",
			"Obtain regulatory correspondence or previous assessment reports related to bio-pharmaceutics performance.",
			"Compile in vitro\u0013in vivo correlation (IVIVC) data, if available.",
			"Gather data on correlations between in vitro dissolution and bioavailability, including pH effect studies and conclusions regarding dissolution specifications.",
			"Collect stability study data that may impact bioavailability (e.g., degradation affecting dissolution rate).",
			"Collect all bio-pharmaceutics study reports relevant to the drug product, including bioavailability (BA) studies, bioequivalence (BE) studies, and in vitro dissolution studies.",
		],
		output: [
			"Ensure all data presented are consistent with corresponding sections in Modules 3 and 5.",
			"Applicants may modify the format of the Overview of Bio-pharmaceutics section if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation of the results by regulatory reviewers.",
			"Present key results in summary tables or figures for clarity, ensuring units and statistical parameters are clearly labeled.",
			"When providing cross-references in the text, include at least the section number in cross strings; write the surrounding text so the reader understands the section content without requiring the full section name.",
			"If detailed statistical analyses or large volumes of data are too extensive for inclusion in the overview, summarize key findings in Module 2 and place full detailed reports in the appropriate Module 5 section, ensuring clear cross-references.",
			"Maintain concise, factual summaries without duplicating detailed data from Module 5 reports.",
			"Include references or electronic links to the full report of each study within the narrative text.",
			"Group similar studies together in the narrative, noting individual study results and important differences among them.",
			"Ensure compliance with regional requirements for inclusion or exclusion of certain study types in the overview.",
			"Summarize findings in both text and tables, using tables to enhance clarity and readability.",
			"Check that any claims about bioavailability or bioequivalence are supported by data and statistical analysis presented in the section.",
			"Include evidence and conclusions regarding formulation and manufacturing changes, food effects, in vitro–in vivo correlations, and comparative bioavailability across dosage strengths and formulations.",
			"If the drug substance is already approved, ensure the overview clearly indicates reliance on existing approvals and references to prior submissions as per health authority guidance.",
			"When presenting stability-related bio-pharmaceutic information, indicate whether data are provided in their entirety or organized per manufacturer or per stability study protocol, ensuring clarity and traceability.",
			"Ensure that tables and figures are clearly labeled and formatted consistently with ICH recommendations.",
			"Organize content logically to cover: (1) formulation development and its impact on bioavailability, (2) summary of in vitro dissolution studies, (3) summary of in vivo BA/BE studies, (4) discussion of IVIVC, and (5) conclusions on bio-pharmaceutic performance.",
			"If the product includes a reconstitution diluent, clearly indicate that the diluent information is treated as a separate drug product and summarize its bio-pharmaceutic relevance accordingly.",
			"Structure the section as a concise, integrated overview summarizing all relevant bio-pharmaceutics data without duplicating detailed study reports from Module 5.",
			"Embed tables and figures within the text when they enhance readability; place lengthy tables in an appendix at the end of the section.",
			"Provide a factual summary of all in vitro dissolution, bioavailability, and comparative bioavailability studies, emphasizing differences in results across studies.",
			"Decide whether to present information and results in tables, text, or figures based on which format best aids clarity; use tables to list studies if results are better shown in text or figures.",
			"Write narrative descriptions briefly, similar to an abstract for a journal article, describing critical design features and critical results.",
			"Confirm that the Overview of Bio-pharmaceutics section does not include individual documents or files at lower heading levels, but rather summarizes and cross-references relevant data sources.",
			"Highlight any differences between test and reference products and provide scientific justification.",
			"Cross-reference detailed study reports in Module 5 and analytical methods in Module 3 where applicable, rather than repeating full details.",
			"Use consistent terminology for bioavailability, bioequivalence, dissolution, and pharmacokinetics in accordance with ICH and regional regulatory definitions.",
			"Ensure that lower-level headings within the Overview of Bio-pharmaceutics do not contain individual documents or files, but only summarized information and cross-references.",
			"Report the source and magnitude of inter- and intrasubject variability for each formulation in comparative bioavailability studies.",
			"When designing tables for bioavailability and in vitro dissolution studies, include study type, design, results, and bioequivalence metrics such as mean ratios (test/reference) for Cmax and AUC with 90% confidence intervals.",
			"Verify that all studies mentioned are appropriately identified by study number, title, and type.",
			"Maintain a clear, factual, and non-promotional tone, focusing on scientific and regulatory relevance.",
		],
	},
	{
		number: "2.5.3",
		title: "Overview of Clinical Pharmacology",
		input: [
			"Ensure availability of the draft or final 'Overview of Clinical Pharmacology' document template as per CTD Module 2.5 structure.",
			"Gather data on clinically relevant pharmacokinetic interactions with other medicinal products or substances.",
			"Obtain summaries and datasets from population PK analyses and exposure-response modeling studies, if available.",
			"Gather data on pharmacokinetics related to intrinsic factors (e.g., age, sex, race, renal and hepatic impairment) and extrinsic factors (e.g., smoking, concomitant drugs, diet).",
			"Identify any detailed statistical outputs or large datasets from clinical pharmacology analyses that may need to be placed in Module 5 appendices rather than in the Module 2 overview.",
			"Obtain data on rate and extent of absorption, distribution (including plasma protein binding), metabolism (including genetic polymorphism and metabolite formation), and excretion.",
			"Collect relevant non-clinical pharmacology data that support the clinical pharmacology findings (e.g., mechanism of action, receptor binding).",
			"Collect pharmacodynamic data on mechanism of action, receptor binding, onset and offset of action, and PK/PD relationships.",
			"Collect comparator product information and reference standards used in clinical pharmacology studies.",
			"If the drug substance is already approved, consult the relevant health authority for guidance on data submission requirements before preparing the clinical pharmacology overview.",
			"Ensure access to the clinical study protocols and statistical analysis plans for all clinical pharmacology studies.",
			"Obtain any integrated analyses of clinical pharmacology data across studies, ensuring they are comprehensive and not merely summaries, in line with FDA guidance.",
			"Gather results and interpretations of immunogenicity studies, clinical microbiology studies, or other drug class–specific PD studies summarized in section 2.7.2.4 of the Clinical Summary.",
			"Collect data on comparative pharmacokinetics in healthy subjects, patients, and special populations.",
			"Gather data from bioavailability and bioequivalence studies that support the clinical pharmacology profile.",
			"Collect all clinical pharmacology study reports, including pharmacokinetic (PK), pharmacodynamic (PD), and dose-response studies relevant to the investigational product.",
			"Collect data on time-dependent changes in pharmacokinetics and stereochemistry issues.",
			"Obtain pharmacodynamic data supporting the proposed dose and dosing interval, including clinically relevant PD interactions and genetic differences in response.",
			"Compile summary tables of key PK parameters (Cmax, AUC, t1/2, clearance, volume of distribution) across studies.",
			"Retrieve any regulatory correspondence or prior agency feedback related to clinical pharmacology aspects of the product.",
			"Gather supportive data from Section 2.7.2 that can be incorporated into the Overview of Clinical Pharmacology where relevant.",
			"Gather data on intrinsic and extrinsic factors affecting pharmacokinetics (e.g., age, gender, renal/hepatic impairment, drug interactions).",
			"Refer to Appendix A or equivalent regulatory appendices for cross‑referenced requirements that may affect the clinical pharmacology overview content or structure.",
			"Obtain literature references supporting the pharmacologic mechanism, metabolism, and pharmacokinetic properties of the drug.",
			"Refer to Appendix A or equivalent regulatory appendices for cross-referenced requirements that may affect the clinical pharmacology overview content or structure.",
			"Gather analytical method validation reports used in PK/PD assessments.",
		],
		output: [
			"Organize content logically to cover pharmacokinetics, pharmacodynamics, and relevant dose-response relationships.",
			"Include a concise, integrated summary of clinical pharmacology findings rather than reproducing detailed data from Module 2.7 or Module 5.",
			"If the drug substance is already approved, ensure the overview clearly indicates reliance on existing approvals and aligns with health authority guidance on referencing approved data.",
			"Avoid repetition of material presented elsewhere; use cross-references to the Clinical Summary (Module 2.7) or Module 5 for detailed data.",
			"Cross-reference detailed study summaries in Module 2.7.2 and full reports in Module 5, avoiding duplication of data.",
			"Structure the section according to CTD Module 2.5.3 requirements under the Clinical Overview (Module 2).",
			"Ensure that the analysis emphasizes interpretation and integration of data rather than descriptive repetition of study results.",
			"Incorporate supportive data from Section 2.7.2 into the Overview of Clinical Pharmacology where it strengthens the interpretation, ensuring proper cross-referencing and avoiding duplication.",
			"Ensure the section is an integrated analysis of all relevant clinical pharmacology data, not just a summary, in line with FDA guidance.",
			"Use graphs and concise tables within the text to enhance clarity and brevity.",
			"Ensure internal consistency between this section and the Summary of Clinical Pharmacology Studies (Module 2.7.2).",
			"Provide a critical analysis of PK, PD, and related in vitro data, explaining how the data support conclusions and highlighting unusual results or potential issues.",
			"If detailed analyses or large statistical outputs are too extensive for Module 2.5.3, summarize key findings in this section and place full details in the appropriate Module 5 section with clear cross-references.",
			"When providing cross-references in the text, include the section number in the cross string and write the surrounding text so the reader understands the section content without needing the full section name.",
			"Follow standard CTD formatting conventions, including section numbering, headings, and pagination consistent with Module 2 layout.",
			"Include summary tables or figures where appropriate to illustrate PK/PD relationships and variability across studies.",
			"Use unique and consistent short study identifiers for all clinical studies referenced in the Overview of Clinical Pharmacology, aligned with identifiers used throughout Modules 2 and 5.",
			"Verify that all referenced studies and data are traceable to corresponding reports in Module 5.",
			"Ensure consistency of terminology and data presentation with other CTD sections (e.g., 2.5.2 Overview of Biopharmaceutics and 2.5.4 Overview of Efficacy).",
			"Maintain concise length appropriate for an overview section, focusing on interpretation and integration rather than raw data presentation.",
			"Applicants may modify the format of the section if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation of the results by regulatory reviewers.",
			"Ensure the Clinical Overview, including section 2.5.3, remains concise (approximately 30 pages for the entire overview) and proportionate to the complexity of the application.",
			"Include interpretation of immunogenicity, clinical microbiology, or other drug class–specific PD studies as relevant.",
			"Explicitly address pharmacokinetics (absorption, distribution, metabolism, excretion, intrinsic/extrinsic factors, interactions, stereochemistry) and pharmacodynamics (mechanism, PK/PD relationships, dose-response, interactions, genetic variability).",
			"Perform a compliance check to confirm that all required subsections and cross-references are present and correctly labeled.",
			"Use clear, scientific language suitable for regulatory review, avoiding promotional or interpretive statements.",
		],
	},
	{
		number: "2.5.4",
		title: "Overview of Efficacy",
		input: [
			"Gather individual efficacy response data and adverse event listings for each patient, as referenced in the efficacy overview.",
			"Collect nonclinical data and clinical pharmacology data needed to support or contextualize human efficacy findings.",
			"Collect dose-response, PK/PD, subgroup, and dosage-modification data referenced in Section 2.7.2.",
			"Collect narrative elements for important efficacy studies, including critical design features, critical results, and exposure/safety collection information for studies contributing to safety analyses.",
			"Ensure availability of any appendices or supplementary reports that will be placed in Module 5 but referenced in the Overview of Efficacy.",
			"Gather all relevant clinical efficacy data from pivotal and supportive clinical trials, including integrated analyses of efficacy (ISE) where applicable.",
			"Collect evidence supporting assay sensitivity and justification for the choice of non-inferiority margin for non-inferiority trials (ICH E10).",
			"Gather any relevant animal data or product quality information that may have clinical implications for efficacy.",
			"Collect information on prematurely terminated studies, including reasons for termination and potential impact on efficacy conclusions.",
			"Identify and collect comparator product information if used in efficacy studies.",
			"Prepare a tabular listing of all studies providing or intended to provide efficacy information (for inclusion in Section 2.7.3.6 Appendix).",
			"Gather individual patient data listings relevant to efficacy analysis (e.g., patients excluded from efficacy analysis, disposition listings).",
			"Obtain documentation of any important modifications to study design, endpoint assessments, or planned analyses, including rationale and protocol versions.",
			"Collect microbiology data from both in vitro and in vivo studies if relevant to efficacy claims.",
			"Collect lists of discontinued patients, protocol deviations, patients excluded from efficacy analysis, and compliance or drug concentration data.",
			"Gather synopses of clinical study reports (ICH E3) to support creation of brief narrative study descriptions.",
			"Gather justification and supporting evidence for use of surrogate endpoints, including validation data for any scales used.",
			"Gather data supporting benefit-risk evaluation, including safety findings relevant to efficacy interpretation.",
			"Gather data on observed relationships between efficacy, dose, and dosage regimen for each indication, including subgroup-specific findings (ICH E4).",
			"Collect information on the extent of exposure of study subjects to the test drug and how safety data were collected for studies contributing to both safety and efficacy, for inclusion in study narratives in Section 2.7.3.2.",
			"Obtain statistical analyses, datasets, and outputs from efficacy studies, including any large-scale statistical listings.",
			"Gather information on unplanned analyses, procedures for handling missing data, and corrections for multiple endpoints.",
			"Obtain signed statements or certifications from principal or coordinating investigators or the sponsor’s responsible medical officer, as required by regulatory authorities.",
			"Gather any relevant nonclinical microbiology information that supports efficacy, if applicable.",
			"Retrieve previous regulatory submissions or correspondence that may inform the efficacy overview content.",
			"Gather audit certificates, documentation of statistical methods, and inter-laboratory standardization and quality assurance procedures if used.",
			"Collect the Clinical Summary document (Module 2.7) to ensure alignment and cross-referencing with the Overview of Efficacy.",
			"Gather information on the clinical relevance of the magnitude of observed effects.",
			"Assemble information on the overall clinical development program, including rationale for study design decisions and critical development milestones.",
			"Collect data supporting applicability of foreign clinical data to the new region (ICH E5).",
			"Gather indication-specific efficacy data and study reports for each indication when multiple indications are being submitted, ensuring they can be organized under indication-specific headings in the CTD numbering system.",
			"Collect demographic data tables, efficacy data tables, and safety data tables referenced in the Overview of Efficacy.",
			"Gather demographic data and baseline characteristics for all study populations across efficacy studies.",
			"Collect publications based on or referenced in the study that support efficacy conclusions.",
			"Gather appendices containing study information such as protocols, protocol amendments, sample case report forms, and lists of investigators and ethics committees.",
			"Gather data on the overall extent of exposure of all subjects (patients and healthy volunteers) exposed to at least one dose of the drug product, including identification of subsets relevant to proposed indications.",
			"Collect documentation demonstrating GCP compliance for clinical studies included in the efficacy overview.",
			"Collect supportive data from Section 2.7.2 that may be incorporated into the Overview of Efficacy.",
			"Collect efficacy data in special populations (e.g., children, elderly) and justification for extrapolation if data are inadequate.",
			"Obtain individual clinical study reports (ICH E3 compliant) for all efficacy studies referenced in the overview.",
			"Collect data on similarities and differences in results among studies and across patient subgroups, including subgroup analyses.",
			"Gather long-term efficacy data, including maintenance of effect, long-term dosage, and tolerance development.",
			"Collect randomization schemes and codes, including patient identification and treatment assignment information.",
			"Assemble combined or pooled datasets required for cross-study comparisons and integrated analyses of efficacy.",
			"Assemble detailed clinical study reports and protocols for efficacy studies (to be referenced or summarized).",
			"Collect data on in vitro susceptibility patterns of bacterial strains from global regions when this information is relevant to contextualizing efficacy but not part of clinical efficacy studies.",
			"Collect data on disease characteristics, prior treatments, inclusion/exclusion criteria, and any differences between study populations.",
			"Collect case report forms (CRFs) for deaths, serious adverse events, and withdrawals due to adverse events.",
			"Compile information and full reports for any bridging studies using clinical endpoints (ICH E5), including PK/PD data supporting extrapolation between regions.",
			"Collect prescribing information drafts or proposed labeling to ensure consistency with efficacy conclusions.",
			"Collect data on plasma concentration monitoring and documentation for optimal plasma concentration ranges, if applicable.",
			"Compile literature references that support efficacy claims.",
			"Gather dropout and discontinuation data, including timing and reasons.",
		],
		output: [
			"When statistical outputs are too extensive for inclusion in the overview, present them in a separate report in section 5.3.5.3 and reference appropriately.",
			"Identify and discuss major inconsistencies in efficacy data and areas requiring further exploration.",
			"Maintain a clear, concise, and interpretive writing style suitable for regulatory reviewers, emphasizing benefit-risk interpretation and clinical relevance.",
			"Summarize results of any bridging studies, including similarity of efficacy between regions and supporting evidence for extrapolation.",
			"For non-inferiority trials, present evidence of assay sensitivity and justify the choice of non-inferiority margin (ICH E10).",
			"Group similar studies together in the narratives and highlight important differences among them.",
			"Describe statistical methods and any issues affecting interpretation, including protocol modifications, unplanned analyses, handling of missing data, and corrections for multiple endpoints.",
			"Discuss efficacy in special populations and justify extrapolation if clinical data are inadequate.",
			"For Module 5.3.5 Reports of Efficacy and Safety Studies, organize by indication with retained CTD numbering (e.g., 5.3.5.UTI, 5.3.5.1 UTI Controlled studies, etc.).",
			"Discuss data suggesting benefits from plasma concentration monitoring and define optimal concentration ranges if applicable.",
			"Ensure study narratives are brief, similar to journal abstracts, and describe critical design features and results.",
			"If relying on surrogate endpoints, explain expected clinical benefit and the basis for these expectations.",
			"Provide a brief overview of clinical findings, highlighting important limitations such as missing populations, endpoints, or comparators.",
			"Discuss implications of study design, including patient selection, study duration, choice of endpoints, and control groups, with justification for surrogate endpoints and validation of scales used.",
			"Include a section for tables, figures, and graphs referred to in the text but not included, ensuring proper numbering and referencing (e.g., Section 14).",
			"Follow CTD M4E guidance for structure and content of the Overview of Efficacy, aligning with ICH E-3 principles where applicable.",
			"Place extensive analytical details in a separate report in Module 5, Section 5.3.5.3, and reference them appropriately.",
			"Ensure that the table summarizing overall extent of exposure includes all subjects exposed to at least one dose of the drug product, and identify subsets relevant to proposed indications.",
			"Ensure that the full title of each cited study is included in the Tabular Listing of All Clinical Studies (Section 5.2).",
			"Describe demographic and baseline characteristics of all study populations, including disease characteristics and prior treatment.",
			"Ensure that patient data listings (e.g., discontinued patients, protocol deviations, excluded patients, compliance data, individual efficacy responses) are available and referenced appropriately.",
			"Use tabular presentations to combine and compare study populations across studies when useful.",
			"Address specific efficacy issues encountered during development and describe how they were evaluated and resolved.",
			"Note prematurely terminated studies and assess their impact on efficacy conclusions.",
			"Analyze similarities and differences in results among studies and across patient subgroups, and discuss their impact on interpretation.",
			"Evaluate the clinical relevance of the magnitude of observed effects.",
			"Evaluate benefits and risks based on conclusions of relevant clinical studies, explaining how efficacy findings support the proposed dose and indication.",
			"Explain the basis for important or unusual aspects of the prescribing information related to efficacy.",
			"Describe and explain the overall approach to clinical development, including rationale for key study design decisions.",
			"Discuss unresolved issues, justify why they are not barriers to approval, and outline plans for resolution.",
			"For long-term use products, discuss maintenance of efficacy, long-term dosage, and tolerance development.",
			"Ensure clarity and ease of navigation for the reader by structuring the overview logically and referencing supporting documents in Module 5.",
			"Use a unique short identifier for each clinical study and apply it consistently throughout the entire application, including the Overview of Efficacy.",
			"Describe observed relationships between efficacy, dose, and dosage regimen for each indication, in overall and subgroup populations (ICH E4).",
			"Do not include detailed information about individual studies; provide only summary-level information.",
			"Ensure demographic, efficacy, and safety data tables are clearly labeled and correspond to referenced sections (14.1–14.3).",
			"Include microbiology efficacy-related information in the Overview of Efficacy if relevant, with detailed reports in the appropriate Module 5 section.",
			"In Section 2.7.3.2 narratives for studies contributing to both safety and efficacy, include a reasonably complete description of the study, including extent of exposure and how safety data were collected, but discuss safety results in Section 2.7.4.",
			"Include a critical analysis of the clinical data, focusing on conclusions and implications rather than raw results.",
			"Present dropout and discontinuation assessments, including timing and reasons.",
			"For studies contributing to safety analyses, include exposure information and methods of safety data collection in narratives.",
			"Cross-reference important dosage, dose interval, subgroup, and PK/PD evidence from Section 2.7.2.",
			"Include a tabular listing of all studies providing efficacy information, with narrative descriptions for important studies.",
			"Ensure that all referenced tables, figures, and appendices are properly cross-referenced and consistent with the main text of the Overview of Efficacy.",
			"Include appendices with study information (protocols, CRFs, investigator lists, ethics committee information, signatures, randomization codes, audit certificates, statistical documentation) as supporting documentation referenced in the Overview of Efficacy.",
			"Assess the quality of study design and performance, and include a statement regarding GCP compliance.",
			"Identify all studies deemed relevant for evaluation of efficacy and provide reasons for excluding any apparently adequate and well-controlled studies.",
			"Present an integrated analysis of all relevant efficacy data rather than a simple summary.",
			"Use cross-references effectively: in paper submissions, include only the section number in cross strings, but write the text so the reader understands the section content.",
			"Ensure that indication-specific sections follow the same organization pattern across all relevant CTD sections where applicable.",
			"Provide a succinct discussion and interpretation of clinical findings rather than a detailed recapitulation of data.",
			"If the Module 2 summary meets the requirements of 21 CFR 314.50, it can fulfill the need for an ISE; otherwise, summarize in Module 2 and place detailed reports in Module 5.",
			"When multiple indications are included, retain current CTD numbering and identify each indication in section headings (e.g., 2.7.3.UTI Summary of Clinical Efficacy, 2.7.3.1.UTI Background, etc.).",
			"Determine the appropriate level of detail for the Overview of Efficacy; it may contain detail similar to an ISE but not as extensive as an ISS, unless justified.",
			"Incorporate supportive data from Section 2.7.2 where relevant to strengthen efficacy interpretation.",
			"Include references or electronic links to full clinical study reports within study narratives.",
			"Discuss applicability of foreign clinical data to the new region, where relevant (ICH E5).",
			"Summarize and analyze bridging studies using clinical endpoints, including conclusions relevant to cross-region extrapolation.",
			"Include references to relevant annexes (e.g., Annex VI and VII for patients excluded from efficacy analysis) when summarizing efficacy data.",
			"Discuss relevant features of patient populations, including demographics, disease stage, important covariates, excluded populations, and participation of children and elderly, and compare to the expected post-marketing population.",
			"Identify and describe differences in baseline characteristics across studies and between efficacy-analysis populations and the target treatment population.",
			"Differentiate Section 2.7.3.3 and Section 2.7.3.4 appropriately: Section 2.7.3.3 summarizes efficacy data across all studies, while Section 2.7.3.4 provides an integrated analysis of dose-response or concentration-response effectiveness.",
			"Summarize results across all studies, addressing whether results reinforce or contradict one another.",
			"Follow ICH E3 structure for appendices and annexes to maintain consistency and traceability of efficacy data sources.",
			"Ensure the overview aligns with and references the Clinical Summary (Module 2.7) and individual study reports (Module 5).",
		],
	},
	{
		number: "2.5.5",
		title: "Overview of Safety",
		input: [
			"Collect all clinical safety study reports relevant to the product, including controlled and uncontrolled clinical studies for inclusion or reference in section 2.5.5.",
			"Prepare a list of all clinical studies contributing to the safety evaluation, including study identifiers and corresponding CTD section numbers for cross-referencing.",
			"Gather integrated safety analyses or any available ISS\u0002level or ISE\u0002level datasets or reports, as section 2.5.5 must be based on integrated analyses of all relevant safety data.",
			"Obtain narrative descriptions from section 2.7.3.2 for studies contributing both efficacy and safety, including details on extent of exposure to the test drug and how safety data were collected, for cross-reference in section 2.5.5.",
			"Gather integrated safety analyses or any available ISS\u0011level or ISE\u0011level datasets or reports, as section 2.5.5 must be based on integrated analyses of all relevant safety data.",
			"Collect any regulatory correspondence or previous submissions discussing safety issues or database limitations.",
			"Identify and extract data subsets relevant to the proposed indications from the overall exposure table for inclusion or discussion in section 2.5.5.",
			"Obtain summaries of postmarketing safety data, if available, to assess limitations and potential implications of the safety database.",
			"Gather integrated safety analyses or any available ISS‑level or ISE‑level datasets or reports, as section 2.5.5 must be based on integrated analyses of all relevant safety data.",
			"Prepare a comprehensive table summarizing the overall extent of exposure to the drug product across all clinical phases, including all subjects (patients and healthy volunteers) exposed to at least one dose.",
			"Collect supportive data from Section 2.7.2 that may be relevant to the Overview of Safety for incorporation or cross-reference.",
			"Gather integrated safety analyses or any available ISS- or ISE-level datasets or reports, as section 2.5.5 must be based on integrated analyses of all relevant safety data.",
			"Collect any appendices or detailed safety analyses intended for placement in Module 5 if they are too extensive to include in the section 2.5.5 narrative.",
			"Gather population pharmacokinetic (PK) study reports (e.g., study 101) that include safety-related findings for cross-referencing in the Overview of Safety.",
			"Gather population pharmacokinetic (PK) study reports that include safety-related findings for cross-referencing in the Overview of Safety.",
			"Compile the safety database used for analysis, including all adverse event data, exposure data, and safety monitoring results from clinical trials.",
			"Gather expert opinions or internal safety assessments addressing the completeness and reliability of the safety database.",
			"Gather information from any bridging studies or analyses that assess the extrapolation of foreign clinical safety data to the target region, as these may inform the interpretation of safety data in section 2.5.5.",
			"Collect all clinical safety study reports relevant to the product, including controlled and uncontrolled clinical studies (e.g., pneumonia study 101A) for inclusion or reference in section 2.5.5.",
		],
		output: [
			"Maintain consistency in terminology and section numbering throughout the document to ensure accurate cross-referencing.",
			"Discuss the potential implications of these limitations for the interpretation of safety data and overall product risk assessment.",
			"Place extensive supporting analyses or large volumes of statistical output in Module 5 rather than in section 2.5.5, and cross‑reference them appropriately.",
			"Ensure that the level of detail included in section 2.5.5 is appropriate for a Module 2 summary, recognizing that it should not contain ISS‑level detail but may contain detail similar to an ISE where appropriate.",
			"Ensure that cross-references to study reports within section 2.5.5 include only the section number (e.g., 5.3.5.2 or 5.3.3.5) in parentheses to maintain clarity and brevity.",
			"Write the text so that the reader can easily identify the content of the referenced section without including the full section name in the cross-reference.",
			"If applicable, include a discussion of postmarketing steps or plans to address identified limitations in the safety database.",
			"Place extensive supporting analyses or large volumes of statistical output in Module 5 rather than in section 2.5.5, and cross\u0002reference them appropriately.",
			"Ensure that the level of detail included in section 2.5.5 is appropriate for a Module 2 summary, recognizing that it should not contain ISS\u0011level detail but may contain detail similar to an ISE where appropriate.",
			"Place extensive supporting analyses or large volumes of statistical output in Module 5 rather than in section 2.5.5, and cross\u0011reference them appropriately.",
			"Use a unique short identifier for each clinical study and apply it consistently throughout the entire application, including section 2.5.5 citations.",
			"When referencing studies that contribute both efficacy and safety data, ensure section 2.5.5 discussion is based on safety-relevant results while cross-referencing the narrative descriptions in section 2.7.3.2.",
			"Ensure that the level of detail included in section 2.5.5 is appropriate for a Module 2 summary, recognizing that it should not contain ISS\u0002level detail but may contain detail similar to an ISE where appropriate.",
			"Clearly describe the limitations of the safety database, including any gaps in data, underrepresented populations, or limited exposure durations.",
			"Place extensive supporting analyses or large volumes of statistical output in Module 5 rather than in section 2.5.5, and cross-reference them appropriately.",
			"Confirm that section 2.5.5 aligns with the outline principles used in ISS/ISE documents while remaining consistent with the CTD Clinical Overview format.",
			"Modify the format of section 2.5.5 when necessary to provide the best possible presentation of safety information and to facilitate regulatory reviewers\u0019 understanding and evaluation of results.",
			"Use the ICH E3 Guideline definition of 'Common Adverse Events' when describing or categorizing adverse events in section 2.5.5 to ensure terminology consistency.",
			"When presenting overall exposure data, ensure that the table or summary includes all subjects exposed to at least one dose of the drug product, and clearly identify subsets relevant to the proposed indications.",
			"Discuss the potential implications of database limitations for the interpretation of safety data and overall product risk assessment.",
			"Ensure that the Overview of Safety is written in a clear, concise, and scientifically objective manner, suitable for regulatory review.",
			"Modify the format of section 2.5.5 when necessary to provide the best possible presentation of safety information and to facilitate regulatory reviewers’ understanding and evaluation of results.",
			"Verify that all referenced study reports are correctly located in the corresponding CTD sections (e.g., 5.3.5.3 for safety study reports).",
			"Follow CTD numbering conventions and retain identification of the indication when applicable to maintain consistency across modules and facilitate reviewer navigation.",
			"Ensure that the level of detail included in section 2.5.5 is appropriate for a Module 2 summary, recognizing that it should not contain ISS-level detail but may contain detail similar to an ISE where appropriate.",
			"If bridging or extrapolation of foreign safety data is relevant, briefly summarize the implications for safety interpretation in section 2.5.5 and cross-reference detailed analyses located in other CTD sections (e.g., 2.7.3.2 or 5.3.5.3).",
			"Ensure that the Overview of Safety narrative reflects the integrated nature of the ISS/ISE framework, emphasizing analysis rather than mere summarization of data.",
			"Ensure that section 2.5.5 provides an integrated analysis of all relevant safety data rather than a simple summary, consistent with FDA guidance on ISS/ISE structure.",
			"Incorporate supportive data from Section 2.7.2 where relevant to strengthen the integrated safety discussion, ensuring proper cross-referencing and consistency.",
			"Write the text so that the reader can easily identify the content of the referenced section without including the full section name in the cross string.",
		],
	},
	{
		number: "2.5.6",
		title: "Benefits and Risks Conclusions",
		input: [
			"Identify and compile 'Key Benefits' of the product, including clinical efficacy data, patient-reported outcomes, and other relevant endpoints.",
			"Ensure access to the CTD Module 2 Table of Contents to confirm correct placement and numbering of Section 2.5.6 within the overall structure.",
			"Gather data on the strengths, limitations, and uncertainties of the benefit and risk information.",
			"Identify and compile limitations or uncertainties in understanding the disease or condition and current therapies.",
			"Collect information on disease severity in relevant subpopulations.",
			"For early clinical trials (e.g., Phase 1 or trials in healthy participants), gather justification and context for minimal expected benefits beyond altruism.",
			"Gather relevant literature references supporting benefit and risk conclusions.",
			"Obtain information on the medical need for a new therapy in the intended population.",
			"If applicable, collect microbiology data from both in vitro and in vivo studies when relevant to the benefit-risk assessment, ensuring summary information is available for Module 2 and detailed reports for Module 5.",
			"If using a quantitative methodology for benefit-risk assessment, prepare detailed methodology documentation for inclusion in the appendix.",
			"Collect any available patient perspective data, including attitudes and preferences regarding therapeutic context, benefits, and risks, obtained directly from patients or indirectly from stakeholders using qualitative, quantitative, or descriptive methods.",
			"Collect supporting documentation or cross-references to relevant protocol sections describing risk mitigation measures for trial interventions.",
			"Gather descriptions of trial-specific intervention risks and corresponding mitigation strategies to be employed within the trial.",
			"If large volumes of statistical output from integrated analyses are relevant to benefit-risk conclusions, prepare separate detailed reports for placement in Module 5, with summaries available for Module 2.",
			"Ensure availability of patient-derived or stakeholder-derived datasets used to capture patient perspectives for potential inclusion in summary tables or graphical displays.",
			"Prepare detailed presentations of methods and results for any quantitative benefit-risk analyses to be placed in Section 2.5.6.5, ensuring availability before writing Section 2.5.6.4.",
			"Gather data on current therapies used in the intended population, including their efficacy, safety, and limitations.",
			"Prepare any summary tables or graphical displays that may help communicate the benefit-risk assessment.",
			"Compile any regulatory correspondence or prior submissions that discuss benefit-risk considerations for the product.",
			"Collect data on known and potential risks and benefits associated with participation in the clinical trial, including the basis of each risk (e.g., nonclinical or prior clinical trials).",
			"Collect descriptive information on patient attitudes and preferences specifically related to therapeutic context, benefits, and risks, including any qualitative, quantitative, or descriptive datasets.",
			"Collect information on potential benefits to society in general, ensuring these are described separately from individual participant benefits.",
			"Review the ICH M4E(R2) guideline and related regulatory background materials to understand the standardized expectations for benefit-risk assessment presentation.",
			"Collect information on the disease or condition relevant to the intended population, including aspects across the spectrum of disease severity.",
			"Clearly identify and document if no benefits to an individual participant can be anticipated or if potential benefits are unknown.",
			"Prepare all tables or figures intended to support or clarify key benefit-risk points or conclusions.",
			"Identify and compile 'Key Risks' of the product, including safety data from clinical and non-clinical studies, post-marketing data if available, and adverse event profiles.",
			"Gather any integrated analyses of all relevant data (not just summaries) that will inform the benefit-risk conclusions, ensuring they are available for synthesis in Section 2.5.6.",
			"Collect information on potential physical, psychological, social, legal, and other benefits to the trial participant, including immediate and long-range potential benefits.",
			"Gather any internal or external documentation that reflects prior benefit-risk assessment approaches used in previous submissions to ensure alignment with the revised M4E(R2) structure.",
		],
		output: [
			"Maintain clarity and brevity in describing trial-specific intervention risks, focusing on key risks relevant to the trial.",
			"Ensure consistency with other benefit-risk relevant ICH guidelines, such as ICH E2C(R2) (PBRER).",
			"For the 'Benefit Summary' subsection, provide a short textual description of potential physical, psychological, social, legal, and other benefits to the trial participant.",
			"Ensure that the section is included once per protocol (cardinality one to many) and follows the required heading conventions.",
			"Ensure Section 2.5.6.5 contains detailed presentations of methods and results used in the benefit-risk assessment that were summarized in Section 2.5.6.4, and ensure consistency between the summary and appendix.",
			"Ensure the section does not describe or critique regulators’ internal benefit-risk assessment methodologies, processes, or decision pathways, as these are out of scope for Section 2.5.6.",
			"Ensure that analyses comparing and/or weighing benefits and risks are adequately justified and clearly communicated.",
			"If choosing a quantitative method, evaluate its utility, complexity, degree of establishment, and ease of interpretation before use.",
			"Ensure that the section reflects the structured framework for benefit-risk assessment as emphasized in the revised guideline.",
			"Consider inclusion of summary tables or graphical displays specifically for presenting patient perspective information where appropriate.",
			"Verify that the narrative focuses solely on the applicant’s benefit-risk conclusions and not on how regulators may interpret, weigh, or conclude on the same information.",
			"In 2.5.6.2 and 2.5.6.3, use the terms 'Key Benefits' and 'Key Risks' in alignment with ICH E2C(R2) (PBRER).",
			"Ensure that the 'Risk Summary and Mitigation Strategy' subsection includes a concise description of potential risks associated with trial interventions and the mitigation strategies to be employed.",
			"In 2.5.6.1, discuss aspects of the disease most relevant to the intended population, current therapies, and limitations or uncertainties in understanding the condition or therapies.",
			"Ensure 'Benefit Summary' content is concise, clear, and aligned with the definition provided in the controlled terminology.",
			"Provide a critical and succinct presentation of the benefit-risk assessment.",
			"Apply a consistent and harmonized approach to presenting benefit-risk conclusions to reduce variability across submissions.",
			"If available, include descriptive information on patient attitudes and preferences regarding therapeutic context, benefits, and risks.",
			"Clearly state in the 'Benefit Summary' if no benefits to an individual participant can be anticipated or if potential benefits are unknown.",
			"Include an assessment of known and potential risks and benefits from the perspective of an individual participant, clearly identifying the basis of each risk (e.g., nonclinical or prior clinical trials).",
			"For early clinical trials (e.g., Phase 1 or trials in healthy participants), note that benefits for an individual participant (other than altruism) are expected to be minimal.",
			"Ensure that the level of detail in Section 2.5.6 is appropriate for a Module 2 summary and not as extensive as an ISS, unless justified and agreed with the reviewing division.",
			"In the 'Benefit Summary', address both immediate potential benefits and long-range potential benefits to the individual participant.",
			"Clearly communicate the thought process behind the applicant's weighing of benefits and risks to the regulator.",
			"Ensure that Section 2.5.6 appears in the CTD Table of Contents under Module 2, following the standardized numbering and placement between Sections 2.5.5 (Overview of Safety) and 2.5.7 (Literature References).",
			"Verify that the section content and organization comply with the harmonized format intended by the M4E(R2) revision.",
			"If large volumes of statistical output are involved, summarize key points in Module 2 and place detailed analyses in a separate report in Module 5, ensuring clear cross-referencing.",
			"Do not present new efficacy or safety data; only summarize and interpret existing data.",
			"Ensure Section 2.5.6 is concise and not overly prescriptive, focusing on suggesting elements for consideration rather than prescribing methods.",
			"If including benefits to society in the 'Benefit Summary', describe them separately from the individual participant perspective.",
			"If applicable, structure the section under one single heading 'Assessment of Risks and Benefits' or under three subheadings: 'Risk Summary and Mitigation Strategy', 'Benefit Assessment', and 'Overall Risk-Benefit Assessment'.",
			"Include tables or figures within Section 2.5.6 to support or clarify key benefit-risk points or conclusions.",
			"Recognize that multiple approaches for benefit-risk assessment exist and the guideline does not prescribe a specific approach.",
			"When referencing other CTD sections in cross-references, include only the section number in the cross string to reduce length, but write the surrounding text so the reader understands the section content.",
			"Ensure that any appendix materials are clearly referenced in the main text.",
			"Ensure that the presentation of benefit-risk information aligns with the standardized structure and expectations introduced in ICH M4E(R2).",
			"Provide cross-references to relevant protocol sections where detailed mitigation strategies are described.",
			"Consider including summary tables and graphical displays to communicate the benefit-risk assessment.",
			"Maintain logical flow and clarity so that the regulator can easily follow the reasoning process.",
			"Describe the characteristics of the key benefits and key risks, including their strengths, limitations, and uncertainties.",
			"In 2.5.6.4, use a descriptive approach for the benefit-risk assessment unless a quantitative method is chosen; if quantitative, summarize and explain conclusions in the main text and place detailed methodology in the appendix.",
			"Follow the revised structure: 2.5.6 Benefits and Risks Conclusions; 2.5.6.1 Therapeutic Context; 2.5.6.1.1 Disease or Condition; 2.5.6.1.2 Current Therapies; 2.5.6.2 Benefits; 2.5.6.3 Risks; 2.5.6.4 Benefit-Risk Assessment; 2.5.6.5 Appendix.",
			"Verify that the section title '2.5.6 Benefits and Risks Conclusions' is used exactly as listed in the CTD Table of Contents to maintain consistency across modules and submissions.",
			"Ensure incorporation of patient perspective information when relevant, including descriptive summaries of patient attitudes and preferences using qualitative, quantitative, or descriptive methodologies.",
			"Ensure conformance with required heading hierarchy and numbering (e.g., 2.2, 2.2.1, 2.2.2, 2.2.3) as per the protocol structure.",
		],
	},
	{
		number: "2.5.7",
		title: "Literature References",
		input: [
			"Collect all literature references cited in the CTD, including published scientific articles, books, and other relevant publications supporting the application.",
			"Ensure that all literature references correspond to data or statements included in Module 2 and Module 4 study reports.",
			"Prepare a list of all literature references to be included in the table of contents of the CTD.",
			"Collect any literature references that are included in Clinical Study Report appendices (ICH E3 Appendix 16.1.12) and ensure they are also available for placement in CTD Module 5.4.",
			"Gather bibliographic details for each reference (authors, title, journal, year, volume, pages, DOI if available).",
			"Collect all nonclinical literature references cited in the nonclinical summaries (Modules 2.6.2.8, 2.6.4.11, and 2.6.6.11) to ensure consistency with the overall literature reference list in Module 2.5.7.",
			"Confirm that all referenced studies (clinical, non-clinical, or other) are properly documented and available for cross-reference.",
			"Obtain copies of full-text articles or abstracts for all cited literature references.",
			"Gather bibliographic details for each reference (authors, title, journal, year, volume, pages, DOI if available)",
			"Verify that each literature reference is linked to the relevant study report or section of the dossier.",
		],
		output: [
			"List all literature references in the CTD table of contents as required.",
			"Ensure that literature references originating from Clinical Study Reports are relocated from ICH E3 Appendix 16.1.12 to CTD Module 5.4 in compliance with CTD organization requirements.",
			"Applicants may modify the format of the literature references section if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation by regulatory reviewers.",
			"Maintain appropriate document granularity—each literature reference should be a distinct document or file to facilitate lifecycle management and replacement if updates occur.",
			"When using cross references within Module 2.5.7, include only the CTD section number in the cross string to keep references concise.",
			"Ensure consistency between the literature references listed in Module 2.5.7 and those cited in other CTD sections (e.g., Modules 2 and 4).",
			"Include a repeated leaf element for each literature reference under the heading 5.4 Literature References in the eCTD structure to comply with CTD placement requirements.",
			"If a list of references section is not explicitly covered in the guidance for certain summaries (e.g., nonclinical summaries), create and include a corresponding reference list section to maintain consistency with the CTD structure and ensure completeness of documentation.",
			"Ensure cross-referencing practices are consistent and clear, supporting ease of navigation for regulatory reviewers.",
			"List all literature references in the CTD table of contents as required by Note 2.",
			"Write accompanying text in a way that clearly indicates the type or content of the referenced section so readers can easily locate the material.",
			"Maintain appropriate document granularity\u0002each literature reference should be a distinct document or file to facilitate lifecycle management and replacement if updates occur.",
			"For eCTD submissions, place literature reference files in the Module 5.4 folder as required.",
			"Verify that all literature references are properly formatted and complete, including full bibliographic information.",
			"Paginate literature references according to the page numbering of the original source (journal, abstract, etc.), without adding new page numbers.",
			"Include a distinct identifier (e.g., abbreviated title or reference ID) in the header or footer of each literature reference document to support navigation and traceability.",
			"Ensure that the literature reference list is clearly organized, logically sequenced, and easy to navigate within the CTD structure.",
			"Place the list of references in the most appropriate location within the CTD to facilitate understanding by reviewers, and create new subsection numbers if necessary to accommodate optimal placement.",
			"Ensure that each literature reference is presented as a separate, clearly identified document or entry.",
			"Follow the CTD structure conventions for Module 2.5.7 when organizing literature references.",
			"Ensure that in eCTD index.xml, leaf elements for literature references are included under the same heading as other study report files, with additional information provided in the associated study tagging file.",
		],
	},
	{
		number: "2.6.1",
		title: "Nonclinical Written Summaries",
		input: [
			"Collect any tables and figures summarizing toxicologic evaluation and conclusions for inclusion in the discussion section.",
			"Gather carcinogenicity study reports (including supportive toxicokinetics) with rationale for study selection and high-dose selection, including long-term studies (by species), short- or medium-term studies, and other studies.",
			"Collect reproductive and developmental toxicity study reports (including range-finding and supportive toxicokinetics) covering fertility and early embryonic development, embryo-fetal development, prenatal and postnatal development (including maternal function), and juvenile animal studies if conducted.",
			"Collect pharmacology study reports (primary, secondary, and pharmacodynamic drug interaction studies) including information on method of administration, testing facility, and GLP compliance statements.",
			"Collect organ distribution study data including radionuclide, specific activity, sampling times, tissue/organ concentrations, and any additional relevant information.",
			"Collect all relevant tables and figures from nonclinical studies for inclusion in the written summaries.",
			"Collect other toxicity study reports if available, including antigenicity, immunotoxicity, mechanistic studies (if not reported elsewhere), dependence, studies on metabolites, studies on impurities, and other relevant studies.",
			"Gather the complete list of nonclinical study reports (pharmacology, pharmacokinetics, toxicology) as organized in Module 4 to ensure consistency between the Written Summaries and Tabulated Summaries.",
			"Collect pharmacokinetic study reports including absorption (single and repeated dose), distribution, metabolism, excretion, pharmacokinetic drug interactions, and other relevant studies, with details on species, gender, feeding condition, vehicle/formulation, method of administration, dose, sample type, analyte, assay method, and PK parameters.",
			"Ensure access to reference standards, comparator product data, and any expert opinions relevant to nonclinical findings.",
			"Obtain any rationale documents for conducting 'other toxicity studies' where appropriate.",
			"Gather genotoxicity study reports in the following categories: in vitro non-mammalian cell system, in vitro mammalian cell system, in vivo mammalian system (including supportive toxicokinetics), and other systems.",
			"Collect safety pharmacology study reports covering all organ systems evaluated, including species/strain, method of administration, dose, gender and number per group, noteworthy findings, and GLP study numbers or report numbers.",
			"Collect Appendix C example tables and templates for reference to ensure alignment with suggested content and format of Tabulated Summaries.",
			"Gather any relevant literature references that support or contextualize the nonclinical findings.",
			"Collect any impurity data for test articles used in early-stage toxicology studies if such analyses were conducted.",
			"Compile toxicology study data including single-dose toxicity, repeat-dose toxicity (with supportive toxicokinetics), genotoxicity, carcinogenicity (with supportive toxicokinetics), reproductive and developmental toxicity (including range-finding and supportive toxicokinetics), local tolerance, and other toxicity studies if available.",
			"Collect cross-reactivity study reports (animal species cross-reactivity and human tissue cross-reactivity) for biologics or monoclonal antibodies, when these studies are part of the nonclinical package and must be summarized in Section 2.6.1.",
			"Obtain templates from Appendices B and C for nonclinical tabulated summaries and any annotated guidance for table preparation.",
			"Retrieve any applicable guidelines on the conduct of nonclinical studies to verify compliance and note any deviations.",
			"If microbiology data (in vitro or in vivo) are relevant to the nonclinical program, collect these data for inclusion or cross-reference in the Nonclinical Written Summaries as appropriate.",
			"Collect all nonclinical study reports relevant to pharmacology, pharmacokinetics, and toxicology for inclusion in the written summaries.",
			"Gather representative human pharmacokinetic data at the maximum recommended dose for comparison in absorption tables.",
			"Gather results of impurity-specification tests for drug substance batches used in nonclinical studies when available, identifying which batches are relevant for impurity qualification.",
			"Gather local tolerance study reports, organized by species, route, and duration.",
			"Gather juvenile animal study reports and data for inclusion in the Nonclinical Written Summaries, ensuring they are tabulated using the appropriate template and referenced to Section 2.6.7.15.",
			"Obtain pharmacokinetic study data including absorption, distribution, metabolism (interspecies comparison), excretion, pharmacokinetic drug interactions, and other pharmacokinetic studies.",
			"Gather data from primary pharmacodynamics, secondary pharmacodynamics, safety pharmacology, pharmacodynamic drug interactions, and other relevant pharmacology studies.",
			"Obtain any regulatory correspondence or prior submissions that may inform the nonclinical summaries.",
		],
		output: [
			"Include footnotes in tables to identify GLP compliance statements and to specify the location of technical reports in the CTD.",
			"Ensure that each repeat-dose toxicity study considered pivotal is included in its own table, consistent with ICH M3 expectations.",
			"Prepare tabulated summaries that include only noteworthy findings, such as statistically significant results or notable non-significant observations.",
			"For carcinogenicity, provide a brief rationale for study selection and high-dose selection, and summarize studies in the specified order: long-term studies (by species, including certain range-finding studies), short- or medium-term studies (including certain range-finding studies), and other studies.",
			"Include impurity data in the drug substance table when available, even if derived from non-GLP studies, noting that such analyses are not required.",
			"For local tolerance, summarize studies in order by species, route, and duration, including brief methodology and important findings.",
			"Ensure that any cross-references or appendices mentioned in the Nonclinical Written Summaries are properly placed and labeled in the corresponding CTD modules (e.g., Module 4 or 5).",
			"In the discussion and conclusions section, discuss the toxicologic evaluation and significance of any issues, and include tables or figures summarizing this information.",
			"Include an introduction section (2.6.1) that outlines the scope and organization of the nonclinical written summaries.",
			"When creating cross-references in text, include the CTD section number in parentheses and write the surrounding text so the reader can infer the section content without needing the full section name.",
			"Modify tabular formats as needed to best present the data and facilitate understanding and evaluation.",
			"Tables and figures may be placed within the text at appropriate points or at the end of the summary.",
			"When analytical methods differ across development stages, use footnotes in drug substance impurity tables to identify which batches are relevant for impurity qualification.",
			"When tabulating juvenile animal studies, ensure they are referenced to Section 2.6.7.15 and formatted using the appropriate template.",
			"For absorption after repeated doses, use the same tabular format as for single-dose absorption if applicable.",
			"For pharmacokinetics tables, include one line per report in the same order as the CTD, identify GLP-compliant reports in footnotes, and indicate the location of the technical report in the CTD.",
			"Ensure that the Nonclinical Written Summaries and Tabulated Summaries together provide a complete and coherent presentation of nonclinical data for primary review in all regions.",
			"Follow the order of presentation from the Nonclinical Written Summaries when preparing Nonclinical Tabulated Summaries.",
			"Ensure that all data presented are factual, concise, and clearly linked to the corresponding study reports in Module 4.",
			"Include one column per study conducted in absorption tables and provide representative human data at the maximum recommended dose for comparison.",
			"Confirm that juvenile animal studies are tabulated using the appropriate template for the study type, consistent with Appendix C guidance.",
			"If microbiology data are included in the Nonclinical Written Summaries, ensure they are clearly identified as nonclinical and cross-referenced to the appropriate clinical or efficacy sections (e.g., 2.7 or 5.3.5.4) where applicable.",
			"When a single nonclinical pharmacokinetic study is relevant to multiple subsections, include the full description in the primary section and use cross-referencing for subsequent sections to avoid unnecessary duplication, particularly in eCTD format.",
			"For absorption after a single dose, tabulate data including species, gender, feeding condition, vehicle/formulation, method of administration, dose, sample type, analyte, assay method, PK parameters, and additional information such as species or gender differences, dose dependency, or special comments.",
			"Maintain consistency in table structure and labeling across pharmacology, pharmacokinetics, and toxicology sections to align with CTD conventions.",
			"Ensure that the level of detail in Tabulated Summaries is sufficient for reviewers to understand the data while maintaining concise overviews of related information.",
			"For pharmacology tables, include one line per pharmacology report in the same order as the CTD, identify GLP-compliant reports in footnotes, and indicate the location of the technical report in the CTD.",
			"For other toxicity studies, summarize them when performed and provide rationale where appropriate; include categories such as antigenicity, immunotoxicity, mechanistic studies, dependence, studies on metabolites, studies on impurities, and other studies.",
			"Follow the harmonised format recommended for CTD nonclinical written summaries, using consistent terminology and units.",
			"For organ distribution studies, use either Format A or Format B as appropriate, including all required fields such as species, gender, feeding condition, vehicle/formulation, method of administration, dose, radionuclide, specific activity, sampling time, tissues/organs, and concentration units.",
			"Summarize non-pivotal studies in less detail than pivotal studies, in line with ICH M3 definitions.",
			"For safety pharmacology tables, summarize all studies, include organ systems evaluated, species/strain, method of administration, dose, gender and number per group, noteworthy findings, and GLP study number or report number.",
			"Use the recommended tabular formats from Appendices B and C for Nonclinical Tabulated Summaries, deleting italicized guidance text before finalizing tables.",
			"Organize content according to the CTD structure for nonclinical written summaries, ensuring clear separation of pharmacology, pharmacokinetics, and toxicology sections.",
			"For genotoxicity, summarize studies in the specified order: in vitro non-mammalian cell system, in vitro mammalian cell system, in vivo mammalian system (including supportive toxicokinetics), and other systems.",
			"Modify the format of the Nonclinical Written Summaries when necessary to improve clarity and facilitate understanding by regulatory reviewers.",
			"Cross-reference tables and figures appropriately, ensuring they are labeled and numbered according to CTD conventions.",
			"Maintain all section headings in the CTD even if certain study types were not conducted, and provide a brief explanation for their absence.",
			"Ensure that the order of presentation in the Nonclinical Written Summaries is mirrored in the Nonclinical Tabulated Summaries.",
			"Structure the Nonclinical Written Summaries to provide a comprehensive factual synopsis of the nonclinical data without interpretation (interpretation belongs in the Nonclinical Overview).",
			"Ensure that the presentation of data in Tabulated Summaries follows the examples in Appendix C while allowing flexibility to optimize clarity and product-specific presentation.",
			"Ensure that tabulated summaries provide sufficient detail for reviewers and concise overviews of related information.",
			"Recognize that in some regions, the tabulated summaries (with written summaries) may be the primary review documents; ensure clarity and completeness accordingly.",
			"For reproductive and developmental toxicity, summarize studies in the specified order: fertility and early embryonic development, embryo-fetal development, prenatal and postnatal development (including maternal function), and juvenile animal studies if conducted; modify subheadings if study designs are modified.",
			"Place the list of references in the most appropriate location within the Nonclinical Written Summaries and create new subsection numbers if needed to improve reviewer comprehension.",
			"Verify that all included studies are conducted in accordance with relevant guidelines, and note any deviations in the appropriate sections.",
			"Use the recommended tabulated-summary templates for nonclinical information but modify them if needed to optimize clarity and understanding.",
			"When juvenile animal studies are conducted, tabulate them using the template appropriate for the study type.",
			"Include a distinct identifier in headers/footers on every page of the Nonclinical Written Summaries; an abbreviation is acceptable and the full title is not required.",
			"Include text tables and figures within the Nonclinical Written Summary wherever possible to facilitate reviewer understanding.",
			"Ensure compliance with any applicable presentation standards for Module 2 documents (e.g., consistent font, margins, pagination, and section numbering).",
			"Ensure that all tables include the International Nonproprietary Name (INN) for the test article and that report numbers or GLP study numbers are clearly indicated on all tables.",
			"Maintain clarity and logical flow, grouping related studies and data together under the correct headings.",
			"When creating cross-references within the document, include the CTD section number in the cross string; including the section name is optional but may improve clarity if space allows.",
		],
	},
	{
		number: "2.6.2",
		title: "Introduction",
		input: [
			"Obtain FDA guidance documents relevant to the format and content of clinical and statistical sections to ensure alignment with regulatory expectations for integrated analyses.",
			"Collect literature references or expert opinions that support the rationale for the clinical pharmacology studies included in the submission.",
			"Obtain information on the investigational product, including its pharmacologic class, mechanism of action, and therapeutic indication, to introduce the clinical pharmacology program.",
			"Collect any relevant appendices or supplementary materials from Module 5 that may be referenced in the introduction for context.",
			"Gather key data and results from pharmacokinetic, pharmacodynamic, and bioavailability/bioequivalence studies to provide context for the introduction.",
			"Consult the health authority for guidance if the investigational drug substance is already approved, to determine whether abbreviated or modified information is acceptable for inclusion in the introduction.",
			"Review Appendix C for any stability-related information or references that may provide context for the clinical pharmacology program or product characteristics discussed in the introduction.",
			"Refer to Appendix A for any cross-referenced regulatory or technical guidance relevant to the preparation of CTD sections, ensuring consistency with the overall CTD structure.",
			"Ensure access to the study numbering system and cross-references to Module 5 study reports for accurate referencing in the introduction.",
			"Collect all relevant clinical, non-clinical, and pharmacological study reports that will be summarized in the Overview of Clinical Pharmacology Studies (Module 2.6).",
			"Compile references to prior regulatory submissions or correspondence that define the scope of the clinical pharmacology program.",
			"Gather any prior ISS/ISE materials or summaries to determine the appropriate level of detail for Module 2.6.2 and ensure consistency with related sections.",
			"Review regional guidance documents to ensure that the preparation of section 2.6.2 meets any specific regional regulatory requirements for Module 2 submissions.",
		],
		output: [
			"Ensure that CTD numbering conventions are retained when multiple indications are discussed, using indication identifiers (e.g., 2.7.3.UTI, 2.7.3.Pneumonia) as a model for consistent labeling across sections.",
			"Follow CTD formatting conventions, including section numbering (2.6.2) and standardized headings.",
			"Determine and apply the appropriate level of detail for the introduction based on whether Module 2 content will fulfill ISS/ISE requirements or will be supplemented by detailed reports in Module 5.",
			"For eCTD submissions, ensure that section 2.6.2 is submitted as a single document at the correct granularity level, as documents rolled up to this level are not considered appropriate unless specifically allowed.",
			"Summarize the overall strategy and objectives of the clinical pharmacology program, including the types of studies conducted (e.g., pharmacokinetics, pharmacodynamics, bioavailability).",
			"Use consistent terminology and study identifiers that align with those used in Modules 2.7 and 5.",
			"For paper CTD submissions, ensure that section 2.6.2 is included in the Module 2 table of contents as required.",
			"Ensure the introduction reflects the concept of an integrated analysis of all relevant data rather than a simple summary, in line with FDA guidance.",
			"Ensure the document is formatted according to eCTD specifications (one file per section, properly labeled).",
			"If the product involves multiple drug substances or components (e.g., reconstitution diluents), ensure that the introduction clearly distinguishes these and references the appropriate sections or separate product information as applicable.",
			"Avoid inclusion of raw data or detailed results; focus on providing context and orientation for the reviewer.",
			"Ensure the section is written in clear, concise, and scientific language appropriate for regulatory review.",
			"Verify that any cross-references to other CTD sections (e.g., 2.7.3, 2.7.4, 5.3.5) use the correct numbering format and indication identifiers where applicable.",
			"Ensure that references to appendices (e.g., Appendix A, Appendix C) are correctly cited and formatted according to CTD conventions.",
			"Verify compliance with the eCTD v3.2.2 specification for Module 2 structure, ensuring that section 2.6.2 is placed in the correct location and labeled appropriately.",
			"Maintain a logical flow that introduces the reader to the subsequent sections (2.6.3–2.6.7) without duplicating detailed data.",
			"Maintain consistency in section numbering and labeling across all CTD modules to facilitate cross-referencing and reviewer navigation.",
			"Begin the section with a concise overview describing the purpose and scope of the clinical pharmacology studies included in the submission.",
			"Confirm that the introduction does not include unnecessary lower-level headings or subfiles, consistent with CTD guidance that lower-level headings at this point are unlikely to contain individual documents.",
			"Verify that all studies mentioned in the introduction are included and correctly cross-referenced in the detailed summaries and Module 5 study reports.",
			"When cross-referencing other sections, include the section number in the cross string and write the text so the reader understands the section content without needing the full section name.",
			"Clearly identify the investigational product, its pharmacologic class, mechanism of action, and therapeutic indication.",
		],
	},
	{
		number: "2.6.3",
		title: "Pharmacology Written Summary",
		input: [
			"Gather any expert opinions or assessments related to pharmacology.",
			"Ensure access to statements of Good Clinical Practice (GCP) compliance for any referenced clinical pharmacology studies if cross-referenced in the summary.",
			"Compile relevant literature references that support pharmacological findings.",
			"If the drug substance is already approved, obtain relevant health authority guidance and any associated approval documentation for reference in preparing the summary.",
			"Obtain any related in vitro and in vivo pharmacology data that support the mechanism of action, efficacy, and safety profile.",
			"Prepare a complete list of references to be cited in the Pharmacology Written Summary so that it can be placed in an appropriate location within section 2.6.3.",
			"Obtain the Clinical Overview (Module 2.5) and Clinical Summary (Module 2.7) documents for cross-referencing and consistency checks, as these may contain relevant clinical interpretations of pharmacologic findings.",
			"Ensure that all referenced pharmacology study reports are correctly located in Module 4 under the appropriate subsections (e.g., 4.2.1.x or 4.2.2.x) as per CTD structure.",
			"Verify that any supporting nonclinical study data referenced in the Pharmacology Written Summary are complete and accessible in Module 4 for both paper and eCTD submissions.",
			"Ensure availability of data and results for each pharmacology study category: primary pharmacodynamics, secondary pharmacodynamics, safety pharmacology, and pharmacodynamic drug interactions.",
			"Gather tabulated pharmacology summary tables (Table X.X, Study/Report Number) for cross-referencing within the written summary.",
			"Collect all tables and figures that will be included either within the text or at the end of the Pharmacology Written Summary.",
			"Collect any pertinent animal data or product quality information that may have clinical implications and could be referenced in the Pharmacology Written Summary for contextual alignment.",
			"Collect integrated analyses of all relevant pharmacology data (note: these are not mere summaries but comprehensive analyses).",
			"Gather all relevant nonclinical pharmacology study reports, including primary pharmacodynamic studies, secondary pharmacodynamic studies, safety pharmacology studies, and pharmacodynamic drug interaction studies.",
			"Prepare appendices with detailed pharmacology data for placement in Module 4 or Module 5 as appropriate, to be referenced in the written summary.",
			"Retrieve relevant regulatory correspondence or prior submissions that may inform the pharmacology summary.",
			"Prepare a brief summary of principal pharmacology findings (approximately 2–3 pages) highlighting notable aspects such as inclusion/exclusion of specific data or models.",
			"Gather all required information for constructing the Pharmacology Overview table (section 2.6.3.1), including: INN of test article, study type classifications (primary PD, secondary PD, drug interaction), method of administration, testing facility, CTD volume/section location, report numbers, and GLP compliance statements.",
			"Confirm that all pharmacology study documents are properly labeled and organized per study type (primary, secondary, safety, interaction) for cross-referencing in section 2.6.3.",
			"Collect any comparator product pharmacology data if applicable.",
			"Collect all required information for Safety Pharmacology summary tables (section 2.6.3.4), including: organ systems evaluated, species/strain, method of administration, dose levels, gender and number of animals per group, noteworthy findings, GLP study numbers or report numbers.",
			"Ensure availability of detailed study protocols and statistical analysis plans for pharmacology studies.",
		],
		output: [
			"Verify that any cross-references to clinical data or product quality issues are clearly contextualized and limited to aspects relevant to pharmacologic interpretation.",
			"Ensure the Pharmacology Written Summary follows the recommended internal sequence: Brief Summary, Primary Pharmacodynamics, Secondary Pharmacodynamics, Safety Pharmacology, Pharmacodynamic Drug Interactions, Discussion and Conclusions, Tables and Figures.",
			"When detailed pharmacology data are too extensive for inclusion in the summary, provide them in separate reports in the appropriate Module 4 or 5 section, with clear cross-references in the summary.",
			"If the drug substance is already approved, clearly note this in the summary and indicate that relevant health authority guidance has been followed.",
			"Keep the Brief Summary section concise, approximately 2–3 pages, summarizing principal findings and noting any notable inclusions or exclusions of data.",
			"Confirm that the Pharmacology Written Summary is consistent with the organization of Module 4 (paper and eCTD) and that all referenced studies are traceable to their correct locations.",
			"Summarize all safety pharmacology studies in accordance with required table fields (organ systems, species/strain, dose, gender/animal numbers, noteworthy findings, GLP/report number).",
			"Include text tables and figures directly within the Nonclinical Written Summary whenever possible, as this is the preferred presentation format.",
			"Indicate that safety pharmacology doses represent single doses unless otherwise specified.",
			"Verify that the summary meets the requirements of 21 CFR 314.50 if applicable, and that it can serve regulatory needs without duplication of ISS/ISE content unless necessary.",
			"Ensure the Pharmacology Written Summary provides a comprehensive factual synopsis of the nonclinical pharmacology data, reserving interpretation, clinical relevance, and cross-linking with quality aspects for the Nonclinical Overview.",
			"Ensure the overall length of the three Nonclinical Written Summaries (pharmacology, pharmacokinetics, toxicology) generally does not exceed 100–150 pages, maintaining proportional length for the Pharmacology Written Summary.",
			"Summarize and evaluate primary pharmacodynamic studies, relating findings to other drugs in the same class where possible (selectivity, safety, potency).",
			"Organize content logically, following the expected sequence for pharmacology data: primary pharmacodynamics, secondary pharmacodynamics, safety pharmacology, pharmacodynamic drug interactions.",
			"Briefly summarize pharmacodynamic drug interaction studies if performed.",
			"Summarize and evaluate secondary pharmacodynamic studies by organ system where appropriate.",
			"Modify the format of the Pharmacology Written Summary as needed to provide the best possible presentation and facilitate regulatory understanding.",
			"Present the Pharmacology Written Summary as an integrated analysis of all relevant pharmacology data, not as a simple summary.",
			"Ensure that cross-references to Module 4 study reports (e.g., 4.2.1.x, 4.2.2.x) are accurate and correspond to the correct study type and numbering.",
			"Structure the Pharmacology Overview table (section 2.6.3.1) using the required fields (INN, study type, administration method, testing facility, CTD volume/section location, report number) and maintain one line per report in CTD order.",
			"Maintain consistency in terminology and data presentation across the summary and referenced reports.",
			"When referencing clinical pharmacology data, ensure that the summary distinguishes between factual nonclinical data and interpretive clinical conclusions, maintaining clarity of scope.",
			"Include a Discussion and Conclusions section to interpret pharmacologic findings and discuss their significance.",
			"Place the list of references in the most appropriate location within section 2.6.3 and create new subsection numbers if needed to improve clarity and reviewer comprehension.",
			"Ensure that the location of each Technical Report in the CTD is indicated within overview tables.",
			"Ensure that the Pharmacology Written Summary maintains consistency with the Clinical Overview (Module 2.5) and Clinical Summary (Module 2.7) where pharmacologic data are referenced or interpreted.",
			"Use cross-references that include at least the section number in cross strings; write the text so the reader understands the section content without requiring the full section name.",
			"For eCTD submissions, omit a separate Table of Contents for Module 4, but ensure that all cross-references in section 2.6.3 correctly point to the electronic structure.",
			"Ensure clarity and accessibility for readers unfamiliar with the dossier by providing sufficient context for cross-referenced material.",
			"Include reference citations to the Tabulated Summaries throughout the text in the format: (Table X.X, Study/Report Number).",
			"Identify GLP-compliant studies within overview tables using footnotes as required.",
			"Maintain the recommended sequence of Nonclinical Written and Tabulated Summaries to ensure logical flow and regulatory consistency: Introduction → Pharmacology Written Summary → Pharmacology Tabulated Summary → Pharmacokinetics Written Summary → Pharmacokinetics Tabulated Summary → Toxicology Written Summary → Toxicology Tabulated Summary.",
			"Include tables and figures either integrated within the text or compiled at the end of the summary, ensuring consistent labeling and referencing.",
			"Follow the general CTD Module 2 structure, ensuring alignment with ICH M4E guidance and relevant FDA recommendations.",
			"Summarize and evaluate safety pharmacology studies, integrating relevant secondary pharmacodynamic data that contribute to safety evaluation.",
			"For paper submissions, ensure that the Table of Contents for Module 4 is complete and accurately reflects all referenced pharmacology studies cited in section 2.6.3.",
		],
	},
	{
		number: "2.6.4",
		title: "Pharmacology Tabulated Summary",
		input: [
			"Collect all study and report numbers corresponding to pharmacology studies to ensure accurate citation in the tabulated summary (e.g., for use in reference format '(Table X.X, Study/Report Number)').",
			"Review Appendix C examples of summary tables to understand suggested content and format for pharmacology tabulated summaries.",
			"Verify that all pharmacology tabulated data correspond to the correct CTD module and subsection numbering as per the CTD Table of Contents structure.",
			"Obtain any impurity data or analytical results relevant to pharmacology test articles if such analyses were conducted, even for non-GLP studies.",
			"Determine if any pharmacology study data need to be presented in multiple tabular formats or combined with other studies in a single table, and gather the relevant datasets accordingly.",
			"Identify any juvenile-animal pharmacology studies conducted and ensure data are available for tabulation using the appropriate template.",
			"Prepare the Pharmacology Tabulated Summary document template as outlined in the CTD format for Module 2.6.4.",
			"Collect information on analytical methods used for test articles, noting any changes across development stages that may affect data comparability.",
			"Gather data from pharmacokinetic (PK) studies and kinetics data from Segment 2 studies, as applicable, since the CTD-S guideline does not prescribe which studies are required but uses available nonclinical data.",
			"Compile a complete list of references relevant to Section 2.6.4, including citations supporting tabulated pharmacology data, for inclusion in an appropriate location within the summary.",
			"Gather any large statistical output datasets or listings from pharmacology-related analyses that are too extensive for inclusion in the summary, for placement in an appropriate separate report or appendix.",
			"Confirm the correct CTD section numbering and placement of Section 2.6.4 within Module 2, ensuring it follows the sequence outlined in the CTD Table of Contents (Module 2.6 Nonclinical Summaries).",
			"Compile all noteworthy findings from pharmacology studies, including statistically significant differences from controls and other noteworthy but non-significant findings.",
			"Assemble reference materials, literature citations, and expert opinions supporting pharmacological findings to ensure completeness of tabulated data.",
			"Obtain the recommended nonclinical tabulated summary table templates from Appendix B of the guideline for use in preparing Section 2.6.4 tables.",
			"Gather any relevant regulatory correspondence or previous submissions that clarify study conduct or data interpretation for pharmacology studies.",
			"Collect all nonclinical pharmacology study reports relevant to the drug, including primary pharmacodynamics, secondary pharmacodynamics, safety pharmacology, and pharmacokinetics studies.",
		],
		output: [
			"Ensure that the Pharmacology Tabulated Summary (Section 2.6.4) follows the recommended sequence within the CTD: Introduction → Written Summary of Pharmacology → Tabulated Summary of Pharmacology → Written Summary of Pharmacokinetics → Tabulated Summary of Pharmacokinetics → Written Summary of Toxicology → Tabulated Summary of Toxicology.",
			"Ensure that Section 2.6.4 is correctly placed and labeled within the CTD structure according to the official Table of Contents for Module 2, maintaining consistency with other sections (e.g., 2.5, 2.7).",
			"Applicants may modify the recommended table format from Appendix B to provide the best possible presentation and facilitate understanding, but must ensure sufficient detail for reviewer evaluation.",
			"Include reference citations to the Tabulated Summaries throughout the text in the format '(Table X.X, Study/Report Number)'.",
			"Although there is no formal page limit for the Nonclinical Written Summaries, ensure that the total length of all three Nonclinical Written Summaries generally does not exceed 100–150 pages; maintain proportional brevity and clarity for the Pharmacology Tabulated Summary to support this overall length recommendation.",
			"Follow the order of presentation given for the Nonclinical Written Summaries when preparing the tables for the Nonclinical Tabulated Summaries, ensuring pharmacology tables align with this sequence.",
			"Include only noteworthy findings in the tabulated summary—these include statistically significant differences from controls and other noteworthy but non-significant results.",
			"Ensure that tables are clearly labeled and organized to facilitate review and comprehension of pharmacology data.",
			"Ensure that any creation or modification of subsection numbering maintains logical flow and facilitates regulatory reviewer comprehension.",
			"Verify that all data presented are traceable to source study reports and that any deviations or missing data are explained in footnotes or accompanying text.",
			"Ensure that the tabulated summary is clearly distinguished from the written summaries and follows the CTD numbering and labeling conventions (e.g., Section 2.6.3 for Pharmacology Tabulated Summary).",
			"If analytical methods have changed across development stages, include footnotes in the tables to identify which batches or data sets are relevant to the qualification of impurities or pharmacological interpretation.",
			"Tables and figures may be placed either within the text of Section 2.6.4 at appropriate points or grouped together at the end of the summary; ensure consistent placement throughout the section.",
			"Ensure that the Pharmacology Tabulated Summary provides a comprehensive factual synopsis of the nonclinical pharmacology data without interpretation, as interpretation belongs in the Nonclinical Overview.",
			"Although there is no formal page limit for the Nonclinical Written Summaries, ensure that the total length of all three Nonclinical Written Summaries generally does not exceed 100\u0013150 pages; maintain proportional brevity and clarity for the Pharmacology Tabulated Summary to support this overall length recommendation.",
			"Ensure that the Pharmacology Tabulated Summary (Section 2.6.4) follows the recommended sequence within the CTD: Introduction \u0000 Written Summary of Pharmacology \u0000 Tabulated Summary of Pharmacology \u0000 Written Summary of Pharmacokinetics \u0000 Tabulated Summary of Pharmacokinetics \u0000 Written Summary of Toxicology \u0000 Tabulated Summary of Toxicology.",
			"Ensure that the Pharmacology Tabulated Summary (Section 2.6.4) follows the recommended sequence within the CTD: Introduction \u0019 Written Summary of Pharmacology \u0019 Tabulated Summary of Pharmacology \u0019 Written Summary of Pharmacokinetics \u0019 Tabulated Summary of Pharmacokinetics \u0019 Written Summary of Toxicology \u0019 Tabulated Summary of Toxicology.",
			"Use the recommended CTD nonclinical tabulated summary format for Module 2.6.4, but modifications are allowed to improve clarity and facilitate understanding and evaluation of results.",
			"One tabular format may contain results from several studies, or data from one study may be cited in several tabular formats; choose the approach that best presents the pharmacology data.",
			"Ensure that the tabulated summary is clearly distinguished from the written summaries and follows the CTD numbering and labeling conventions (e.g., Section 2.6.4 for Pharmacology Tabulated Summary).",
			"Ensure that the Pharmacology Tabulated Summary content is harmonized with the rest of the Nonclinical Written and Tabulated Summaries in terms of structure, terminology, and presentation style.",
			"Include only noteworthy findings in the tabulated summary\u0019these include statistically significant differences from controls and other noteworthy but non-significant results.",
			"Maintain all section headings in the CTD document, even if certain pharmacology studies were not conducted, and provide a brief explanation for their absence.",
			"Include only noteworthy findings in the tabulated summary\u0014these include statistically significant differences from controls and other noteworthy but non-significant results.",
			"When creating cross-references within the document, include at least the section number in the cross string; write the surrounding text so the reader can understand the section content without needing the full section title.",
			"Place the list of references for Section 2.6.4 in the most appropriate location within the summary and create new subsection numbers if needed to enhance reviewer understanding.",
			"Ensure that juvenile-animal pharmacology studies, if conducted, are tabulated using the template appropriate for the type of study.",
			"Ensure consistency in terminology and data presentation across all pharmacology tables within the section.",
			"Although there is no formal page limit for the Nonclinical Written Summaries, ensure that the total length of all three Nonclinical Written Summaries generally does not exceed 100\u00192150 pages; maintain proportional brevity and clarity for the Pharmacology Tabulated Summary to support this overall length recommendation.",
			"If statistical or analytical outputs related to pharmacology are too extensive for inclusion in Section 2.6.4, summarize key findings in the section and place the full detailed outputs in a separate report or appendix, with clear cross-references.",
			"Follow CTD formatting conventions for tables, numbering, and cross-referencing within Module 2.6.4 and to related sections (e.g., 2.6.2, 2.6.6).",
			"Verify that the numbering and titling of Section 2.6.4 align with the CTD Table of Contents conventions to ensure proper navigation and cross-referencing in the submission.",
			"Delete any italicized instructional text from the Appendix B templates when preparing final tables for submission.",
			"Apply cross-referencing for pharmacokinetic study information appearing in multiple places within the CTD to avoid unnecessary duplication, especially in eCTD submissions.",
		],
	},
	{
		number: "2.6.5",
		title: "Pharmacokinetics Written Summary",
		input: [
			"Gather information on particular efficacy or safety issues encountered during development and their resolution.",
			"Collect information from ICH E3 clinical study reports relevant to pharmacokinetics for inclusion or cross-reference in section 2.6.5.",
			"Obtain International Nonproprietary Name (INN) for the test article to be included in pharmacokinetics tables.",
			"Compile tabular listings of all pharmacokinetic and biopharmaceutical studies, including in vitro and in vivo data relevant to bioavailability and bioequivalence.",
			"If the pharmacokinetic data relate to a drug substance that is already approved, obtain relevant regulatory information or correspondence from the health authority to confirm acceptable data referencing or bridging approaches.",
			"For organ distribution studies, collect detailed study information: species, gender/number of animals, feeding condition, vehicle/formulation, method of administration, dose (mg/kg), radionuclide, specific activity, sampling time, tissues/organs analyzed, concentration/unit, half-life if applicable, and any additional relevant information.",
			"Obtain the proposed prescribing information to align Clinical Overview discussion with labeling content.",
			"Compile tabulated summary references that will need to be cited in the required citation format.",
			"Obtain cross-references or identifiers for study reports if they will be referenced rather than duplicated in multiple subsections.",
			"Collect any post-marketing pharmacokinetic or clinical pharmacology data available for the product if marketed in other regions.",
			"Collect any other relevant reports that may have clinical implications for pharmacokinetics (e.g., pertinent animal data, product quality reports).",
			"Compile any relevant datasets, tables, and analytical results from nonclinical pharmacokinetic studies.",
			"Gather all individual clinical study reports (ICH E3 format) relevant to pharmacokinetics and other clinical findings to support interpretation in the Clinical Overview.",
			"Gather analytical method validation data emphasizing performance characteristics such as linearity range, sensitivity, specificity, accuracy, and precision for assays used in pharmacokinetic studies.",
			"For absorption after a single dose tables, gather representative human pharmacokinetic information at the maximum recommended dose for comparison.",
			"Identify and record the location of each technical report in the CTD for inclusion in pharmacokinetics tables.",
			"Compile details of unresolved issues and plans to address them, particularly those with pharmacokinetic relevance.",
			"Gather a complete list of pharmacokinetics study reports in the same order as the CTD, noting which contain a GLP Compliance Statement.",
			"Gather analytical method information for biological sample analysis, including detection and quantification limits.",
			"Obtain the comprehensive Clinical Summary document for reference when preparing the Clinical Overview.",
			"Obtain any guidelines or literature references used in planning and conducting pharmacokinetic or bioavailability/bioequivalence studies to support methodological rationale.",
			"For absorption after repeated dose studies, collect equivalent data as for single dose studies if applicable.",
			"Gather any relevant FDA or ICH guidance documents (e.g., FDA Guideline for the Format and Content of Clinical and Statistical Sections, ICH E3, M4E Q&A) that provide context for integrated data presentation and cross-referencing practices applicable to section 2.6.5.",
			"For absorption after a single dose studies, collect detailed study information: species, gender/number of animals, feeding condition, vehicle/formulation, method of administration, dose (mg/kg), sample type, analyte, assay method, PK parameters, and any additional information such as species/gender differences, dose dependency, or special comments.",
			"Gather any meta-analyses or cross-study analyses that include pharmacokinetic data, ensuring full reports are available in Module 5 for reference.",
			"Collect any correspondence or clarifications from the reviewing division regarding acceptable integration of data or cross-referencing approaches for pharmacokinetic summaries.",
			"Assemble information on the overall clinical development plan, including critical study design decisions and rationale.",
			"Collect benefit–risk evaluation data from clinical studies, including efficacy and safety findings supporting proposed dose and indication.",
			"Gather any nonclinical pharmacokinetic studies that may be relevant to multiple subsections within section 2.6.5.",
			"Ensure access to previous regulatory submissions or correspondence that may contain relevant pharmacokinetic data.",
			"Refer to Appendix A for any additional guidance or templates applicable to pharmacokinetic data presentation or integration.",
			"Compile summaries of clinical findings, including limitations such as missing comparator data, absent patient populations, or missing endpoints relevant to pharmacokinetics.",
			"Collect all relevant nonclinical pharmacokinetic study reports, including absorption, distribution, metabolism, and excretion (ADME) studies.",
			"If stability data are referenced in pharmacokinetic studies, ensure that the stability study protocols and related data (as per Appendix C) are collected and available for cross-reference.",
			"Prepare a list of references for the pharmacokinetics written summary, even though placement is flexible.",
			"Gather statements or documentation regarding GCP compliance for relevant clinical studies.",
			"Assemble literature references and citations relevant to the pharmacokinetics of the investigational product.",
			"Obtain validation data for analytical methods used in pharmacokinetic studies.",
			"Collect stability data for biological samples analyzed in pharmacokinetic studies.",
		],
		output: [
			"Ensure the overall sequence of nonclinical summaries places the Pharmacokinetics Written Summary after the Pharmacology Tabulated Summary and before the Pharmacokinetics Tabulated Summary.",
			"Ensure that comparisons and analyses of results across pharmacokinetic studies focus on factual observations rather than interpretation or critical analysis, which belongs in the Clinical Overview.",
			"Ensure the Clinical Overview includes a critical analysis of clinical data, highlighting strengths and limitations of the development program and study results.",
			"Place the list of references in the most appropriate location within the pharmacokinetics written summary to facilitate reviewer understanding; new subsection numbers may be created if needed.",
			"In the Methods of Analysis section, summarize methods for biological sample analysis, including detection and quantification limits.",
			"Include references or electronic links to the full report of each pharmacokinetic or biopharmaceutical study when summarizing individual study results.",
			"Evaluate benefits and risks based on conclusions of relevant clinical studies, explaining how efficacy and safety findings support the proposed dose and indication.",
			"When creating cross-references within section 2.6.5 or to other CTD sections, include the section number in the cross string; the section name may be omitted to maintain brevity, but the text should make the section content clear.",
			"Applicants may modify the format of section 2.6.5 to provide the best possible presentation of information and to facilitate understanding and evaluation of results.",
			"Ensure cross-references are clear and accurate when referring to study reports located in other subsections or modules.",
			"For absorption after repeated dose tables, use the same format as single dose tables if applicable.",
			"For organ distribution tables, include all specified fields: species, gender/number of animals, feeding condition, vehicle/formulation, method of administration, dose, radionuclide, specific activity, sampling time, tissues/organs analyzed, concentration/unit, half-life if applicable, and any additional relevant information.",
			"Ensure that table formats for pharmacokinetics subsections (overview, absorption, distribution) follow the provided templates or acceptable alternate formats.",
			"Group similar pharmacokinetic studies together when appropriate, noting individual study results and any important differences among them.",
			"Ensure that the Pharmacokinetics Written Summary follows the recommended sequence: Brief Summary, Methods of Analysis, Absorption, Distribution, Metabolism, Excretion, Pharmacokinetic Drug Interactions, Other Pharmacokinetic Studies, Discussion and Conclusions, Tables and Figures.",
			"Ensure the Clinical Overview is succinct, well-structured, and facilitates regulatory review by integrating relevant information from other modules without unnecessary duplication.",
			"For absorption after a single dose tables, include columns for each study conducted and provide representative human pharmacokinetic information at the maximum recommended dose for comparison.",
			"Address particular efficacy or safety issues encountered in development, describing how they were evaluated and resolved.",
			"In the Clinical Overview, focus on presenting conclusions and implications of data rather than repeating detailed results from the Clinical Summary or study reports.",
			"Organize content to maximize clarity and facilitate regulatory review, even if this requires deviating from the default template.",
			"Summarize findings in both text and tables, ensuring that tables are consistent with the appendix format used for pharmacokinetic data presentation.",
			"For eCTD submissions, avoid submitting multiple copies of the same file; instead, provide references to the single file location.",
			"Assess and comment on the quality of study design and performance, and include a statement on GCP compliance.",
			"Maintain clear cross-referencing between section 2.6.5 and related sections in the Clinical Summary (e.g., 2.7.1 and 2.7.2) to ensure traceability of pharmacokinetic data sources.",
			"For absorption after a single dose tables, include all specified fields: species, gender/number of animals, feeding condition, vehicle/formulation, method of administration, dose, sample type, analyte, assay method, PK parameters, and additional information such as species/gender differences, dose dependency, or special comments.",
			"Ensure that analytical method overviews emphasize assay validation performance characteristics (linearity, sensitivity, specificity) and quality control parameters (accuracy, precision).",
			"Include an explanation of the overall approach to clinical development, including rationale for critical study design decisions.",
			"Include text tables and figures with the Nonclinical Written Summary where possible for clarity.",
			"When summarizing individual pharmacokinetic studies, provide concise narrative descriptions similar to journal abstracts, describing critical design features and key results.",
			"Ensure the Brief Summary includes description of the scope of the pharmacokinetic evaluation, including species/strains used and formulation similarity.",
			"If pharmacokinetic data are derived from or related to an already approved drug substance, include a clear statement referencing the existing approval and summarize any bridging rationale or justification as per health authority guidance.",
			"Ensure that the pharmacokinetics written summary maintains factual consistency with the Clinical Summary and Module 5 study reports.",
			"Provide a brief overview of clinical findings, noting important limitations such as missing comparator data, absent patient populations, or missing endpoints.",
			"Include discussion of analytical method validation data and sample stability in the Methods of Analysis section.",
			"Ensure that any references to appendices (e.g., Appendix A or Appendix C) are properly cited and that cross-references are functional within the eCTD structure.",
			"Follow FDA and ICH guidance principles for integrated data presentation, ensuring that section 2.6.5 provides a coherent synthesis of pharmacokinetic data rather than a simple compilation of study summaries.",
			"Use the required citation format when referencing Tabulated Summaries: (Table X.X, Study/Report Number).",
			"Provide a factual summary of all in vitro dissolution, bioavailability, and comparative bioavailability studies relevant to pharmacokinetics, highlighting differences in results across studies.",
			"Discuss unresolved issues, justify why they are not barriers to approval, and outline plans to resolve them.",
			"Do not include detailed information about individual studies in the overview section; reserve such details for the individual study summaries or appendices.",
			"Include tables and figures either within the text at appropriate locations or consolidated at the end of the summary.",
			"In pharmacokinetics overview tables, include one line for each pharmacokinetics report in the same order as the CTD, identify reports with GLP Compliance Statements in a footnote, and indicate the location of the technical report in the CTD.",
			"Discuss the potential impact of differences in analytical methods on interpretation of results in relevant sections.",
			"Explain the basis for important or unusual aspects of the prescribing information in the Clinical Overview.",
			"Limit the Brief Summary section to approximately 2–3 pages, summarizing principal pharmacokinetic findings.",
			"Include discussion of the effects of formulation and manufacturing changes on in vitro dissolution and bioavailability, and provide conclusions regarding bioequivalence where applicable.",
			"If a nonclinical pharmacokinetic study appears in more than one place in section 2.6.5, either place the full study report in the first relevant subsection (e.g., Absorption) and cross-reference it in other subsections, or include the full report in each relevant subsection.",
			"Ensure that any integrated analyses or summaries in section 2.6.5 are concise and do not include excessive detail; detailed analyses should be placed in the appropriate full study reports or appendices (e.g., Module 4 or 5) and referenced appropriately.",
		],
	},
	{
		number: "2.6.6",
		title: "Pharmacokinetics Tabulated Summary",
		input: [
			"For absorption after a single dose studies, collect representative human PK information at the maximum recommended dose for comparison.",
			"If the drug substance is already approved, consult the relevant health authority for guidance on data requirements before preparing the Pharmacokinetics Tabulated Summary.",
			"Gather International Nonproprietary Name (INN) of the test article for inclusion in PK tables.",
			"Prepare the Pharmacokinetics Tabulated Summary document template as per CTD Module 2.6.6 requirements.",
			"Collect the location references of each PK technical report within the CTD (volume and section numbers).",
			"Identify and collect GLP compliance statements for PK study reports, to be noted in footnotes.",
			"Compile datasets and tables summarizing PK parameters such as Cmax, Tmax, AUC, clearance, volume of distribution, and half-life from nonclinical studies.",
			"Ensure availability of any comparator or reference product data if used in PK studies.",
			"Gather any kinetic data obtained from Segment 2 (reproductive toxicity) studies if available and relevant to pharmacokinetics.",
			"Collect any supportive pharmacokinetic data or analyses from Section 2.7.2 (Clinical Pharmacology Written Summary) that are relevant to the nonclinical pharmacokinetics tabulated summary for cross-reference or contextual comparison.",
			"Obtain detailed study-level data for each PK study, including species, gender, number of animals, feeding condition, vehicle/formulation, method of administration, dose, sample type, analyte, assay method, PK parameters, and any additional relevant information (e.g., species/gender differences, dose dependency).",
			"Gather literature references or expert opinions used to interpret or support PK findings.",
			"Collect all pharmacokinetic (PK) study reports relevant to the nonclinical pharmacokinetics of the drug, including absorption, distribution, metabolism, and excretion (ADME) studies.",
			"Collect any regulatory correspondence or previous submissions that clarify which PK studies were conducted or omitted.",
			"For organ distribution studies, collect radionuclide information, specific activity, sampling times, tissue/organ concentration data, and analyte/assay details.",
			"Refer to Appendix A for any additional instructions or clarifications relevant to the preparation of the Pharmacokinetics Tabulated Summary.",
			"Obtain analytical data and test results used to determine PK parameters, including bioanalytical method validation reports if applicable.",
		],
		output: [
			"Include only noteworthy or significant PK findings in the tabulated summary, such as statistically significant differences or other notable observations.",
			"Include additional information fields in tables for brief textual results, species differences, gender differences, dose dependency, or special comments where relevant.",
			"For organ distribution tables, include radionuclide, specific activity, sampling times, tissues/organs, and concentration units, and indicate whether half-life (t1/2) is reported.",
			"If supportive data from Section 2.7.2 are incorporated, clearly identify their source and ensure consistency in data presentation and interpretation across sections.",
			"If references are included in the PK tabulated summary (e.g., 2.6.6.11), place them in the most appropriate location and create new subsection numbers if needed to improve reviewer understanding.",
			"For assay methods, specify the analytical technique used (e.g., HPLC, LSC with radiolabeled compound) in the table.",
			"Indicate in the table the location of each technical report in the CTD (volume and section).",
			"Use the required citation format when referring to tabulated summaries within the text: (Table X.X, Study/Report Number).",
			"Ensure that the tables are structured to facilitate review and understanding of PK data, clearly identifying study type, species, dose, route, and key PK parameters.",
			"When PK study reports appear in multiple sections, ensure proper cross-referencing to avoid duplication and maintain clarity, particularly in eCTD submissions.",
			"List one line for each pharmacokinetics report in the same order as the CTD, ensuring consistent sequencing with the overall dossier.",
			"Cross-reference the tabulated summary with detailed study reports in Module 4 for traceability and verification.",
			"For absorption after a single dose tables, include one column for each study conducted and, for comparison, representative human PK information at the maximum recommended dose.",
			"Maintain the section heading '2.6.6 Pharmacokinetics Tabulated Summary' even if certain PK studies were not conducted, and provide a brief explanation for their absence.",
			"If the drug substance is already approved, ensure that the tabulated summary clearly indicates reliance on existing data and aligns with health authority guidance.",
			"Use the recommended CTD nonclinical tabulated summary format as outlined in the ICH M4S guideline; modifications are allowed if they improve clarity and understanding.",
			"Ensure consistency in terminology, units, and abbreviations across all tables and summaries.",
			"Identify in a footnote any PK reports that contain a GLP Compliance Statement.",
			"Ensure that the tabulated summary is concise, clear, and logically organized to facilitate regulatory review.",
			"If analytical methods or data sources differ between studies, use footnotes or annotations to clarify differences and maintain transparency.",
			"Confirm that the tabulated summary structure adheres to CTD conventions, even if lower-level headings do not contain individual documents or files, maintaining consistency with CTD formatting expectations.",
			"When preparing cross-references in paper submissions, keep cross strings concise by using only the section number, but write surrounding text so the reader understands the section content.",
			"Ensure the Tabulated Summary of Pharmacokinetics is placed in the recommended sequence following the Written Summary of Pharmacokinetics and preceding the Written Summary of Toxicology.",
			"Applicants may modify the table format if needed to provide the best possible presentation and facilitate understanding and evaluation of PK results.",
			"Verify that all data presented in the tables correspond accurately to the underlying study reports and datasets.",
			"Ensure that cross-references within the PK tabulated summary include at least the section number; including the section name is optional but can improve clarity for readers.",
		],
	},
	{
		number: "2.6.7",
		title: "Toxicology Written Summary",
		input: [
			"Collect GLP-status information for all toxicology studies to be included in the written summary.",
			"Gather reproductive and developmental toxicity study data including fertility, early embryonic development, embryo\u0011fetal development, prenatal and postnatal development, and any juvenile animal dosing/evaluation studies.",
			"Gather supportive toxicokinetic data for repeat-dose toxicity, genotoxicity, and carcinogenicity studies, where applicable.",
			"Gather any reference materials or literature citations used in the Toxicology Written Summary to support study interpretation or conclusions, in preparation for inclusion in a reference list if appropriate.",
			"Gather carcinogenicity study information, including rationale for study selection and scientific basis for high\u0011dose selection.",
			"Collect repeat-dose toxicity study methodology details, including target organ findings, severity, dose/exposure\u0013response relationships, and NOAELs.",
			"Gather for each toxicology report: type of study, species and strain, method of administration, duration of dosing, doses (mg/kg), GLP compliance status, testing facility, study number, and location in CTD.",
			"Gather juvenile‑animal study data specifically for tabulation using appropriate templates.",
			"Prepare explanations for any toxicology study categories not conducted (e.g., carcinogenicity), including scientific justification.",
			"Collect all relevant toxicology study reports, including repeat-dose toxicity studies specified by ICH Guideline M3 and any other repeat-dose toxicity studies considered pivotal.",
			"Gather carcinogenicity study information, including rationale for study selection and scientific basis for high–dose selection.",
			"Gather reproductive and developmental toxicity study data including fertility, early embryonic development, embryo–fetal development, prenatal and postnatal development, and any juvenile animal dosing/evaluation studies.",
			"Collect any regulatory correspondence or prior submissions that clarify study conduct or omission rationale.",
			"Gather highest NOAEL values for repeat-dose toxicity studies, ensuring identification for underlining in tables.",
			"Collect all genotoxicity study reports, including in vitro non-mammalian, in vitro mammalian, in vivo mammalian, and any other systems.",
			"Collect repeat-dose toxicity study methodology details, including target organ findings, severity, dose/exposure–response relationships, and NOAELs.",
			"Ensure all toxicology study reports referenced in section 2.6.7 are properly located and cross-referenced in Module 4 (sections 4.2.3 and 4.2.4) for traceability and consistency.",
			"Prepare tabulated summaries for each pivotal repeat-dose toxicity study (e.g., Table 2.6.7.7).",
			"Gather toxicokinetics study information including type of study, test system, method of administration, doses (mg/kg), GLP compliance, study number, and location in CTD.",
			"Gather juvenile–animal study data specifically for tabulation using appropriate templates.",
			"Gather single-dose toxicity study data, summarized by species and route.",
			"Gather carcinogenicity study information, including rationale for study selection and scientific basis for high‑dose selection.",
			"Gather reproductive and developmental toxicity study data including fertility, early embryonic development, embryo‑fetal development, prenatal and postnatal development, and any juvenile animal dosing/evaluation studies.",
			"Gather local tolerance study data organized by species, route, and duration.",
			"Gather juvenile\u0011animal study data specifically for tabulation using appropriate templates.",
			"Compile noteworthy toxicological findings from studies, including statistically significant differences from controls and noteworthy non-significant findings.",
			"Gather all toxicology study information needed to compile a table listing principal toxicologic studies, including study type, duration, route, species, and test article.",
			"Gather any pharmacokinetic or kinetic data from toxicology studies if relevant to the toxicology summary.",
			"Obtain impurity specification test results for test articles used in toxicology studies, if available, especially for GLP studies; include results for non-GLP studies only if analyses were conducted.",
			"Gather data from all pivotal toxicology studies, including both early and later studies if applicable (e.g., 3-month and 9-month toxicity studies).",
			"Collect data from 'other toxicity studies' (e.g., antigenicity, immunotoxicity, mechanistic studies, dependence, metabolite studies, impurity studies) including rationale for their conduct when applicable.",
			"Identify and document batches relevant to qualification of impurities, noting any analytical method changes over development.",
		],
		output: [
			"Follow the required sequence of the Toxicology Written Summary, including all major sections: Brief Summary; Single-Dose Toxicity; Repeat\u0011Dose Toxicity; Genotoxicity; Carcinogenicity; Reproductive and Developmental Toxicity; Juvenile Animal Studies; Local Tolerance; Other Toxicity Studies; Discussion and Conclusions; Tables and Figures.",
			"Place text tables and figures either embedded within the text or grouped at the end of the summary, ensuring consistent placement.",
			"Applicants may modify the format of section 2.6.7 if needed to provide the best possible presentation of information and to facilitate understanding and evaluation of results.",
			"If analytical methods for impurity testing changed during development, use footnotes in the 'Drug Substance' table to identify batches relevant to impurity qualification.",
			"Indicate the scope of the toxicologic evaluation in relation to the intended clinical use within the Brief Summary.",
			"Summarize local tolerance studies in order by species, by route, and by duration, including brief methodology and key findings.",
			"Include a comment on the GLP status of studies in the Brief Summary.",
			"For 'Other Toxicity Studies,' summarize all studies performed and provide rationale when appropriate.",
			"Ensure juvenile\u0011animal studies are tabulated using the appropriate template for the study type.",
			"Ensure that all toxicology study summaries in section 2.6.7 correspond to the full study reports located in Module 4, maintaining consistent numbering and cross-references.",
			"Follow the order of the Nonclinical Written Summaries when preparing the Nonclinical Tabulated Summaries.",
			"Include impurity specification test results for test articles in the 'Drug Substance' table if analyses were conducted, even for non-GLP studies.",
			"In the toxicokinetics table (2.6.7.2), list one line for each toxicokinetics report in the same order as the CTD, including type of study, test system, method of administration, doses (mg/kg), GLP compliance, study number, and location in CTD.",
			"Provide a rationale in the carcinogenicity section explaining study selection and high\u0011dose justification, including supportive toxicokinetic considerations.",
			"Summarize single‑dose toxicity studies very briefly, organized by species and route; tables may be used if helpful.",
			"Summarize repeat-dose studies in order by species, by route, and by duration, highlighting methodology, target organ toxicity, severity, dose/exposure\u0013response, and NOAELs; non\u0011pivotal studies should be summarized in less detail.",
			"Use templates in Appendix B and follow content examples in Appendix C when assembling tabulated summaries, modifying as needed to best present the data.",
			"Follow the required sequence of the Toxicology Written Summary, including all major sections: Brief Summary; Single-Dose Toxicity; Repeat‑Dose Toxicity; Genotoxicity; Carcinogenicity; Reproductive and Developmental Toxicity; Juvenile Animal Studies; Local Tolerance; Other Toxicity Studies; Discussion and Conclusions; Tables and Figures.",
			"Summarize reproductive and developmental toxicity studies in the required order: fertility/early embryonic development; embryo‑fetal development; prenatal and postnatal development; juvenile animal dosing/evaluation studies. Modify sub‑headings if study design is modified.",
			"In the toxicology table (2.6.7.1), list one line for each toxicology report in the same order as the CTD, including all specified columns: type of study, species and strain, method of administration, duration of dosing, doses (mg/kg), GLP compliance, testing facility, study number, and location in CTD.",
			"Ensure tables and summaries are clear, concise, and facilitate regulatory review and evaluation.",
			"Summarize single\u0011dose toxicity studies very briefly, organized by species and route; tables may be used if helpful.",
			"Summarize repeat-dose studies in order by species, by route, and by duration, highlighting methodology, target organ toxicity, severity, dose/exposure–response, and NOAELs; non‑pivotal studies should be summarized in less detail.",
			"Summarize carcinogenicity studies in the following order: long\u0011term studies (by species), short\u0011/medium\u0011term studies, and other studies.",
			"Summarize reproductive and developmental toxicity studies in the required order: fertility/early embryonic development; embryo\u0011fetal development; prenatal and postnatal development; juvenile animal dosing/evaluation studies. Modify sub\u0011headings if study design is modified.",
			"Limit the Brief Summary section to a few pages, generally not more than 6 pages.",
			"Summarize repeat-dose studies in order by species, by route, and by duration, highlighting methodology, target organ toxicity, severity, dose/exposure–response, and NOAELs; non–pivotal studies should be summarized in less detail.",
			"Maintain all section headings in the Toxicology Written Summary, even if a study category was not conducted, and provide a brief explanation for omission.",
			"Ensure juvenile‑animal studies are tabulated using the appropriate template for the study type.",
			"When preparing tabulated summaries, delete italicized guidance text from template files before submission.",
			"Summarize carcinogenicity studies in the following order: long‑term studies (by species), short‑/medium‑term studies, and other studies.",
			"Summarize genotoxicity studies in the required order: in vitro non‑mammalian, in vitro mammalian, in vivo mammalian (including supportive TK), and other systems.",
			"Retain the current CTD numbering for section 2.6.7 and its subsections, ensuring consistency with the overall CTD numbering system.",
			"Ensure juvenile–animal studies are tabulated using the appropriate template for the study type.",
			"Ensure that section numbering and titles in 2.6.7 align with the CTD format and remain unaltered even when multiple indications or study categories are discussed.",
			"Provide a rationale in the carcinogenicity section explaining study selection and high‑dose justification, including supportive toxicokinetic considerations.",
			"Use the recommended CTD nonclinical tabulated summary format for Module 2.6, but modify if needed to best present and facilitate understanding of results.",
			"When referencing other CTD sections in cross strings, include only the section number in the cross string itself, but write the surrounding text so the reader understands the section content.",
			"Underline the highest NOAEL in repeat-dose toxicity entries in the toxicology table.",
			"Summarize reproductive and developmental toxicity studies in the required order: fertility/early embryonic development; embryo–fetal development; prenatal and postnatal development; juvenile animal dosing/evaluation studies. Modify sub–headings if study design is modified.",
			"Summarize genotoxicity studies in the required order: in vitro non\u0011mammalian, in vitro mammalian, in vivo mammalian (including supportive TK), and other systems.",
			"Summarize single-dose toxicity studies very briefly, organized by species and route; tables may be used if helpful.",
			"Verify that the Toxicology Written Summary (2.6.7) aligns with the structure of Module 4 (Nonclinical Study Reports) to ensure traceability between summary and source data.",
			"Summarize carcinogenicity studies in the following order: long–term studies (by species), short–/medium–term studies, and other studies.",
			"Include one table for each pivotal repeat-dose toxicity study as specified by ICH M3, plus any other pivotal repeat-dose studies.",
			"Provide a rationale in the carcinogenicity section explaining study selection and high–dose justification, including supportive toxicokinetic considerations.",
			"Follow CTD structure and numbering for section 2.6.7, keeping headings consistent with guidance.",
			"For the Local Tolerance subsection (2.6.7.16), use the same tabulated summary template as for section 2.6.7.17, ensuring consistency in presentation and structure.",
			"Tabulate only noteworthy toxicological findings, including statistically significant differences from controls and noteworthy non-significant findings.",
			"Include a table listing principal toxicologic studies in the Brief Summary, without presenting results in this table.",
			"If references are included in the Toxicology Written Summary, place the list of references in the most appropriate location within section 2.6.7 and create new subsection numbers as needed to facilitate reviewer understanding.",
			"Follow the required sequence of the Toxicology Written Summary, including all major sections: Brief Summary; Single-Dose Toxicity; Repeat–Dose Toxicity; Genotoxicity; Carcinogenicity; Reproductive and Developmental Toxicity; Juvenile Animal Studies; Local Tolerance; Other Toxicity Studies; Discussion and Conclusions; Tables and Figures.",
			"Summarize genotoxicity studies in the required order: in vitro non–mammalian, in vitro mammalian, in vivo mammalian (including supportive TK), and other systems.",
			"In the Discussion and Conclusions section, discuss the toxicologic evaluation and significance of key issues; include tables/figures summarizing this information.",
		],
	},
	{
		number: "2.6.8",
		title: "Toxicology Tabulated Summary Nonclinical Tabulated Summaries",
		input: [
			"Collect all toxicology study identifiers and metadata required for the 2.6.8 toxicology tables, including species and strain, method of administration, duration, doses (mg/kg), GLP compliance status, testing facility, study number, and CTD location.",
			"Collect all toxicology study identifiers and metadata required for the 2.6.7.1 toxicology table, including species and strain, method of administration, duration, doses (mg/kg), GLP compliance status, testing facility, study number, and CTD location.",
			"Collect results from any analyses performed on drug substances used in non-GLP studies; include these if available.",
			"Identify which batches of drug substance are relevant to impurity qualification and note any analytical method changes across development stages.",
			"Collect all nonclinical toxicology study reports relevant to the product, including repeat-dose toxicity studies, carcinogenicity, reproductive toxicity (Segment 2), and other pivotal toxicology studies as defined by ICH M3.",
			"Gather all relevant tables and datasets summarizing toxicology results, including those for repeat-dose, carcinogenicity, and reproductive toxicity studies.",
			"Gather data from pharmacokinetic (PK) or kinetics studies conducted within Segment 2 studies, as applicable, to support toxicology tabulations.",
			"Gather batch numbers for all drug substance test articles used in toxicology and toxicokinetics studies for inclusion in section 2.6.7.4.",
			"Prepare a list of references supporting the nonclinical toxicology data presented in the tabulated summaries.",
			"Collect all toxicokinetics study reports and data packages required to support toxicology tabulations, ensuring availability of test system, dose levels, methods of administration, GLP compliance status, and CTD study locations.",
			"Gather batch numbers for all drug substance test articles used in toxicology and toxicokinetics studies for inclusion in the toxicology tabulated summaries.",
			"Collect Appendix C example tables and templates from the guideline to use as reference for content and format of the Tabulated Summaries.",
			"Compile all noteworthy toxicological findings from each study, including statistically significant differences from controls and other noteworthy but non-significant findings.",
			"Collect datasets and study reports for any juvenile-animal studies, ensuring availability of all data needed to tabulate these studies using the appropriate template.",
			"Ensure access to previous regulatory correspondence or submissions that define which studies are considered pivotal for inclusion in the tabulated summary.",
			"Obtain impurity data for drug substances used in toxicology studies, including impurity-specification test results and analytical method details for each batch used.",
			"Obtain the completed juvenile animal study table formatted according to the appropriate study type template for inclusion in Section 2.6.7.15, if applicable to toxicology tabulations.",
			"Collect all toxicokinetics study reports and data packages required for 2.6.7.2 and 2.6.7.3, ensuring availability of test system, dose levels, methods of administration, GLP compliance status, and CTD study locations.",
		],
		output: [
			"Use Appendix C example tables as guidance for suggested content and format, but adapt as necessary to best present the data for the specific product.",
			"Ensure that the order of presentation for the Nonclinical Written Summaries matches that of the Nonclinical Tabulated Summaries to maintain consistency and facilitate review.",
			"Verify that the tabulated summaries facilitate reviewer understanding and evaluation of the nonclinical toxicology results.",
			"When a juvenile animal study is conducted, ensure it is tabulated using the correct template for its study type and cross-referenced appropriately within toxicology tabulations.",
			"Ensure that the presentation of data in the tabulated summaries provides concise overviews of related information while maintaining sufficient detail for reviewer assessment.",
			"Prepare one table for each repeat-dose toxicity study specified by ICH Guideline M3, as well as any other repeat-dose toxicity studies considered pivotal.",
			"Provide a list of references for the nonclinical summary (2.6.8) even though not explicitly covered in the guidance, to maintain consistency with other CTD sections.",
			"Combine multiple studies into a single table when appropriate, or cite data from one study in multiple table formats if needed to ensure clarity.",
			"Ensure that toxicokinetics tables include required fields: type of study, test system, method of administration, doses, GLP compliance, study number, and CTD location.",
			"Ensure that the order of presentation for the Nonclinical Tabulated Summaries matches that of the Nonclinical Written Summaries to maintain consistency and facilitate review.",
			"Ensure the tabulated summaries are organized clearly by study type and include all relevant data fields (e.g., study ID, species, duration, dose, findings).",
			"Follow the recommended sequence for Nonclinical Written and Tabulated Summaries: Introduction – Written Summary of Pharmacology – Tabulated Summary of Pharmacology – Written Summary of Pharmacokinetics – Tabulated Summary of Pharmacokinetics – Written Summary of Toxicology – Tabulated Summary of Toxicology.",
			"Clearly indicate the CTD location (volume and section) for each toxicology and toxicokinetics technical report in the tabulated summaries.",
			"Maintain all section headings in the CTD document, even if certain categories of toxicology studies (e.g., carcinogenicity) were not conducted; provide a brief explanation for their omission.",
			"Applicants may modify the tabulated summary format if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation of the results.",
			"Place the list of references in the most appropriate location within section 2.6.8 to facilitate reviewer understanding, and create new subsection numbers if necessary.",
			"Ensure that the level of detail in the tables is sufficient for primary review of nonclinical information in regions where tabulated summaries are the main review tool.",
			"Include only noteworthy findings in the tabulated summaries—these include statistically significant differences from controls and other noteworthy, non-significant findings.",
			"Underline the highest NOAEL (No Observed Adverse-Effect Level) in repeat‑dose toxicity tables.",
			"When a juvenile animal study is conducted, ensure it is tabulated using the correct template for its study type and placed in Section 2.6.7.15, with cross-reference in toxicology tabulations if relevant.",
			"Ensure that toxicology tables include all required fields: type of study, species/strain, method of administration, dosing duration, doses, GLP compliance, testing facility, study number, and CTD location.",
			"Ensure one line is provided for each toxicology or toxicokinetics report in the tables, in the same order as the CTD.",
			"Use the recommended CTD nonclinical tabulated summary templates as outlined in the guideline; modifications are permitted if they improve clarity and facilitate understanding of results.",
			"Use footnotes in the 'Drug Substance' table to identify batches relevant to impurity qualification, especially when analytical methods have changed during development.",
			"Include impurity-specification test results for test articles used in early-stage toxicology studies if available, even if the studies were non-GLP.",
			"Follow the order of presentation used for the Nonclinical Written Summaries when preparing the Nonclinical Tabulated Summaries.",
			"Tabulate juvenile-animal studies using the template appropriate for their study type.",
			"Include reference citations to the Tabulated Summaries throughout the text in the format: (Table X.X, Study/Report Number).",
			"Ensure that the tables follow the recommended formats in Appendices B and C; delete all italicized instructional text when preparing final tables.",
			"Ensure that the Nonclinical Written Summaries (all three combined) generally do not exceed 100–150 pages in total, even though there is no formal limit.",
			"Include only noteworthy findings in the tabulated summaries\u0000these include statistically significant differences from controls and other noteworthy, non-significant findings.",
		],
	},
	{
		number: "2.7.1.1",
		title: "Background and Overview",
		input: [
			"Obtain summaries of any alternative forms, formulations, or routes of administration considered during development.",
			"Confirm that all study identifiers and summaries referenced in the background and overview correspond to the correct study reports listed in Module 4 (4.2.1 and 4.2.2).",
			"Obtain the basis for important or unusual aspects of the proposed prescribing information.",
			"Gather information on how safety data were collected and the extent of exposure of study subjects to the test drug, as referenced in related efficacy and safety sections.",
			"Gather statements or documentation regarding GCP compliance for the clinical studies referenced.",
			"Obtain the comprehensive Clinical Summary (Module 2.7) for reference to detailed factual data.",
			"Collect benefit–risk evaluation data, including efficacy and safety findings supporting proposed dose and indication.",
			"Compile summaries of important limitations in the clinical data set (e.g., missing populations, endpoints, comparator data).",
			"Gather any other relevant reports that may provide context, including pertinent animal data or product quality issues with clinical implications.",
			"Compile summaries of pivotal clinical and non-clinical studies, including study identifiers, objectives, and major findings.",
			"Obtain individual clinical study reports (ICH E3) from Module 5 for cross-referencing and verification of study details.",
			"Obtain summaries of the drug substance and drug product properties from relevant quality sections (e.g., 3.2.S and 3.2.P) to provide context.",
			"Obtain documentation of the prevailing ethical, legal, and regulatory guidelines applicable to the clinical trial(s) referenced in the background and overview section.",
			"Ensure access to Module 3 (Quality) and Module 4 (Nonclinical Study Reports) documents for cross-referencing and consistency checks when preparing the background and overview section.",
			"Obtain cross-references to the Summary of Clinical Efficacy (2.7.3) and Summary of Clinical Safety (2.7.4) to ensure alignment of background context and study descriptions.",
			"Gather key regulatory background information, including previous regulatory interactions, approvals, or advice relevant to the product.",
			"Collect information on critical study design decisions made during development, including rationale and alternatives considered.",
			"Collect epidemiological and disease background information relevant to the therapeutic area.",
			"Gather information on the mechanism of action, pharmacological class, and any unique features of the drug.",
			"Obtain expert opinions or advisory board conclusions that influenced the development strategy.",
			"Collect a high-level summary of the drug development program, including rationale for development and intended indication(s).",
			"Gather applicable international and local regulatory guidance documents (e.g., ICH GCP, Declaration of Helsinki, regional clinical trial regulations) referenced in the section.",
			"Gather information on particular efficacy or safety issues encountered during development and how they were addressed.",
			"Collect details of unresolved clinical issues, rationale for non-impact on approval, and plans for resolution.",
			"Collect relevant literature references that support the development rationale and clinical positioning.",
			"Gather comparator product information, if applicable, including regulatory status and key differences.",
			"Collect institutional review board (IRB) or ethics committee approvals or summaries confirming ethical oversight of the clinical trials included in the development program.",
		],
		output: [
			"Ensure the section presents a succinct discussion and interpretation of clinical findings rather than repeating detailed data from the Clinical Summary or study reports.",
			"Ensure the 2.7.1.1 Background and Overview document is submitted at the correct eCTD granularity level, following Module 2 rules indicating that one document may be submitted at this level.",
			"Ensure internal consistency between the background and overview section and the corresponding quality and nonclinical modules (Modules 3 and 4).",
			"Incorporate an assessment of the quality of study design and performance, including a statement on GCP compliance.",
			"Discuss unresolved issues, justify why they are not barriers to approval, and outline plans for resolution.",
			"Check that the section is concise and focused, typically limited to a few pages, to maintain readability.",
			"Ensure that the heading 'Trial Oversight and Other General Considerations' (11) and subheading 'Regulatory and Ethical Considerations' (11.1) are correctly labeled and formatted according to CTD conventions, even if no text is required under the main heading.",
			"Confirm that no documents are incorrectly submitted at document levels that are disallowed in eCTD (e.g., levels marked as 'documents may not be submitted at this level for eCTD submissions').",
			"Follow ICH CTD structure for section 2.7.1.1, ensuring the heading 'Background and Overview' is clearly indicated.",
			"Explain the basis for important or unusual aspects of the prescribing information.",
			"Organize content logically: start with disease/condition background, then product background, then development rationale.",
			"Provide a brief overview of clinical findings, noting important limitations such as missing comparator data, unstudied populations, or absent endpoints.",
			"Ensure that CTD Module 2 placement of 2.7.1.1 is consistent with the regional guidance on Module 2 organization and granularity.",
			"Maintain consistency in terminology with other CTD sections, especially 2.7 summaries and Module 3 quality information.",
			"Ensure that the subheading 'Regulatory and Ethical Considerations' contains a concise, high-level statement rather than detailed procedural descriptions.",
			"Verify that the Background and Overview section appropriately references where safety-related results are discussed (i.e., in 2.7.4 Summary of Clinical Safety) when studies contribute to both efficacy and safety evaluations.",
			"Address specific efficacy or safety issues encountered during development, explaining how they were evaluated and resolved.",
			"Maintain all relevant CTD section headings even if no studies were conducted for that category, and provide a brief explanation for their absence rather than deleting the heading or renumbering subsequent sections.",
			"Confirm that cross-references to other CTD sections (e.g., 2.7.3.1 Background, 2.7.3.2 Summary of Results of Individual Studies, 2.7.4 Summary of Clinical Safety) are accurate and consistent with the numbering and structure used in the dossier.",
			"Ensure that any mention of alternative forms or formulations is consistent with information in Module 3.",
			"Use non-technical, plain language where possible to ensure clarity for multidisciplinary reviewers.",
			"Confirm that the section heading is present and correctly placed in the table of contents, as conformance is required and cardinality is one-to-one.",
			"Cross-check that all study identifiers and summaries referenced in this section align with the structure and numbering used in Module 4 (e.g., 4.2.1.x and 4.2.2.x).",
			"Avoid duplicating detailed data tables; instead, summarize and refer to the relevant CTD sections for full details.",
			"Ensure that all statements are supported by data or references, with cross-references to detailed sections of the CTD where applicable.",
			"Include an evaluation of benefits and risks, interpreting how efficacy and safety findings support the proposed dose and indication, and how prescribing information and other measures will optimize benefits and manage risks.",
			"Do not include additional text under the main heading 'Trial Oversight and Other General Considerations' if the guidance specifies 'No text is intended here (heading only)'.",
			"Use section numbers (rather than full section names) in cross-references (cross strings) to improve clarity and avoid overly long references, ensuring the surrounding text makes the section content clear.",
			"Ensure that the discussion integrates relevant nonclinical or quality data only when they have clinical implications.",
			"Ensure that any discussion of studies contributing both efficacy and safety data in the Background and Overview section aligns with the placement of detailed narratives in 2.7.3.2 and safety results in 2.7.4, avoiding duplication.",
			"Ensure that CTD numbering conventions are retained and consistent across all modules and indications, including the use of indication identifiers (e.g., 2.7.3.UTI, 2.7.3.Pneumonia) where applicable.",
			"Include a description and explanation of the overall approach to clinical development, highlighting critical study design decisions.",
			"Begin the section with a concise, clear overview of the product and its development history, avoiding excessive technical detail.",
			"Include a high-level statement summarizing the ethical, legal, and regulatory frameworks applied to the clinical trials discussed, consistent with the user guidance for 'Regulatory and Ethical Considerations'.",
			"Verify that the section provides sufficient context for understanding the subsequent clinical summary sections.",
		],
	},
	{
		number: "2.7.1.2",
		title: "Summary of Results of Individual Studies",
		input: [
			"Collect all individual clinical study reports relevant to efficacy and safety, including pivotal and supportive studies.",
			"Ensure availability of case report forms (CRFs) for relevant studies, located in Module 5.3.7 as per CTD organization.",
			"Retrieve statistical output and datasets from individual studies, including tables, listings, and figures that summarize study results.",
			"Collect narrative summaries (or information needed to prepare them) of critical design features and outcomes for each individual biopharmaceutical study.",
			"Ensure availability of individual patient data listings for relevant studies, located in Module 5.3.7 as per CTD organization.",
			"Ensure availability of electronic links or precise references to the full biopharmaceutical study reports in Module 5 for inclusion in the narratives.",
			"Gather integrated analyses of all relevant data from individual studies, as these summaries are expected to reflect integrated results rather than simple listings.",
			"Ensure access to detailed reports of analyses from more than one study (to be referenced or summarized in this section, with full reports placed in Module 5.3.5.3).",
			"Obtain microbiology data from both in vitro and in vivo studies if applicable to the products efficacy profile.",
			"Gather a complete tabular listing of all biopharmaceutical studies to be included in Section 2.7.1.2, including BA, BE, comparative BA, and relevant in vitro studies.",
			"Gather any relevant expert opinions or literature references that support interpretation of individual study results.",
			"Ensure that for each study report included in Module 4 or 5, a single complete document is available; if the report is large (e.g., carcinogenicity study), ensure that the text portion and appendices are available as separate documents as needed.",
			"Retrieve the ICH E3 study synopses for relevant biopharmaceutical studies to support preparation of narrative abstracts.",
			"Gather information on any post-marketing biopharmaceutical data if applicable and relevant to individual study summaries.",
			"Ensure availability of publications and literature references related to the studies, located in Module 5.4 as per CTD organization.",
			"Obtain narrative descriptions for studies that contributed both efficacy and safety data, including details on extent of exposure of study subjects to the test drug and how safety data were collected.",
			"Confirm availability of cross-referencing information for each study (study ID, title, and location in Module 5).",
			"Collect any previous regulatory submissions or correspondence that clarify expectations for the level of detail required in the CTD Module 2 summaries versus Module 5 reports.",
			"Obtain microbiology data from both in vitro and in vivo studies if applicable to the product’s efficacy profile.",
			"Obtain microbiology data from both in vitro and in vivo studies if applicable to the product\u0000s efficacy profile.",
			"Obtain microbiology data from both in vitro and in vivo studies if applicable to the product\u0004s efficacy profile.",
			"Prepare a list of literature references cited in the section to ensure they can be included in the table of contents as required.",
		],
		output: [
			"When referencing study reports in cross strings, include only the section number (e.g., 5.3.5.2) to maintain brevity, but write the text so the reader understands the section content.",
			"Use a unique short identifier for each clinical study and apply it consistently throughout the CTD, including Module 2 summaries and citations of Module 5 study reports.",
			"Verify that all cross-references point to the correct CTD section (e.g., 5.3.5.3 for detailed reports of analyses from more than one study).",
			"When determining document granularity, consider lifecycle management implications—replacement of complete documents/files is required when relevant information changes.",
			"Provide a tabular listing of all biopharmaceutical studies in Section 2.7.1.2 or reference it in Section 2.7.1.4 Appendix.",
			"Organize the section so that each individual study\u0019s results are clearly summarized and traceable to the corresponding full report in Module 5.",
			"Organize the section so that each individual study’s results are clearly summarized and traceable to the corresponding full report in Module 5.",
			"Ensure that any results pertinent to safety evaluation from studies described in 2.7.3.2 are discussed in the Summary of Clinical Safety (2.7.4) section.",
			"Include sufficient detail to meet 21 CFR 314.50 requirements if applicable, but avoid excessive detail that belongs in Module 5.",
			"Ensure the section provides integrated analyses of individual study results rather than simple summaries, consistent with FDA guidance.",
			"Applicants may modify the format of the section if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation of the results by regulatory reviewers.",
			"Ensure that each study report is treated as a single document for submission purposes; if a report is large, separate the text portion and appendices into distinct documents, maintaining clear labeling and cross-references.",
			"Organize the section so that each individual study\u0014s results are clearly summarized and traceable to the corresponding full report in Module 5.",
			"When determining document granularity, consider lifecycle management implications\u0014replacement of complete documents/files is required when relevant information changes.",
			"Retain current CTD numbering and identify the indication in the section title (e.g., 2.7.3.2.UTI Summary of Results of Individual Studies) when there is more than one indication.",
			"Ensure clarity and readability for reviewers unfamiliar with the submission by maintaining consistent terminology and structure across studies.",
			"Check that all referenced appendices and reports are correctly cited and located in the appropriate Module 5 sections.",
			"Ensure comparisons and analyses provided in the section focus strictly on factual observations, reserving interpretation for the Clinical Overview.",
			"In study narratives for studies contributing both efficacy and safety data, include information on extent of exposure and how safety data were collected, but reserve detailed safety results for section 2.7.4.",
			"Avoid including long section names in cross strings to prevent clutter; rely on clear narrative text to convey the context of the reference.",
			"Describe critical design features and critical results for each study in the narratives.",
			"Follow the outline and structure aligned with the Integrated Summary of Safety (ISS) and Integrated Summary of Efficacy (ISE) formats, modified per ICH E3 experience.",
			"Include all literature references cited in this section in the overall table of contents to comply with CTD documentation standards.",
			"Ensure that cross-references in the text are clear and informative, using examples such as '...as seen in the population PK study 101 (5.3.3.5)' to guide the reviewer to the correct section.",
			"Include references or electronic links to the full study reports within each narrative.",
			"When the statistical output is too extensive for inclusion in this section, summarize key findings and place detailed analyses in a separate report in Module 5.3.5.3, with appropriate cross-references.",
			"Verify that microbiology data summaries are included in the appropriate efficacy section (2.7 Clinical Summary) and that detailed reports are filed in 5.3.5.4.",
			"Group similar studies together where appropriate, clearly identifying individual study results and differences.",
			"Ensure narrative descriptions for each biopharmaceutical study are brief, similar to journal article abstracts.",
			"Use clear cross-references to other CTD sections; include section numbers in cross strings, and write text so the reader understands the referenced content.",
			"Incorporate supportive data from Section 2.7.2 where appropriate to enhance interpretation of individual study results.",
			"Maintain consistency with the overall CTD Module 2 format and ensure logical sequencing of studies and results.",
			"For multiple indications, organize the section by indication, following the CTD numbering sequence for each (e.g., 2.7.3.UTI, 2.7.3.1 UTI Background, 2.7.3.2 UTI Summary of Results of Individual Studies, etc.).",
			"Organize the section so that each individual study\u0004s results are clearly summarized and traceable to the corresponding full report in Module 5.",
		],
	},
	{
		number: "2.7.1.3",
		title: "Comparison and Analyses of Results Across Studies",
		input: [
			"Collect the statistical models, hypotheses, and methods of analysis used for each secondary objective to support summarization of supplementary analyses in cross-study comparisons.",
			"Collect data and analyses from bridging studies using clinical endpoints (ICH E5) that evaluate extrapolation of foreign clinical data to the new region.",
			"Obtain reports of analyses of data from more than one study (Module 5.3.5.3) for reference and integration into the summary comparisons.",
			"Gather results and interpretations of exploratory analyses from each relevant study, or note 'Not applicable' if no exploratory objectives exist.",
			"Gather all relevant clinical study reports and datasets from multiple studies that will be compared and analyzed for efficacy and safety.",
			"Gather pharmacokinetic (PK) and pharmacodynamic (PD) data relevant to dose-response or concentration-response relationships for inclusion in cross-study comparisons.",
			"Collect descriptions and results of supplementary analyses conducted in addition to main and sensitivity analyses for each relevant secondary objective, if applicable.",
			"Retrieve the tabular listing of all clinical studies (Module 5.2) to ensure completeness and traceability of studies included in cross-study comparisons.",
			"Ensure access to protocols, statistical analysis plans, and analysis datasets for each study included in the comparison.",
			"Collect integrated analyses of efficacy (ISE) and/or integrated summaries of safety (ISS) data relevant to the comparison across studies.",
			"Obtain narrative summaries or synopses of important efficacy studies, including critical design features and results, abstracted from clinical study reports (ICH E3).",
			"Retrieve microbiology data from both in vitro and in vivo studies if relevant to the product\u0019s efficacy, for inclusion in the comparison.",
			"Obtain references or electronic links to full clinical study reports for inclusion in study narratives.",
			"Retrieve supportive data from Section 2.7.2 (Summary of Clinical Studies) for incorporation into cross-study comparisons where relevant.",
			"Gather literature references (Module 5.4) that provide external context or validation for cross-study comparisons.",
			"Collect descriptions of statistical models, hypotheses, and methods of analysis for each exploratory objective within the trials included in the cross-study comparison, if applicable.",
			"Compile any previous regulatory submissions or correspondence that provide context or precedent for cross-study comparisons.",
			"Collect data on patient withdrawals, timing of discontinuation, and reasons for discontinuation across studies.",
			"Retrieve data supporting dosage and administration recommendations, including dosage intervals, individualization of dosage, and modifications for specific subgroups (e.g., pediatric, geriatric, hepatic or renal impairment).",
			"Collect tabular presentations that combine and compare study populations across studies for inclusion in the section.",
			"Obtain statistical output and listings from multiple studies, including pooled analyses, meta-analyses, and subgroup analyses.",
			"Access individual clinical study reports from Module 5.3.5.1 and 5.3.5.2 to extract data for comparative analyses.",
			"Assemble detailed reports of analyses from more than one study for placement in Module 5.3.5.3 if too extensive for Module 2.7.1.3.",
			"Gather information on study populations across all efficacy studies, including demographic and baseline characteristics, disease severity, duration, prior treatment, and inclusion/exclusion criteria.",
			"Collect any relevant post-marketing experience data (Module 5.3.6) if used to contextualize or support cross-study findings.",
			"Gather any additional datasets, statistical outputs, and interpretation notes that provide further insights into treatment effects from supplementary analyses.",
			"Gather nonclinical and clinical pharmacology data that may be referenced to provide a comprehensive summary of human experience related to efficacy.",
			"Collect tabular listings of all efficacy studies (as referenced in section 2.7.3.6 Appendix) that provided or were designed to provide information relevant to product efficacy.",
			"Retrieve microbiology data from both in vitro and in vivo studies if relevant to the product’s efficacy, for inclusion in the comparison.",
			"Gather literature references or external comparator data if used in cross-study comparisons.",
			"Collect relevant nonclinical data if it supports or explains differences or similarities observed across clinical studies.",
			"Retrieve data on exposure of study subjects to the test drug or control agent and methods of safety data collection for studies contributing to both efficacy and safety analyses.",
		],
		output: [
			"When cross-referencing other sections, include the section number in the cross string; write the text so the reader understands the section content without including the full section name.",
			"Create additional subsections for each exploratory objective as needed, ensuring one-to-one correspondence with objectives and consistent formatting.",
			"Ensure that cross-study comparisons in Module 2.7.1.3 are consistent with the data and conclusions presented in the Clinical Overview (Module 2.5) and Clinical Summary (Module 2.7).",
			"Structure supplementary analysis descriptions under the appropriate secondary objective heading, following the protocol hierarchy and numbering conventions.",
			"Clearly identify the strengths and limitations of the studies being compared, including any gaps in data or differences in design that affect interpretation.",
			"Use text, figures, and tables as appropriate to summarize all available data characterizing efficacy, ensuring visual clarity and logical flow.",
			"Cross-reference important evidence from Section 2.7.2, particularly data supporting dosage, administration, and dose-response relationships.",
			"Ensure that descriptions of exploratory analyses include the statistical model, hypothesis, and methods of analysis, consistent with source documentation.",
			"Summarize any information supporting extrapolation of efficacy data to new regions, including PK/PD and other relevant data.",
			"Use tabular presentations to combine and compare study populations across studies where useful.",
			"Ensure clarity and accessibility for the reviewing division, with logical sequencing of comparisons and analyses.",
			"Do not include detailed information about individual studies; provide only summary-level information appropriate for Module 2.",
			"Use a unique short identifier for each study and apply it consistently throughout the CTD, including in Module 2.7.1.3, to ensure clear and uniform citation of clinical studies.",
			"Maintain traceability between summarized analyses in Module 2.7.1.3 and the detailed reports in Module 5.3.5.3 through consistent referencing and section numbering.",
			"Ensure that the section contains integrated analyses rather than simple summaries, synthesizing results across studies.",
			"Include analyses of all data, regardless of whether they support the overall efficacy conclusion, and discuss the extent to which results reinforce or contradict each other.",
			"Ensure that the discussion of cross-study results supports the overall benefit-risk evaluation and conclusions presented in the Clinical Overview.",
			"Ensure that summaries of statistical analysis methods for supplementary or secondary objective analyses accurately reflect the statistical models, hypotheses, and methods used, consistent with source study documentation.",
			"Verify compliance with 21 CFR 314.50 requirements if applicable, ensuring that the Module 2 summary fulfills regulatory needs for integrated analyses.",
			"If exploratory analyses are included in cross-study comparisons, describe them under a clearly labeled subsection for each exploratory objective, following the protocol hierarchy numbering (e.g., 10.6).",
			"Address any major inconsistencies in efficacy data and identify areas needing further exploration.",
			"Include supplementary analyses only when they exist for a secondary objective, and clearly distinguish them from main and sensitivity analyses.",
			"Ensure that conclusions from bridging study analyses are clearly noted at the start of Section 2.7.3.3.2 and that full reports are located in Module 5.",
			"Ensure that details of analyses too extensive for the summary are placed in Module 5, Section 5.3.5.3, with appropriate cross-references.",
			"Incorporate supportive data from Section 2.7.2 where relevant, ensuring proper cross-referencing and consistency of interpretation across sections.",
			"Include a subsection describing study populations across all efficacy studies, covering demographics, disease characteristics, prior treatment, inclusion/exclusion criteria, and dropout information.",
			"When presenting supplementary analyses tied to secondary objectives, ensure conformance with protocol hierarchy numbering conventions (e.g., 10.5.X structure) even when summarized in Module 2.7.1.3.",
			"Maintain consistency with ICH E3 and E5 guidance when summarizing study narratives and bridging analyses.",
			"Follow the general outline and structure informed by ISS/ISE formats and ICH E-3 guidance, adapted for CTD Module 2 requirements.",
			"Summarize results of bridging studies using clinical endpoints and include analysis of similarity of efficacy between regions, referencing ICH E5 guidance.",
			"Avoid recapitulating detailed data from individual study reports; focus on interpretation, synthesis, and implications of cross-study findings.",
			"Organize content to clearly compare and analyze results across studies, highlighting similarities, differences, and trends.",
			"Ensure that supplementary analyses are repeatable for each objective as needed, maintaining consistent formatting and section numbering.",
			"If microbiology data are part of the efficacy comparison, summarize them in the appropriate part of section 2.7 and ensure detailed reports are in section 5.3.5.4.",
			"Present integrated analyses in Module 2.7.1.3 only at a level of detail appropriate for a summary; place extensive details in a separate report in Module 5.3.5.3.",
			"Use only the section number (not the full section title) in cross strings to keep references concise, while ensuring the narrative text makes the section content clear to the reader.",
			"If no exploratory objectives exist, explicitly state 'Not applicable' in the relevant subsection to maintain completeness and compliance.",
			"Ensure that repeating elements (e.g., supplementary analysis components for each secondary objective) follow a consistent, sequential, and logically ordered structure.",
			"Maintain consistency in terminology, statistical presentation, and interpretation across the section.",
		],
	},
	{
		number: "3.1",
		title: "Table of Contents of Module 3",
		input: [
			"Collect the complete list of all documents included in Module 3 (Quality) to ensure accurate representation in the Table of Contents.",
			"Obtain stability-related distinguishing information (e.g., per manufacturer, per stability protocol) to determine whether multiple stability documents must be represented individually in the TOC.",
			"Obtain examples or templates of cross strings used in previous submissions to align section numbering and naming conventions in the Table of Contents.",
			"Obtain the list of any additional attachments or appendices intended for Module 3 sections where multiple documents are permitted, along with their cross-references.",
			"Confirm whether section 3.3 (References) contains multiple references and obtain the list of reference files to ensure accurate TOC entries.",
			"Ensure access to the finalized structure and numbering scheme of Module 3 as defined by the CTD guideline.",
			"Obtain the list of literature references specific to section 3.3 to prepare a dedicated Table of Contents for that section.",
			"Gather the list of all distinct documents that may appear under subsections where multiple files are permitted (e.g., 3.2.P.7, 3.2.P.8.3, 3.2.A.1, 3.2.A.2, 3.2.A.3).",
			"Obtain the applicable eCTD standard version being used for the submission, as Module 3 granularity recommendations depend on it.",
			"Identify whether any Module 3 subsections require multiple documents due to product complexity (e.g., multiple container closure systems, multiple facilities, multiple excipients, multiple components).",
			"Gather finalized filenames or document identifiers for electronic submissions to ensure consistency between the TOC and the actual files.",
			"Gather full titles and any abbreviated titles used on paper submission tabs to ensure accurate correspondence in the Table of Contents.",
			"Obtain the CTD granularity key or legend (as shown in regional guidance tables) to confirm which levels allow single or multiple documents and which levels are not appropriate for document submission, ensuring consistency in the Module 3 Table of Contents.",
			"Obtain the CTD/eCTD hierarchy table from the Granularity Document to determine at which levels single or multiple documents are appropriate for Module 3.",
			"Gather document titles, section numbers, and sub-section identifiers for all Module 3 components (e.g., 3.2.S, 3.2.P, etc.).",
			"Collect any internal or regional formatting requirements for the Table of Contents (e.g., EU, US, Japan) to ensure compliance with local expectations.",
			"Obtain the list of reconstitution diluents associated with the drug product and collect the complete 'P' information for each diluent when provided as a separate drug product.",
			"Obtain volume numbers and tab identifiers used for Module 3 to include them in the Table of Contents.",
			"Gather applicable regional guidance on amendments/variations to determine whether any region-specific rules affect how Module 3 Table of Contents should be prepared for such submissions.",
			"Collect any FDA or regional guidance documents that define cross-referencing conventions (e.g., cross strings) for paper submissions to ensure consistency in TOC labeling.",
			"Gather information on the adopted granularity approach for Module 3 (single vs multiple documents per section) to ensure consistency throughout the dossier lifecycle.",
		],
		output: [
			"Once a granularity approach (single vs multiple documents per section) is adopted for Module 3, apply it consistently throughout the life of the dossier.",
			"Ensure that section 3.3 (References) is represented as 'one file per reference' with each reference appearing as its own TOC line item.",
			"Ensure that the Table of Contents reflects the CTD-defined section numbering (e.g., 3.2.S, 3.2.P) without adding lower-level sub-numbering beyond what is specified in the CTD guideline.",
			"For amendments or variations submitted in CTD format, do not include unused modules or 'not applicable' pages in the Table of Contents, consistent with CTD guidance that unused modules should simply be omitted.",
			"When preparing cross-references or cross strings in paper submissions, include only the section number (not the full section name) to maintain brevity while ensuring clarity of reference.",
			"In electronic submissions, ensure that a new file starts at the same point where a tab divides documents in paper submissions, maintaining equivalent document boundaries.",
			"Exclude lower-level Table of Contents described under Document Pagination and Segregation from the 3.1 Table of Contents.",
			"If a section contains multiple documents, an internal Table of Contents for that section may be included to show chronology and subject matter, but it should not appear in the 3.1 Table of Contents.",
			"Do not include page numbers in the Table of Contents unless specifically required by regional authorities, as there are no global CTD guidelines for TOC pagination.",
			"Ensure that the Table of Contents accounts for subsections where multiple documents may be submitted (e.g., for multiple container closure systems, facilities, excipients, or components) by listing each document as a separate entry.",
			"Ensure all Table of Contents title entries match M4Q-defined headings and section numbering or tab identifiers (for paper submissions), preferably using full titles that clearly identify any abbreviations.",
			"Prepare a dedicated Table of Contents for literature references in section 3.3.",
			"Follow CTD expectations that P.2 content may appear as 3.2.P.2 (rolled up) or as multiple 3.2.P.2.x subsections, and ensure the TOC reflects the chosen structure.",
			"Ensure that the Table of Contents structure for Module 3 aligns with the CTD hierarchy and granularity key, maintaining consistency with the approach used in other modules (e.g., Module 2).",
			"Follow the CTD/eCTD hierarchy guidance from the Granularity Document to determine where single or multiple documents are appropriate for Module 3.",
			"Maintain consistent layout and structure across all entries in the Table of Contents to align with CTD format expectations.",
			"Do not create new headers or subsection numbering beyond M4Q definitions in the 3.1 Table of Contents; such additions may only appear within individual documents.",
			"Ensure that each document listed in the Table of Contents has a distinct identifier in its header or footer; abbreviations may be used instead of full titles.",
			"If additional sub-numbering (e.g., 3.2.P.3.3.1, 3.2.P.3.3.2) is used within documents for navigation, these should not appear in the overall Table of Contents but may be included as bookmarks in electronic files.",
			"Ensure that stability-related entries in the TOC reflect whether information is provided in its entirety or split by manufacturer, by stability study protocol, or by other distinguishing factors.",
			"Do not include TOC entries for levels where documents are not considered appropriate or where documents must be submitted at a higher level according to the CTD granularity key.",
			"Ensure that the text surrounding cross strings provides sufficient context so that the reader can understand the section content even if only the section number is shown.",
			"Ensure that the granularity of Module 3 in paper and electronic submissions is equivalent, with any changes in granularity for eCTD justified by lifecycle management needs.",
			"Ensure that the Table of Contents is comprehensive and accurately reflects the organization of Module 3, including all required subsections and attachments.",
			"Do not specify page numbers in the 3.1 Table of Contents.",
			"Do not create TOC entries for lower-level CTD-Q headings that are unlikely to contain individual documents or files, consistent with CTD expectations.",
			"Ensure that the Table of Contents for Module 3 follows the same granularity principles as defined in the CTD granularity key, meaning that documents should only be listed at levels where one or multiple documents are permitted.",
			"For eCTD submissions, ensure that the Table of Contents does not include entries for levels where documents may not be submitted (documents written at that level must be submitted at the higher level).",
			"Do not incorporate additional attachments or appendices into the 3.1 Table of Contents formatting unless they are separate documents under a section where multiple documents are permitted; otherwise, integrate them into the main document.",
			"Verify that all documents referenced in the Table of Contents are present and correctly numbered in the submission.",
			"Include module numbers, volume numbers, and tab dividers in the Table of Contents for Module 3.",
			"When a drug product is supplied with reconstitution diluents, ensure the TOC includes separate 'P' information entries for each diluent presented as its own drug product, as required.",
		],
	},
	{
		number: "3.2.S.1.1",
		title: "Nomenclature",
		input: [
			"Gather any synonyms or alternative names used in literature or regulatory correspondence.",
			"Obtain the European Pharmacopoeia (Ph. Eur.) name if applicable.",
			"Collect the CAS (Chemical Abstracts Service) registry number.",
			"Obtain the nonproprietary name(s) for the investigational product, ensuring it is descriptive of its chemical structure or public name.",
			"Gather the official International Nonproprietary Name (INN) for the drug substance.",
			"Gather the chemical name according to IUPAC nomenclature rules.",
			"Obtain any company or laboratory code names used during development.",
			"Collect reference documents or authoritative sources confirming the nomenclature (e.g., WHO INN list, pharmacopoeia monographs).",
			"Collect any other national or regional pharmacopoeial names relevant to the product.",
			"Obtain any relevant regulatory correspondence confirming or approving the proposed nomenclature.",
			"Obtain the sponsor's investigational product code(s) assigned to uniquely identify the experimental intervention.",
			"Obtain the United States Adopted Name (USAN) if applicable.",
		],
		output: [
			"Confirm that the section conforms to the optional inclusion rule—include only if country/region-specific differences exist, otherwise indicate 'Not applicable'.",
			"Include a distinct identifier (e.g., abbreviation or code) in the header or footer on every page of the section; full title is not required.",
			"If both sponsor investigational product code(s) and nonproprietary name(s) are available, include both; if only one is available, ensure at least one is present to meet the 'optional required either/or' rule.",
			"Use lower-level sub-numbering within the document (e.g., 3.2.S.1.1.1, 3.2.S.1.1.2) if helpful for navigation, but do not include these lower-level headings in the overall CTD Table of Contents.",
			"Ensure that the identifier used in headers/footers is consistent throughout the section.",
			"When cross-referencing this section elsewhere in the dossier, include at least the section number (3.2.S.1.1) in the cross string; section name may be omitted if too long.",
			"Verify that all nomenclature entries are accurate and match authoritative references before finalizing the section.",
			"Present the nomenclature in a clear, structured format, typically listing INN, pharmacopoeial name(s), chemical name, CAS number, and synonyms in a logical order.",
			"If there are no country- or region-specific differences in nomenclature, mark the section as 'Not applicable' while retaining the heading.",
			"Write cross-references in a way that the reader can understand the section content from the context, even if only the section number is given.",
			"Confirm that the section conforms to the optional inclusion rule\u0002—include only if country/region-specific differences exist, otherwise indicate 'Not applicable'.",
			"Use consistent terminology for all names provided, ensuring alignment with official sources (e.g., INN, pharmacopoeia).",
			"Maintain one-to-one correspondence for the main nomenclature entry; do not repeat or reuse headings unnecessarily.",
			"Include lower-level headings as PDF bookmarks if preparing an electronic submission, even though they must not appear in the overall CTD TOC.",
			"Maintain one-to-one correspondence between each investigational product code or nonproprietary name and the protocol identifier when applicable.",
			"When preparing cross-references in paper submissions, it is recommended to include only the section number in the cross string to reduce length, but write the surrounding text so the reader can understand the section content without the section name.",
			"If country- or region-specific nomenclature differences exist, list them clearly under appropriate subheadings using valid country/region identifiers.",
			"If multiple investigational products are involved, repeat and reuse the sponsor investigational product code(s) entry for each product as required.",
			"Ensure that any country or region identifiers used (if applicable) conform to ISO 3166 Alpha-2 codes.",
			"Ensure that the heading 'Intervention:' is included as a required one-to-one heading in the section when applicable.",
		],
	},
	{
		number: "3.2.S.1.2",
		title: "Structure",
		input: [
			"Compile data from X-ray crystallography or other confirmatory structural studies, if available.",
			"If the drug substance is already approved, obtain relevant health authority guidance or prior approval documentation to ensure alignment with existing authorizations.",
			"Obtain structural elucidation data from analytical techniques such as NMR, IR, MS, and UV spectroscopy to confirm the proposed structure.",
			"Collect reference standards or authenticated samples used to verify the structure.",
			"Gather stereochemical information, including configuration and identification of chiral centers, if applicable.",
			"Collect information identifying the drug substance name and structure as part of the established conditions (ECs) for section 3.2.S.1.2.",
			"Ensure availability of any relevant certificates of analysis or characterization reports for the drug substance.",
			"If multiple structural forms (e.g., polymorphs, solvates, salts) exist, collect data for each relevant form.",
			"Collect chemical structure information for the drug substance, including molecular formula, molecular weight, and structural formula.",
			"Compile data from X‑ray crystallography or other confirmatory structural studies, if available.",
			"Compile data from X\u0011ray crystallography or other confirmatory structural studies, if available.",
			"Ensure that the structural information aligns with the general information provided in section 3.2.S.1.1 (Nomenclature) to maintain consistency across established conditions.",
			"Gather literature references or prior regulatory submissions that support the proposed structure.",
		],
		output: [
			"If applicable, describe stereochemistry and indicate chiral centers using standard notation (R/S, D/L, etc.).",
			"Include molecular formula, molecular weight, and structural formula in the section.",
			"Refer to Appendix A for additional guidance on preparing section 3.2.S.1.2 content, especially in cases where the drug substance is already approved.",
			"Verify that only one file is submitted per reference or per structure, as applicable, following eCTD file organization rules.",
			"Cross-reference supporting analytical data or reports in appropriate CTD sections (e.g., 3.2.S.3.1 Elucidation of Structure and other Characteristics).",
			"Present the chemical structure clearly using standard chemical drawing conventions (e.g., line-angle formula).",
			"Ensure consistency of structural information with data presented in other sections (e.g., 3.2.S.1.3 General Properties).",
			"Ensure that all structural representations are consistent with analytical data and nomenclature used elsewhere in the dossier.",
			"Provide clear labeling of all structural diagrams and ensure legibility in both electronic and paper formats.",
			"Present the chemical structure clearly using standard chemical drawing conventions (e.g., line\u0011angle formula).",
			"Present the chemical structure clearly using standard chemical drawing conventions (e.g., line‑angle formula).",
			"Maintain alignment of section 3.2.S.1.2 content with section 3.2.S.1.1 (Nomenclature) to ensure consistency of established conditions across the CTD.",
			"Ensure that the section 3.2.S.1.2 (Structure) is clearly identified as containing established conditions (ECs) related to the drug substance name and structure.",
			"Do not include 'not applicable' pages for unused CTD headings when submitting updates or variations; omit unused modules entirely.",
			"Verify that the placement of structure information follows the CTD organization guidance, ensuring it is located under 3.2.S.1.2 and not duplicated in supportive sections.",
			"Do not include drawings of secondary, tertiary, or quaternary structures in section 3.2.S.1.2; ensure these are placed in section 3.2.S.3.1 instead.",
			"Confirm that the document complies with regional eCTD technical specifications for file naming, format, and placement.",
			"Follow CTD formatting conventions for section numbering and titles (3.2.S.1.2 Structure).",
			"Ensure that any updates to section 3.2.S.1.2 follow regional guidance for applicability of CTD format in amendments and variations.",
			"When submitting amendments or variations affecting section 3.2.S.1.2, use the same CTD format and structure as the original submission; do not create a separate format.",
		],
	},
	{
		number: "3.2.S.1.3",
		title: "General Properties",
		input: [
			"Physicochemical property data of the drug substance, including but not limited to solubility, melting point, pKa, hygroscopicity, polymorphism, and particle size distribution",
			"Health authority guidance or regulatory documentation applicable when the drug substance is already approved (as referenced by the instruction to consult the health authority)",
			"A compiled list of the general properties of the drug substance (distinct from detailed physicochemical characterization data, which are to be included in section 3.2.S.3.1)",
			"Documentation confirming the specific form of the drug substance used in the drug product (e.g., form designation, characterization data)",
			"Analytical test results and characterization data supporting the general properties (e.g., spectral data, chromatograms, thermal analysis)",
			"Certificates of analysis for batches used to determine general properties",
			"Biological activity data of the drug substance for the form used in the drug product",
			"Any prior regulatory submissions or correspondence that describe the general properties of the drug substance",
			"Data identifying the polymorphic form(s) present in the proposed active substance for inclusion in the general properties list",
			"Reference standards and specifications used for determining general properties",
			"Expert opinions or reports interpreting the significance of the general properties for development and manufacturing",
			"Information on possible alternative forms of the drug substance (e.g., polymorphs, solvates, hydrates, amorphous forms, salts, esters)",
			"Appendix A or equivalent reference material cited in the CTD guidance for section 3.2.S.1.3, to ensure correct interpretation of the section’s scope and structure",
			"Relevant literature references describing the general properties of the drug substance",
		],
		output: [
			"Ensure that only the properties for the specific form of the drug substance used in the drug product are included, excluding possible alternative forms",
			"Confirm that the information provided in 3.2.S.1.3 aligns with the established conditions framework described in ICH Q12, ensuring consistency with related sections such as 3.2.S.3 (Characterisation)",
			"Include only a list of the general properties in section 3.2.S.1.3, and place detailed study descriptions and data for physicochemical characterization in section 3.2.S.3.1",
			"Ensure that the general properties section supports and is consistent with the supportive information expected under ICH Q12 for characterization (3.2.S.3), without duplicating detailed data",
			"Include a summary of possible alternative forms of the drug substance, with cross-reference to section 3.2.S.3.1 for more detailed information",
			"Present information in a clear format, using tables or bullet points where appropriate to improve readability",
			"Ensure that all data presented are traceable to source documents or studies and are consistent with other sections of the CTD",
			"Use consistent scientific terminology and units of measurement throughout the section",
			"Clearly describe the general physicochemical and other relevant properties of the drug substance in a concise and scientifically accurate manner",
			"Cross-reference Appendix A for structural and formatting expectations applicable to section 3.2.S.1.3",
			"Verify that the section complies with regional regulatory expectations for the scope and level of detail in 3.2.S.1.3",
			"Ensure that only the properties for the specific form of the drug substance used in the drug product are included, excluding possible alternative forms except as a brief summary with cross-reference to section 3.2.S.3.1",
			"Avoid duplicating detailed data that are presented in other sections; instead, provide summaries and cross-references",
			"Recognize that lower-level CTD-Q headings (such as 3.2.S.1.3) are unlikely to contain individual documents or files; compile the information as a single integrated text or table rather than as separate attachments",
			"When applicable, list the polymorphic form(s) present in the proposed active substance as part of the general properties in 3.2.S.1.3",
			"Organize the content logically, grouping related properties together (e.g., physical properties, chemical properties, other relevant characteristics)",
			"Include biological activity as part of the list of general properties when applicable",
		],
	},
	{
		number: "3.2.S.2.1",
		title: "Manufacturer(s) (Name, Physical Address)",
		input: [
			"Obtain the full legal name and physical address of each manufacturer involved in the drug substance manufacturing process.",
			"Gather GMP (Good Manufacturing Practice) certificates or equivalent regulatory approvals for each manufacturer.",
			"Gather details of the specific manufacturing activities performed at each site (e.g., synthesis, purification, testing, packaging).",
			"Collect site master files or summaries describing the facilities, equipment, and quality systems of each manufacturer.",
			"Gather information identifying all drug substance manufacturing sites, including those performing testing activities, as these are considered part of the manufacturing process.",
			"Collect regulatory correspondence or previous approvals related to the listed manufacturing sites.",
			"Obtain contact information for the Qualified Person (QP) or responsible manufacturing representative at each site.",
			"Obtain copies of quality agreements or technical agreements between the applicant and each manufacturer, if applicable.",
			"If contract manufacturers are used, obtain copies of contractual arrangements or letters of authorization allowing reference to their data.",
			"Gather any relevant inspection reports or audit summaries for the manufacturing sites.",
			"Collect manufacturing authorization or license certificates for each manufacturing site listed.",
		],
		output: [
			"Ensure that the section is concise and factual, avoiding narrative or interpretive text.",
			"Confirm that the information presented aligns with the general CTD structure and established condition (EC) framework, ensuring that manufacturing site details are treated as ECs rather than supportive information.",
			"Ensure that the section title 'Manufacturer(s) (name, manufacturer)' is used exactly as per CTD Table of Contents to maintain alignment with the dossier structure.",
			"Ensure that manufacturer name and address entries function as table row headings when presented in a tabular format.",
			"Repeat the manufacturer name and address entries for each manufacturing site involved in the drug substance manufacturing process.",
			"Ensure consistency of manufacturer names and addresses with other CTD sections (e.g., 3.2.S.2.2, 3.2.P.3.1) and with regulatory certificates.",
			"Ensure that the section explicitly identifies all drug substance manufacturing sites, including those performing testing, as part of the established conditions (ECs) for the drug substance.",
			"Follow one-to-one cardinality: include one manufacturer name and one manufacturer address entry per manufacturing site.",
			"List the name, full physical address (including country), and contact details of each manufacturer involved in the drug substance manufacturing process.",
			"Use standardized terminology and official company names as registered with regulatory authorities.",
			"Present manufacturer information in a tabular format for clarity, if appropriate.",
			"Ensure that manufacturer name and address entries function as table row headings when presented in tabular format.",
			"Check that all manufacturing sites performing critical steps are included and that no site is omitted.",
			"Ensure that the section title 'Manufacturer(s) (Name, Physical Address)' is used exactly as per CTD Table of Contents to maintain alignment with the dossier structure.",
			"Verify that all listed sites are covered by valid GMP certification or equivalent documentation.",
			"Cross-reference any supporting documentation (e.g., GMP certificates, quality agreements) included elsewhere in the dossier.",
			"Clearly identify the role or function of each manufacturer (e.g., API synthesis, intermediate production, testing, packaging).",
			"Ensure that the presentation of manufacturing site information is consistent with the CTD table conventions, where 3.2.S.2.1 corresponds to 'Drug Substance Manufacturing Site(s) (including testing)'.",
			"Ensure that the manufacturer name and address appear as a clear heading when presented in a list or table.",
			"Maintain consistent formatting, including section numbering (3.2.S.2.1), headings, and alignment with CTD structure requirements.",
		],
	},
	{
		number: "3.2.S.2.2",
		title: "Description of Manufacturing Process and Process Controls",
		input: [
			"Collect data and documentation describing which portions of the manufacturing process are continuous, including integrated flow diagrams if applicable.",
			"Collect process validation and/or evaluation study reports for aseptic processing and sterilisation steps.",
			"Obtain references to applicable ICH guidelines (e.g., Q6B) to ensure alignment with their requirements.",
			"Obtain a narrative description of the manufacturing process for the drug product, including packaging operations and scale of production.",
			"Gather information on all critical steps, intermediate tests, and final product controls conducted during the manufacturing process.",
			"Gather data on continuous manufacturing (CM)-related process parameters, controls, and criteria, such as input rates, mass flow rates, and feeder operating ranges.",
			"Gather information on any novel processes or technologies used in manufacturing that directly affect product quality.",
			"Gather detailed information on all process controls applied during manufacturing, including in-process controls, environmental controls, and equipment controls.",
			"Gather data on all process parameters and their control ranges, including normal operating ranges and proven acceptable ranges.",
			"Gather information on any novel processes or technologies used in manufacturing or packaging that directly affect product quality.",
			"Obtain information on equipment design and system integration aspects that are critical to output material quality in continuous manufacturing.",
			"Obtain historical manufacturing data, including deviations, investigations, and corrective actions related to process controls.",
			"Collect any available process flow diagrams, batch manufacturing records, and process schematics.",
			"Obtain details on the location and function of active process controls used in continuous manufacturing.",
			"Collect data and justification for any proposed reprocessing of materials, including supporting studies or references.",
			"Obtain environmental condition requirements (e.g., humidity control for effervescent products) relevant to the manufacturing process.",
			"Collect critical process control values from relevant batches to support numeric ranges and limits for critical process controls, ensuring consistency with data referenced in 3.2.P.3.4.",
			"Obtain expert opinions or technical assessments on process design and control strategy.",
			"Gather information identifying the established conditions (ECs) for individual unit operations in the manufacturing process, including inputs (process parameters, material attributes) and outputs, as referenced in Chapter 3, section 3.2.3.1 \u0003 Identification of ECs for the Manufacturing Processes.",
			"Collect information on any reprocessing operations, including justification for reprocessing if applicable.",
			"Collect any regulatory correspondence or prior submissions that describe the manufacturing process or process controls for the same drug substance.",
			"Gather data on process parameters for each step (e.g., time, temperature, pH) and their expected numeric ranges.",
			"For biotech products, obtain stability data supporting storage conditions for intermediates and critical steps.",
			"Obtain description of container closure system(s) used for storage of the drug substance, including materials, configuration, and suitability for intended storage and shipping conditions.",
			"Gather information on quality and control of intermediates isolated during the manufacturing process.",
			"Collect information on the location points at which process controls or testing are conducted in continuous manufacturing processes.",
			"Obtain technical documents such as manufacturing protocols, standard operating procedures (SOPs), and master batch records relevant to the drug substance production.",
			"Collect justification data for numeric ranges of critical steps (to be cross-referenced with Section 3.2.P.3.4).",
			"Gather information on scale-up or technology transfer processes if applicable.",
			"Gather information on batch definition, including batch size or range and the approach to achieving the intended batch size or range for continuous manufacturing processes.",
			"Gather information identifying the established conditions (ECs) for individual unit operations in the manufacturing process, including inputs (process parameters, material attributes) and outputs, as referenced in Chapter 3, section 3.2.3.1 – Identification of ECs for the Manufacturing Processes.",
			"For biotech products, gather validation and evaluation study data demonstrating suitability of the manufacturing process, including reprocessing steps, and justification for selection of critical process controls and their limits.",
			"Obtain complete manufacturing process description for the drug substance, including all steps from starting materials to final drug substance.",
			"Gather information on the quality and control of intermediates isolated during the manufacturing process, including specifications, analytical methods, and acceptance criteria, in alignment with ICH Q2A, Q2B, Q6A, and Q6B.",
			"Collect a detailed process flow diagram for the drug product manufacturing process, showing all steps and points where materials enter.",
			"Collect analytical procedures and corresponding validation reports used to justify selection of critical process controls and acceptance criteria.",
			"Gather data on storage and shipping conditions for the drug substance, including temperature, humidity, and other environmental requirements.",
			"Collect equipment information, including equipment type (e.g., tumble blender, in-line homogeniser) and working capacity where relevant.",
			"Collect information on controls of critical steps identified in 3.2.S.2.2, including tests performed, acceptance criteria, and supporting experimental data.",
			"Obtain plans, protocols, results, analyses, and conclusions from executed process validation/evaluation studies.",
			"Obtain references to applicable ICH guidelines (e.g., Q6B) and ensure alignment with their requirements.",
			"Gather information on criteria for product collection, including strategies for material diversion and collection in continuous manufacturing.",
		],
		output: [
			"Include a clear, sequential description of the manufacturing process, supported by process flow diagrams where appropriate.",
			"Describe each manufacturing step with sufficient detail to understand the process and associated controls.",
			"When describing intermediates, ensure inclusion of quality and control information in accordance with ICH Q2A, Q2B, Q6A, and Q6B.",
			"Include CM-related process parameters, controls, and criteria such as input rates, mass flow rates, and feeder operating ranges, and specify the location points where process controls or testing are conducted.",
			"Identify critical steps and points where process controls, intermediate tests, or final product controls are conducted within the flow diagram.",
			"Ensure alignment with ICH Q6B and other applicable guidelines for manufacturing process description and control documentation.",
			"If container closure system and storage/shipping conditions are described in this section, ensure they are clearly linked to process steps and cross-referenced to 3.2.S.6 as appropriate.",
			"Cross-reference related sections (e.g., 3.2.S.2.4 for critical controls) as required to maintain CTD structure compliance.",
			"When describing controls of intermediates, include quality attributes and control measures applied.",
			"Use consistent terminology for process steps and controls throughout the section.",
			"When describing controls of critical steps, include both the tests performed and the acceptance criteria, with justification supported by experimental data.",
			"Ensure that the section includes identification and description of established conditions (ECs) for individual unit operations, including inputs (process parameters and material attributes) and outputs, as required for 3.2.S.2.2.",
			"Describe novel processes or technologies and packaging operations that directly affect product quality with greater detail than standard processes.",
			"Ensure that the description of the continuous manufacturing process aligns with ICH M4Q expectations for section 3.2.S.2.2.",
			"For biotech products, describe validation/evaluation studies in sufficient detail to demonstrate suitability of the manufacturing process, including reprocessing steps, and to substantiate selection of critical process controls and their limits.",
			"Ensure that process validation/evaluation information is clearly linked to the manufacturing steps described in 3.2.S.2.2, with cross-references to analytical validation sections (e.g., 3.2.S.4.3).",
			"Include justification for any reprocessing operations directly in this section, ensuring clarity and regulatory compliance.",
			"Ensure that all process controls are identified and described in section 3.2.S.2.2, with critical controls cross-referenced to section 3.2.S.2.4.",
			"Describe novel processes or technologies that directly affect product quality with greater detail than standard processes.",
			"Cross-reference analytical procedures for in-process material tests to the appropriate analytical sections (e.g., 3.2.S.4) when such tests are used to control critical steps.",
			"Describe criteria for product collection, including the strategy for material diversion and collection in continuous manufacturing.",
			"Maintain logical organization and clarity, grouping related process steps and controls together.",
			"For continuous manufacturing processes, clearly indicate which portions of the manufacturing process are continuous within the narrative and flow diagram.",
			"Describe equipment design and system integration aspects when they are critical to output material quality in continuous manufacturing.",
			"Identify equipment by type and include working capacity where relevant to process understanding.",
			"Ensure that the description covers all manufacturing sites and scales relevant to the drug substance.",
			"Include an integrated flow diagram if the drug substance and drug product manufacturing processes are integrated, with appropriate cross-references between 3.2.S and 3.2.P sections.",
			"Include justification and supporting data for any proposed reprocessing of materials within this section or by reference.",
			"Identify the location of active process controls if used, and describe their function and relevance to maintaining process performance.",
			"Verify that established conditions (ECs) are described at the appropriate level of detail and aligned with expectations from Chapter 3, section 3.2.3.1 \u0003 Identification of ECs for the Manufacturing Processes.",
			"Verify that the section is complete and self-contained, providing all necessary context for understanding the manufacturing process without referring to external documents unless cross-referenced.",
			"Ensure that batch definition, including batch size or range and the approach to achieving the intended batch size or range, is clearly described for continuous manufacturing processes.",
			"Verify that established conditions (ECs) are described at the appropriate level of detail and aligned with expectations from Chapter 3, section 3.2.3.1 – Identification of ECs for the Manufacturing Processes.",
			"Explicitly present the sequence of individual unit operations to meet expectations for EC-related content in CTD section 3.2.S.2.2.",
			"Ensure that numeric ranges and limits for critical process controls described in 3.2.S.2.2 are consistent with supporting data presented in 3.2.P.3.4.",
			"Provide a narrative description of the manufacturing process that follows the sequence of operations and indicates the production scale.",
			"Ensure that numeric ranges for critical steps are justified and cross-referenced to Section 3.2.P.3.4.",
			"Provide a narrative description of the manufacturing process, including packaging, that follows the sequence of operations and indicates the production scale.",
			"Present a process flow diagram that clearly shows all process steps and points where materials enter the process.",
			"Specify process parameters for each step (e.g., time, temperature, pH) and present associated numeric values as expected ranges.",
			"For biotech products, include stability data supporting storage conditions for intermediates and critical steps, ensuring compliance with ICH Q5C.",
			"Ensure compliance with CTD-Q structure and headings, placing all required information under the correct subheading.",
			"State environmental conditions required for specific process steps (e.g., low humidity for effervescent products).",
		],
	},
	{
		number: "3.2.S.2.3",
		title: "Control of Materials",
		input: [
			"For biologically sourced materials, gather detailed information on source, manufacture, and characterisation, including media components, monoclonal antibodies, and enzymes.",
			"For biologically sourced materials, collect summaries of viral safety information (cross-reference to 3.2.A.2).",
			"Gather detailed source and control information for materials of biological origin, including cell and seed sources and raw materials used.",
			"Obtain relevant chromatograms for inclusion in section 3.2.S.4.3.",
			"Obtain relevant regulatory correspondence or prior approvals related to starting materials or reagents.",
			"Collect information demonstrating that all materials meet standards appropriate for their intended use, including clearance or control of adventitious agents where applicable.",
			"Collect starting material specifications, including tests, analytical procedures, and acceptance criteria, as part of the established conditions for section 3.2.S.2.3.",
			"Collect information on the source, quality, and control of reagents, including those manufactured via recombinant DNA technology.",
			"Gather analytical procedures for the control of materials, including starting materials, reagents, raw materials, and solvents.",
			"Collect technical documents such as supplier qualification reports, material specifications, and test methods.",
			"Gather documentation on critical controls for raw materials, reagents, and solvents used in the manufacturing process.",
			"Gather documentation on the cell banking system, quality control activities, and cell line stability during production and storage, including procedures used to generate Master and Working Cell Banks, as per ICH Q5B and Q5D.",
			"Gather reference standards and comparator product information if used in material control testing.",
			"Collect documentation on the generation and control of Master and Working Cell Banks or Master and Working Seed Lots when applicable for biotechnological or biological products.",
			"Collect detailed information and justification for all starting materials used in the manufacture of the drug substance.",
			"List all materials used in the manufacture of the drug substance (raw materials, starting materials, solvents, reagents, catalysts) and identify where each is used in the process.",
			"Obtain information on the source, history, and generation of the cell substrate, including analysis of the expression construct used to genetically modify cells and incorporated in the initial cell clone used to develop the Master Cell Bank, as per ICH Q5B and Q5D.",
			"Collect details of all analytical procedures used to control the drug substance, including associated acceptance criteria, for inclusion in the specification in section 3.2.S.4.1.",
			"Obtain literature references or expert opinions supporting the selection and justification of starting materials.",
			"Gather data and documentation related to materials of biological origin, including adventitious agent safety evaluation data if applicable.",
			"Obtain specifications, certificates of analysis, and quality standards for all materials used in the manufacturing process.",
			"Gather all specifications for the drug substance from both the manufacturer and the applicant, if they differ, for inclusion in section 3.2.S.4.1.",
		],
		output: [
			"List any analytical procedure used to control the drug substance, along with its acceptance criteria, in the specification in section 3.2.S.4.1.",
			"Ensure that section 3.2.S.2.3 aligns with ICH Q12 expectations for established conditions, clearly identifying which material control elements (e.g., specifications, analytical procedure elements, acceptance criteria) are considered ECs and which are supportive information.",
			"When multiple specifications exist for the drug substance (e.g., manufacturer and applicant), include all relevant specifications in section 3.2.S.4.1.",
			"Present analytical procedures for the control of materials (starting materials, reagents, raw materials, solvents) in section 3.2.S.2.3.",
			"For biologically sourced materials, include details on source, manufacture, and characterisation, and reference relevant ICH guidelines (Q6A, Q6B, Q5A, Q5B, Q5C, Q5D) where applicable.",
			"Follow CTD structure conventions\u0000do not add new headings; include all relevant material control information under the existing 'Control of Materials' heading.",
			"Verify that the presentation of established conditions in section 3.2.S.2.3 is consistent with the general list of ECs in ICH Q12, maintaining traceability and clarity for regulatory review.",
			"Follow CTD structure conventions—do not add new headings; include all relevant material control information under the existing 'Control of Materials' heading.",
			"Include information on the quality and control of each material, ensuring standards are appropriate for intended use.",
			"For cell substrates, describe the source, history, and generation, including analysis of the expression construct, as per ICH Q5B and Q5D.",
			"Include relevant chromatograms in section 3.2.S.4.3.",
			"Ensure consistency and cross-referencing between 3.2.S.2.3 and related sections (e.g., 3.2.A.2 for biological materials).",
			"Maintain clear, concise, and scientifically accurate language consistent with CTD-Q formatting and terminology standards.",
			"Include a discussion and justification of starting materials within section 3.2.S.2.3.",
			"Ensure that the section is organized logically, grouping materials by type (starting materials, reagents, solvents, etc.) for clarity and regulatory compliance.",
			"Verify that all analytical procedures and justifications are clearly described, validated, and traceable to supporting data.",
			"For biologically sourced materials, summarise viral safety information and cross-reference to section 3.2.A.2.",
			"Follow CTD structure conventions do not add new headings; include all relevant material control information under the existing 'Control of Materials' heading.",
			"Describe the cell banking system, characterisation, and testing, including quality control activities and cell line stability, as per ICH Q5B and Q5D.",
			"For materials of biological origin, ensure that analytical procedures related to adventitious agent safety evaluation are referenced in section 3.2.A.2.",
			"Clearly identify and present established conditions (ECs) within section 3.2.S.2.3, specifically starting material specifications (tests, analytical procedure elements, and acceptance criteria) and critical controls for raw materials, reagents, and solvents.",
			"Ensure that all information related to reagents manufactured via recombinant DNA technology is located in section 3.2.S.2.3.",
			"Ensure that supportive information related to material control is appropriately distinguished from established conditions within the section.",
			"List each material with its name and manufacturer, and indicate where in the manufacturing process it is used.",
			"For biological or biotechnological products, ensure inclusion of established condition elements related to the source and control of biological materials, including cell banks or seed lots, when relevant to material control.",
			"Confirm that the presentation of ECs aligns with the general CTD structure and regional expectations for established conditions documentation.",
		],
	},
	{
		number: "3.2.S.2.4",
		title: "Controls of Critical Steps and Intermediates",
		input: [
			"Gather information on any critical controls associated with reprocessing operations when such controls are designated as critical and must be described in 3.2.S.2.4.",
			"For biotech products, obtain stability data supporting storage conditions for intermediates, in accordance with ICH Q5C.",
			"Collect information from the manufacturing process description (3.2.P.3.3 or equivalent) identifying all process controls, including which are designated as critical, to ensure consistency with 3.2.S.2.4.",
			"Collect batch data specifically for intermediates and critical steps that are subjected to release testing instead of relying on drug substance release tests.",
			"Gather critical process control values from relevant manufacturing batches to support numeric ranges, limits, and justification of critical process controls.",
			"Gather test descriptions, acceptance criteria, and supporting experimental data justifying the controls applied at each critical step identified in 3.2.S.2.2.",
			"Compile technical documents describing the manufacturing process flow with identification of critical steps and intermediates.",
			"Gather details of any reprocessing operations described in the manufacturing process section to identify associated critical controls that must be included in 3.2.S.2.4.",
			"Obtain any regulatory correspondence or prior approvals related to changes in control of critical steps or intermediates.",
			"Collect detailed information for all critical steps and intermediates that have been identified in 3.2.S.2.3 (or equivalent process description section) to ensure consistency and completeness in 3.2.S.2.4.",
			"Collect quality and control information for intermediates isolated during the manufacturing process, including analytical results and specifications.",
			"Collect any relevant stability study data for intermediates where storage conditions are critical.",
			"Obtain any internal documentation or regulatory guidance defining how ECs are identified and located within the CTD structure for manufacturing processes.",
			"Gather acceptance criteria and analytical procedures used when intermediates or critical steps undergo release testing to ensure proper inclusion in 3.2.S.2.4 and cross-reference to 3.2.S.4.",
			"Collect batch records or in-process control data demonstrating compliance with specifications for critical steps and intermediates.",
			"Gather raw material and intermediate certificates of analysis relevant to critical steps.",
			"Obtain validation information or summaries from process validation documentation (3.2.P.3.5 or equivalent) when validation data support the control of critical steps or intermediates relevant to 3.2.S.2.4.",
			"Gather analytical method descriptions and validation summaries relevant to testing of critical steps and intermediates.",
			"Gather quality and control information for intermediates isolated during the process specifically in alignment with ICH Q2A, Q2B, Q6A, and Q6B requirements.",
			"Collect information on established conditions (ECs) relevant to 3.2.S.2.4, including process parameters, material attributes, and outputs of individual unit operations that are designated as ECs.",
			"Collect analytical procedure descriptions and validation information for any in-process material tests performed in lieu of final drug substance tests, ensuring equivalence to finished product test documentation.",
			"Gather supportive information from related CTD sections (e.g., 3.2.S.2.2 and 3.2.S.2.3) that define or justify established conditions applicable to controls of critical steps and intermediates.",
			"Gather specifications for each critical step in the manufacturing process, including defined tests, elements of analytical procedures, and acceptance criteria.",
			"Obtain storage condition requirements for each critical intermediate, including temperature, humidity, and duration limits.",
			"Obtain expert opinions or internal quality risk assessments identifying and justifying designation of critical steps and intermediates.",
			"Collect specifications for intermediates, including defined tests, analytical procedures, and acceptance criteria.",
		],
		output: [
			"Ensure that established conditions (ECs) relevant to 3.2.S.2.4 are clearly identified and aligned with the general CTD structure guidance for ECs.",
			"Format tables of specifications consistently, with columns for test, method, and acceptance criteria.",
			"Ensure terminology is consistent with ICH guidelines and internal quality documentation.",
			"When applicable, reference Chapter 3, section 3.2.3.1 (Identification of ECs for the Manufacturing Processes) to maintain alignment with EC identification principles.",
			"Ensure that the description of intermediate controls in 3.2.S.2.4 aligns with the expectations of ICH Q2A, Q2B, Q6A, and Q6B for analytical procedure standards and specification justification.",
			"Ensure that the location and description of ECs in 3.2.S.2.4 are consistent with the overall CTD mapping of ECs for manufacturing processes.",
			"Ensure consistency between the critical controls described in 3.2.S.2.4 and those identified in the manufacturing process description (3.2.P.3.3 or equivalent).",
			"Clearly distinguish between ECs and supportive information when presenting controls of critical steps and intermediates.",
			"Present specifications for each critical step and intermediate in a structured format, including test name, analytical procedure reference, and acceptance criteria.",
			"For biotech products, explicitly include stability data supporting storage conditions for intermediates, ensuring compliance with ICH Q5C.",
			"Include batch data, analytical procedures, and acceptance criteria for intermediates and critical steps directly in section 3.2.S.2.4 as required.",
			"Ensure compliance with applicable ICH Q12 requirements for established conditions.",
			"If a process test replaces an end-product test, ensure it is clearly identified as a process test and cross-referenced to the specification section (3.2.S.4.1 or equivalent).",
			"Include storage conditions for critical intermediates where applicable, specifying parameters and limits.",
			"Use clear, concise, and unambiguous language suitable for regulatory review.",
			"Include critical process control values from relevant batches to justify numeric ranges and limits for critical process parameters.",
			"Verify that all specifications provided are current, approved, and match supporting data.",
			"Ensure acceptance criteria discussed in 3.2.S.2.4 are properly referenced to 3.2.S.4.1.",
			"Cross-reference related sections (e.g., manufacturing process description, analytical procedures) where appropriate.",
			"Organize content in a logical sequence: identification of critical steps/intermediates → specifications → analytical procedures → storage conditions.",
			"Provide detailed information in 3.2.S.2.4 for all critical steps and intermediates that are controlled, ensuring alignment with the process description section.",
			"Ensure that all data supporting numeric ranges and limits for critical process controls are traceable to actual manufacturing batch data.",
			"Provide justification for tests and acceptance criteria at critical steps, including reference to experimental data as supporting evidence.",
			"When an in-process material test replaces a finished product test, include the same level of detail (analytical procedure, validation information) as would be provided for a finished product test.",
			"Ensure analytical procedures discussed in 3.2.S.2.4 are properly referenced to 3.2.S.4.2.",
			"If validation information supports the control of critical steps or intermediates, reference the relevant validation section (e.g., 3.2.P.3.5) to maintain traceability and regulatory alignment.",
			"Clearly describe each critical step and intermediate in the manufacturing process, including rationale for designation as critical.",
			"Include critical controls associated with reprocessing operations when applicable and ensure that they are integrated clearly into the section narrative.",
		],
	},
	{
		number: "3.2.S.2.5",
		title: "Process Validation and/or Evaluation",
		input: [
			"Compile data from manufacturing batches used for validation, including batch records, in-process control results, and analytical test results.",
			"Obtain any validation information related to reprocessing operations if such operations are justified and performed.",
			"Collect process validation protocols and reports demonstrating that the manufacturing process consistently produces drug substance meeting predetermined specifications.",
			"Collect data from an appropriate number of production batches, considering process complexity, variability, and available process knowledge (per ICH Q7 Section 12.5).",
			"If continuous process verification is used, gather relevant protocols and data supporting its application for initial commercial production and process changes.",
			"Gather data demonstrating that small-scale models are representative and scalable to the proposed commercial-scale process.",
			"Gather experimental data, protocols, and results demonstrating successful validation of critical manufacturing steps.",
			"Gather relevant chromatograms that support validation of analytical procedures used in process validation or evaluation studies for inclusion in section 3.2.S.4.3.",
			"Gather experimental and confirmatory data on the lifetime of chromatography columns, including small-scale and commercial-scale confirmation.",
			"Ensure availability of relevant standard operating procedures (SOPs) for process validation and reprocessing activities.",
			"Ensure that any viral safety evaluation data relevant to the process are available for cross-reference in section 3.2.A.2, if applicable.",
			"Obtain studies demonstrating the ability of the process to remove product-related impurities, process-related impurities, and potential contaminants (including viral clearance studies per ICH Q5A).",
			"Collect any risk assessments or statistical analyses used to support process validation conclusions.",
			"Gather evaluation reports or studies supporting process performance qualification (PPQ) or equivalent validation exercises.",
			"Collect data assessing the limit of in vitro cell age for commercial production (per ICH Q5B and Q5D).",
			"Obtain any supporting data or reports referenced in ICH Q6B related to process validation for the drug product.",
			"Obtain full-scale validation data from the final manufacturing process and site(s) intended for commercial production, especially when platform manufacturing experience is used.",
			"Collect information on critical process parameters and critical quality attributes identified during process development and control strategy establishment.",
			"Collect validation and/or evaluation study documentation for critical steps or critical assays used in the manufacturing process of the drug product (e.g., sterilisation, aseptic processing, or filling).",
			"Collect validation and/or evaluation study documentation for critical steps or critical assays used in the manufacturing process of the drug substance (e.g., sterilisation, aseptic processing, or filling).",
			"Gather any prior regulatory correspondence or approvals related to process validation or reprocessing justification.",
			"Obtain process validation data for biotechnological/biological drug substances, including both commercial-scale process validation studies and small-scale studies.",
			"As applicable, obtain expert opinions or technical justifications supporting the validation approach or reprocessing rationale.",
		],
		output: [
			"When small-scale studies are used in place of certain commercial-scale studies, provide scientific justification or reference to guidelines that support this approach.",
			"Verify compliance with regional expectations for the level of detail and data presentation in process validation summaries.",
			"Follow ICH Q6B guidance for the level of detail and data presentation in process validation summaries for the drug product.",
			"Ensure that validation of sterilisation, aseptic processing, or filling operations is described in sufficient technical detail.",
			"Organize the section logically to demonstrate that the manufacturing process is under control and reproducible.",
			"Cross-reference viral safety evaluation data to section 3.2.A.2 when applicable, rather than duplicating it in 3.2.P.3.5.",
			"When platform manufacturing experience is referenced, demonstrate suitability of the control strategy and provide full-scale validation data from the intended commercial process and site(s).",
			"Cross-reference viral safety evaluation data to section 3.2.A.2 when applicable, rather than duplicating it in 3.2.S.2.5.",
			"Ensure that validation batches are representative of the commercial process, consistent with the batch definition in the process description.",
			"Structure the section to clearly distinguish between validation of critical steps and validation of critical assays.",
			"Include validation information in section 3.2.S.2.5 only if warranted by regional authority requirements.",
			"For section 3.2.P.3.5, provide a clear description, documentation, and results of validation and/or evaluation studies for critical manufacturing steps or assays.",
			"Ensure that all validation data presented are traceable to specific batches and analytical results.",
			"Use consistent terminology and section numbering aligned with CTD format requirements.",
			"Include studies demonstrating removal of product-related impurities, process-related impurities, and potential contaminants, with reference to relevant ICH guidelines (e.g., Q6B, Q5A).",
			"Include assessment of the limit of in vitro cell age for commercial production when applicable.",
			"Maintain clarity and conciseness while providing sufficient technical justification for process robustness and reproducibility.",
			"Cross-reference related sections appropriately: 3.2.S.2.2 for process description, 3.2.S.2.4 for critical controls, and 3.2.S.4 for analytical procedures and acceptance criteria.",
			"Include relevant chromatograms in section 3.2.S.4.3 when they support validation of analytical procedures related to process validation.",
			"Ensure that justification for reprocessing is not duplicated here; it should be described in 3.2.S.2.2, with critical controls in 3.2.S.2.4, and only validation data related to reprocessing included in 3.2.S.2.5.",
			"If continuous process verification is used, describe its application and justification clearly, including its role in initial commercial production and lifecycle process changes.",
			"Ensure that all validation documentation is complete, traceable, and consistent with the overall manufacturing process description in 3.2.P.3.",
			"For biotechnological/biological drug substances, include both commercial-scale and small-scale study data, ensuring small-scale models are justified as representative and scalable.",
			"Ensure that data from commercial-scale batches confirm results obtained from small-scale studies.",
			"Ensure that all validation documentation is complete, traceable, and consistent with the overall manufacturing process description in 3.2.S.2.",
			"Ensure alignment with ICH Q12 expectations that section 3.2.S.2.5 contains supportive information related to established conditions, without expanding beyond what is required for this section.",
			"Clearly describe the scope, methodology, and results of process validation or evaluation studies.",
		],
	},
	{
		number: "3.2.S.3.1",
		title: "Elucidation of Structure and Other Characteristics",
		input: [
			"Collect reference standards and comparator data used in the elucidation of structure and determination of characteristics.",
			"Collect all study reports and data from studies conducted to determine the physicochemical characteristics of the drug substance (e.g., solubility, melting point, pKa, hygroscopicity, polymorphism, spectral data).",
			"Obtain any relevant technical reports describing the methods and results of structural elucidation of the drug substance.",
			"Gather any expert opinions or interpretations of analytical data supporting the proposed structure and characteristics.",
			"Ensure availability of any regulatory correspondence or prior submissions that include relevant characterization data for cross-reference.",
			"Collect supportive information required under ICH Q12 for section 3.2.S.3.1, including data and documentation that substantiate the elucidation of structure and other characteristics as part of the established conditions framework.",
			"Collect data, analytical results, and study reports related to any possible alternative forms of the drug substance (e.g., polymorphs, hydrates, solvates, amorphous forms), since detailed information on these forms must be included in 3.2.S.3.1.",
			"Collect any applicable health authority guidance or regulatory instructions that apply when the drug substance is already approved, to ensure the correct preparation and presentation of 3.2.S.3.1.",
			"Collect study reports and results from investigations performed to identify potential polymorphic forms of the drug substance, including the total number of polymorphs identified.",
			"Collect study reports and datasets from studies performed to determine the particle size distribution of the drug substance, as required for inclusion in section 3.2.S.3.1.",
			"Gather analytical test results and datasets from characterization studies (e.g., NMR, IR, MS, UV spectra, elemental analysis, X-ray crystallography).",
			"Compile literature references that support the structural assignment and physicochemical properties of the drug substance.",
			"Gather structural drawings and models needed to depict secondary, tertiary, and, if applicable, quaternary structures of proteins for inclusion in section 3.2.S.3.1.",
		],
		output: [
			"Confirm that the section numbering and file naming for 3.2.S.3.1 comply with the CTD/eCTD structure and that the document is placed correctly within Module 3.",
			"Ensure that the supportive information provided in 3.2.S.3.1 aligns with the overall characterization narrative and supports the control strategy described in subsequent sections (e.g., 3.2.S.4).",
			"Use precise scientific terminology consistent with ICH and regulatory expectations for characterization data.",
			"Ensure that only one file is provided per reference when including supporting references or literature in the dossier, consistent with CTD formatting conventions.",
			"Include detailed information on the studies conducted to determine the physicochemical characteristics of the drug substance in section 3.2.S.3.1.",
			"Clearly identify the information in 3.2.S.3.1 as 'supportive information' under the ICH Q12 established conditions framework, ensuring that it is distinguishable from information defining established conditions.",
			"Include drawings depicting secondary, tertiary, and, if applicable, quaternary structures of proteins within section 3.2.S.3.1, as required by regulatory guidance.",
			"Do not create unnecessary individual files for lower-level headings within 3.2.S.3.1, as CTD-Q guidance indicates these levels typically do not require separate documents or files.",
			"Follow eCTD structural conventions—no separate table of contents is required for eCTD submissions, but ensure proper electronic organization and file naming for section 3.2.S.3.1.",
			"Organize the content to clearly describe the methods used, the results obtained, and the conclusions drawn from the characterization studies.",
			"Ensure that the description covers both the elucidation of the chemical structure and other relevant physicochemical characteristics.",
			"Cross-reference related sections or modules if supporting data is located elsewhere in the dossier.",
			"Include study results identifying the particle size distribution of the drug substance as part of the characterization information required in section 3.2.S.3.1.",
			"Verify that all included data are consistent with other sections of the CTD and that there are no discrepancies in reported characteristics.",
			"When describing polymorphism in 3.2.S.3.1, include study results identifying potential polymorphic forms, list the total number of polymorphs identified, and ensure consistency with the summary in 3.2.S.1.3.",
			"Do not include only a list of general properties in this section; such lists belong in section 3.2.S.1.3.",
			"Ensure that the section includes more detailed information on the properties of the drug substance, including possible alternative forms (e.g., polymorphs, hydrates, solvates), as required for 3.2.S.3.1.",
		],
	},
	{
		number: "3.2.S.3.2",
		title: "Impurities",
		input: [
			"Obtain justification of drug product impurity specifications from section 3.2.P.5.6.",
			"Gather linked information on impurity levels of batches described in 3.2.S.3.2 and 3.2.P.5.5, ensuring connection to batch history and development history as applicable.",
			"Compile relevant literature references or expert opinions supporting impurity identification, qualification, or toxicological assessment.",
			"Gather results of stability studies and impurity data from section 3.2.P.8.3 to ensure consistency of impurity profiles over time.",
			"Assemble analytical data and chromatograms related to impurities (noting that chromatograms themselves are included in section 3.2.S.4.3, but must be referenced here).",
			"Retrieve validation reports of drug product analytical procedures for impurities from section 3.2.P.5.3.",
			"Collect any internal calculation sheets or datasets used to determine whether impurities exceed reporting, identification, or qualification thresholds.",
			"Gather impurity quantitation results in both percentage and calculated total daily intake (TDI in mg) for comparison against thresholds.",
			"Gather analytical procedures for impurity testing from section 3.2.S.4.2.",
			"Obtain results of drug product batch analyses (all batches including development, clinical, stability) from section 3.2.P.5.4.",
			"Collect information from section 3.2.S.2.4 on batch data, analytical procedures, and acceptance criteria for intermediates or critical steps that may contribute to impurity formation.",
			"Gather drug product impurity specifications from section 3.2.P.5.1.",
			"Collect drug product analytical procedures for impurities from section 3.2.P.5.2.",
			"Gather any process validation or evaluation data from section 3.2.S.2.5 that may relate to impurity formation or control during manufacturing.",
			"Collect characterization data for drug product impurities not already discussed under 3.2.S from section 3.2.P.5.5.",
			"Obtain maximum daily dose data for the drug substance to determine applicable impurity reporting, identification, and qualification thresholds.",
			"Gather definitions and classification criteria for impurity types (specified, unspecified, identified, unidentified) as per regulatory guidance for accurate categorization in the section.",
			"Gather any regulatory correspondence or prior approvals related to impurity limits or qualification thresholds.",
			"Collect applicable impurity threshold values (reporting, identification, qualification) from regulatory guidance based on maximum daily dose.",
			"Retrieve impurity reference standards and their characterization data (noting that detailed characterization is provided in section 3.2.S.5).",
			"Obtain justification of impurity specifications from section 3.2.S.4.5.",
			"Collect structural characterization data for each identified impurity.",
			"Collect validation reports of analytical procedures for impurities from section 3.2.S.4.3.",
			"Retrieve acceptance criteria for intermediates or critical steps from section 3.2.S.4.1 and analytical procedures from section 3.2.S.4.2 to ensure linkage between process controls and impurity profiles.",
			"Collect information on qualified impurity levels, including cross-references to supporting nonclinical and clinical studies that justify impurity qualification.",
			"Retrieve relevant ICH guidelines (Q3B, Q5C, Q6A, Q6B) for reference when preparing impurity characterization and justification content.",
			"Collect batch analysis reports showing impurity profiles for representative production, clinical, and stability batches.",
			"Obtain specifications for impurities as defined in section 3.2.S.4.1.",
			"Collect characterization data for impurities from section 3.2.P.5.5 if not already provided in section 3.2.S.3.2.",
			"Retrieve results of batch analyses for all batches (including development, clinical, and stability) from section 3.2.S.4.4.",
			"Gather a summary of the method of preparation for each impurity.",
			"Obtain data on observed impurities from relevant batches, including clinical, nonclinical, and stability batches.",
		],
		output: [
			"Ensure inclusion of specifications, analytical procedures, validation of analytical procedures, results of batch analyses, and justification of specifications for impurities as per sections 3.2.S.4.1–3.2.S.4.5.",
			"Summarize the qualified level of each impurity and provide cross-references to supporting nonclinical and clinical studies.",
			"Maintain consistency in terminology and impurity naming conventions throughout the section.",
			"Link impurity level data to batch history and development history where relevant, ensuring traceability and consistency across sections.",
			"Ensure that impurity qualification levels are justified and traceable to supporting toxicological or clinical data.",
			"For drug product impurities, ensure inclusion of specifications, analytical procedures, validation of analytical procedures, results of batch analyses, characterization of impurities not discussed under 3.2.S, and justification of specifications as per sections 3.2.P.5.1–3.2.P.5.6.",
			"Cross-reference impurity data appropriately to support other sections of the dossier as needed.",
			"Include discussion on impurities and their qualification, referencing pre-clinical and clinical studies to define the absolute amount at which impurities can be considered qualified.",
			"Include structural characterization data and a summary of the method of preparation for each impurity in section 3.2.S.3.2.",
			"Ensure that references to ICH guidelines (Q3B, Q5C, Q6A, Q6B) are correctly cited and applied when describing impurity characterization and justification.",
			"Confirm that the section meets ICH Q12 expectations that 3.2.S.3.2 content is considered supportive information and not part of Established Conditions, ensuring no unintended designation of EC elements.",
			"Verify that all impurity data presented are consistent with analytical validation and batch analysis data elsewhere in the dossier.",
			"Present data on observed impurities for relevant batches (clinical, nonclinical, stability) in this section, regardless of whether the impurity is included in the specification.",
			"Apply regulatory definitions for impurity types (specified, unspecified, identified, unidentified) consistently when describing and categorizing impurities.",
			"Ensure that impurity reporting, identification, and qualification thresholds are correctly applied based on the maximum daily dose of the drug substance, using the lower of percentage or mg/day criteria where applicable.",
			"Ensure cross-references are made to section 3.2.S.4.3 for chromatograms and to section 3.2.S.5 for impurity reference standard characterization.",
			"Clearly indicate in the impurity tables whether each impurity exceeds the reporting, identification, or qualification thresholds and the corresponding required actions.",
			"Cross-reference acceptance criteria and analytical procedures for intermediates or critical steps (from 3.2.S.4.1 and 3.2.S.4.2) when discussing impurity origins or control strategies.",
			"Confirm that impurity control strategies described in section 3.2.S.3.2 align with process validation and evaluation data from section 3.2.S.2.5, ensuring consistency in impurity control rationale.",
			"Do not include raw analytical data in this section; present only processed and relevant impurity results in accordance with regulatory expectations.",
			"Ensure that impurity discussions in section 3.2.S.3.2 are consistent with process control and intermediate data presented in section 3.2.S.2.4, particularly where impurities arise from critical steps or intermediates.",
			"Include calculated total daily intake (TDI) values for impurities alongside percentage values to support threshold assessments.",
			"Cross-reference impurity characterization data with stability data in section 3.2.P.8.3 to demonstrate impurity profile stability over time.",
			"Organize impurity information clearly, distinguishing between identified, unidentified, process-related, and degradation impurities as applicable.",
			"Ensure that any illustrative examples or threshold calculations included are adapted to the specific product and are not copied directly from guidance examples.",
			"Ensure consistency between impurity characterization data in section 3.2.S.3.2 and corresponding data in section 3.2.P.5.5, avoiding duplication or omission.",
		],
	},
	{
		number: "3.2.S.4.1",
		title: "Specifications",
		input: [
			"Compile any alternative analytical procedures used to control the drug substance, along with their acceptance criteria.",
			"Obtain the current specification(s) for the drug substance from the manufacturer).",
			"Obtain batch data for intermediates or critical steps if acceptance criteria for these are referenced in 3.2.S.4.1, to support justification of specifications.",
			"Collect acceptance criteria for intermediates or critical steps that are referenced in section 3.2.S.4.1.",
			"Obtain the current specification(s) for the drug substance from the applicant (if different from the manufacturer).",
			"Obtain the current specification(s) for the drug substance from the manufacturer.",
			"Gather the complete list of drug substance quality attributes to ensure all required attributes are represented in the specification.",
			"Gather analytical procedures for intermediates or critical steps that are referenced in section 3.2.S.4.2, to ensure consistency with specifications in 3.2.S.4.1.",
			"Gather all analytical procedures used to control the drug substance.",
			"Collect supportive information from section 3.2.S.4.5 (Justification of Specification) that provides rationale or data supporting the specification limits presented in 3.2.S.4.1.",
			"Gather reference material specifications (tests, analytical procedure elements, and acceptance criteria) from section 3.2.S.5 to ensure alignment with the drug substance specifications in 3.2.S.4.1.",
			"Gather reference standards or materials used in the analytical procedures for the drug substance.",
			"Collect the associated acceptance criteria for each analytical procedure used to control the drug substance.",
			"Ensure access to any relevant regulatory correspondence or approvals that define or impact the specifications.",
		],
		output: [
			"Confirm that the specification in 3.2.S.4.1 aligns with the reference material specifications described in 3.2.S.5, maintaining consistency in test methods and acceptance criteria.",
			"Verify that all specifications and analytical procedures listed are current, accurate, and consistent with supporting data in other sections of the dossier.",
			"Include more than one specification in section 3.2.S.4.1 when appropriate (e.g., if manufacturer and applicant specifications differ).",
			"Do not include 'not applicable' pages or placeholder text for unused CTD headings when updating or varying section 3.2.S.4.1.",
			"Cross-reference acceptance criteria for intermediates or critical steps from section 3.2.S.2.4 within 3.2.S.4.1 to maintain traceability and consistency.",
			"Ensure consistency between the specifications presented in 3.2.S.4.1 and the supportive justification information provided in 3.2.S.4.5, as per ICH Q12 expectations.",
			"Ensure that analytical procedures for intermediates or critical steps referred to in 3.2.S.4.2 are properly linked to the acceptance criteria presented in 3.2.S.4.1.",
			"For each analytical procedure listed, include the associated acceptance criteria in the specification.",
			"List every analytical procedure used to control the drug substance in the specification.",
			"For each drug substance quality attribute included in the specification, explicitly include the corresponding test method and acceptance criteria, in alignment with ICH Q12 requirements.",
			"When submitting amendments or variations affecting section 3.2.S.4.1, use the same CTD structure and format as for the original submission; do not create a separate or modified format.",
			"Do not create separate documents or files for lower-level headings under 3.2.S.4.1, in accordance with CTD-Q expectations that such headings typically do not contain standalone documents.",
			"Present specifications in a clear, organized format that aligns with CTD structure for section 3.2.S.4.1.",
			"Follow regional guidance for applicability of CTD format in amendments or variations that include updates to section 3.2.S.4.1.",
			"Ensure that alternative analytical procedures used to control the drug substance are also listed in the specification, with their acceptance criteria.",
		],
	},
	{
		number: "3.2.S.4.2",
		title: "Analytical Procedures",
		input: [
			"Gather analytical procedures used for intermediates or critical steps when these tests are performed in lieu of drug substance release testing, as these procedures must be referenced in section 3.2.S.4.2.",
			"Collect any analytical procedures that are currently applied to the drug substance, even if similar methods exist for the drug product.",
			"Gather descriptions of any analytical procedures that are part of a registered alternative control strategy to RTRT, along with their validation information.",
			"Obtain validated analytical method descriptions for identification, assay, impurities, and other quality attributes of the drug substance.",
			"Obtain high-level overview of PQS elements for model monitoring and maintenance, including diagnostic tools and outlier handling approaches.",
			"Gather defined performance criteria for multivariate model validation.",
			"Gather analytical procedures and corresponding method validation information for any in-process material test performed in lieu of a finished product test that is relevant to drug substance control.",
			"Collect detailed descriptions of analytical procedures used for RTRT, including property/attribute of interest, desired quantitative ranges/limits, measurement principle, instrument operating parameters, calibration data acquisition, type of multivariate model, reference analytical procedure or prepared reference samples, and calculation methods for model output adjustment.",
			"If the drug substance is already approved, retrieve relevant health authority guidance or correspondence to ensure alignment with existing approvals before preparing section 3.2.S.4.2.",
			"Gather discussion documents linking model performance criteria to attribute specification limits.",
			"Retrieve method parameters, instrument settings, reagents, and sample preparation details specific to the drug substance.",
			"Collect detailed descriptions of multivariate models used as part of drug substance specifications, including for RTRT approaches.",
			"Gather technical documents describing analytical methods, including method development reports and standard operating procedures (SOPs).",
			"Refer to Appendix A for any additional guidance or templates applicable to analytical procedures for the drug substance.",
			"Collect evaluation results of model validation against performance criteria.",
			"Gather validation information for analytical procedures used as reference analytical procedures, including model development, calibration, and validation data.",
			"Collect all current analytical procedures used to control the drug substance.",
			"Gather reference standards and materials used in the analytical procedures.",
			"Gather analytical methods and associated validation data relevant to polymorphism testing, ensuring consistency with sections 3.2.S.3.1 and 3.2.S.4.3.",
			"Collect any regulatory correspondence or prior submissions that describe analytical methods for the same drug substance.",
			"Obtain supporting data packages or reports that demonstrate the use of these analytical procedures in batch analyses.",
			"Obtain description of validation set with independent samples for multivariate models.",
			"Ensure access to the latest version of the analytical procedures that are currently in use for release and control testing of the drug substance.",
			"Collect any analytical procedures related to the characterization of polymorphic forms of the drug substance, as these may be referenced in section 3.2.S.4.2.",
		],
		output: [
			"Include validation information for analytical procedures used as reference analytical procedures, either directly in section 3.2.S.4.2 or as an appended document.",
			"Ensure that the analytical procedures are clearly described with sufficient detail for replication by a qualified laboratory.",
			"If the drug substance is already approved, confirm that the analytical procedure descriptions are consistent with the approved dossier and any applicable health authority guidance before submission.",
			"When describing RTRT analytical procedures, include property/attribute of interest, desired quantitative ranges/limits, measurement principle, instrument operating parameters, calibration data acquisition, type of multivariate model, reference analytical procedure or prepared reference samples, and calculation methods for model output adjustment.",
			"Ensure that the section is organized logically, typically by test type (e.g., identification, assay, impurities).",
			"When describing analytical procedures for in-process material tests performed in lieu of a finished product test, provide the same level of detail and validation information as would be provided for a finished product test.",
			"Maintain consistency between the analytical procedures listed in 3.2.S.4.2 and those referenced in the specification (3.2.S.4.1).",
			"Verify that the description of analytical procedures in 3.2.S.4.2 enables clear identification of ECs and non-ECs in accordance with ICH Q12.",
			"Do not include historical analytical procedures used only for data generation; these belong in section 3.2.S.4.4.",
			"If analytical methods for the drug substance and drug product are identical, describe them in both 3.2.S and 3.2.P sections, with appropriate cross-references.",
			"Ensure alignment with ICH Q12 expectations for Established Conditions (ECs) by identifying which elements of the analytical procedures constitute ECs, as referenced in Chapter 3, section 3.2.3.2.",
			"For multivariate models used in specifications (including RTRT), describe the validation approach and results, including validation set description, performance criteria, evaluation against criteria, and relationship to specification limits.",
			"Include descriptions of any analytical procedures that are part of a registered alternative control strategy to RTRT, with cross-reference to validation information in section 3.2.S.4.3.",
			"Confirm that all referenced analytical procedures for intermediates or critical steps comply with the structure and alignment expectations of section 3.2.S.4.2.",
			"Confirm that all referenced analytical procedures correspond to the acceptance criteria defined in the specification.",
			"Cross-reference related validation data in section 3.2.S.4.3 where applicable.",
			"Do not include analytical procedures used exclusively for stability studies; these belong in section 3.2.S.7.3.",
			"If release testing is performed on intermediates or critical steps instead of on the drug substance, ensure that the analytical procedures for those tests are referenced in section 3.2.S.4.2, as required.",
			"Verify that the analytical procedures described for polymorphism testing are consistent with the manufacturing process and specification sections, ensuring traceability across the CTD.",
			"Provide a high-level overview of PQS elements for model monitoring and maintenance, including diagnostic tools and outlier handling, when describing multivariate models.",
			"Use clear, standardized terminology consistent with ICH and pharmacopoeial conventions when describing analytical methods.",
			"Ensure that any procedures classified as Established Conditions are described with sufficient detail to meet regulatory expectations for lifecycle management.",
			"Recognize that lower-level CTD-Q headings such as 3.2.S.4.2 are not expected to contain individual documents or files; instead, compile the information as a single integrated narrative or table within the section.",
			"Include only analytical procedures currently used to control the drug substance in section 3.2.S.4.2.",
			"Verify that all analytical procedures correspond to the acceptance criteria defined in the specification.",
			"If analytical methods for the drug substance and drug product are identical, describe them in both 3.2.S and 3.2.P sections, with appropriate cross-references, because sample preparation will usually differ.",
			"Ensure that analytical procedures related to polymorphism are appropriately referenced and aligned with data presented in sections 3.2.S.1.3, 3.2.S.2.2, 3.2.S.3.1, and 3.2.S.4.1.",
		],
	},
	{
		number: "3.2.S.4.3",
		title: "Validation of Analytical Procedures",
		input: [
			"Obtain raw analytical data, calculations, and statistical analyses supporting validation parameters (accuracy, precision, specificity, detection limit, quantitation limit, linearity, range, robustness).",
			"Ensure that documentation is securely stored and readily available for regulatory inspection or upon request.",
			"Gather reference standards and information on their qualification used in validation.",
			"Ensure availability of instrument calibration and qualification records used during validation.",
			"Collect multivariate model calibration datasets, including all reference sample data and associated measurement outputs.",
			"Collect documentation describing the relationship between model performance criteria and the attribute specification limits.",
			"Compile performance criteria defined for validation of multivariate models (e.g., accuracy thresholds, prediction error limits).",
			"Assemble PQS (Pharmaceutical Quality System) documentation relevant to model monitoring and maintenance (e.g., diagnostic tools used, outlier identification and handling procedures).",
			"Prepare a summary table of all relevant validation reports for each analyte, including partial and cross-validation reports, with method identification codes and reasons for new or additional validation.",
			"Prepare a summary table cross-referencing multiple identification codes when a method has different codes for the method, validation reports, and bioanalytical reports.",
			"Assemble any comparative data if alternative analytical procedures were validated.",
			"Gather model development documentation for any multivariate analytical procedures used as validated methods (e.g., model design history, rationale, algorithms used).",
			"Collect records supporting procedural, operational, and environmental conditions during validation studies.",
			"Compile method SOPs (Standard Operating Procedures) for each validated analytical procedure.",
			"Compile documentation required for data audit and inspection, including validation and bioanalytical reports.",
			"Gather validation information for any analytical procedures included in an alternative control strategy to RTRT when such procedures are validated and placed into section 3.2.S.4.3.",
			"Collect relevant chromatograms for impurities as identified in ICH Q3A that are part of analytical validation studies for inclusion in section 3.2.S.4.3.",
			"Ensure availability of records of regulatory site inspections, including dates and outcomes for each analytical site, if applicable.",
			"Collect relevant chromatograms generated during validation studies for each analytical method.",
			"Assemble correspondence records between all involved parties related to analytical method validation.",
			"Obtain multivariate model validation datasets, including independent samples used for validation.",
			"Ensure availability of general and specific SOPs related to analytical method validation and record keeping.",
			"Collect any supportive information identified as part of Established Conditions for validation of analytical procedures under ICH Q12 (e.g., data, reports, or documentation demonstrating that the validated methods meet regulatory expectations).",
			"Collect reference analytical procedure documentation used to generate calibration or validation samples for multivariate model development.",
			"Collect documentation of method changes (e.g., evolution, reasons for revisions, unique aspects).",
			"Gather all source data, protocols, and reports supporting analytical method validation to ensure the study can be reconstructed as conducted and reported.",
			"Gather complete validation reports for all analytical procedures used to control the drug substance.",
			"Gather results of evaluating model validation performance against the predefined criteria.",
			"Collect any regulatory correspondence or prior approvals related to analytical method validation.",
			"Obtain relevant literature references or pharmacopeial method references if applicable.",
		],
		output: [
			"Use consistent terminology and units throughout the section to align with ICH and pharmacopeial standards.",
			"If multivariate model development, calibration and validation information is appended instead of placed directly in section 3.2.S.4.3, clearly reference its location.",
			"Ensure that documentation of analytical method validation is contemporaneous with the event and that any alterations do not obscure the original data.",
			"Ensure that chromatograms for impurities, as identified in ICH Q3A, are included in section 3.2.S.4.3 as part of analytical validation studies.",
			"Include all relevant chromatograms directly in section 3.2.S.4.3 to support validation results.",
			"Clearly indicate that the information provided in section 3.2.S.4.3 constitutes supportive information for Established Conditions as per ICH Q12, ensuring alignment with the regulatory definition of supportive information.",
			"Cross-reference analytical procedures described in section 3.2.S.4.2 where applicable.",
			"Ensure that validation information for analytical procedures supporting alternative control strategies to RTRT is included in this section when applicable.",
			"Organize the section to include an introduction, summary of methods, validation results by parameter, chromatograms, and conclusions.",
			"Include a clear evaluation comparing model validation results against the performance criteria.",
			"Maintain internal cross-references to ensure traceability between validation data in 3.2.S.4.3 and related manufacturing or control sections (3.2.S.2.4, 3.2.S.4.1, 3.2.S.4.2).",
			"Confirm that validation data correspond to the analytical procedures used for intermediates or critical steps if referenced from section 3.2.S.2.4.",
			"Document the basis for any data changes or reprocessing with sufficient detail, maintaining the original record.",
			"Include the predefined performance criteria for validation of multivariate models.",
			"Ensure that any results from tests not listed in the specifications but relevant to analytical validation are appropriately referenced or summarized in section 3.2.S.4, maintaining clarity on their relationship to validated methods.",
			"Verify that all data presented are traceable to original raw data and are consistent with other sections of the CTD.",
			"Include a summary table of all relevant validation reports for each analyte, identifying partial and cross-validation reports and reasons for new or additional validation.",
			"Present validation data in a clear, organized manner, typically by validation parameter (accuracy, precision, specificity, etc.).",
			"Ensure that documentation format (paper or electronic) complies with good record-keeping practices and regulatory expectations for data integrity.",
			"Ensure compliance with applicable ICH guidelines (e.g., Q2(R1)) for validation of analytical procedures.",
			"Ensure that all validation results meet acceptance criteria defined in the analytical method SOP or regulatory guidelines.",
			"Include a summary table cross-referencing multiple identification codes when applicable.",
			"For multivariate analytical procedures included in validated methods, include validation information describing the validation set with independent samples.",
			"If collated data from multiple batch analyses are used to support validation conclusions, ensure that such data are clearly summarized and cross-referenced to section 3.2.S.4.4 for traceability.",
			"Include summary information in the CTD that provides method titles, identification codes, assay types, report codes, effective dates, and associated validation report codes.",
			"Ensure that analytical procedures validated and presented in section 3.2.S.4.3 are consistent with those referenced in section 3.2.S.4.2 (Analytical Procedures) and acceptance criteria in section 3.2.S.4.1 (Specifications).",
			"Ensure that all documentation is maintained in a secure environment and is readily available for regulatory inspection or audit.",
			"Provide a high-level description of PQS elements for model monitoring and maintenance (e.g., diagnostic tools, handling of outliers) when multivariate models are validated.",
			"Include a discussion of method changes, including evolution, reasons for revisions, and unique aspects.",
			"Ensure that chromatograms are properly labeled with sample identification, date, method, and relevant parameters.",
			"Include a discussion explaining the relationship between model performance criteria and attribute specification limits.",
		],
	},
	{
		number: "3.2.S.4.4",
		title: "Batch Analyses",
		input: [
			"Collect analytical results from all relevant drug substance batches, including clinical, nonclinical, and stability batches.",
			"Gather any regulatory correspondence or prior submissions that describe batch testing or analytical results for the same substance.",
			"Ensure availability of reference standards and comparator materials used in the batch analyses.",
			"Assemble collated data sets for tests where data from multiple batch analyses are warranted.",
			"Collect supportive information as required under ICH Q12 for section 3.2.S.4.4, including data demonstrating consistency of manufacturing and control of the drug substance across batches.",
			"Retrieve historical analytical procedures used to generate the batch analysis data, if applicable.",
			"Collect information on historical analytical procedures specifically used to generate data included in the batch analyses for inclusion in 3.2.S.4.4.",
			"Obtain analytical test results used to justify acceptance criteria for the drug substance.",
			"Collect relevant stability study data if stability batches are included in the batch analyses.",
			"Ensure access to validated analytical methods and corresponding validation reports used for batch testing.",
			"Collect any polymorphism-related batch analysis data if polymorphic form is a controlled attribute, ensuring linkage to relevant sections (3.2.S.1.3, 3.2.S.2.2, 3.2.S.3.1, 3.2.S.4.1–3.2.S.4.3).",
			"Collect any large-volume statistical output or detailed analysis reports that cannot be fully presented in the section, for placement in an appropriate appendix or referenced module.",
			"Gather any integrated analyses or statistical outputs relevant to batch data if multiple studies or datasets are combined for presentation in 3.2.S.4.4.",
			"Compile results from any tests performed that are not listed in the official specifications.",
			"Gather batch descriptions for each batch analyzed, including batch number, manufacturing site, and intended use.",
			"Gather applicable health authority guidance or regulatory instructions when the drug substance is already approved, to determine any additional expectations for presenting batch analyses in 3.2.S.4.4.",
		],
		output: [
			"Ensure that the supportive information provided in 3.2.S.4.4 is sufficient to demonstrate consistency of quality attributes across batches and supports the defined ECs.",
			"Use clear tabular presentation for batch analysis results to facilitate review and comparison.",
			"Identify section 3.2.S.4.4 as containing supportive information under ICH Q12, ensuring alignment with the concept of Established Conditions (ECs) where applicable.",
			"Include results from all relevant batches (clinical, nonclinical, stability) in section 3.2.S.4.4.",
			"Ensure that results from tests not listed in the specifications are placed in 3.2.S.4 (parent section) rather than incorrectly placed in 3.2.S.4.4, with proper cross-referencing from 3.2.S.4.4 where relevant.",
			"Provide descriptive information for each batch, including batch number, manufacturing site, and intended use, within the section.",
			"If the volume of analytical or statistical output is too large to be included in full in 3.2.S.4.4, summarize key results in this section and place detailed reports in an appropriate referenced module or appendix, ensuring clear cross-referencing.",
			"When providing cross-references within the section, include at least the section number in the reference string to maintain clarity and brevity, and ensure the surrounding text makes the section content clear.",
			"Include descriptions of historical analytical procedures within 3.2.S.4.4 when they were used to generate the batch analysis data.",
			"Present results from tests not listed in the specifications within this section, clearly identifying them as such.",
			"If polymorphism is a controlled attribute, ensure that batch analysis results in 3.2.S.4.4 clearly indicate the polymorphic form present and are consistent with related information in sections 3.2.S.1.3, 3.2.S.2.2, 3.2.S.3.1, and 3.2.S.4.1–3.2.S.4.3.",
			"Cross-reference analytical procedures and specifications appropriately to avoid duplication and ensure traceability.",
			"Ensure that the supportive information provided in 3.2.S.4.4 is sufficient to demonstrate consistency of quality attributes across batches and supports the defined Established Conditions (ECs).",
			"If collated data from multiple batch analyses are warranted, present the summarized data in this section.",
			"Do not create separate documents or files for lower-level subheadings within section 3.2.S.4.4, as these levels are not intended to contain individual standalone files according to CTD-Q conventions.",
			"Verify that all data presented are consistent with acceptance criteria and specifications described elsewhere in the dossier.",
			"Maintain consistency between analytical methods described in 3.2.S.4.2 and the data presented in 3.2.S.4.4.",
			"Ensure that only one file is created per reference or per dataset when preparing supporting appendices or references related to batch analyses, consistent with CTD file management conventions.",
			"Follow eCTD structural conventions for section numbering and file organization; no separate table of contents is required for eCTD submissions for this section.",
			"Ensure the section is complete, internally consistent, and compliant with CTD-Q structure and formatting conventions.",
			"Ensure that all analytical data are clearly organized and traceable to the corresponding batch.",
			"Confirm that the presentation of batch analysis data supports the control strategy and established conditions described in related sections (3.2.S.4.1–3.2.S.4.3).",
			"Ensure that any supporting appendices or references linked to 3.2.S.4.4 follow the 'one file per reference' rule to maintain traceability and compliance with CTD structure.",
		],
	},
	{
		number: "3.2.S.4.5",
		title: "Justification of Specification",
		input: [
			"Supportive information required under ICH Q12 for section 3.2.S.4.5, as part of established conditions",
			"Any alternative specifications used by different manufacturers or applicants, if applicable",
			"Information on reference standards used in analytical procedures",
			"Acceptance criteria for intermediates or critical steps when these are relevant to the justification of the drug substance specification",
			"Validation reports and data for analytical procedures used in the specification",
			"ICH guidelines referenced for this section, specifically ICH Q3A, Q3C, Q6A, and Q6B, which may need to be consulted when preparing justification",
			"Analytical procedures for intermediates or critical steps when these are relevant to the justification of the drug substance specification",
			"Stability study data if used to justify certain specification parameters",
			"Analytical procedures used to control the drug substance, including acceptance criteria",
			"Historical analytical procedures and data supporting the development of the current specification",
			"Summaries or cross-referenced data from other CTD sections (e.g., 3.2.S.4.1–3.2.S.4.4) that support the justification of specification",
			"Comparative data showing equivalence or superiority of proposed specification to established standards",
			"Justification data for each test parameter and acceptance criterion, including scientific rationale",
			"Reference to relevant pharmacopeial standards or literature supporting the specification limits",
			"Batch analysis data demonstrating compliance with the proposed specification",
			"Batch analysis results from relevant batches (e.g., clinical, nonclinical, stability) used to justify acceptance criteria",
			"Regulatory correspondence or prior approvals related to specification changes or acceptance criteria",
			"Data supporting justification for skip testing, including rationale and supporting evidence",
			"Batch data for intermediates or critical steps when these are used to support the drug substance specification justification",
			"Final proposed drug substance specification, including all tests, analytical procedures, and acceptance criteria",
		],
		output: [
			"Include justification for skip testing within this section when applicable",
			"Avoid unnecessary repetition of data already presented in other CTD sections by using cross-references appropriately",
			"When summarizing data from other sections, provide concise summaries with clear cross-references to detailed information elsewhere in the dossier",
			"Ensure that the justification aligns with ICH Q12 concepts related to established conditions, specifically that this section provides 'supportive information' and is not itself designated as an established condition",
			"Ensure that the section heading 'Justification of Specification' is correctly labeled and formatted as a heading element",
			"Confirm that the section is presented as a single, non-repeating element (cardinality one-to-one) consistent with CTD structure",
			"Clearly present the rationale for each test and acceptance criterion in the specification",
			"Use clear, scientific language and avoid ambiguous terminology",
			"Organize justification in a logical sequence, typically parameter-by-parameter as listed in the specification",
			"Ensure that section headings and subheadings follow CTD conventions and are not repeated or reused unless explicitly allowed",
			"Verify that the section content provides a clear scientific rationale for the specification parameters and acceptance criteria, consistent with the definition of justification sections in CTD-Q",
			"Cross-reference related sections (e.g., 3.2.S.4.1 Specification, 3.2.S.4.2 Analytical Procedures, 3.2.S.4.3 Validation) where applicable",
			"Reference supporting data sources (e.g., batch data, validation reports, literature) directly in the justification text",
			"Include any relevant comparisons to pharmacopeial or regulatory standards",
			"When acceptance criteria or analytical procedures for intermediates or critical steps are relevant to the drug substance specification, ensure they are appropriately referred to in 3.2.S.4.1 and 3.2.S.4.2",
			"Verify that all analytical procedures mentioned in the justification are described and validated in the appropriate sections",
			"Maintain compliance with CTD-Q structure and formatting requirements for section 3.2.S.4.5",
			"Ensure all acceptance criteria are justified with data or scientific rationale",
			"Ensure consistency between the specification in 3.2.S.4.1 and the justification in 3.2.S.4.5",
			"Ensure alignment of justification content with the principles outlined in ICH Q3A, Q3C, Q6A, and Q6B, as these guidelines govern impurity control and specification setting",
			"Present data in tables or figures where it improves clarity, ensuring proper labeling and referencing",
		],
	},
	{
		number: "3.2.S.5",
		title: "Reference Standards or Materials",
		input: [
			"Collect information on the source, manufacturer, and lot numbers of reference standards or materials.",
			"Gather stability study data supporting the assigned shelf life or requalification period of reference standards.",
			"Ensure availability of technical specifications and analytical methods used to characterize and qualify reference standards.",
			"Gather detailed characterization data for each reference standard, including identity, purity, potency, and stability information.",
			"Collect characterization data for each reference standard to be included in section 3.2.S.5, ensuring completeness for identity, purity, and other relevant attributes.",
			"Obtain documentation demonstrating traceability of reference standards to official compendial standards (e.g., USP, EP, JP) or to in-house standards if compendial standards are not available.",
			"Obtain regulatory correspondence or approvals related to the use of specific reference standards, if applicable.",
			"Gather analytical data comparing in-house reference standards to compendial or primary standards, including equivalence or qualification studies.",
			"Refer to Appendix A for any additional guidance or requirements applicable to section 3.2.S.5 Reference Standards or Materials, particularly when the drug substance is already approved.",
			"Gather the formal Reference Material specification, including required tests, elements of the analytical procedure, and acceptance criteria, as described in ICH Q12.",
			"Obtain certificates of analysis (CoA) for all reference standards and materials used for testing the drug substance.",
			"Gather information on all reference standards used for the active moiety and impurities, if applicable.",
			"Collect any relevant literature references or expert justifications supporting the selection and use of reference standards or materials.",
			"Collect validation or qualification reports for in-house reference standards, including preparation, storage, and requalification procedures.",
		],
		output: [
			"Ensure consistency of reference standard information with analytical methods and specifications presented elsewhere in Module 3.",
			"Provide a structured description including name, source, lot number, characterization data, and intended use for each reference standard.",
			"Apply Note 4 guidance that lower-level CTD-Q headings (including 3.2.S.5) are unlikely to contain individual documents or files; compile information within the main section text rather than as separate attachments unless justified.",
			"Clearly identify each reference standard or material used in testing the drug substance, specifying whether it is compendial or in-house.",
			"Follow CTD formatting conventions for section numbering and headings (e.g., 3.2.S.5 Reference Standards or Materials).",
			"If in-house reference standards are used, describe preparation, characterization, and qualification procedures in sufficient detail to demonstrate suitability.",
			"Use clear, concise, and scientifically accurate language consistent with ICH CTD terminology.",
			"Place characterization data for each reference standard within section 3.2.S.5, with cross-references to other sections (e.g., 3.2.S.3.2) as appropriate.",
			"Cross-reference analytical procedures and test methods described in section 3.2.S.4 (Control of Drug Substance) where applicable.",
			"Include information on all relevant reference standards (for active moiety and impurities) in section 3.2.S.5 when warranted.",
			"Include the Reference Material specification in section 3.2.S.5, ensuring that tests, analytical procedure elements, and acceptance criteria are clearly presented in accordance with ICH Q12.",
			"Include certificates of analysis and qualification data in an organized and traceable manner.",
			"Follow CTD guidance that lower-level headings in quality sections typically do not require submission of separate files or documents unless justified.",
			"Verify that all reference standards are traceable to recognized primary standards or are appropriately justified if not compendial.",
			"Ensure that all data tables, certificates, and supporting documents are legible, properly labeled, and paginated according to CTD requirements.",
			"When reference standards are cited in both 3.2.S.5 and 3.2.P.6, ensure proper cross-referencing between sections to avoid duplication and maintain consistency.",
			"If the drug substance is already approved, consult the relevant health authority for guidance on how to present or reference existing reference standard information in section 3.2.S.5.",
		],
	},
	{
		number: "3.2.S.6",
		title: "Container Closure Systems",
		input: [
			"Obtain information on protection from moisture and light provided by the container closure system for the drug product.",
			"Gather additional detailed information for functional secondary packaging components, including specifications and performance data.",
			"Gather any relevant stability data or references from 3.2.S.7 (Stability) that demonstrate the container closure system’s performance over time, if applicable to the drug substance.",
			"Collect any relevant literature references supporting material selection, compatibility, or safety of the container closure system.",
			"Obtain identity information for materials of construction of each primary packaging component.",
			"Obtain reference standards or comparator product information if used in container closure system evaluation.",
			"Collect any photostability study data relevant to the container closure system’s protective function (if applicable to drug substance).",
			"Gather information on the storage and shipping conditions for the drug substance as they relate to and justify the container closure system used for storage (per reference to 3.2.S.6).",
			"Collect safety data for materials of construction used in the container closure system for the drug product.",
			"Collect cross-references or supporting data from 3.2.P.2.4 (Container Closure System) and 3.2.P.7 (Container Closure System) sections to ensure consistency of information presented in 3.2.S.6.",
			"Gather compatibility data between the container closure materials and the dosage form, including sorption and leaching studies specific to the drug product.",
			"Collect data on the suitability of the container closure system for storage, transportation, and use of the drug product, including performance data such as dose delivery reproducibility for device-containing products.",
			"Collect validation reports for any non-compendial analytical methods used for container closure system testing.",
			"Collect any photostability study data relevant to the container closure system\u0019s protective function (if applicable to drug substance).",
			"Obtain results from extractables studies for the container closure system, including identification and quantification of extractable compounds.",
			"Gather cleaning validation study reports for container closure components, if applicable (e.g., for reusable or specialized systems).",
			"Collect performance testing data for the container closure system relevant to the drug substance (e.g., sealing integrity, compatibility, functionality tests).",
			"Prepare brief descriptions for non-functional secondary packaging components.",
			"Collect data and assessments on container closure system suitability, including choice of materials, protection from moisture and light, compatibility with the drug substance (including sorption and leaching), and safety of materials of construction.",
			"Collect formal specifications for each container closure component, including acceptance criteria, as required for established conditions under ICH Q12.",
			"Obtain results from leachables studies for the container closure system, including identification and quantification of leachable compounds.",
			"Gather regulatory correspondence or prior approvals related to the container closure system, if available.",
			"Gather material-of-construction documentation specifically required as established conditions under ICH Q12 for CTD section 3.2.S.6.",
			"Gather detailed descriptions and specifications of the container closure system for the drug substance, including materials of construction and design features.",
			"Gather any relevant references or data from 3.2.P.7 (Container Closure System) to support the discussion of suitability in 3.2.P.2.4.",
			"Obtain light protection data for the container closure system, such as light transmission test results.",
			"Gather specifications for each primary packaging component, including description, identification, and critical dimensions with drawings where appropriate.",
		],
		output: [
			"Consider using separate documents for each container closure system type (e.g., bottles vs. blisters) when this improves clarity and organization.",
			"Maintain consistency in structure and labeling across multiple container closure system documents to facilitate regulatory review and traceability.",
			"Ensure the section clearly presents material of construction and component specifications, as these constitute established conditions under ICH Q12 for CTD section 3.2.S.6.",
			"Provide additional detailed information for functional secondary packaging components, including specifications and performance characteristics.",
			"Present performance characteristics of the container closure system in a clear and organized manner, including any relevant functional testing results.",
			"When multiple documents are included, assign priority numbers to control their display order within the section.",
			"Discuss the suitability of the container closure system to protect the drug substance from light, supported by light transmission data.",
			"Include description of cleaning procedures and validation results for container closure components, if applicable.",
			"If photostability data are relevant, cross-reference to the stability section where such data are reported.",
			"Ensure that the section describes the storage and shipping conditions of the drug substance insofar as they relate to and justify the selected container closure system (per cross-reference from 3.2.S.2.4).",
			"Organize the section to cover: description of the system, materials of construction, compatibility with drug substance, performance characteristics, extractables/leachables data, cleaning validation (if applicable), and light protection.",
			"Ensure the discussion covers choice of materials, protection from moisture and light, compatibility with the dosage form (including sorption and leaching), safety of materials of construction, and performance characteristics such as dose delivery reproducibility for device-containing products.",
			"If multiple documents are used within the section, use informative document titles to differentiate content (e.g., Description, Manufacturers, Specification).",
			"When warranted, cross-reference leachables information to relevant analytical procedures and validation sections (e.g., 3.2.S.4 or 3.2.S.7 equivalents for drug substance) and to stability data sections if leachables are monitored over shelf-life.",
			"Include information on both extractables and leachables in the 3.2.S.6 section, ensuring clear distinction between the two and summarizing study results.",
			"In the discussion of container closure system suitability, explicitly address storage, transportation, and use conditions of the drug product.",
			"Use descriptive and specific document titles when multiple container closure systems are included (e.g., identifying packaging components such as aluminum lidding or PVC laminate).",
			"Cross-reference the container closure system description in 3.2.P.7 when discussing suitability in 3.2.P.2.4 to maintain consistency and traceability.",
			"Include specifications for each primary packaging component, covering description, identification, and critical dimensions with drawings where appropriate.",
			"Confirm that the section numbering and titles conform to the CTD structure (e.g., 3.2.S.6 Container Closure System) and align with the overall Module 3 organization.",
			"Ensure all data are presented in a clear, concise, and scientifically justified manner, using consistent terminology for container closure components.",
			"Use the optional 'container' keyword strategically if needed; each keyword value will generate a separate section for different container closure systems.",
			"Verify that all referenced studies and data are traceable to original reports and are consistent with information in other CTD sections.",
			"Ensure the section aligns with ICH Q6A and Q6B principles regarding specifications and quality attributes relevant to container closure systems.",
			"Ensure that the organization of the 3.2.S.6 section aligns with Appendix E recommendations when multiple container closure systems are involved.",
			"Select an appropriate level of document granularity for container closure system information; all information may be placed in one document or multiple documents depending on business needs.",
			"Discuss suitability of the container closure system with respect to choice of materials, protection from moisture and light, compatibility with the drug substance (including sorption and leaching), and safety of materials of construction.",
			"Provide only a brief description for non-functional secondary packaging components.",
			"Verify that specification information is complete and suitable for inclusion as established conditions, ensuring regulatory consistency post-approval.",
			"Include identity of materials of construction for each primary packaging component in the description.",
			"Ensure compliance with applicable ICH guidelines (e.g., Q1A/Q1B for photostability, Q6A for specifications) when discussing container closure system attributes.",
			"If more than one container closure system is used for the drug product, information may be presented either as a combined document or separately per system or per other distinguishing information, as per Note 9 guidance.",
			"Include validated non-compendial analytical methods used for container closure system testing, where applicable.",
			"Ensure cross-referencing between 3.2.S.6 and related sections (3.2.P.2.4 and 3.2.P.7) is accurate and consistent to maintain traceability of container closure system information across the CTD.",
		],
	},
	{
		number: "3.2.S.7",
		title: "Stability",
		input: [
			"Collect information on analytical procedures that are used only for stability studies for inclusion in 3.2.S.7.3.",
			"Obtain detailed statistical analysis reports of stability data, including raw datasets and summary tables.",
			"Gather detailed records of historical analytical procedures used to generate stability data for inclusion in 3.2.S.7.3.",
			"Obtain the finalized post-approval stability protocol and written stability commitment statements as required for 3.2.S.7.2.",
			"Collect data defining the established conditions for the drug substance, specifically storage conditions and shelf-life (or retest period for chemicals), as required for 3.2.S.7.1.",
			"Gather data from supporting stability studies that provide additional evidence for stability conclusions.",
			"Ensure access to ICH Q1A, Q1B, Q2A, Q2B, and Q5C guidelines for reference during preparation of the stability section.",
			"Collect information on analytical procedures unique to the stability program for inclusion in 3.2.S.7.3.",
			"Obtain reference standards and materials used in stability testing, ensuring traceability to 3.2.S.5 Reference Standards.",
			"Collect all stability study results in tabular, graphical, or narrative form for inclusion in 3.2.S.7.3.",
			"Ensure availability of the stability protocol and any amendments or deviations recorded during the study.",
			"Collect stress study data for inclusion in 3.2.S.7.3, ensuring they can be cross-referenced for analytical procedure validation as appropriate.",
			"Gather literature references or prior data supporting the stability profile of the active substance.",
			"Compile information on analytical procedures used during stability testing, including any historical or modified methods used over the course of the studies.",
			"Ensure access to ICH Q1A, Q1B, Q2A, Q2B, Q5C, and Q12 guidelines for reference during preparation of the stability section.",
			"Collect results and reports from forced degradation studies and stress condition studies for inclusion in 3.2.S.7.1 and 3.2.S.7.3.",
			"Collect complete stability datasets for each manufacturer for inclusion in 3.2.S.7.3.",
			"Collect expert opinions or justifications supporting the stability study design, including rationale for test conditions and duration.",
			"Obtain post-approval stability protocol and stability commitment documents for each manufacturer for inclusion in 3.2.S.7.2.",
			"Gather supportive information required for 3.2.S.7.2 (Post-approval stability protocol and stability commitments) and 3.2.S.7.3 (Stability data) as indicated in ICH Q12.",
			"Ensure that any established conditions related to stability (e.g., storage temperature, humidity, duration) are documented and justified for inclusion in 3.2.S.7.1.",
			"Collect validation data for analytical procedures used in the stability program, especially if stress study data are referenced for validation.",
			"Gather validated analytical procedure documentation and corresponding validation reports referenced in 3.2.S.7.3, consistent with ICH Q2A and Q2B.",
			"Collect all stability study reports for the drug substance, including long-term, accelerated, and stress studies.",
			"Gather any regulatory correspondence or prior approvals related to stability protocols or shelf-life determinations.",
			"Assemble information on storage conditions, testing intervals, and container closure systems used in stability studies.",
			"Prepare stability summary and conclusion documents specific to each manufacturer for inclusion in 3.2.S.7.1.",
		],
		output: [
			"Include all stability data for the drug substance in section 3.2.S.7, organized by study type (e.g., long-term, accelerated, stress).",
			"Present information on analytical procedures unique to the stability program within 3.2.S.7.3.",
			"Verify that the structure of 3.2.S.7 follows CTD format conventions, including subsections for Stability Summary and Conclusion, Post-approval Stability Protocol, and Stability Data.",
			"If included, clearly present data from supporting studies in 3.2.S.7.3, ensuring they are identified as supportive and appropriately integrated.",
			"Include information on historical analytical procedures used to generate stability data within 3.2.S.7.3.",
			"Summarize the types of studies conducted, protocols used, and results in 3.2.S.7.1, including forced degradation and stress condition results, and provide conclusions on storage conditions and retest date or shelf-life.",
			"Incorporate data from supporting studies in 3.2.S.7 if they contribute to the overall stability assessment.",
			"Ensure compliance with CTD guidance that lower-level headings under section 3.2.S.7 are not expected to contain separate individual documents or files.",
			"Explicitly state the established conditions for the drug substance in 3.2.S.7.1, including storage conditions and shelf-life (or retest period for chemicals), as per ICH Q12.",
			"Verify that the stability summary and conclusions section (3.2.S.7.1) provides a concise yet comprehensive overview of study types, protocols, results, and conclusions.",
			"Ensure that the post-approval stability protocol and stability commitment are clearly presented in 3.2.S.7.2, consistent with ICH Q1A and Q5C.",
			"Organize stability information either in its entirety or separated per manufacturer, per stability study protocol, or using any other distinguishing criteria when compiling section 3.2.S.7, in accordance with regulatory guidance.",
			"Maintain consistent terminology and units across all stability data tables and narratives.",
			"Provide details of analytical procedures unique to the stability program directly in 3.2.S.7.",
			"Include information on any changes in analytical procedures used during stability testing within 3.2.S.7.",
			"Present stress study data within 3.2.S.7, and cross-reference them to analytical validation sections as appropriate.",
			"Ensure that stress studies are located in 3.2.S.7.3 and are clearly identified as such.",
			"Cross-reference related sections (e.g., 3.2.S.4 Control of Drug Substance, 3.2.S.5 Reference Standards) where applicable.",
			"Ensure that analytical procedures used only for stability studies are included in 3.2.S.7.3, as per regulatory guidance.",
			"Ensure that the stability data presentation format (tabular, graphical, or narrative) is appropriate for the data type and facilitates regulatory review.",
			"Include the detailed statistical analysis report of stability data in 3.2.S.7, ensuring that summaries or conclusions are appropriately referenced in the summary section (3.2.S.7.1).",
			"Allow stability information to be organized per container closure system, manufacturer, strength, stability study protocol, or other distinguishing criteria, as permitted by Note 10.",
			"Identify and clearly distinguish supportive information in 3.2.S.7.2 and 3.2.S.7.3, ensuring alignment with ICH Q12 expectations for post-approval stability protocols and stability data.",
			"Check that the presentation of data complies with regulatory expectations for clarity, completeness, and traceability.",
			"Ensure that forced degradation and stress condition results are summarized in 3.2.S.7.1 and detailed in 3.2.S.7.3, maintaining consistency between summary and data sections.",
			"Clearly separate and label subsections 3.2.S.7.1, 3.2.S.7.2, and 3.2.S.7.3 by manufacturer name as indicated in the CTD structure.",
			"Ensure that the stability section reflects the established conditions framework, linking stability data and conclusions to the defined storage conditions and shelf-life parameters.",
			"Include information on analytical procedures used to generate stability data and their validation within 3.2.S.7.3, referencing ICH Q2A and Q2B.",
			"Follow ICH Q1A, Q1B, Q2A, Q2B, and Q5C guidance when compiling and presenting stability data and conclusions.",
			"Ensure that all data are clearly labeled with study identifiers, conditions, and time points for traceability.",
			"Present stability data in 3.2.S.7.3 in an appropriate format such as tabular, graphical, or narrative, ensuring clarity and consistency.",
			"Ensure that all tables, figures, and appendices are properly numbered and referenced within the text.",
		],
	},
	{
		number: "3.2.P.1",
		title: "Description and Composition of the FPP",
		input: [
			"Refer to Appendix A for additional guidance or templates relevant to section 3.2.P.1.",
			"Collect specifications and identification details for each excipient, including grade, function, and regulatory status.",
			"If the FPP has more than one container closure system, gather composition and description information for each system separately.",
			"Gather microbiological data relevant to the dosage form, including rationale for microbial limits testing (or omission), preservative system selection and effectiveness, and container closure integrity for sterile products.",
			"Obtain reference to pharmacopeial standards or in-house specifications for each component.",
			"Obtain batch formula information, including target batch size and manufacturing scale.",
			"Collect justification and supporting data for the choice and concentration of excipients, including their influence on drug product performance.",
			"Reference ICH Guidelines Q6A and Q6B for applicable quality and specification standards relevant to the description and composition of the FPP.",
			"If the drug substance is already approved, obtain and review relevant health authority guidance or approval documentation to ensure alignment with existing authorizations.",
			"Obtain the finalized formulation details of the finished pharmaceutical product (FPP), including qualitative and quantitative composition of all active ingredients and excipients.",
			"Gather data and study reports from pharmaceutical development studies that establish the appropriateness of the dosage form, formulation, manufacturing process, container closure system, microbiological attributes, and usage instructions.",
			"Collect information and data supporting the selection and optimization of the manufacturing process, including identification of critical process parameters and justification for sterilization methods, if applicable.",
			"Collect data and justification for the suitability of the container closure system, including material compatibility, protection from moisture and light, leachables/sorption data, and performance characteristics such as dose delivery reproducibility.",
			"For FPPs with multiple container types (e.g., PVC blister and PE bottle), gather complete composition and description information applicable to all containers, and identify any container-specific differences for inclusion in the section.",
			"For combination products, gather compatibility data between drug substances.",
			"Collect data on compatibility studies between the drug substance and excipients listed in 3.2.P.1, including physicochemical characteristics such as water content, solubility, particle size distribution, and polymorphic form.",
			"Collect certificates of analysis or batch data for excipients, if required to support the description and composition section or cross-referenced justification in other sections.",
			"Gather information on overages (if any) and justification for their use.",
			"Collect details of the container closure system(s) used for the FPP, including materials of construction and configurations.",
			"Obtain information on any colorants, flavors, or other additives, including regulatory compliance status.",
			"Gather data on physicochemical and biological properties relevant to product performance, such as pH, ionic strength, dissolution, redispersion, reconstitution, particle size distribution, aggregation, polymorphism, rheological properties, biological activity, or potency.",
			"Gather data comparing manufacturing processes used for pivotal clinical batches and the proposed commercial process, highlighting any differences that may affect product performance.",
			"Gather literature references or expert opinions supporting the choice of excipients and formulation design.",
			"Collect any relevant certificates of analysis for components, if required for description and composition.",
			"Gather comparative in vitro (e.g., dissolution) and in vivo (e.g., bioequivalence) study results comparing clinical and proposed commercial formulations, if applicable.",
			"Collect data and justification for any formulation overages described in 3.2.P.1.",
			"For drug products supplied with reconstitution diluent(s), gather full composition and description information for each diluent as a separate drug product, including all associated data and documentation.",
			"Gather specifications and identification details for each active pharmaceutical ingredient (API) used in the FPP.",
			"Collect any relevant regulatory correspondence or prior approvals related to formulation or composition changes.",
		],
		output: [
			"For products with more than one container closure system, organize the description and composition information either in its entirety or separately per system, ensuring clarity and traceability.",
			"Use consistent terminology and nomenclature in line with pharmacopeial and regulatory standards.",
			"Confirm compliance with CTD-Q guidance that lower-level headings in section 3.2.P.1 are not expected to contain individual documents or files, and ensure the structure reflects this requirement.",
			"If certificates of analysis or batch data for excipients are referenced in 3.2.P.1, ensure they are either included in the section or appropriately cross-referenced to their location in other sections (e.g., 3.2.P.4.4) to avoid duplication and maintain traceability.",
			"Verify that all data referenced from development studies (e.g., compatibility, physicochemical properties, container closure suitability) are traceable to the corresponding sections of the dossier and consistent with the composition data in 3.2.P.1.",
			"Present the description and composition of the FPP in a clear, structured format consistent with CTD section 3.2.P.1 requirements.",
			"Ensure that any comparative data (e.g., clinical vs. commercial formulations) discussed in 3.2.P.2 are reflected accurately in the composition details of 3.2.P.1.",
			"Ensure that the table or list format used is easy to read, with clear headings for component name, function, and quantity.",
			"Cross-reference ICH Guidelines Q6A and Q6B to ensure terminology, specification standards, and quality attributes are consistent with international expectations.",
			"For FPPs with multiple container types (e.g., PVC blister and PE bottle), present a single 3.2.P.1 section covering all containers, with subsections clearly divided and identified by container type to ensure clarity and traceability.",
			"Cross-reference Appendix A and any applicable health authority guidance to confirm correct structure and content presentation for 3.2.P.1.",
			"Ensure that the description and composition information in 3.2.P.1 aligns with the data and discussions presented in 3.2.P.2 (Pharmaceutical Development), particularly regarding formulation development, excipient choice, and overages.",
			"If overages are included, clearly indicate them and provide justification in the appropriate section, cross-referenced from 3.2.P.1.",
			"List all components of the FPP by their proper name, quantity per unit dose, and function in the formulation.",
			"Include a clear description of the dosage form and its physical characteristics (e.g., color, shape, imprint).",
			"Identify each component as active ingredient or excipient, and state its quality standard (e.g., pharmacopeial reference or in-house specification).",
			"Maintain internal consistency between the overage justification in 3.2.P.2.2.2 and the quantitative composition table in 3.2.P.1.",
			"Ensure consistency of component names and quantities with other sections of the dossier (e.g., manufacturing process, control of excipients).",
			"Ensure that the container closure system description in 3.2.P.1 is consistent with the suitability discussion in 3.2.P.2.4, including materials, configuration, and performance attributes.",
			"When the FPP includes a reconstitution diluent, present the 'P' information for the diluent as a separate, complete drug product section, ensuring full traceability and compliance with CTD structure.",
			"Specify quantities using standard units of measure and indicate whether amounts are expressed as base or salt forms.",
			"Verify that all information provided complies with applicable regional guidance and CTD formatting rules.",
			"Confirm that the justification for excipient selection and concentration in 3.2.P.2.1.2 is consistent with the excipient listing and functions described in 3.2.P.1.",
			"Ensure that the level of detail provided under 3.2.P.1 aligns with CTD-Q expectations, recognizing that lower-level headings may not require separate documents or files.",
		],
	},
	{
		number: "3.2.P.2.1",
		title: "Components of the FPP",
		input: [
			"Obtain regulatory guidance or documentation applicable to an already approved drug substance when included as a component of the FPP (refer to health authority guidance).",
			"If the drug product is supplied with reconstitution diluent(s), gather full component information for each diluent, as each diluent must be treated as a separate drug product for 'P' information (refer to Note 6).",
			"Gather certificates of analysis or batch data for excipients to support justification of specifications in 3.2.P.4.4.",
			"Gather supportive information on batch analyses relevant to FPP components.",
			"Gather supportive information on process validation and/or evaluation relevant to FPP components.",
			"Gather information on analytical procedures relevant to FPP component control, including identification of established conditions for analytical procedures.",
			"If the drug product is supplied with reconstitution diluent(s), gather full component information for each diluent, as each diluent must be treated as a separate drug product for \b‘P\b’ information (refer to Note 6).",
			"Gather supportive information on characterisation of FPP components, including elucidation of structure, other characteristics, and impurities where applicable.",
			"Gather supportive information on validation of analytical procedures relevant to FPP components.",
			"Gather supportive information on manufacturing process development relevant to FPP components.",
			"Gather any previous regulatory correspondence or approvals related to the components of the FPP.",
			"If multiple container closure systems are used, gather component information per system or per distinguishing feature as applicable (refer to Appendix E).",
			"For biotechnological/biological product components, obtain generation and control records for Master and Working Cell Banks or Master and Working Seed Lots.",
			"For components of biological origin, gather source material documentation (e.g., cell and seed source, raw materials) and control measures for critical materials.",
			"If the FPP includes multiple components (e.g., combination products or multi-component vaccines), gather component-specific documentation per component (refer to Appendix F).",
			"Collect a complete list of all components of the finished pharmaceutical product (FPP), including active pharmaceutical ingredients (APIs) and excipients.",
			"Collect information on the grade, function, and manufacturer of each component.",
			"Obtain regulatory documentation for each excipient, including compendial references or justification for non-compendial excipients.",
			"If the drug product is supplied with reconstitution diluent(s), gather full component information for each diluent, as each diluent must be treated as a separate drug product for \b\u0018P\b\u0019 information (refer to Note 6).",
			"Collect reference standards or comparator product information if used in formulation development or testing.",
			"Collect any available data summaries for excipients that can be cross-referenced to detailed information in other sections to support justification of specifications.",
			"Ensure availability of supporting analytical data and test results for each component to confirm identity, purity, and quality.",
			"If multiple facilities are involved in component manufacture or testing, collect documentation per facility (refer to Appendix F).",
			"Collect specifications for critical steps and intermediates related to FPP components, including test methods, analytical procedure elements, acceptance criteria, and storage conditions where applicable.",
			"If the drug product is supplied with reconstitution diluent(s), gather full component information for each diluent, as each diluent must be treated as a separate drug product for \u0018P\u0019 information (refer to Note 6).",
			"Obtain any relevant technical data packages, including formulation composition tables and batch formulae.",
			"Gather specifications, certificates of analysis, and quality data for each component used in the FPP.",
			"If multiple excipients are used, collect documentation per excipient (refer to Note 13).",
			"If the drug product is supplied with reconstitution diluent(s), gather full component information for each diluent, as each diluent must be treated as a separate drug product for ‘P’ information (refer to Note 6).",
			"Obtain drug substance specifications for each quality attribute relevant to FPP components, including test methods and acceptance criteria.",
		],
		output: [
			"Ensure that each excipient is clearly identified and documented separately when more than one excipient is used (refer to Note 13).",
			"When including stability-related component information, present it either in its entirety or organized per manufacturer, stability study protocol, or other distinguishing information, ensuring alignment with Appendix C (refer to Note 5).",
			"Ensure that no information intended for drug substance sections (3.2.S) is incorrectly included in 3.2.P.2.1; maintain clear separation between FPP component information and drug substance data.",
			"Avoid combining all P.2 subsections into a single document for Quality by Design or large molecule applications, as a single 3.2.P.2 document is not recommended.",
			"If multiple container closure systems exist, organize the information either in its entirety or per system, ensuring clarity and traceability (refer to Appendix E).",
			"Recognize that lower-level headings within CTD-Q at this point are unlikely to contain individual documents or files (refer to Note 4), and structure documentation accordingly.",
			"When justifying specifications for excipients, it is acceptable to provide a summary of data from other sections with a cross-reference to the detailed information rather than repeating the data in full.",
			"For components of biological origin, clearly describe the source materials and control measures, ensuring alignment with ICH Q12 established conditions requirements.",
			"When specifications for critical steps and intermediates are relevant to FPP components, present them with associated test methods, analytical procedure elements, acceptance criteria, and storage conditions in a clear, tabulated or structured format.",
			"Verify that all information is complete, accurate, and consistent with data provided in other CTD sections (e.g., 3.2.S for API information).",
			"Ensure clarity and logical organization of component information to facilitate regulatory review.",
			"Confirm that references to drug substance information (e.g., alternative forms, manufacturing process, control of materials, process validation) are correctly cross-referenced to the appropriate 3.2.S subsections (e.g., 3.2.S.3.1, 3.2.S.2.2, 3.2.S.2.3, 3.2.S.2.4, 3.2.S.2.5) to maintain consistency and traceability.",
			"Follow the structure defined for 3.2.P.2 subsections (P.2.1 to P.2.6) and ensure correct placement within the CTD hierarchy.",
			"When applicable to biotechnological/biological products, include detailed description of generation and control of Master and Working Cell Banks or Seed Lots in the component information.",
			"Maintain compliance with eCTD structure requirements; one file per reference should be used where applicable.",
			"Prepare the 3.2.P.2.1 section as part of the overall 3.2.P.2 Pharmaceutical Development documentation.",
			"If the drug product is supplied with reconstitution diluent(s), present the component information for each diluent as a separate drug product in its entirety within the CTD structure (refer to Note 6).",
			"If multiple facilities or components are involved, structure the documentation per facility or per component as appropriate (refer to Appendix F).",
			"Use consistent terminology and naming conventions for all components throughout the section.",
			"Ensure that any analytical procedure information relevant to FPP components is clearly linked to established conditions and identified as such in the documentation.",
			"Ensure that the section is formatted according to CTD/eCTD specifications, including correct section numbering and file naming conventions.",
			"Ensure cross-referencing to related sections (e.g., 3.2.P.4 for excipient control, 3.2.P.3 for manufacturing) is accurate and consistent.",
		],
	},
	{
		number: "3.2.P.2.2",
		title: "Finished Pharmaceutical Product",
		input: [
			"If the drug substance used in the FPP is already approved, obtain relevant health authority guidance or documentation confirming its approval status",
			"If applicable, stability study protocols per manufacturer or per distinguishing study design, when stability data are organized in this manner",
			"Documentation of any overages in the formulation and justification data for their inclusion",
			"Analytical procedures for testing excipients, where appropriate",
			"For novel excipients, full details of manufacture, characterisation, and controls, with cross-references to supporting safety data (nonclinical and/or clinical) per drug substance format (cross-reference to 3.2.A.3)",
			"If the FPP is supplied with a reconstitution diluent, complete pharmaceutical development information for the diluent as a separate drug product",
			"Comparative data (e.g., dissolution profiles) for different formulations or manufacturing processes, if applicable",
			"Justification for proposed drug product specifications",
			"Data from compatibility studies of reconstitution diluents to support label claims",
			"Justification for proposed excipient specifications, where appropriate",
			"Analytical validation data, including experimental results, for drug product testing methods",
			"Data from compatibility studies with co-administered drugs",
			"Information on the selection of manufacturing site(s) and equipment used during development",
			"Documentation and results of process validation and/or evaluation studies for critical manufacturing steps or assays (e.g., sterilisation, aseptic processing, filling)",
			"Specifications for each excipient used in the FPP",
			"Container closure system data including material specifications, compatibility, protection from moisture and light, sorption/leaching studies, and performance testing (e.g., dose delivery reproducibility)",
			"Physicochemical and biological property data relevant to product performance (e.g., pH, ionic strength, dissolution, redispersion, reconstitution, particle size distribution, aggregation, polymorphism, rheological properties, biological activity, potency, immunological activity)",
			"Manufacturing process development reports, including scale-up and process optimization studies",
			"Data from container closure system selection and compatibility studies relevant to the FPP",
			"Regulatory correspondence or prior approvals relevant to the FPP formulation or manufacturing process",
			"Description of batches and results of batch analyses for the drug product",
			"Analytical validation data, including experimental results, for excipient testing methods, where appropriate",
			"Reference to relevant pharmacopeial standards or literature supporting formulation and process choices",
			"Stability study data supporting the choice of formulation and packaging for the FPP",
			"Data from pharmaceutical development studies demonstrating suitability of the formulation for its intended use",
			"Specifications for the drug product",
			"For excipients of human or animal origin, information on adventitious agents, including sources, specifications, testing performed, and viral safety data (cross-reference to 3.2.A.2)",
			"Information on the quality and control of intermediates isolated during the manufacturing process, including test results and specifications",
			"Reports on any pilot or pivotal batches manufactured during development, including batch records and in\u0011process control data",
			"Information on differences between clinical and commercial manufacturing processes that could influence product performance",
			"Comparative in vitro study data (e.g., dissolution) and comparative in vivo study data (e.g., bioequivalence) supporting formulation development",
			"Results from studies on critical quality attributes (CQAs) of the FPP and how they are controlled",
			"Detailed description of the finished pharmaceutical product (FPP) manufacturing process, including formulation development history and rationale for formulation components",
			"Reference to Appendix A for guidance on content organization and cross-referencing requirements",
			"Information on incompatible diluents and supporting data",
			"Analytical procedures for testing the drug product",
			"Data and rationale supporting the selection and optimization of the manufacturing process, including sterilization method justification where applicable",
			"Manufacturing process development reports, including scale\u0011up and process optimization studies",
			"Viral safety evaluation data, if applicable, for relevant manufacturing steps (cross-reference to 3.2.A.2)",
			"Reports on any pilot or pivotal batches manufactured during development, including batch records and in‑process control data",
			"Technical documents describing the composition of the FPP, including qualitative and quantitative details of all ingredients",
			"Microbiological attribute data including preservative system effectiveness, microbial limits testing rationale, and container closure integrity data for sterile products",
			"Reports on any pilot or pivotal batches manufactured during development, including batch records and in-process control data",
			"Manufacturing process development reports, including scale‑up and process optimization studies",
			"Information on selection and compatibility of excipients with the active pharmaceutical ingredient (API) and with each other",
			"Information on characterisation of impurities in the drug product, if not already provided in 3.2.S.3.2",
		],
		output: [
			"Describe the evolution of the manufacturing process from laboratory scale to commercial scale, highlighting any changes and their justification",
			"Use consistent terminology for ingredients, processes, and quality attributes throughout the section",
			"Do not include individual documents or separate files under lower‑level headings of CTD‑Q such as 3.2.P.2.2, as these levels are not intended to contain standalone documents",
			"When preparing the P.2 content, use either the consolidated 3.2.P.2 level (roll‑up of P.2.1 to P.2.6) or individual 3.2.P.2.x subsections, in accordance with Note 7 guidance",
			"For control of drug product, structure content under subsections 3.2.P.5.1 to 3.2.P.5.6, ensuring inclusion of specifications, analytical methods, validation, batch analyses, impurity characterisation, and justification of specifications per ICH guidelines",
			"Include summaries of supporting data rather than raw data, with references to detailed reports in appendices or other CTD sections",
			"Ensure that all data presented are traceable to specific studies or reports, with appropriate cross\u0011references to other CTD sections where detailed data are located",
			"Explain and justify the selection and optimization of the manufacturing process, including sterilization method where relevant",
			"Address physicochemical and biological parameters relevant to product performance, such as pH, ionic strength, dissolution, redispersion, reconstitution, particle size distribution, aggregation, polymorphism, rheological properties, biological activity, potency, and immunological activity",
			"If the FPP includes a reconstitution diluent, ensure that the diluent’s full 'P' information is written as a separate drug product section in accordance with guidance",
			"Ensure that all data presented are traceable to specific studies or reports, with appropriate cross‑references to other CTD sections where detailed data are located",
			"Ensure compliance with ICH M4Q(R1) structure for section 3.2.P.2.2, including required subheadings such as Components of the Drug Product, Formulation Development, Manufacturing Process Development, Container Closure System, and Microbiological Attributes (if applicable)",
			"Verify that all claims and conclusions are supported by data presented in this section or cross\u0011referenced from other sections",
			"Cross-reference Appendix A for structural and content alignment of CTD-Q subsections",
			"If applicable, organize stability information either as a complete consolidated set or separated by manufacturer, stability protocol, or other distinguishing parameters, ensuring consistency with Appendix C guidance",
			"Include in 3.2.P.2.6 compatibility information with co-administered drugs",
			"Include in 3.2.P.2.6 information on incompatible diluents",
			"Discuss differences between manufacturing processes used for pivotal clinical batches and the commercial process described in 3.2.P.3.3 that could influence product performance",
			"Present the information in a clear, logical sequence describing the development of the finished pharmaceutical product",
			"For intermediates, provide a clear description of their quality attributes and control measures, referencing applicable ICH guidelines (Q2A, Q2B, Q6A, Q6B)",
			"Maintain a professional, scientific writing style suitable for regulatory submission, avoiding unnecessary repetition",
			"Ensure that all data presented are traceable to specific studies or reports, with appropriate cross-references to other CTD sections where detailed data are located",
			"For novel excipients, present manufacturing, characterisation, and control information in the drug substance format, with cross-references to safety data in 3.2.A.3",
			"Discuss results from comparative in vitro (e.g., dissolution) and in vivo (e.g., bioequivalence) studies when appropriate",
			"Follow Note 4 guidance that lower-level CTD-Q headings such as 3.2.P.2.2 should not contain individual documents or files, but rather integrated narrative content",
			"Do not include individual documents or separate files under lower-level headings of CTD-Q such as 3.2.P.2.2, as these levels are not intended to contain standalone documents",
			"Verify that all claims and conclusions are supported by data presented in this section or cross-referenced from other sections",
			"If the FPP includes a reconstitution diluent, ensure that the diluent\u0019s full \u0018P\u0019 information is written as a separate drug product section in accordance with guidance",
			"When presenting stability information, follow Note 5 guidance allowing organization either as a complete set or separated by manufacturer, stability protocol, or other distinguishing parameters, ensuring consistency with Appendix C",
			"For excipients of human or animal origin, clearly describe adventitious agent control measures and reference relevant viral safety data in 3.2.A.2",
			"For excipient control, structure content under subsections 3.2.P.4.1 to 3.2.P.4.6 as applicable, ensuring each includes required specifications, analytical methods, validation, and justifications per ICH guidelines",
			"When preparing the P.2 content, use either the consolidated 3.2.P.2 level (roll-up of P.2.1 to P.2.6) or individual 3.2.P.2.x subsections, in accordance with Note 7 guidance",
			"Include in 3.2.P.2.6 information on compatibility of reconstitution diluents that supports label claims",
			"When preparing the P.2 content, use either the consolidated 3.2.P.2 level (roll\u0011up of P.2.1 to P.2.6) or individual 3.2.P.2.x subsections, in accordance with Note 7 guidance",
			"Include rationale for formulation design, choice of excipients, and manufacturing process parameters",
			"When the FPP includes reconstitution diluent(s), follow Note 6 guidance to provide the full 'P' information for each diluent as a separate drug product section",
			"If comparative studies were conducted, present results in tabular or graphical form for clarity",
			"Discuss the suitability of the container closure system for storage, transport, and use, considering material choice, protection from moisture and light, compatibility, safety, and performance (e.g., dose delivery reproducibility)",
			"If the FPP includes a reconstitution diluent, ensure that the diluent’s full ‘P’ information is written as a separate drug product section in accordance with guidance",
			"Discuss microbiological attributes of the dosage form, including rationale for microbial limits testing, preservative system selection and effectiveness, and container closure integrity for sterile products",
			"If applicable, include a Control Strategy Summary at 3.2.P.2 as allowed by guidance",
			"Ensure alignment with ICH Q6A and Q6B guidelines when describing quality attributes and specifications",
			"If the FPP includes a reconstitution diluent, ensure that the diluent\u0019s full 'P' information is written as a separate drug product section in accordance with guidance",
			"Discuss differences between clinical formulations and the final formulation described in 3.2.P.1",
			"Justify any overages included in the formulation(s) described in 3.2.P.1",
			"Include a brief summary describing the development of the drug product, considering the proposed route of administration and usage",
			"For process validation/evaluation, describe the scope, methodology, and results for each critical step or assay, ensuring clarity and traceability to supporting data",
			"Clearly identify and describe critical formulation attributes and how they are controlled during manufacturing",
			"Do not include individual documents or separate files under lower\u0011level headings of CTD\u0011Q such as 3.2.P.2.2, as these levels are not intended to contain standalone documents",
			"Avoid preparing a single consolidated 3.2.P.2 document for Quality by Design (QbD) or large molecule applications, per Note 7 recommendation",
			"Verify that all claims and conclusions are supported by data presented in this section or cross‑referenced from other sections",
			"Provide justification for the selection of the container closure system in relation to the FPP stability and compatibility",
		],
	},
	{
		number: "3.2.P.2.3",
		title: "Manufacturing Process Development",
		input: [
			"Collect supporting information and data consistent with ICH Q3A for new chemical entities (NCEs).",
			"Obtain experimental data and acceptance criteria for tests performed at critical steps of the manufacturing process.",
			"Collect any regulatory correspondence or prior submissions related to manufacturing process development for consistency and traceability.",
			"Obtain data or studies identifying the influence of polymorphism on the drug substance and dosage form, as relevant to manufacturing process development.",
			"Gather narrative descriptions of the manufacturing process, including packaging operations, sequence of steps, and production scale.",
			"Obtain references to ICH Q6A decision tree evaluations for particle size influence, if applicable to process development.",
			"Gather data or analyses demonstrating the impact of any process differences on product performance.",
			"Gather results from studies identifying potential polymorphic forms of the drug substance, including total number of polymorphs and those intended for the active form, if relevant to process development.",
			"Collect proposals and supporting data for any reprocessing of materials, including justification.",
			"Gather data from scale-up and technology transfer studies, if applicable, to support process development.",
			"Gather information on alternative manufacturing processes or formulations considered during development and justification for the selected process.",
			"Collect documentation identifying established conditions (ECs) associated with the manufacturing process, including parameters and controls that are considered critical to product quality.",
			"Obtain supportive information linking manufacturing process development data to established conditions that may be subject to post-approval change management protocols.",
			"Gather references to drug substance data provided in section 3.2.S.4.4 to support discussion of process changes.",
			"Collect detailed equipment information, including type and working capacity, relevant to the manufacturing process.",
			"Collect validation and/or evaluation study reports for critical steps or assays in the manufacturing process, including sterilisation or aseptic processing validation where applicable.",
			"Collect documentation describing significant changes made to the manufacturing process and/or manufacturing site of the drug substance used in producing nonclinical, clinical, scale-up, pilot, and production scale batches, as applicable.",
			"Obtain detailed information on individual unit operations and their sequence in the manufacturing process, as part of established conditions per ICH Q12.",
			"Gather technical documents describing the manufacturing process flow, including process steps, equipment used, and process parameters.",
			"Collect detailed information on the development of the manufacturing process for the drug product, including rationale for process selection and optimization.",
			"Gather environmental condition requirements for specific process steps (e.g., low humidity for effervescent products).",
			"Obtain references to relevant sections of the CTD (e.g., 3.2.S.2.2, 3.2.S.2.4, 3.2.S.2.5) for cross-referencing of process control and validation data.",
			"Obtain data and reports from process development studies demonstrating how the manufacturing process was designed to ensure product quality, consistency, and reproducibility.",
			"Obtain information on control strategies developed during process development, including in-process controls and acceptance criteria.",
			"Collect any relevant validation or evaluation data that support the robustness of the manufacturing process.",
			"Collect data or studies identifying the influence of particle size on drug product performance (e.g., dissolution), as relevant to manufacturing process development.",
			"Obtain a detailed flow diagram of the manufacturing process showing process steps, material inputs, and points of process control, intermediate testing, and final product control.",
			"Gather information on the quality and control of intermediates isolated during the manufacturing process.",
			"Gather documentation and justification related to the selection and optimisation of the manufacturing process described in 3.2.P.3.3.",
			"Gather supportive information as defined under ICH Q12 for established conditions relevant to manufacturing process development.",
			"Obtain the developmental history of the manufacturing process for the drug substance, as described in 3.2.S.2.2.",
			"Collect information on critical process parameters (CPPs) and critical quality attributes (CQAs) identified during development.",
			"Obtain numeric ranges for process parameters (e.g., time, temperature, pH) for each step, with justification for ranges of critical steps to be provided in 3.2.P.3.4.",
			"Obtain records detailing differences between manufacturing processes used for pivotal clinical batches and the final commercial process described in 3.2.P.3.3.",
			"Collect development studies or technical data supporting the chosen sterilisation method, where applicable.",
		],
		output: [
			"Use consistent terminology aligned with ICH Q8 (R2) and CTD quality module conventions.",
			"Organize the content logically to show how process parameters and controls were established to ensure product quality.",
			"Discuss any differences between clinical batch manufacturing processes and the final proposed commercial process, specifically addressing their potential impact on product performance.",
			"Ensure that the section explicitly links development decisions to final process design described in 3.2.P.3.3.",
			"Provide information on the quality and control of intermediates isolated during the process.",
			"Confirm that supportive information provided in this section aligns with the overall control strategy and established conditions framework described in ICH Q12.",
			"Ensure that the developmental history of the manufacturing process for the drug substance is clearly described, consistent with 3.2.S.2.2.",
			"Explicitly list individual unit operations and their sequence in the manufacturing process as part of the established conditions, ensuring alignment with ICH Q12 guidance.",
			"Explain and justify the selection and optimisation of the manufacturing process, focusing particularly on critical aspects.",
			"Include a process flow diagram showing all process steps, material inputs, and points of control/testing.",
			"If relevant to manufacturing process development, discuss the influence of particle size on drug product performance (e.g., dissolution), referencing ICH Q6A decision tree evaluations where applicable.",
			"Ensure traceability between manufacturing process development data and the established conditions that will be maintained post-approval.",
			"Include description, documentation, and results of validation/evaluation studies for critical steps or assays, ensuring alignment with ICH Q6B and other relevant guidelines.",
			"If a Control Strategy Summary is included at 3.2.P.2, ensure consistent cross-referencing from 3.2.P.2.3 and avoid duplication.",
			"If relevant to manufacturing process development, discuss the influence of polymorphism on the drug substance and dosage form, ensuring cross-reference to supporting studies and specifications in other CTD sections.",
			"Ensure the section clearly describes the development history and rationale of the manufacturing process for the drug product.",
			"Clearly indicate which process parameters and controls are considered established conditions and provide supportive information accordingly.",
			"Maintain clarity and conciseness; avoid inclusion of raw data tables unless necessary to support conclusions.",
			"Reference the drug substance data provided in section 3.2.S.4.4 when discussing process changes.",
			"Describe any novel processes or technologies and packaging operations that directly affect product quality in greater detail.",
			"Present data and discussion in a structured format, typically including subsections for process selection, optimization, scale-up, and control strategy development.",
			"Ensure compliance with regional formatting and submission requirements for CTD Module 3 (e.g., electronic submission format, pagination, and section numbering).",
			"Identify equipment by type and working capacity where relevant.",
			"When compiling 3.2.P.2.3 as part of the overall P.2 section, follow Note 7 guidance by using the 3.2.P.2.x level structure rather than a single consolidated 3.2.P.2 document, especially for QbD or large-molecule applications.",
			"Clearly identify process parameters for each step, presenting numeric values as expected ranges, and ensure ranges for critical steps are justified in 3.2.P.3.4.",
			"Ensure proposals for reprocessing are justified and supported by referenced or filed data in this section.",
			"Include cross-references to related CTD sections (e.g., 3.2.P.3.3 for process controls, 3.2.P.3.5 for process validation) where applicable.",
			"Ensure that the section identifies and discusses established conditions (ECs) relevant to the manufacturing process, consistent with ICH Q12 principles.",
			"State any specific environmental conditions required for certain process steps.",
			"Provide a narrative description of the manufacturing process, including packaging, with sequence of steps and production scale.",
			"Include a description and discussion of significant changes made to the manufacturing process and/or manufacturing site of the drug substance used in producing nonclinical, clinical, scale-up, pilot, and production scale batches, as applicable.",
			"Verify that justification for any reprocessing or rework steps is clearly described and supported by data, if applicable.",
			"For critical steps, present tests and acceptance criteria with justification, including experimental data.",
			"Ensure alignment with ICH Q3A for NCEs and with ICH Q5B/Q5D for biotech products when describing process development history and changes.",
			"Ensure that the section explicitly links development decisions to the final process design described in 3.2.P.3.3.",
			"Ensure all critical process controls and validation data are appropriately referenced and not duplicated from other sections.",
			"Perform a compliance check to confirm that all process development information aligns with the final manufacturing process described in 3.2.P.3.",
			"If sterilisation is used, clearly justify the chosen method and describe its relevance to product quality.",
		],
	},
	{
		number: "3.2.P.2.4",
		title: "Container Closure System",
		input: [
			"Collect information on packaging components such as lidding materials, laminates, and secondary packaging if relevant to the closure system.",
			"Obtain previous regulatory correspondence or commitments related to the container closure system.",
			"Gather test reports and data demonstrating suitability of the container closure system for the drug product (e.g., compatibility, protection, safety, performance).",
			"Obtain cleaning study reports for metered dose inhalers, if applicable.",
			"Gather additional detailed information for functional secondary packaging components, including specifications and performance data.",
			"Obtain stability study data supporting the container closure system\u0019s ability to maintain product quality over shelf life.",
			"Collect data and discussion on suitability of the container closure system with respect to choice of materials, protection from moisture and light, compatibility with the drug substance (including sorption and leaching), and safety of materials of construction.",
			"Gather any relevant literature references or expert opinions on the suitability of the chosen container closure system.",
			"Collect any comparative data if multiple container closure systems are used for the same product.",
			"Collect manufacturer information for each container closure system, including facility names, addresses, and contact details.",
			"Collect any available data or studies on dose delivery reproducibility for container closure systems that include a delivery device component.",
			"Compile regulatory certificates or approvals for container closure materials (e.g., DMF references, compendial compliance certificates).",
			"Collect performance testing data for the container closure system (e.g., priming and re-priming studies for metered dose inhalers).",
			"Collect supportive information as required under ICH Q12 for section 3.2.P.2.4, including data and rationale demonstrating that the container closure system supports the pharmaceutical development of the drug product.",
			"Gather leachables study data, including any data confirmed during formal stability studies.",
			"Prepare brief descriptions for non-functional secondary packaging components.",
			"Obtain specifications for each primary packaging component, including description, identification, and critical dimensions (with drawings where appropriate).",
			"Collect validated non-compendial test methods used for container closure system components, where applicable.",
			"Gather drawings for critical dimensions of each primary packaging component where appropriate (to support specifications in 3.2.P.7).",
			"Gather complete technical descriptions of each container closure system used for the drug product (e.g., blister packs, HDPE bottles, vials, ampoules).",
			"Obtain specifications for each container closure component, including materials of construction, dimensions, and performance characteristics.",
			"Gather identity of materials of construction for each primary packaging component of the container closure system.",
			"Gather extractables study reports for each container closure system.",
			"Obtain stability study data supporting the container closure system’s ability to maintain product quality over shelf life.",
			"Gather data or documentation demonstrating the suitability of the container closure system for storage, transportation (shipping), and use conditions of the drug product.",
			"Collect light protection data for the container closure system (e.g., light transmission data).",
		],
		output: [
			"Ensure that the discussion covers all required aspects: choice of materials, protection from moisture and light, compatibility (including sorption and leaching), safety of materials, and performance (e.g., dose delivery reproducibility).",
			"When multiple documents are included under the section, use informative and descriptive document titles to differentiate them (e.g., 'Description - Blister', 'HDPE Bottle - 50 mL - Specification').",
			"Decide on the granularity of documentation for the container closure system \u0014 either all information in one document or split into multiple documents for each system type.",
			"Ensure that performance characteristics of the container closure system, such as priming/re-priming studies for metered dose inhalers, are included in 3.2.P.2.4.",
			"Verify that drawings for critical dimensions are included where appropriate within 3.2.P.7 to meet specification expectations.",
			"Include a clear discussion of the container closure system’s suitability for storage, transportation, and use, addressing each condition explicitly.",
			"In the description of the container closure system, include identity of materials of construction, specifications, and critical dimensions with drawings where appropriate.",
			"Ensure that the content of 3.2.P.2.4 aligns with the ICH Q12 framework by presenting supportive information that justifies the container closure system’s suitability within pharmaceutical development.",
			"Ensure that 3.2.P.7 sections can be repeated with different and unique 'container' keyword values corresponding to each container closure system.",
			"Clearly identify the information in 3.2.P.2.4 as 'supportive information' in alignment with ICH Q12, distinguishing it from established conditions or critical parameters.",
			"Include a clear discussion of the container closure system\u0019s suitability for storage, transportation, and use, addressing each condition explicitly.",
			"Provide a discussion on the light protection characteristics of the container closure system, supported by light transmission data, within 3.2.P.2.4, with cross-reference to photostability data in 3.2.P.8.3 as needed.",
			"Verify that all container closure system documents are placed under the correct CTD section (3.2.P.2.4) and are not duplicated unnecessarily in other sections.",
			"Ensure that the content of 3.2.P.2.4 aligns with the ICH Q12 framework by presenting supportive information that justifies the container closure system\u0019s suitability within pharmaceutical development.",
			"If multiple container closure systems are described, use unique 'container' keyword values to generate separate sections for each system.",
			"Provide only a brief description for non-functional secondary packaging components, but include detailed specifications and suitability data for functional secondary packaging components.",
			"When a drug product contains more than one container closure system, ensure that information may be provided in its entirety or separated per system or other distinguishing characteristics, in alignment with Note 9 and Appendix E.",
			"Include information on extractables and leachables directly within 3.2.P.2.4, and ensure appropriate cross-referencing to sections 3.2.P.5.1, 3.2.P.5.5, and 3.2.P.8.3 when warranted.",
			"Follow Appendix E guidance on granularity: all container closure system (CCS) information may be presented in one document or split into multiple documents depending on business needs.",
			"Decide on the granularity of documentation for the container closure system — either all information in one document or split into multiple documents for each system type.",
			"Discuss suitability of the container closure system in terms of material choice, protection from environmental factors, compatibility with the drug substance, and safety of materials, ensuring each aspect is addressed in the narrative.",
			"Ensure that the narrative distinguishes between suitability discussion (3.2.P.2.4) and specification details (3.2.P.7) to avoid redundancy.",
			"Assign priority numbers to documents when multiple are included under the section to control the order in which they appear.",
			"Ensure that 3.2.P.7 includes only descriptive and specification-related information and does not include suitability information, which must instead be placed in 3.2.P.2.",
			"Verify that the chosen granularity approach (single vs. multiple documents) avoids unnecessary splitting and maintains clarity and traceability.",
			"Ensure that document titles are descriptive and clearly identify the container closure system type and distinguishing characteristics.",
			"Ensure that each container closure system type (e.g., bottles vs. blisters) is clearly separated if provided as individual documents.",
			"Ensure that the structure and organization of documents allow clear identification of each container closure system and its associated data.",
			"Use of the 'container' keyword is optional; if used, each keyword value generates a separate section for that container closure system.",
			"Include additional descriptive information in document titles (e.g., packaging component details such as 'Al lidding', 'PVC laminate') to aid differentiation.",
			"Include descriptions and supporting data for cleaning procedures related to metered dose inhalers within 3.2.P.2.4.",
			"Cross-reference the description of the container closure system in 3.2.P.7 when discussing suitability in 3.2.P.2.4 to maintain consistency and traceability.",
			"Maintain consistent naming conventions and terminology across all container closure system documents.",
			"Follow ICH Q6A and Q6B guidance principles when discussing performance and quality attributes relevant to the container closure system.",
			"Apply priority numbers to container closure system documents to control their display order within the eCTD structure.",
			"For non-compendial methods included in the section, ensure validation data is provided and clearly linked to the relevant component specifications.",
			"Ensure compliance with ICH eCTD v4.0 document granularity and keyword usage guidance for container closure system information.",
		],
	},
	{
		number: "3.2.P.2.5",
		title: "Microbiological Attributes",
		input: [
			"Obtain relevant regulatory correspondence or previous submissions addressing microbiological quality requirements.",
			"Gather information on preservatives or antimicrobial agents included in the formulation and their effectiveness data.",
			"Gather any relevant microbiology data from in vitro and in vivo studies that support microbiological attributes of the product, ensuring alignment with efficacy-related data where applicable.",
			"Gather reference standards or comparator product data used for microbiological testing.",
			"Gather any supportive data or published literature that justify microbiological control strategies or preservative system selection as part of pharmaceutical development.",
			"Collect specifications and acceptance criteria for microbiological quality of the finished product.",
			"Gather validation reports for sterilization or aseptic processing methods used in manufacturing.",
			"Collect data on the selection and effectiveness of preservative systems in products containing antimicrobial preservatives.",
			"Gather justification and supporting data for not performing microbial limits testing for nonsterile products, if applicable.",
			"Reference and review ICH Guidelines Q6A and Q6B for guidance on specifications and quality standards relevant to microbiological attributes.",
			"Collect microbiological test results for the drug product, including bioburden, sterility, and endotoxin data as applicable.",
			"Obtain environmental monitoring data from manufacturing areas relevant to microbiological control.",
			"Collect information on container closure integrity testing relevant to microbiological protection.",
			"Reference and review ICH Guidelines Q2A, Q2B, and Q6B for analytical validation and quality standards relevant to microbiological testing.",
			"Collect literature references or expert opinions supporting microbiological control strategy and test methods.",
			"Obtain stability study data related to microbiological quality over the product shelf life.",
			"Obtain container closure system integrity data specifically addressing prevention of microbial contamination for sterile products.",
		],
		output: [
			"Applicants may modify the format of the section if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation by regulatory reviewers.",
			"Ensure consistency with ICH Q2A, Q2B, and Q6B guidelines when describing analytical validation and microbiological quality standards.",
			"If the drug product has more than one container closure system, microbiological attribute information may be presented in its entirety or organized per container closure system or other distinguishing factor, ensuring clarity and traceability.",
			"For sterile products, describe sterilization method, validation, aseptic process controls, and explicitly address container closure system integrity in relation to prevention of microbial contamination.",
			"Use consistent terminology aligned with pharmacopeial standards (e.g., USP, Ph. Eur., JP).",
			"Describe the microbiological attributes of the drug product, including rationale for microbiological specifications and controls.",
			"For products containing antimicrobial preservatives, describe the selection process and provide evidence of preservative system effectiveness.",
			"Ensure the section is clearly titled '3.2.P.2.5 Microbiological Attributes' and follows CTD-Q structure.",
			"Include a summary of microbiological test methods, acceptance criteria, and validation status.",
			"Ensure the discussion of microbiological attributes is concise and focused on the appropriateness of the dosage form for its intended use, consistent with the overall Pharmaceutical Development section.",
			"Verify compliance with regional microbiological quality guidelines and pharmacopeial requirements before submission.",
			"Cross-reference related sections such as 3.2.P.3.5 (Process Validation) and 3.2.P.5.1 (Specifications) where applicable.",
			"If the product is non-sterile, justify microbiological limits and describe control measures to prevent contamination.",
			"Organize information logically: start with product type (sterile/non-sterile), followed by microbiological specifications, test methods, validation, and control strategy.",
			"For sterile products, explicitly address container closure system integrity in relation to prevention of microbial contamination.",
			"Ensure consistency with ICH Q2A, Q2B, Q6A, and Q6B guidelines when describing analytical validation and microbiological quality standards.",
			"For nonsterile products, clearly present the rationale for not performing microbial limits testing, if applicable.",
			"For nonsterile products, clearly present the rationale for not performing microbial limits testing, if applicable, and justify microbiological limits and control measures to prevent contamination.",
			"Ensure data tables and results are clearly labeled and traceable to source reports.",
			"If the product is sterile, describe sterilization method, validation, and aseptic process controls.",
			"Reference ICH Guidelines Q6A and Q6B when defining microbiological specifications and acceptance criteria to ensure alignment with international standards.",
		],
	},
	{
		number: "3.2.P.2.6",
		title: "Compatibility",
		input: [
			"Gather any regulatory correspondence or prior approvals related to compatibility claims on the label.",
			"Consult the relevant health authority for guidance if the drug substance or product is already approved, to determine if additional compatibility data or justification is required.",
			"Gather data on compatibility of reconstitution diluents that support claims made on the product label.",
			"Collect relevant literature references or expert opinions supporting compatibility or incompatibility findings.",
			"Refer to Appendix A for any additional guidance or templates relevant to the preparation of section 3.2.P.2.6.",
			"Compile technical reports, analytical data, and test results demonstrating compatibility or incompatibility with specific diluents and co-administered drugs.",
			"Obtain information on incompatible diluents, including supporting data or references.",
			"Collect information on compatibility with co-administered drugs, including any relevant study reports or literature references.",
			"Retrieve results from any constitution or dilution studies performed outside of formal stability studies if they are relevant to compatibility claims (note: formal stability study data for constitution/dilution goes in 3.2.P.8.3, but may be referenced here).",
			"If the drug product is supplied with reconstitution diluent(s), gather compatibility information for each diluent separately, ensuring all required information per diluent is available as if it were a separate drug product.",
		],
		output: [
			"Ensure that all compatibility claims are supported by data and are consistent with the product labeling.",
			"Ensure compliance with Note 6: for a drug product supplied with reconstitution diluent(s), provide the 'P' information on the diluent(s) in its entirety as separate drug product(s), as appropriate, and cross-reference these appropriately within 3.2.P.2.6.",
			"Follow Note 4 guidance that the lower level of each heading in CTD-Q (including 3.2.P.2.6) is unlikely to contain individual documents or files; structure the section accordingly as a narrative or summary rather than as separate files.",
			"Cross-reference related sections (e.g., 3.2.P.8.3) where applicable to avoid duplication and maintain regulatory compliance.",
			"Follow Note 7 guidance that for P.2 content, the section may be prepared either as a roll-up of P.2.1 to P.2.6 or at the 3.2.P.2.x level; ensure that 3.2.P.2.6 is properly integrated within the chosen structure.",
			"Applicants may modify the format of section 3.2.P.2.6 if needed to provide the best possible presentation of the information and to facilitate the understanding and evaluation of the results.",
			"Include information on incompatible diluents in this section.",
			"Ensure that the section structure and file organization comply with the recommendation that a single 3.2.P.2 document is not used for Quality by Design or large molecule applications; maintain 3.2.P.2.6 as a distinct subsection within the modular structure.",
			"When providing cross-references within the section, include the section number in the cross-reference string and write accompanying text that makes the referenced section content clear without requiring inclusion of the full section name.",
			"Clearly identify and organize compatibility and incompatibility information by category (e.g., reconstitution diluents, co-administered drugs).",
			"If the drug product is supplied with reconstitution diluent(s), present compatibility information separately for each diluent to align with requirements that diluent-related P information be handled as separate drug products.",
			"Include in section 3.2.P.2.6 only the compatibility information for reconstitution diluents that supports label claims.",
			"If a Control Strategy Summary is included at 3.2.P.2, ensure that compatibility information in 3.2.P.2.6 aligns with and supports the overall control strategy presentation.",
			"When preparing amendments or variations in CTD format for section 3.2.P.2.6, follow the standard CTD structure and omit modules or sections that are not used, without inserting 'not applicable' pages for unused headings.",
			"Do not include data from constitution or dilution studies performed as part of formal stability studies in this section; instead, reference that such data is located in section 3.2.P.8.3 if applicable.",
			"Include compatibility information with co-administered drugs in this section.",
		],
	},
	{
		number: "3.2.P.3.1",
		title: "Manufacturer(s)",
		input: [
			"Table or list identifying established conditions (ECs) related to manufacturing sites, as applicable to section 3.2.P.3.1, to ensure alignment with ICH Q12 expectations.",
			"Documentation identifying the legal entity responsible for the final product release.",
			"For combination products, documentation describing the device assembly site(s) and their regulatory compliance status.",
			"Site master files or equivalent documentation describing facility capabilities and quality systems.",
			"Drug substance manufacturing site information, including testing facilities, when applicable to the drug product manufacturer(s) section for cross-reference consistency.",
			"Addresses and contact information for each manufacturing site.",
			"Details of the specific manufacturing roles and responsibilities of each site (e.g., bulk production, packaging, testing).",
			"Information on subcontractors or contract manufacturing organizations (CMOs) involved in any stage of drug product manufacture.",
			"Information describing the specific responsibilities of each manufacturer, including contractors, in the manufacturing and testing process.",
			"Regulatory approvals or licenses for each manufacturing site from relevant health authorities.",
			"Device manufacturer name(s) for any device component included in a combination product.",
			"Legally registered address(es) of each device manufacturer associated with the combination product.",
			"Manufacturing authorization or GMP certificates for each manufacturing site.",
			"Identification of multiple device manufacturers if more than one device is used in the finished product (repeatable as needed).",
			"If the drug substance used in the product is already approved, obtain relevant regulatory documentation or confirmation from the health authority to determine submission requirements for manufacturer information.",
			"List of all drug product manufacturing sites involved in production, testing, primary and secondary packaging, and device assembly (for combination products).",
			"Documentation identifying each proposed production site or facility involved in manufacturing and testing.",
			"Contracts or quality agreements between the applicant and each manufacturing site (if applicable).",
		],
		output: [
			"Include the name, address, and responsibility of each manufacturer, including contractors, in a clear and consistent format.",
			"Use consistent terminology for site functions (e.g., 'drug product manufacturing', 'testing', 'packaging', 'device assembly').",
			"Ensure that the section 3.2.P.3.1 content aligns with the established conditions (ECs) framework, identifying which manufacturing site information constitutes ECs versus supportive information.",
			"Ensure consistency between section 3.2.P.3.1 (Manufacturer(s)) and section 3.2.S.2.1 (Drug Substance Manufacturer(s)) for cross-referencing and traceability of manufacturing site information.",
			"Ensure that each proposed production site or facility involved in manufacturing and testing is explicitly identified and described.",
			"Verify that all listed sites correspond to valid GMP-certified facilities and that documentation supports their inclusion.",
			"When applicable, indicate whether manufacturing site information is considered an established condition (EC) or supportive information, consistent with ICH Q12 guidance.",
			"Include device manufacturer name and address information only when applicable to combination products involving a device component.",
			"Maintain clarity and traceability between manufacturing site information and subsequent sections describing manufacturing processes and controls.",
			"Organize information in a tabular or structured format consistent with CTD section 3.2.P.3.1 conventions.",
			"Verify that the information provided aligns with the manufacturing process description in section 3.2.P.3.3 and related sections.",
			"Confirm that the section is complete and up to date with current manufacturing arrangements before submission.",
			"Ensure that the manufacturer name corresponds to the organization responsible for creating the device as identified on the supplied product packaging.",
			"Cross-reference each manufacturing site with relevant sections of the dossier (e.g., process description, validation, control of materials).",
			"If the product includes a drug-device combination, ensure that the manufacturer information reflects the appropriate CTD location and regional expectations for device-related manufacturing information.",
			"Follow CTD section numbering and heading conventions (e.g., '3.2.P.3.1 Manufacturer(s) (name, dosage form)').",
			"Repeat manufacturer name/address entries as needed when multiple device manufacturers are involved.",
			"Ensure that each device manufacturer name and address entry follows a one-to-one structure (one name paired with one address).",
			"When more than one facility is involved, separate documents or entries may be provided per facility in accordance with Note 11, ensuring clarity and proper structuring.",
			"When more than one facility is involved, separate documents or entries may be provided per facility in accordance with applicable CTD guidance, ensuring clarity and proper structuring.",
			"Ensure compliance with ICH Q12 expectations for established conditions related to manufacturing sites.",
			"Present device manufacturer information under a clear heading consistent with CTD formatting conventions (e.g., 'Device Manufacturer Name and Address').",
			"If the drug substance is already approved, consult the relevant health authority guidance to determine whether and how manufacturer information should be presented in section 3.2.P.3.1.",
			"Ensure that each site is identified by full legal name, complete address, and specific manufacturing function.",
			"Clearly list all manufacturing sites involved in the drug product lifecycle, including those responsible for testing, primary and secondary packaging, and device assembly (if applicable).",
		],
	},
	{
		number: "3.2.P.3.2",
		title: "Batch Formula",
		input: [
			"Collect reference standards or pharmacopeial references for listed components where applicable.",
			"Refer to Appendix A for any additional guidance or templates relevant to the preparation of the batch formula section.",
			"Gather any relevant stability or manufacturing data that supports the inclusion of overages in the batch formula.",
			"Retrieve manufacturing records or master manufacturing formula documents that detail the standard batch size and composition.",
			"Consult the health authority for guidance if the drug substance used in the batch formula is already approved, to ensure alignment with existing regulatory expectations.",
			"If the drug product is supplied with reconstitution diluent(s), gather complete 'P' information for the diluent(s) as separate drug product(s), including full batch formula details.",
			"Obtain any regulatory correspondence or prior submissions that reference the batch formula for consistency verification.",
			"Obtain the complete quantitative batch formula for the drug product, listing all components including active pharmaceutical ingredients (APIs), excipients, and processing aids.",
			"If stability information is relevant to the batch formula presentation, gather stability data in its entirety or organized per manufacturer, stability study protocol, or other distinguishing criteria, as applicable, and refer to Appendix C for guidance.",
			"If the batch formula involves multiple container closure systems, collect information for each system separately or in its entirety, as applicable, and refer to Appendix E for guidance.",
			"Collect technical specifications and quality standards for each component in the batch formula.",
			"Gather information on any overages of active ingredients or excipients included in the manufacturing batch formula, along with justification for their inclusion.",
		],
		output: [
			"Confirm that the section does not include unnecessary sub-level documents or attachments, as lower-level CTD-Q headings (such as 3.2.P.3.2) are not expected to contain individual files.",
			"Ensure that overages are explicitly included and clearly identified in the batch formula table.",
			"Ensure that each component listed in the batch formula includes a reference to its applicable quality standard (e.g., pharmacopeial monograph or in-house specification).",
			"If the drug product includes more than one container closure system, ensure that the batch formula information is presented either in its entirety or per system or other distinguishing information, consistent with Appendix E guidance.",
			"If the product includes reconstitution diluent(s), clearly present the diluent(s) as separate drug product(s) with their own complete batch formula information in accordance with CTD structure.",
			"Verify that the total quantities and proportions match the intended batch size and formulation specifications.",
			"Use consistent terminology and nomenclature in accordance with pharmacopeial or regulatory standards.",
			"Clearly present the batch formula in a tabular format, listing each component by its proper name, quantity per batch, and unit of measure.",
			"Include a clear heading for the section '3.2.P.3.2 Batch Formula' and ensure proper pagination and formatting according to CTD structure.",
			"Ensure that the batch formula is presented as both qualitative and quantitative, in alignment with ICH Q12 expectations for established conditions.",
			"Present quantities in standard units (e.g., mg, g, kg, mL, L) and avoid ambiguous abbreviations.",
			"Cross-check the batch formula against other sections of the dossier (e.g., manufacturing process description) for consistency.",
			"Ensure that any references to appendices (e.g., Appendix A) or health authority guidance are properly cited and consistent with the dossier structure.",
			"Ensure that the batch formula reflects the actual quantities used in manufacturing, including any justified overages.",
			"If stability-related details are included in the batch formula section, ensure they are organized either in their entirety or per manufacturer/study protocol/other distinguishing criteria, and reference Appendix C as applicable.",
			"Organize the components in a logical sequence, typically starting with active ingredients followed by excipients.",
			"Verify that the batch formula fully meets the definition of an Established Condition (EC) and is described with the level of detail required to support regulatory control.",
		],
	},
	{
		number: "3.2.P.3.3",
		title: "Description of Manufacturing Process and Process Controls",
		input: [
			"Obtain CM-specific information for continuous manufacturing processes, including which portions of the manufacturing process are continuous.",
			"Collect criteria for product collection, including any strategy for diversion in continuous manufacturing.",
			"Obtain equipment lists identifying type (e.g., tumble blender, in-line homogeniser) and working capacity where relevant.",
			"Gather technical documents such as manufacturing protocols, standard operating procedures (SOPs), and process flow diagrams.",
			"Gather information on environmental conditions required for specific steps (e.g., low humidity for effervescent products).",
			"Obtain documentation on the generation and control of Master and Working Cell Banks or Seed Lots for biotechnological or biological products, if relevant to the manufacturing process description.",
			"Collect process validation or evaluation data relevant to the manufacturing process, if available, to support process control descriptions.",
			"Obtain analytical data or test results for in-process controls and intermediates, if applicable, to support process control descriptions.",
			"Obtain details on the location of active process controls, if used, in continuous manufacturing.",
			"Obtain the complete manufacturing process description for the drug product, including all unit operations, process steps, and flow diagrams.",
			"Gather a detailed flow diagram of the manufacturing process showing all steps, material inputs, and points where process controls, intermediate tests, or final product controls are conducted.",
			"Gather regulatory correspondence or prior approvals related to manufacturing process changes or process control updates.",
			"Gather integrated flow diagram(s) for continuous manufacturing processes, clearly indicating continuous and non-continuous steps.",
			"Obtain information on reprocessing steps, if applicable, including justification and associated process controls.",
			"Collect expert opinions or internal technical assessments on critical process parameters and control strategies.",
			"Obtain a statement regarding manipulation of ruminant-derived materials in the drug product manufacturing facility, including assessment of potential for cross-contamination with adventitious agents.",
			"Collect detailed information on inputs and outputs for each individual unit operation, including material attributes and process parameter ranges as part of established conditions (per ICH Q12).",
			"Gather information on location points where process controls or testing are conducted in continuous manufacturing.",
			"Collect numeric values or expected ranges for process parameters (e.g., time, temperature, pH) for each step, including justification for ranges of critical steps (to be cross-referenced to 3.2.P.3.4).",
			"Gather batch manufacturing records or master batch records that describe the sequence of operations and equipment used.",
			"Collect detailed process control information for each manufacturing step, including in-process controls, critical process parameters, and monitoring methods.",
			"Collect detailed descriptions and supporting data for any novel processes or technologies and packaging operations that directly affect product quality.",
			"Collect data on materials used in the manufacturing process (e.g., excipients, solvents, reagents) to ensure consistency with the control of materials section.",
			"Collect equipment design and system integration details when these are critical to output material quality in continuous manufacturing.",
			"Collect information on the quality and control of intermediates isolated during the manufacturing process, including analytical data and specifications, as referenced in ICH Q2A, Q2B, Q6A, and Q6B.",
			"Collect CM-related process parameters, controls, and criteria (e.g., input rates/mass flow rates, relevant feeder operating ranges).",
			"Collect information on any over-fill amounts used in the manufacturing process, including rationale and impact on product quality.",
			"Collect information on the source and control of critical materials of biological origin (e.g., cell and seed sources, raw materials) if applicable to the manufacturing process.",
			"Obtain supporting data or references for reprocessing proposals, including justification and any experimental or validation data.",
		],
		output: [
			"Include inputs and outputs associated with each unit operation (e.g., process parameters, material attributes) when describing the manufacturing process, consistent with established conditions expectations.",
			"Identify equipment by type and working capacity where relevant in the process description.",
			"Identify and describe all process controls within this section; ensure that critical controls are cross-referenced to section 3.2.P.3.4 (Control of Critical Steps and Intermediates) if applicable.",
			"Include justification for any reprocessing operations as part of the process description, ensuring consistency with validation information in section 3.2.P.3.5.",
			"Identify and describe the location points at which process controls or testing are conducted in continuous manufacturing.",
			"Include a statement regarding manipulation of ruminant-derived materials in the drug product manufacturing facility; if potential for cross-contamination with adventitious agents exists, cross-reference to sections 3.2.A.1 and 3.2.A.2.",
			"Describe equipment design and system integration aspects when these are critical to output material quality in continuous manufacturing.",
			"State process parameters for each step (e.g., time, temperature, pH) as expected ranges; ensure numeric ranges for critical steps are justified in section 3.2.P.3.4.",
			"Organize the section to include a narrative description supported by flow diagrams or schematics where appropriate.",
			"Present a flow diagram that clearly shows all process steps, material entry points, and locations of process controls, intermediate tests, and final product controls.",
			"Maintain clarity and traceability between described process steps and corresponding control measures.",
			"Use consistent terminology and technical language aligned with ICH CTD-Q standards for manufacturing process descriptions.",
			"Include information on the quality and control of intermediates isolated during the process as part of the manufacturing process description, ensuring alignment with ICH Q2A, Q2B, Q6A, and Q6B guidelines.",
			"For biotechnological or biological products, ensure that the description of the manufacturing process includes reference to the source and control of biological materials (e.g., cell banks, seed lots) as part of the established conditions framework.",
			"Provide a narrative description that includes packaging operations and scale of production, with greater detail for novel processes or technologies affecting product quality.",
			"For continuous manufacturing processes, clearly indicate in the narrative and flow diagram which portions of the manufacturing process are continuous.",
			"Include CM-related process parameters, controls, and criteria (e.g., input rates/mass flow rates, relevant feeder operating ranges) in the process description.",
			"Ensure cross-references to analytical procedures and acceptance criteria are correctly placed in the appropriate CTD sections.",
			"Verify that all process steps, controls, and reprocessing justifications are complete and consistent with related sections (e.g., 3.2.P.3.4 and 3.2.P.3.5).",
			"Ensure proposals for reprocessing are justified within this section and supported by referenced or filed data.",
			"Clearly describe the manufacturing process for the drug product in a logical, stepwise manner, including all major processing steps and controls.",
			"Ensure that all process controls are appropriately identified and described in this section, with critical controls highlighted and referenced to the appropriate section.",
			"For biotech products, reference section 3.2.A.1 for facility information if appropriate.",
			"Ensure the description explicitly includes individual unit operations and their sequence, as required by ICH Q12 established conditions.",
			"Include environmental conditions in the description where relevant to product quality (e.g., low humidity for effervescent products).",
			"Identify any over-fill in the manufacturing process description, including rationale and impact on product quality.",
			"Describe criteria for product collection, including any strategy for diversion, in continuous manufacturing.",
			"Identify the location of active process controls, if used, in continuous manufacturing.",
			"Confirm that the section complies with regional regulatory expectations for completeness and level of detail in process description and control documentation.",
		],
	},
	{
		number: "3.2.P.3.4",
		title: "Controls of Critical Steps and Intermediates",
		input: [
			"Obtain critical process control values from relevant manufacturing batches to support numeric ranges and limits for critical process controls.",
			"Collect detailed information for all critical steps and intermediates that are controlled, as identified in section 3.2.P.3.3.",
			"Compile technical documents describing the manufacturing process flow with identification of critical steps and intermediates.",
			"Gather relevant process development reports that identify and justify the designation of critical steps and intermediates.",
			"Gather experimental data supporting justification of tests and acceptance criteria used at critical steps, as required in 3.2.S.2.4.",
			"Gather specifications for each identified critical step in the manufacturing process, including defined tests, elements of analytical procedures, and acceptance criteria.",
			"Gather information on the quality attributes of intermediates isolated during the process, including test results and acceptance criteria, in accordance with ICH Q6A and Q6B.",
			"Collect specifications for each identified intermediate, including defined tests, elements of analytical procedures, and acceptance criteria.",
			"Collect control strategy documentation for intermediates, including descriptions of in-process controls, analytical methods, and validation data where applicable.",
			"Obtain expert opinions or risk assessments used to determine which steps and intermediates are critical.",
			"Obtain any regulatory correspondence or prior approvals related to changes in control of critical steps or intermediates.",
			"Obtain information from section 3.2.P.3.3 identifying all process controls, including those designated as critical, to ensure consistency and completeness in 3.2.P.3.4.",
			"Gather details of any reprocessing operations described in 3.2.P.3.3 that have associated critical controls requiring inclusion in 3.2.P.3.4.",
			"Collect biotech-specific stability data supporting storage conditions for intermediates, as required by ICH Q5C.",
			"Obtain data on storage conditions for each critical intermediate, including temperature, humidity, and duration limits.",
			"Collect batch records or in-process control data demonstrating compliance with specifications for critical steps and intermediates.",
			"Gather analytical procedure descriptions and validation information for any in-process material test performed in lieu of a finished product test.",
			"Gather analytical method descriptions and validation summaries relevant to testing of critical steps and intermediates.",
			"Gather batch data specifically generated for intermediates or critical steps that support their control strategy, including any release test data performed at these stages.",
			"Collect stability data for intermediates where applicable to support storage condition specifications.",
		],
		output: [
			"Cross-reference related sections (e.g., manufacturing process description, analytical procedures) where applicable.",
			"Identify and clearly denote established conditions related to specifications for critical steps and intermediates, including tests, analytical procedure elements, and acceptance criteria, in accordance with ICH Q12.",
			"Use footnotes in data tables to clarify applicability or relevance of specific batch data, particularly when analytical methods have changed or when certain data are not applicable to qualification.",
			"Include batch data for intermediates or critical steps within this section as required to demonstrate compliance with defined controls.",
			"Include detailed information for all controlled critical steps and intermediates, not just summaries.",
			"For any in-process material test performed in lieu of a finished product test, provide the same level of information as for a finished product test, including analytical procedure and validation details.",
			"Present specifications for each critical step and intermediate in a structured format, including test name, analytical procedure reference, and acceptance criteria.",
			"Ensure compliance with applicable regulatory definitions of 'critical step' and 'intermediate'.",
			"Ensure that only noteworthy or significant findings are tabulated or summarized, avoiding unnecessary data that do not contribute to understanding control of critical steps or intermediates.",
			"Include justification with supporting experimental data for tests and acceptance criteria applied at critical steps, as required in 3.2.S.2.4.",
			"Ensure that any critical controls associated with reprocessing operations described in 3.2.P.3.3 are fully detailed in 3.2.P.3.4, including control parameters and acceptance criteria.",
			"Include critical process control values from relevant batches to justify numeric ranges and limits for critical process controls.",
			"Include storage condition requirements for each critical intermediate where applicable.",
			"Ensure that information on the quality and control of intermediates is complete and aligns with ICH Q2A, Q2B, Q6A, and Q6B requirements.",
			"Verify that all specifications provided are consistent with those in other parts of the dossier (e.g., drug substance or product specifications).",
			"Follow recommended CTD table formats for clarity and consistency, but modify as needed to best present the data and facilitate regulatory review.",
			"Ensure terminology is consistent with ICH guidelines and internal quality documents.",
			"Cross-reference 3.2.P.3.3 for identification of all process controls and ensure that only critical controls are elaborated in 3.2.P.3.4.",
			"Clearly describe each critical step and intermediate in the manufacturing process, including the rationale for its designation as critical.",
			"For biotech products, include stability data supporting storage conditions of intermediates, in alignment with ICH Q5C.",
			"Use clear, concise, and unambiguous language to describe controls and specifications.",
			"Format tables of specifications in a consistent style, with columns for parameter, method, and acceptance criteria.",
			"Maintain all relevant section headings in the CTD even if certain studies or data are not applicable, and provide a brief justification or explanation for their omission rather than deleting the heading.",
			"Avoid attaching separate individual documents or files at lower-level CTD headings within 3.2.P.3.4, as these levels are generally not intended to contain standalone documents.",
			"If a process test replaces an end-product test, ensure it is referenced appropriately in section 3.2.P.5.1 and identified as a process test in accordance with ICH Q6A.",
			"Organize content in a logical sequence: identification of critical steps/intermediates → specifications → analytical methods → acceptance criteria → storage conditions.",
		],
	},
	{
		number: "3.2.P.3.5",
		title: "Process Validation and/or Evaluation",
		input: [
			"Obtain batch manufacturing records and data from validation batches, including in-process and finished product test results.",
			"Gather analytical test results and statistical analyses supporting process consistency and control.",
			"Collect data from scale-up or pilot-scale studies used to justify process parameters.",
			"Obtain details of any reprocessing operations performed during manufacturing that require validation, including associated critical controls and acceptance criteria.",
			"Collect any expert reports or technical justifications supporting the validation approach or evaluation methodology.",
			"Collect documentation and results of validation and/or evaluation studies for critical steps or critical assays used in the manufacturing process (e.g., sterilisation process, aseptic processing, or filling).",
			"Gather any prior regulatory correspondence or approvals related to process validation strategy or comparability protocols.",
			"Collect data from process performance qualification (PPQ) batches, including critical process parameters and acceptance criteria.",
			"Collect any supportive information identified as an Established Condition under ICH Q12 for section 3.2.P.3.5, including data or documentation that demonstrates control and reproducibility of the manufacturing process.",
			"Obtain information on any revalidation or continued process verification activities, if applicable.",
			"Gather process validation reports or evaluation reports demonstrating reproducibility and consistency of the manufacturing process.",
			"Obtain reference to critical steps and controls identified in section 3.2.P.3.4 to ensure alignment with validation data.",
			"Collect the process validation protocol(s) for the drug product manufacturing process.",
			"Gather stability data or ongoing process verification data if used as part of process evaluation.",
			"Gather supporting data and reports referenced under ICH Guideline Q6B relevant to process validation and evaluation.",
			"Obtain information on equipment qualification (IQ/OQ/PQ) relevant to the validated process.",
		],
		output: [
			"If multiple container closure systems or product variants are validated, organize validation data per system or per distinguishing feature, ensuring clarity and traceability.",
			"Ensure data tables and figures are clearly labeled, with units and batch identifiers.",
			"Describe acceptance criteria and demonstrate that all validation results meet predefined limits.",
			"If continuous process verification (CPV) is used instead of traditional validation, clearly describe the approach and justify its application within the context of 3.2.P.3.5.",
			"Explicitly identify and present any supportive information that constitutes an Established Condition under ICH Q12 for section 3.2.P.3.5, ensuring it is clearly distinguished from non-EC information.",
			"Clearly identify the number of batches validated, their scale, and manufacturing sites involved.",
			"Ensure that the section organization aligns with CTD modular structure and regional guidance for electronic submissions (e.g., one file per reference or per facility as applicable).",
			"Summarize validation results rather than reproducing full reports; detailed data should be available upon request or in appendices.",
			"Include description, documentation, and results of validation and/or evaluation studies specifically for critical steps or critical assays used in the manufacturing process.",
			"Maintain compliance with ICH Q8, Q9, and Q10 principles for process validation and lifecycle management.",
			"Include cross\u0011references to related sections such as 3.2.P.3.3 (Description of Manufacturing Process) and 3.2.P.3.4 (Controls of Critical Steps and Intermediates).",
			"When including cross-references in paper submissions, include only the section number in the cross string to reduce length, but write the surrounding text so the reader understands the section content.",
			"If multiple manufacturing facilities are involved in process validation, provide separate documentation or clearly identify data per facility, consistent with Appendix F guidance.",
			"Include cross-references to related sections such as 3.2.P.3.3 (Description of Manufacturing Process) and 3.2.P.3.4 (Controls of Critical Steps and Intermediates).",
			"Provide justification if full validation is not yet completed, including a plan for completion or ongoing process verification.",
			"Present validation data in a logical sequence: objective, protocol summary, methods, results, and conclusions.",
			"Ensure the section is clearly titled '3.2.P.3.5 Process Validation and/or Evaluation' and follows CTD-Q structure.",
			"If applicable, ensure that viral safety evaluation data are referenced in section 3.2.A.2 and not duplicated here.",
			"Include cross‑references to related sections such as 3.2.P.3.3 (Description of Manufacturing Process) and 3.2.P.3.4 (Controls of Critical Steps and Intermediates).",
			"If validation information is warranted for reprocessing operations described in 3.2.P.3.3, include the relevant validation data and clearly link it to the described process steps.",
			"Verify that all data presented are traceable to source documents and consistent with other CTD sections.",
			"Follow eCTD structural conventions for section numbering and file organization; ensure that 3.2.P.3.5 is a distinct file within the eCTD sequence and properly linked in the Table of Contents.",
			"Ensure the section provides supportive information required under ICH Q12 for established conditions relevant to process validation and/or evaluation.",
			"Ensure the section is clearly titled '3.2.P.3.5 Process Validation and/or Evaluation' and follows CTD\u0011Q structure.",
			"Use consistent terminology for process parameters, critical quality attributes (CQAs), and critical process parameters (CPPs).",
			"Ensure the section is clearly titled '3.2.P.3.5 Process Validation and/or Evaluation' and follows CTD‑Q structure.",
			"Ensure that any stability or ongoing process verification data referenced are organized consistently with Appendix C guidance (e.g., per container closure system, manufacturer, or strength).",
			"Ensure alignment with ICH Guideline Q6B for the presentation and evaluation of validation data.",
			"Ensure the writing is clear, concise, and technical, avoiding redundancy with other sections.",
			"Provide justification for the number of validation batches based on process complexity, process variability, and available process knowledge, consistent with ICH Q7 Section 12.5.",
		],
	},
	{
		number: "3.2.P.4.1",
		title: "Specifications",
		input: [
			"Gather excipient specifications for all excipients included in the drug product, ensuring they include quality attributes, test methods, and acceptance criteria.",
			"Obtain the complete specification(s) for the drug product as per section 3.2.P.4.1, including all acceptance criteria.",
			"If there are different specifications for the drug product from different manufacturers and/or the applicant, gather all versions of these specifications.",
			"Gather established conditions related to the drug product specifications as defined under ICH Q12, ensuring that any elements designated as 'established conditions' are identified and documented.",
			"Obtain the drug substance specification from section 3.2.S.4.1, including for each quality attribute the associated test method and acceptance criteria, to ensure alignment with the drug product specifications where applicable.",
			"Gather any collated data summaries from batch analyses that support the establishment or justification of specification limits for the drug product.",
			"Obtain reference standards and materials used in the analytical procedures listed in the specifications.",
			"Collect details of any alternative analytical procedures used to control the drug product, including method descriptions and associated acceptance criteria.",
			"Collect acceptance criteria for intermediates or critical steps that are referenced in section 3.2.S.4.1, to ensure consistency with the drug product specifications in 3.2.P.4.1.",
			"Gather analytical procedures for intermediates or critical steps that are referenced in section 3.2.S.4.2, to confirm alignment with the analytical methods used in the drug product specifications.",
			"If the drug substance is already approved, obtain relevant health authority guidance or documentation to determine if existing specifications can be referenced or adapted.",
			"Gather supporting technical documents such as analytical method SOPs, validation summaries (if applicable), and method transfer reports related to the listed specifications.",
			"For drug products supplied with reconstitution diluent(s), obtain the complete 'P' information (including specifications) for each diluent as if it were a separate drug product.",
			"Obtain applicable pharmacopoeial monographs for excipients where a monograph may serve as the reference standard for the specification.",
			"Collect batch analysis results from all relevant batches (e.g., clinical, nonclinical, stability) that were used to justify the acceptance criteria included in the drug product specifications.",
			"Obtain supportive information from related CTD sections (e.g., 3.2.P.2 Pharmaceutical Development) that justify or inform the selection of tests and acceptance criteria included in the specifications.",
			"Obtain results from tests not listed in the specification if they were used to support the selection or justification of acceptance criteria for inclusion in 3.2.P.4.1.",
			"Collect any regulatory correspondence or approvals that define or agree upon specific acceptance criteria for the drug product.",
			"Collect any reference material specifications (tests, analytical elements, and acceptance criteria) that are linked to the analytical procedures used in the drug product specifications.",
			"Compile all analytical procedures relevant to the drug product specifications, even if multiple methods exist for the same test.",
		],
		output: [
			"Confirm that supportive information from related CTD sections (e.g., 3.2.P.2) is appropriately referenced to justify the inclusion or limits of specific tests in the specification.",
			"Ensure that acceptance criteria referenced from other sections (e.g., 3.2.S.4.1 for intermediates or critical steps) are consistent and correctly cross-referenced in 3.2.P.4.1.",
			"Maintain consistency between the specification content and the established conditions list to facilitate lifecycle management and post-approval change control.",
			"For each quality attribute listed in the specification, explicitly present the associated test method and acceptance criteria in accordance with ICH Q12 established conditions requirements.",
			"When excipients are included in drug product specifications, apply the correct organizational level (3.2.P.4 or 3.2.P.4.x) according to excipient-specific guidance outlined in Appendix D.",
			"For excipient specifications included within 3.2.P.4.1, ensure each quality attribute is paired with its test method and acceptance criteria, or alternatively, provide a clear reference to the applicable pharmacopoeial monograph.",
			"Present specifications in a clear, tabulated format that aligns each test with its analytical procedure and acceptance criteria.",
			"Include all applicable specifications for the drug product in section 3.2.P.4.1 when more than one specification is appropriate.",
			"When preparing or updating 3.2.P.4.1 for amendments or variations, follow the standard CTD structure without creating a separate format.",
			"Ensure that the justification for acceptance criteria in 3.2.P.4.1 is supported by batch analysis data provided in 3.2.S.4.4, with appropriate cross-references included.",
			"If data from tests not listed in the specification were used to establish acceptance criteria, ensure these are properly referenced to 3.2.S.4 or 3.2.S.4.4 as supporting evidence.",
			"Ensure that any elements of the specification designated as 'established conditions' under ICH Q12 are clearly identified and described in accordance with regulatory expectations.",
			"Confirm that analytical procedures referenced from 3.2.S.4.2 are properly cited and harmonized with the analytical methods listed in the drug product specifications.",
			"Do not include unused CTD headings or 'not applicable' pages when updating the specification as part of an amendment or variation.",
			"If the drug product is supplied with reconstitution diluent(s), present the 'P' information for each diluent in its entirety as a separate drug product specification section, ensuring clear separation from the main drug product specifications.",
			"Verify that the specifications are complete, accurate, and consistent with other sections of the dossier (e.g., analytical procedures, validation data).",
			"Ensure that alternative analytical procedures are clearly identified in the specification and linked to their respective acceptance criteria.",
			"Ensure terminology and test names are consistent with pharmacopeial or regulatory standards where applicable.",
			"Ensure excipient-related content within the specification adheres to ICH Q12 requirements for established conditions where applicable.",
			"Cross-reference analytical procedures listed in the specification to their detailed descriptions in section 3.2.P.4.2.",
			"When summarizing data to justify specification limits, provide concise summaries in 3.2.P.4.1 with cross-references to detailed data in other CTD sections rather than duplicating information.",
			"List every analytical procedure used to control the drug product in the specification, along with the corresponding acceptance criteria.",
		],
	},
	{
		number: "3.2.P.4.2",
		title: "Analytical Procedures",
		input: [
			"Obtain method validation reports or summaries supporting the analytical procedures described in this section.",
			"Collect all analytical procedures used to control the drug product, including detailed method descriptions and associated acceptance criteria.",
			"Identify and collect any analytical procedures for control of materials (e.g., starting materials, reagents, raw materials, solvents) if these are relevant to the drug product analytical procedures and are cross-referenced from 3.2.S.2.3.",
			"Gather validated analytical methods specific to the drug product, even if similar methods exist for the drug substance.",
			"Collect documentation discussing the relationship between model performance criteria and attribute specification limits for multivariate models.",
			"If applicable, collect descriptions and validation information for analytical procedures that are part of a registered alternative control strategy to RTRT, ensuring alignment with validation information in the appropriate CTD section.",
			"Collect analytical procedures and corresponding validation information for any in-process material tests that are performed in lieu of finished product tests, ensuring these are consistent with the analytical procedures described for finished product testing.",
			"Obtain reference standards and information on reference materials used in the analytical procedures.",
			"Gather detailed descriptions of validation sets with independent samples for multivariate models used in drug product specifications, including RTRT approaches.",
			"Refer to Appendix A for any additional guidance or templates applicable to analytical procedures in 3.2.P.4.2.",
			"Collect any cross-references to analytical methods described in 3.2.S (drug substance) if the same or similar methods are used, ensuring both sections contain the relevant information.",
			"Obtain any historical analytical procedures that were used to generate data for the drug product batch analyses, if relevant for context or justification.",
			"Gather analytical procedures used for stability studies of the drug product, ensuring they are clearly identified as stability-specific methods.",
			"Collect analytical procedures used for release testing and in-process controls of the drug product.",
			"Collect validation information for analytical procedures used as reference analytical procedures, including model development, calibration, and validation data if applicable.",
			"Gather supporting technical documents such as analytical method SOPs, chromatographic conditions, instrument parameters, and sample preparation details.",
			"Obtain performance criteria defined for validation of multivariate models and corresponding evaluation results against these criteria.",
			"Obtain any analytical procedures for intermediates or critical steps that are relevant to the drug product and are cross-referenced from 3.2.S.2.4, ensuring alignment with acceptance criteria in 3.2.P.5.1.",
			"If the drug substance used in the analytical procedures is already approved, consult the relevant health authority guidance to determine whether cross-referencing or abbreviated information is acceptable.",
			"Collect any regulatory correspondence or prior approvals related to analytical method changes or justifications for method selection.",
			"Gather high-level overviews of PQS elements for model monitoring and maintenance, including diagnostic tools for assessing sample data appropriateness and approaches for handling outliers.",
			"If RTRT analytical procedures are relevant to the drug product, collect descriptions of the property or attribute of interest, desired quantitative ranges or limits, measurement principles, instrument operating parameters, calibration data sources, type of multivariate model, reference analytical procedures or prepared reference samples, and any calculations needed to adjust model outputs.",
		],
		output: [
			"Do not include historical analytical procedures used only for data generation; these belong in 3.2.P.4.4 (Batch Analyses).",
			"Include a high-level overview of PQS elements for model monitoring and maintenance, including diagnostic tools and outlier handling approaches, when relevant to analytical procedures.",
			"For multivariate models used in drug product specifications (including RTRT), describe the validation set with independent samples, performance criteria, evaluation results, and relationship to attribute specification limits.",
			"Ensure analytical methods are presented in the appropriate section (3.2.P.4.2) even if similar methods are described in 3.2.S, since sample preparation differs between drug substance and drug product.",
			"Include detailed descriptions of each analytical procedure used to test the drug product, ensuring clarity and reproducibility.",
			"Ensure consistency with any overarching CTD-Q structural notes (e.g., Note 4) indicating that sub-levels under 3.2.P.4 should be presented as part of a unified section rather than as separate attachments.",
			"Check that all methods described are current and applicable to the commercial manufacturing process.",
			"Provide cross-references between 3.2.S and 3.2.P sections when analytical methods are identical or similar, ensuring traceability and consistency.",
			"Maintain consistent terminology and method naming across the dossier to avoid confusion between drug substance and drug product methods.",
			"Ensure that excipient-related analytical procedures are placed at the correct level (3.2.P.4 versus 3.2.P.4.x) in accordance with excipient-specific guidance referenced in Appendix D.",
			"If RTRT analytical procedures are relevant, ensure descriptions include property/attribute of interest, quantitative ranges/limits, measurement principles, instrument parameters, calibration data sources, model type, reference procedures or samples, and calculation methods for adjusting outputs.",
			"If analytical procedures are part of a registered alternative control strategy to RTRT, ensure their description is included in the appropriate section and that validation information is placed in the correct validation section (e.g., 3.2.P.5.3 for drug product).",
			"Ensure all analytical procedures are described in sufficient detail to allow replication by a qualified laboratory.",
			"Ensure the section is organized logically, typically by test type (e.g., appearance, assay, impurities, dissolution).",
			"Do not include analytical procedures used exclusively for stability studies; these belong in 3.2.P.8.3 (Stability Data).",
			"Verify that all analytical procedures correspond to the specifications listed in 3.2.P.5.1 (Specifications).",
			"Recognize that lower-level CTD-Q headings such as 3.2.P.4.2 are not expected to contain separate individual files; compile the analytical procedures within a single integrated document under this heading.",
			"When analytical procedures are cross-referenced from other CTD sections (e.g., 3.2.S.2.3 for control of materials or 3.2.S.2.4 for intermediates/critical steps), clearly indicate the source section and ensure consistency in method description and acceptance criteria.",
			"If an in-process material test is performed in lieu of a finished product test, ensure that the analytical procedure and validation information are presented in the same level of detail as for finished product tests, and that the corresponding process test is referenced in the specification (3.2.P.5.1).",
			"Do not include bioanalytical methods or their validation reports in 3.2.P.4.2, as these belong in Module 4 (nonclinical studies) or Module 5 (clinical studies).",
			"When including validation information for reference analytical procedures, ensure that model development, calibration, and validation details are either integrated into the section or clearly referenced in appended documents.",
		],
	},
	{
		number: "3.2.P.4.3",
		title: "Validation of Analytical Procedures",
		input: [
			"Obtain raw analytical data, calculations, and statistical analyses supporting validation parameters (accuracy, precision, specificity, detection limit, quantitation limit, linearity, range, robustness).",
			"Ensure availability of comparator product analytical data if used in validation.",
			"Gather any regulatory correspondence or prior approvals related to analytical method validation for the drug product.",
			"Gather complete validation reports for all analytical procedures used for the drug product, including method validation protocols and results.",
			"Obtain a high-level overview of PQS (Pharmaceutical Quality System) elements for model monitoring and maintenance, including diagnostic tools and outlier handling approaches.",
			"Collect relevant chromatograms for impurities as identified under ICH Q3A that are part of analytical validation studies for the drug substance or drug product, ensuring they are available for inclusion in section 3.2.P.4.3 where applicable.",
			"Compile reference standards and system suitability test results used during validation.",
			"Collect literature references or pharmacopeial method references if applicable to the validated procedures.",
			"Obtain stability\u0011indicating method validation data if applicable to the drug product.",
			"Gather validation information for analytical procedures used as reference analytical procedures, including model development, calibration, and validation data.",
			"Obtain stability-indicating method validation data if applicable to the drug product.",
			"Gather calibration model data, including sample preparation approach, reference analytical procedure, and type of multivariate model used.",
			"Collect data sets and documentation describing the validation set with independent samples used for multivariate model validation.",
			"Obtain defined performance criteria and acceptance limits used during validation of multivariate models.",
			"Collect information on any analytical procedures that are part of a registered alternative control strategy to RTRT, including their validation data for inclusion in section 3.2.P.4.3.",
			"Gather supportive information as defined under ICH Q12 for validation of analytical procedures, ensuring alignment with established conditions for the drug substance.",
			"Gather evaluation results comparing model validation outcomes against performance criteria.",
			"Obtain stability‑indicating method validation data if applicable to the drug product.",
			"Collect relevant chromatograms generated during validation studies for each analytical method used for the drug product.",
			"Collect documentation discussing the relationship between model performance criteria and attribute specification limits.",
		],
		output: [
			"Ensure that chromatograms for impurities, when part of analytical validation studies as per ICH Q3A, are included in section 3.2.P.4.3 in compliance with regulatory expectations.",
			"Clearly identify the analytical procedure being validated, including method name, purpose, and reference to the procedure description in 3.2.P.4.2.",
			"Ensure chromatograms are legible, properly labeled (including sample identity, date, method conditions), and correspond to the validation data presented.",
			"Present validation data in a clear, organized manner, linking each analytical method to its corresponding validation results.",
			"Ensure that all validation parameters required by ICH Q2(R1) or applicable regulatory guidelines are addressed for each method.",
			"Ensure that the content provided in section 3.2.P.4.3 is clearly identified as supportive information in line with ICH Q12 expectations for established conditions.",
			"For multivariate models used in specifications or RTRT approaches, describe the validation approach and results, including validation set composition, performance criteria, evaluation results, and relationship to specification limits.",
			"Ensure that the content provided in section 3.2.P.4.3 is clearly identified as 'supportive information' in line with ICH Q12 expectations for established conditions.",
			"Ensure that validation information for analytical procedures related to polymorphism, if applicable to the drug product, is clearly distinguished from drug substance validation data and appropriately located in section 3.2.P.4.3.",
			"Cross-reference related sections (e.g., 3.2.P.4.2 Analytical Procedures) where appropriate to avoid duplication and ensure traceability.",
			"For analytical procedures involving excipients, ensure correct placement of validation information at the 3.2.P.4 or 3.2.P.4.x level following Appendix D guidance.",
			"Include validation information for analytical procedures used as reference analytical procedures, either directly in section 3.2.P.4.3 or as appended documents, ensuring traceability and completeness.",
			"Verify that all data presented comply with applicable regulatory requirements for analytical method validation, including completeness and accuracy.",
			"Ensure that the validation information for multivariate models is clearly structured and logically presented, linking model validation results to analytical performance and control strategy.",
			"Ensure compliance with CTD Note 4 that lower-level headings such as 3.2.P.4.3 are not expected to contain individual standalone files, and information should be consolidated appropriately.",
			"Ensure that any appended documents containing model development, calibration, or validation information are clearly referenced and properly labeled within section 3.2.P.4.3.",
			"Use consistent terminology and units throughout the section to align with specifications and analytical procedures described elsewhere in the dossier.",
			"Cross-reference related CTD sections (e.g., 3.2.P.5.2 for analytical procedure description and 3.2.P.5.3 for validation of alternative control strategies) to maintain consistency and regulatory traceability.",
			"Include relevant chromatograms directly in section 3.2.P.4.3 to support validation results.",
			"Confirm that analytical validation data for the drug product are not confused with bioanalytical method validation data, which belong in Modules 4 or 5, ensuring correct placement and regulatory compliance.",
			"Provide a high-level overview of PQS elements for model monitoring and maintenance, including diagnostic tools and handling of outliers, to demonstrate ongoing model control.",
		],
	},
	{
		number: "3.2.P.4.4",
		title: "Justification of Specifications",
		input: [
			"Retrieve detailed statistical analysis reports of stability data that support specification limits.",
			"Ensure access to analytical data summaries, statistical analyses, and trend data supporting specification ranges.",
			"Collect the proposed drug product specifications, including all test parameters, analytical procedures, and acceptance criteria that require justification.",
			"If multiple excipients are used, ensure justification data are available per excipient where relevant to specification limits.",
			"Gather justification data and rationale for any proposed skip testing, including supporting studies or risk assessments.",
			"Collect certificates of analysis or batch data for excipients that are required to support the justification of specifications.",
			"Obtain information on analytical procedures unique to the stability program that are relevant to specification justification.",
			"If multiple manufacturing sites or facilities are involved, collect specification justification data per facility as needed.",
			"Collect historical analytical procedures and data used to generate batch analysis results relevant to the justification of specifications.",
			"Retrieve stability study data and results that support specification limits (e.g., degradation limits, impurity acceptance criteria).",
			"Gather data and rationale supporting each specification limit, including development data, validation results, and batch analysis data.",
			"Gather data from supporting stability studies that may be relevant to specification limits.",
			"Retrieve stress study data that may be referenced to support analytical procedure validation or specification justification.",
			"Obtain analytical method validation reports for all analytical procedures referenced in the specification.",
			"For drug products supplied with reconstitution diluent(s), gather complete 'P' information for the diluent(s) as separate drug product(s), including any specification justification data.",
			"Gather regulatory correspondence or prior approvals related to specification limits or analytical methods, if applicable.",
			"Collect information on historical analytical procedures used during stability studies that are relevant to specification justification.",
			"Obtain reference standards and comparator product information used to establish specification limits.",
			"Collect relevant literature references or pharmacopeial standards used to justify specification parameters.",
			"Retrieve any expert reports or scientific justifications used to define acceptance criteria for critical quality attributes.",
			"Identify and compile summaries of relevant data from other CTD sections that will be cross-referenced in the justification of specifications.",
			"If the drug substance is already approved, obtain relevant health authority guidance or documentation to inform the justification of specifications.",
			"If the drug product has more than one container closure system, gather specification justification data per container closure system or per distinguishing factor as applicable.",
		],
		output: [
			"Include cross-references to related sections such as 3.2.P.4.1 (Specification), 3.2.P.4.2 (Analytical Procedures), and 3.2.P.5.4 (Batch Analyses) where applicable.",
			"For stability-related justifications, consider whether to present information in its entirety or organized per manufacturer, stability study protocol, or other distinguishing factors, ensuring clarity and traceability.",
			"If referencing stability data or stress studies from section 3.2.P.8.3, ensure proper cross-referencing and alignment of analytical procedures and results with the justification of specifications.",
			"Maintain compliance with CTD-Q structure and formatting conventions for section 3.2.P.4.4, including appropriate headings and subheadings.",
			"Organize the justification by test parameter or quality attribute (e.g., appearance, assay, impurities, dissolution).",
			"Provide a concise summary of supporting data from other CTD sections with appropriate cross-references to detailed information, avoiding unnecessary repetition.",
			"If the product includes multiple container closure systems, organize the justification either as a single integrated document or per container closure system, ensuring clarity and traceability.",
			"Verify regional formatting or content requirements during drafting to ensure compliance with ICH and local expectations.",
			"Clearly justify each test parameter and acceptance criterion included in the specification, explaining its relevance to product quality and safety.",
			"If the drug substance is already approved, include a statement referencing relevant health authority guidance and how it impacts the justification of specifications.",
			"If multiple facilities or excipients are involved, structure the justification per facility or per excipient as appropriate, following CTD modular organization principles.",
			"Ensure that the section structure aligns with CTD conventions and any applicable appendices (e.g., Appendix D or Appendix E) for multi-component or multi-system products.",
			"If skip testing is proposed, include a clear and scientifically supported justification within the section.",
			"When including statistical analysis of stability data to support specification limits, ensure that detailed reports are appropriately referenced and summaries are consistent with conclusions in related sections.",
			"Perform a compliance check to confirm that all specification justifications are supported by data and align with regulatory expectations.",
			"Ensure consistency between the justification and data presented in analytical validation and stability sections.",
			"Ensure that the section structure aligns with CTD conventions and any applicable appendices for multi-component or multi-system products.",
			"When possible, provide a concise summary of supporting data from other CTD sections with appropriate cross-references to detailed information, avoiding unnecessary repetition.",
			"Acknowledge that while the CTD provides a common format across ICH regions, regional differences in content expectations may apply; verify regional formatting or content requirements during drafting.",
			"Use clear, concise, and scientifically justified language when describing the rationale for each specification limit.",
			"Ensure that all analytical procedures and acceptance criteria discussed are consistent with those listed in 3.2.P.4.1.",
			"Verify that all referenced analytical methods are current and validated; historical methods should be clearly identified as such.",
			"Provide a logical and traceable link between the specification limits and supporting data (e.g., development, validation, stability).",
			"For drug products with reconstitution diluent(s), ensure that the justification of specifications for the diluent(s) is prepared and presented as a separate drug product section, in accordance with CTD-Q structure.",
			"Confirm that the section adheres to CTD M4 general format principles, including consistency with the harmonized structure and granularity conventions referenced in the M4 guidance.",
		],
	},
	{
		number: "3.2.P.4.5",
		title: "Excipients of Human or Animal Origin",
		input: [
			"Obtain viral safety data relevant to excipients of human or animal origin (noting that detailed data will be located in section 3.2.A.2).",
			"Collect quantitative composition data for excipients of human or animal origin, including amounts (mg) and proportions (% w/w) relative to total formulation weight, as shown in ICH M9 examples.",
			"Prepare informative document titles and/or descriptor keyword values (e.g., storage condition, container orientation, 'primary' vs. 'supportive') if needed to clarify the scope of each document.",
			"Collect any relevant literature references or expert opinions on the safety and regulatory status of the excipients of human or animal origin.",
			"Obtain justification or supporting data for any excipient quantity differences within acceptable ranges (e.g., ±10%) for excipients with known or suspected effects on drug absorption, such as sorbitol.",
			"Obtain source and origin documentation for each excipient of human or animal origin, including species and tissue/organ of origin.",
			"Obtain a statement regarding manipulation of ruminant-derived materials in the drug product manufacturing facility, if applicable, including details on potential for cross-contamination with adventitious agents.",
			"Obtain justification or supporting data for any excipient quantity differences within acceptable ranges (e.g., \u0000b110%) for excipients with known or suspected effects on drug absorption, such as sorbitol.",
			"Collect documentation describing the source and controls applied to excipients of human or animal origin, including traceability and control measures implemented by the supplier or manufacturer.",
			"Collect any regulatory certificates or attestations related to compliance with relevant pharmacopeial or regulatory standards for excipients of human or animal origin.",
			"Obtain certificates or declarations from suppliers regarding the absence or control of transmissible spongiform encephalopathy (TSE) / bovine spongiform encephalopathy (BSE) risk, as per region-specific guidance.",
			"Gather comparative formulation tables showing reference and test product excipient compositions, including absolute percentage differences relative to core weights, where applicable.",
			"Collect detailed descriptions and results of testing performed on excipients of human or animal origin, including any assays related to adventitious agent control.",
			"Gather information on adventitious agent safety evaluation (note: detailed evaluation to be included in section 3.2.A.2, but relevant summary or reference needed here).",
			"Gather excipient specifications specifically for excipients of human or animal origin, as they may be referenced in the section.",
			"Identify and assign any 'excipient' keyword values (e.g., specific excipient name, 'compendial', 'coating agent', 'Human-Animal-Novel') if using multiple excipient sections, to distinguish content clearly.",
			"Gather manufacturing process descriptions for each excipient of human or animal origin, including any steps to inactivate or remove adventitious agents.",
			"Determine the intended granularity approach for presenting excipient information in section 3.2.P.4.5 (single section vs. multiple sections, grouped vs. individual excipients) based on business needs and regulatory appropriateness.",
			"Gather previous regulatory correspondence or approvals related to the use of these excipients in the product.",
			"Collect detailed information on all excipients of human or animal origin used in the drug product.",
			"Collect information on the Biopharmaceutics Classification System (BCS) class of the drug substance (e.g., Class I or Class III) to contextualize excipient use and potential impact on absorption.",
			"Obtain supplier qualification documents and audit reports for suppliers of human or animal origin excipients.",
		],
		output: [
			"Present any differences in excipient quantities within acceptable regulatory ranges (e.g., \u0000b110%) clearly and justify them based on scientific rationale or regulatory precedent.",
			"Ensure that all quantitative and comparative data presented are internally consistent and traceable to validated formulation records or source data.",
			"Clearly identify each excipient of human or animal origin, its source species, and tissue/organ of origin.",
			"When applicable, include a concise explanation of the Biopharmaceutics Classification System (BCS) class of the drug substance to contextualize excipient use and potential impact on absorption.",
			"Select and apply an appropriate granularity option (single section, multiple sections without lower-level granularity, or multiple sections with 3.2.P.4.x granularity) based on the volume and type of excipient information, ensuring consistency across the dossier.",
			"Ensure the section clearly presents 'Excipient source and controls' as the main focus, consistent with ICH Q12 expectations for established conditions.",
			"Ensure cross-references are accurate and point to the correct sections containing detailed data or certificates.",
			"If more than one excipient of human or animal origin is included, consider providing document(s) per excipient, consistent with Note 13 guidance.",
			"Use consistent terminology for excipients, species, and tissues/organs throughout the section to align with regulatory and pharmacopeial nomenclature.",
			"Ensure document titles and/or descriptor keyword values clearly convey the scope and content of each document, including distinctions such as storage conditions, container orientation, or 'primary' vs. 'supportive' information.",
			"Present any differences in excipient quantities within acceptable regulatory ranges (e.g., ±10%) clearly and justify them based on scientific rationale or regulatory precedent.",
			"Use tabular presentation formats consistent with ICH M9 examples to facilitate comparison of excipient compositions between reference and test formulations.",
			"Avoid using overly general umbrella terms such as 'all strengths' in descriptor keyword values or document titles; instead, provide specific, informative descriptors.",
			"Applicants may modify the format and structure of the section if needed to provide the best possible presentation of information and facilitate regulatory understanding, provided CTD conventions remain respected.",
			"Structure the section to explicitly describe both the origin (source) and the control measures applied to each excipient of human or animal origin.",
			"If a statement regarding manipulation of ruminant-derived materials is included, ensure it is clearly presented in this section and cross-referenced to 3.2.A.1 and 3.2.A.2 if additional adventitious agent risk information is provided there.",
			"Organize the content logically, grouping excipients by type or origin, and present information in a clear, tabular or narrative format as appropriate.",
			"Reference the location of TSE/BSE certifications in accordance with region-specific guidance, rather than duplicating them in this section.",
			"Ensure the section explicitly includes information on sources, specifications, testing performed, and viral safety data for excipients of human or animal origin, as required by the guideline.",
			"Confirm that all adventitious agent–related information is aligned with ICH Q5A, Q5D, and Q6B expectations.",
			"Confirm that the structure and titling of the section are consistent with CTD conventions and regional expectations for Module 3 content organization.",
			"Verify that all required certificates and declarations are current, valid, and compliant with applicable regional requirements before finalizing the section.",
			"Verify that any cross-references to appendices or regional information sections are accurate and comply with the relevant region’s documentation order and titling requirements.",
			"Ensure that the section 3.2.P.4.5 is harmonized with other related sections (e.g., 3.2.A.3 for novel excipients) and does not duplicate information already presented elsewhere.",
			"Provide a concise summary of adventitious agent safety evaluation in this section, with a cross-reference to detailed information in section 3.2.A.2.",
			"When multiple manufacturing sites or container types are involved, ensure that the information relevant to excipients of human or animal origin remains consistent across all applicable product presentations and is clearly identified within the single drug product part of Module 3.",
			"If no human, animal, or novel excipients are used, follow regional guidance for granularity and consider whether a separate section with an 'excipient' keyword such as 'Human-Animal-Novel' is applicable for 3.2.P.4.5 and 3.2.P.4.6.",
			"Follow Appendix D guidance when deciding whether to use the 3.2.P.4 level or 3.2.P.4.x sub-levels for excipient-related granularity.",
			"When combining granularity options (e.g., grouping compendial excipients in one section and providing granular detail for non-compendial excipients), ensure the structure is logical and clearly documented.",
			"Ensure that excipients with known or suspected effects on drug absorption (e.g., sorbitol) are clearly identified and their quantities justified within the permitted range.",
			"Ensure the section is complete, accurate, and free from contradictions with other parts of the dossier.",
			"Include quantitative composition tables for excipients of human or animal origin, showing both reference and test product formulations, with amounts in mg and proportions (% w/w) relative to total formulation weight.",
			"Include all information on excipients of human or animal origin in section 3.2.P.4.5 of the CTD.",
			"Ensure that lower-level headings under CTD-Q (including 3.2.P.4.5) do not incorrectly include individual standalone documents or files, in line with Note 4 guidance.",
			"If multiple excipient sections are used, apply the 'excipient' keyword to identify and distinguish each section’s content, using either general terms (e.g., 'compendial') or specific excipient names as appropriate.",
		],
	},
	{
		number: "3.2.P.4.6",
		title: "Novel Excipients",
		input: [
			"Complete 3.2.A.3 section for each novel excipient, containing detailed safety information and supporting data, to be prepared in parallel and cross-referenced in 3.2.P.4.6.",
			"Analytical data and test results used to establish the excipient\u0019s quality attributes and specifications.",
			"If no pharmacopoeial monograph exists for the novel excipient, gather full analytical procedure details in accordance with Chapter 3, section 3.2.3.2 requirements.",
			"Control data for the novel excipient, including specifications, analytical methods, and validation data.",
			"Expert opinions or literature references supporting the safety and suitability of the novel excipient for the intended route of administration.",
			"If both drug substance and drug product information are included in appendices related to novel excipients (e.g., 3.2.A.3), ensure that the drug substance information is presented first, followed by the drug product information, as per CTD appendix organization guidance.",
			"Characterisation data for the novel excipient, including physicochemical properties, structural elucidation, and impurity profile.",
			"Analytical data and test results used to establish the excipient\u0003s quality attributes and specifications.",
			"If more than one novel excipient is included in the submission, prepare separate 3.2.P.4.6 documents per excipient, as indicated by Note 13.",
			"Supporting safety study reports (nonclinical and/or clinical) relevant to the novel excipient, as referenced in section 3.2.A.3.",
			"If the novel excipient is part of a drug product supplied with reconstitution diluent(s), gather complete 'P' information for the diluent(s) as separate drug product(s), as appropriate.",
			"Excipient specification for the novel excipient, including for each quality attribute: test method and acceptance criteria, or reference to pharmacopoeial monograph if applicable.",
			"Full details of manufacture of the novel excipient, including process description, process controls, and manufacturing site information, prepared according to the drug substance format.",
			"Certificates of analysis and batch data for the novel excipient used in development or clinical batches.",
			"Regulatory correspondence or prior communications regarding the novel excipient, if applicable.",
			"Analytical data and test results used to establish the excipient’s quality attributes and specifications.",
			"Cross-references to supporting safety data, including nonclinical (toxicology) and/or clinical studies demonstrating safety of the novel excipient.",
			"Reference standards and comparator materials used in analytical characterization of the novel excipient.",
		],
		output: [
			"Verify that lifecycle changes (renaming, suspension of sections, status updates) are applied consistently across all relevant CTD sections referencing the excipient.",
			"Present data and descriptions in a clear, logical order following CTD formatting conventions (headings, numbering, and cross-references).",
			"When grouping excipients under keywords (e.g., 'compendial', 'non\u0011compendial', 'Human\u0011Animal\u0011Novel'), ensure clear, consistent application for sections including 3.2.P.4.6.",
			"Use consistent terminology and nomenclature for the excipient throughout the section.",
			"Ensure that the section title and labeling conform to the current ICH terminology, where 3.2.A.3 is titled 'Excipients' to include both novel and noncompendial excipients, while 3.2.P.4.6 remains focused on novel excipients.",
			"If regional guidance requires separate identification of novel excipients, ensure appropriate labeling or keywording (e.g., 'Human-Animal-Novel') for sections covering 3.2.P.4.6.",
			"Apply the status code value 'suspended' for 3.2.A.3 or 3.2.P.4.6 when information on a previously noncompendial or novel excipient is no longer being maintained or lifecycle\u0011managed.",
			"When an excipient is no longer regarded as novel, update section 3.2.P.4 to explicitly acknowledge this change in status.",
			"Apply the rule that lower\u0011level CTD\u0011Q headings generally should not contain separate individual documents or files; consolidate content appropriately under higher\u0011level headings when preparing section 3.2.P.4.6.",
			"If regional guidance requires separate identification of novel excipients, ensure appropriate labeling or keywording (e.g., 'Human‑Animal‑Novel') for sections covering 3.2.P.4.6.",
			"When combining Option 2 and Option 3 granularity approaches, verify that novel excipient information remains clearly separated and easily identifiable for regulatory review.",
			"Ensure compliance with relevant ICH guidelines (e.g., Q6B for specifications and controls).",
			"Avoid use of vague or umbrella excipient descriptors such as 'all strengths' in section titles or descriptor fields.",
			"Provide additional or contextual information in descriptor fields or document titles when relevant (e.g., storage condition, container orientation), ensuring clarity and precision.",
			"Ensure that all information provided is complete for excipients used for the first time in a drug product or by a new route of administration.",
			"If the excipient name or keyword value needs updating (e.g., renaming), apply the eCTD v4.0 functionality allowing changes to the keyword value or display name.",
			"Consider excipient granularity based on amount of information, lifecycle potential, and global documentation processes to ensure appropriate structuring of 3.2.P.4.6.",
			"Avoid creating multiple documents for compendial excipients when content merely repeats or references pharmacopoeial monographs; apply parallel discipline when preparing novel excipient documents to avoid unnecessary fragmentation.",
			"Follow the CTD appendix organization rule that, when both drug substance and drug product information are included in appendices (e.g., 3.2.A.3), the drug substance information should be presented first, followed by the drug product information.",
			"Apply the rule that lower‑level CTD‑Q headings generally should not contain separate individual documents or files; consolidate content appropriately under higher‑level headings when preparing section 3.2.P.4.6.",
			"For each novel excipient described in 3.2.P.4.6, ensure that a corresponding complete 3.2.A.3 section is prepared and referenced, in accordance with CTD requirements.",
			"If the novel excipient is part of a drug product supplied with reconstitution diluent(s), present the 'P' information for the diluent(s) in its entirety as a separate drug product section, as appropriate.",
			"Confirm that all referenced data and documents (e.g., safety studies, analytical data) are properly cited and available in the dossier.",
			"The section should be structured according to the drug substance format, including subsections for manufacture, characterisation, and controls.",
			"Ensure that the use of 3.2.P.4 and/or 3.2.P.4.x levels for excipient information follows Appendix D guidance, maintaining appropriate granularity and document organization.",
			"When multiple documents are used for excipient sections, ensure clear, informative document titles that identify the specific excipient or grouping relevant to novel excipients.",
			"Include clear cross‑references to supporting safety data (nonclinical and/or clinical) provided in section 3.2.A.3.",
			"Check that the section aligns with the overall CTD Module 3 structure and integrates seamlessly with related sections (e.g., 3.2.A.3 for safety data).",
			"Ensure consistency in organization whether excipient data is provided in a single section or in multiple granular 3.2.P.4.x sections.",
			"Ensure correct lifecycle management by suspending the original 3.2.P.4.6 section when transitioning the excipient out of novel status.",
			"Verify that all manufacturing, characterization, and control data are traceable and consistent with referenced studies and data sources.",
			"When a non\u0011compendial excipient becomes compendial and affects a section containing novel excipient information (e.g., 3.2.P.4.x structures), ensure appropriate lifecycle updates, including replacing, updating, or suspending affected documents as needed.",
			"Apply the status code value 'suspended' for 3.2.A.3 or 3.2.P.4.6 when information on a previously noncompendial or novel excipient is no longer being maintained or lifecycle‑managed.",
			"Ensure that relisting of excipients in 3.2.P.4 is not duplicated unnecessarily; link back to 3.2.P.1 instead of repeating excipient lists.",
			"If multiple 3.2.P.4 or 3.2.P.4.x sections are used, apply the 'excipient' keyword consistently to clearly identify and distinguish novel excipient content.",
			"If referencing a pharmacopoeial monograph for a novel excipient, ensure the reference is accurate and complete; if no monograph exists, provide full analytical procedure details in accordance with Chapter 3, section 3.2.3.2.",
			"When presenting excipient specifications for novel excipients, include for each quality attribute the test method and acceptance criteria, or a reference to the applicable pharmacopoeial monograph if one exists.",
			"Ensure that significant data for a novel excipient that exceeds what belongs in 3.2.P.4.6 is properly placed in 3.2.A.3, as required by CTD guidance.",
			"When a non‑compendial excipient becomes compendial and affects a section containing novel excipient information (e.g., 3.2.P.4.x structures), ensure appropriate lifecycle updates, including replacing, updating, or suspending affected documents as needed.",
			"When grouping excipients under keywords (e.g., 'compendial', 'non‑compendial', 'Human‑Animal‑Novel'), ensure clear, consistent application for sections including 3.2.P.4.6.",
			"Include clear cross-references to supporting safety data (nonclinical and/or clinical) provided in section 3.2.A.3.",
			"Maintain clarity and conciseness while providing sufficient technical detail to support regulatory review.",
			"Ensure that the section\u0019s granularity is selected appropriately based on regulatory expectations for novel excipients, following Appendix D guidance.",
			"When more than one novel excipient is included, provide separate 3.2.P.4.6 documents per excipient, as specified in Note 13, to maintain clarity and traceability.",
			"Include clear cross\u0011references to supporting safety data (nonclinical and/or clinical) provided in section 3.2.A.3.",
			"Ensure status code 'suspended' is applied appropriately when discontinuing maintenance of novel excipient information in 3.2.P.4.6 or 3.2.A.3.",
			"Ensure that the section’s granularity is selected appropriately based on regulatory expectations for novel excipients, following Appendix D guidance.",
		],
	},
	{
		number: "3.2.P.5.1",
		title: "Specifications (S)",
		input: [
			"Gather validated analytical methods relevant to the drug product specifications.",
			"Gather a comprehensive list of all quality attributes included in the drug product specification, ensuring each attribute is linked to its corresponding test method and acceptance criteria.",
			"Collect references to applicable pharmacopoeial monographs for any tests or quality attributes that are controlled by compendial methods.",
			"Obtain documentation identifying which elements of the drug product specification are considered Established Conditions (ECs) under ICH Q12, including tests, analytical procedures, and acceptance criteria.",
			"Gather detailed information on any process test that replaces an end‑product test, including test description, analytical procedure, validation information, and acceptance criteria, for inclusion in 3.2.P.5.1.",
			"Obtain reference standards or materials required for the analytical procedures listed in the specifications.",
			"Gather both release specifications and shelf\u0011life specifications for the drug product for inclusion in section 3.2.P.5.1.",
			"Collect and review applicable ICH guidelines (Q3B, Q6A, and Q6B) referenced for section 3.2.P.5.1 to ensure alignment of specification content and format with regulatory expectations.",
			"Gather both release specifications and shelf‑life specifications for the drug product for inclusion in section 3.2.P.5.1.",
			"If there are different specifications for the drug product from different manufacturers or applicants, gather all versions of these specifications.",
			"Gather detailed information on any process test that replaces an end\u0011product test, including test description, analytical procedure, validation information, and acceptance criteria, for inclusion in 3.2.P.5.1.",
			"Obtain the complete specification(s) for the drug product as defined for section 3.2.P.5.1, including all tests, analytical procedures, and acceptance criteria.",
			"Collect relevant technical documents such as method SOPs, analytical method summaries, and validation summaries that support the listed specifications.",
			"Collect details of any alternative analytical procedures used to control the drug product, along with their associated acceptance criteria.",
			"Compile any regulatory correspondence or approvals related to the agreed specifications for the drug product.",
		],
		output: [
			"Ensure that for each quality attribute listed in the specification, the corresponding test method and acceptance criteria are explicitly stated or referenced to a pharmacopoeial monograph where applicable.",
			"Maintain clarity and traceability by clearly linking each analytical procedure to its corresponding acceptance criteria within the specification.",
			"Confirm that the specification table or list format allows clear association between each test, its analytical procedure, and acceptance criteria, consistent with ICH Q12 expectations for Established Conditions.",
			"Present the specifications in a clear, structured format that aligns with CTD requirements for section 3.2.P.5.1.",
			"Ensure that the specification(s) are presented in accordance with the structure and expectations outlined in ICH Q3B, Q6A, and Q6B, including clarity on impurity limits, test methods, and acceptance criteria.",
			"Ensure that both release and shelf\u0011life specifications are included in section 3.2.P.5.1 as required.",
			"Verify that the terminology used for tests, procedures, and acceptance criteria is consistent with pharmacopeial or regulatory standards.",
			"Ensure completeness by cross-checking that all analytical procedures controlling the drug product are represented in the specification.",
			"If a process test replaces an end‑product test, ensure it is listed in section 3.2.P.5.1 and explicitly identified as a process test, in accordance with ICH Q6A.",
			"Include all applicable specifications for the drug product in section 3.2.P.5.1 when more than one specification exists.",
			"Ensure that alternative analytical procedures, if used, are explicitly included in the specification with their acceptance criteria.",
			"List every analytical procedure used to control the drug product in the specification, together with the corresponding acceptance criteria.",
			"If a process test replaces an end\u0011product test, ensure it is listed in section 3.2.P.5.1 and explicitly identified as a process test, in accordance with ICH Q6A.",
			"Ensure that both release and shelf‑life specifications are included in section 3.2.P.5.1 as required.",
			"Clearly identify which parts of the specification (tests, analytical procedures, acceptance criteria) are considered Established Conditions (ECs) in accordance with ICH Q12.",
			"Verify that the specification document clearly identifies the drug product name and dosage form as required by CTD section 3.2.P.5.1 heading format.",
		],
	},
	{
		number: "3.2.P.5.2",
		title: "Analytical Procedures",
		input: [
			"Obtain supporting documentation for analytical methods used in stability studies, ensuring correct placement in 3.2.P.8.3 if applicable.",
			"Collect any cross-referenced analytical methods that are identical or similar between drug substance and drug product, ensuring both are available for inclusion in their respective sections.",
			"Obtain analytical procedures used for testing the drug product in quality control, release, and stability studies (if applicable to the product).",
			"Refer to Appendix A for any additional guidance or clarifications relevant to analytical procedures and ensure any referenced materials are obtained before drafting.",
			"Collect all analytical procedures used to control the drug product, including current and historical versions if relevant to data presented.",
			"If the drug substance is already approved, consult the relevant health authority for guidance and obtain any necessary regulatory documentation or correspondence before preparing section 3.2.P.5.2.",
			"Confirm that bioanalytical methods and their validation reports used in clinical or nonclinical studies are not included in 3.2.P.5.2 but are instead located in Module 4 (4.2.2.1) or Module 5 (5.3.1.4), ensuring correct cross-referencing if applicable.",
			"Gather any regulatory correspondence or prior approvals related to analytical method changes or justifications.",
			"Gather historical analytical procedures that were used to generate data presented in Batch Analyses (for correct placement in 3.2.P.5.4, even though they are not included in 3.2.P.5.2).",
			"Gather validated analytical methods specific to the drug product, including sample preparation details.",
			"Obtain reference standards and information on reference materials used in the analytical procedures.",
			"Gather data and information on analytical techniques used (e.g., chromatographic, spectroscopic, titrimetric methods) and their corresponding parameters.",
			"Collect technical documents such as method development reports, standard operating procedures (SOPs), and analytical method descriptions.",
		],
		output: [
			"Include all analytical procedures used to control the drug product in section 3.2.P.5.2, ensuring completeness and clarity.",
			"Clearly identify any alternative analytical procedures used to control the drug product and ensure they are appropriately referenced.",
			"Follow CTD formatting conventions for section numbering, headings, and subheadings within 3.2.P.5.2.",
			"If analytical methods are identical between drug substance and drug product, include them in both 3.2.S and 3.2.P sections, with appropriate cross‑references.",
			"If analytical methods are identical between drug substance and drug product, include them in both 3.2.S and 3.2.P sections, with appropriate cross\u0011references.",
			"Ensure that identical methods appearing in both drug substance and drug product sections are fully described in each section due to differences in sample preparation.",
			"Exclude historical analytical procedures used solely to generate batch analysis data from 3.2.P.5.2 and ensure they are instead placed in 3.2.P.5.4.",
			"Ensure that bioanalytical methods and their validation reports are not included in 3.2.P.5.2 but are referenced appropriately to their respective modules (Module 4 or 5) if relevant to the submission.",
			"Ensure analytical methods are described in sufficient detail to allow reproduction, including sample preparation, equipment, parameters, and conditions.",
			"Verify that all analytical procedures correspond to the acceptance criteria and tests listed in the specification section.",
			"Recognize that the lower level of each heading in CTD-Q (including 3.2.P.5.2) is unlikely to contain individual documents or files; structure the section accordingly to avoid unnecessary file fragmentation.",
			"Do not include analytical procedures used only for stability studies in this section; these should be placed in 3.2.P.8.3.",
			"If analytical methods are identical between drug substance and drug product, include them in both 3.2.S and 3.2.P sections, with appropriate cross-references.",
			"Maintain consistent terminology and method naming across sections to facilitate regulatory review.",
			"Ensure consistency between analytical procedures listed in 3.2.P.5.2 and those referenced in the specification (3.2.P.5.1).",
			"Ensure cross-references to validation data (3.2.P.5.3) are accurate and complete.",
		],
	},
	{
		number: "3.2.P.5.3",
		title: "Validation of Analytical Procedures",
		input: [
			"Information on validation of analytical procedures that are part of a registered alternative control strategy to RTRT, if applicable",
			"Any regulatory correspondence or prior approvals related to analytical method validation",
			"Historical validation data if methods have evolved during development and are still relevant to the current submission",
			"Summary table of all relevant Validation Reports for each analyte, including Partial Validation and Cross Validation Reports",
			"Cross-references to related analytical procedures in 3.2.S if methods are similar but adapted for drug product",
			"Summary table cross-referencing multiple identification codes (method, Validation Reports, Bioanalytical Reports)",
			"Acceptance criteria for each analytical method as per specification",
			"Validation protocols for each analytical method used for the drug product",
			"Details of analytical equipment and instrumentation used in validation",
			"Relevant chromatograms generated during validation studies for the drug product analytical methods",
			"Documentation of method changes, including reasons for revisions and unique aspects",
			"Summary of methods used for each study, including method title, identification code, assay type, Bioanalytical Report code, effective date, and associated Validation Report codes",
			"Source data, protocols, and reports supporting analytical method validation studies",
			"Records of data alterations or reprocessing, including justification and preservation of original data",
			"Discussion data linking model performance criteria to attribute specification limits",
			"Validated analytical procedure reports for all analytical methods used to test the drug product",
			"Raw validation data, including accuracy, precision, specificity, detection limit, quantitation limit, linearity, range, robustness, and system suitability results",
			"If analytical procedures for polymorphism control are relevant to the drug product, gather validation data for these methods for inclusion in 3.2.P.5.3",
			"Records supporting procedural, operational, and environmental conditions during validation",
			"Reference analytical procedure descriptions or high-level descriptions of prepared reference samples used in model calibration",
			"Validation information for any in-process material test performed in lieu of a finished product test, if applicable to the drug product analytical procedures",
			"Correspondence records between all involved parties related to analytical method validation",
			"Reference standards and materials used in validation studies",
			"Secure storage and retrieval system for validation documentation, ensuring availability for audit or inspection",
			"Validation information for analytical procedures used as reference analytical procedures",
			"Description and dataset of the validation set with independent samples used for multivariate model validation",
			"List of regulatory site inspections (dates and outcomes) for analytical sites involved in validation or bioanalytical studies, if applicable",
			"Model development, calibration, and validation data for multivariate analytical models used in drug product specifications, including RTRT approaches",
			"Defined performance criteria to be met during validation of the multivariate model",
			"High-level overview of PQS (Pharmaceutical Quality System) elements for model monitoring and maintenance, including diagnostic tools and outlier management approach",
			"Evaluation results comparing model validation outcomes against performance criteria",
		],
		output: [
			"If an in-process material test replaces a finished product test, include the same level of analytical procedure and validation information in 3.2.P.5.3 as would be provided for a finished product test",
			"Ensure that validation information for analytical procedures forming part of a registered alternative control strategy to RTRT is included in section 3.2.P.5.3",
			"Ensure that all validation documentation is securely stored and readily retrievable upon request by regulatory authorities",
			"Provide a high-level overview of PQS elements for model monitoring and maintenance, including diagnostic tools and handling of outliers, within the validation description",
			"Ensure that any process test replacing an end-product test is clearly cross-referenced to the specification section (3.2.P.5.1) and identified as a process test in accordance with ICH Q6A",
			"Ensure that all validation documentation is contemporaneous, traceable, and auditable, maintaining original records even after data reprocessing",
			"Ensure that all multivariate model validation descriptions align with the analytical procedure descriptions provided in 3.2.P.5.2 for RTRT analytical procedures",
			"Present validation results in a clear, logical sequence covering all ICH Q2(R1) validation parameters where applicable",
			"Maintain good record-keeping practices and ensure all validation documentation is available for regulatory audit or inspection",
			"Maintain a professional, concise, and factual writing style suitable for regulatory review",
			"Maintain alignment between the validation documentation presented in 3.2.P.5.3 and any related bioanalytical or validation reports referenced elsewhere in the CTD",
			"If analytical procedures for polymorphism control are relevant to the drug product, ensure that validation information is presented in 3.2.P.5.3 in alignment with related sections (e.g., 3.2.S.4.3) and cross-referenced appropriately",
			"Maintain consistency in terminology with ICH Q2 and ICH Q14 definitions (e.g., analytical procedure, analytical target profile, calibration model, analytical procedure validation strategy)",
			"Clearly distinguish between model development, calibration, and validation information, whether included directly in the section or appended",
			"Include relevant chromatograms within section 3.2.P.5.3 to support validation results",
			"Organize validation information method-by-method, clearly linking each validation dataset to the corresponding analytical procedure",
			"Document any data changes or reprocessing with justification and ensure the original data remain visible and accessible",
			"Include summary tables of validation reports and method identification codes in a clear, organized format within the section or appendices",
			"Ensure compliance with applicable regulatory guidelines for analytical method validation (e.g., ICH Q2(R1))",
			"Clearly identify and discuss any method changes, including reasons for revisions and their impact on validation outcomes",
			"Ensure cross-references are provided if related analytical methods are also described in 3.2.S, noting any differences in sample preparation or application",
			"Include validation information for analytical procedures used as reference analytical procedures within this section or as an appended document, ensuring traceability and completeness",
			"For multivariate models used in drug product specifications (including RTRT), describe the validation approach and results comprehensively, covering validation set composition, performance criteria, evaluation results, and relationship to specification limits",
			"Verify that all acceptance criteria used in validation match those stated in the specification section",
			"Ensure that validation data presented corresponds specifically to the analytical procedures described for the drug product in 3.2.P.5.2",
			"Clearly label and reference all chromatograms, tables, and figures within the text",
			"Ensure that all documentation and summary information are consistent with the corresponding analytical method and validation report codes",
			"Use consistent terminology and units throughout the section to align with specifications in 3.2.P.5.1",
		],
	},
	{
		number: "3.2.P.5.4",
		title: "Batch Analyses",
		input: [
			"Ensure access to the specifications and acceptance criteria used to justify inclusion of batch data.",
			"Collect supporting documentation from manufacturing and quality control departments detailing batch production and testing records.",
			"If the drug substance is already approved, obtain relevant regulatory information or correspondence from the health authority to determine applicable batch analysis requirements.",
			"Retrieve historical analytical procedures used to generate the batch analysis data, even if those procedures have since changed.",
			"Obtain analytical test results for all tests performed on the batches, including those not listed in the official specifications.",
			"Obtain supportive information as defined under ICH Q12 for section 3.2.S.4.4, which may include representative batch data demonstrating consistency of manufacturing and control.",
			"For drug products supplied with reconstitution diluent(s), gather complete 'P' information for the diluent(s) as separate drug product(s), including any associated batch analysis data.",
			"Gather any documentation that supports the established conditions related to batch analyses, such as evidence of control strategy implementation or verification of analytical performance.",
			"Gather batch descriptions for each batch analyzed, including batch number, manufacturing site, and intended use (e.g., clinical, nonclinical, stability).",
			"Gather any relevant stability study data associated with the batches included in the analysis.",
			"Ensure availability of validated analytical methods or references to methods used for batch testing.",
			"Collect results from all relevant batches, including clinical, nonclinical, and stability batches.",
			"Compile collated data for tests from multiple batch analyses, if applicable.",
		],
		output: [
			"Verify that all data presented are consistent with the analytical methods and acceptance criteria described elsewhere in the dossier.",
			"Ensure that the presentation of batch analysis data aligns with the concept of 'supportive information' under ICH Q12, meaning it should substantiate the control strategy and demonstrate process consistency.",
			"If the drug substance is already approved, clearly indicate in the section how the batch analysis requirements have been adapted in accordance with health authority guidance.",
			"Present results from tests not listed in the specification within this section (3.2.P.5.4).",
			"Organize data in a clear tabular format to facilitate comparison across batches.",
			"Provide descriptive information for each batch, including batch number, manufacturing site, and intended use.",
			"Include results from all relevant batches (clinical, nonclinical, stability) in section 3.2.P.5.4.",
			"Ensure that the section clearly distinguishes between different batch types (e.g., clinical vs. stability).",
			"Ensure that the content adheres to principles in referenced ICH guidelines (Q2A, Q2B, Q6B, Q3B, Q3C, Q6A) where applicable to batch analysis presentation.",
			"When cross-referencing other CTD sections within 3.2.P.5.4, include the section number in the cross-reference string to maintain clarity and brevity.",
			"Ensure completeness by confirming that all relevant batches used to justify acceptance criteria are included.",
			"Ensure that cross-references are clear and concise, avoiding overly long section names in cross strings.",
			"If collated data from multiple batch analyses are warranted, present the summarized data in this section.",
			"Write the text surrounding cross-references so that the reader can easily understand the content of the referenced section without requiring the full section title.",
			"Confirm that the batch analysis section supports the established conditions for analytical control without redefining them, maintaining alignment with the overall control strategy described in the dossier.",
			"Maintain consistency in terminology and units across all batch data tables and summaries.",
			"Cross-reference analytical procedures and specifications appropriately to related sections (3.2.P.5.1 and 3.2.P.5.2) where applicable.",
			"Verify that the section includes a clear description of the batches and batch analysis results, as explicitly required.",
			"For drug products with reconstitution diluent(s), ensure that the batch analysis section either references or includes the complete 'P' information for the diluent(s) as separate drug product(s), as appropriate.",
		],
	},
	{
		number: "3.2.P.5.5",
		title: "Characterization of Impurities",
		input: [
			"Nonclinical and clinical study numbers associated with specific batches used to support impurity qualification",
			"Batch analysis data for impurities, whether or not the impurity is included in the specification",
			"Structural characterization data for each identified impurity in the drug product",
			"Relevant chromatograms supporting impurity characterization (if applicable to 3.2.P.5.5) to illustrate analytical results",
			"Cross-reference to impurity information already provided in section 3.2.S.3.2 Impurities to avoid duplication",
			"Qualified level of each impurity with cross-reference to supporting nonclinical studies",
			"Qualified level of each impurity with cross-reference to supporting clinical studies",
			"Analytical data supporting impurity characterization (e.g., spectral data, chromatograms if relevant to characterization rather than validation)",
			"Cross-references to other dossier sections where supporting data is located (e.g., Module 4 or 5 for toxicology/clinical data)",
			"Drug product batch information from 3.2.P.5.4 that links batch identity with impurity levels for inclusion in impurity characterization",
			"Drug substance and drug product batch numbers relevant to impurities to ensure linkage of impurity data across development history",
			"Summary of the method of preparation for each identified impurity",
			"Reference to impurity reference standards characterization (from section 3.2.S.5 if applicable)",
			"Data on observed impurities for relevant batches, including clinical batches, nonclinical batches, and stability batches",
			"Any relevant literature references or expert reports supporting impurity identification and qualification",
			"Reference and alignment with applicable ICH guidelines Q3B, Q5C, Q6A, and Q6B for impurity characterization requirements",
			"A complete list of all observed impurities, including those not included in the drug product specification",
		],
		output: [
			"Include relevant chromatograms in the impurity characterization section if they are necessary to support identification or quantification of impurities",
			"Ensure impurity data is clearly organized and can be cross-referenced to support other sections of the dossier as appropriate",
			"Clearly link impurity characterization data in 3.2.P.5.5 with batch history information described in 3.2.P.5.4 to demonstrate consistency and traceability",
			"Clearly distinguish between identified, unidentified, specified, and unspecified impurities in the presentation",
			"Present impurity characterization information in a logical sequence: identification, structural elucidation, preparation method, qualification data, batch occurrence data",
			"Ensure compliance with ICH Q3B, Q5C, Q6A, and Q6B guidelines when describing impurity characterization data and presentation format",
			"Ensure that data tables, figures, and summaries are clear, legible, and appropriately labeled for regulatory review",
			"Ensure that impurity levels are traceable to specific drug substance and drug product batches used in nonclinical and clinical studies, supporting qualification rationale",
			"Provide data on observed impurities for all relevant batches (clinical, nonclinical, stability), regardless of whether the impurity is included in the specification",
			"Include structural characterization data and a summary of the method of preparation for each impurity in section 3.2.P.5.5",
			"Verify that all impurity levels reported comply with ICH Q3A/Q3B thresholds and relevant regulatory limits",
			"Explicitly list all observed impurities in section 3.2.P.5.5, including those not included in the drug product specification",
			"Ensure that all cross-references to other CTD sections (e.g., impurity reference standards in 3.2.S.5, toxicology data in Module 4, clinical data in Module 5) are accurate and functional",
			"Maintain consistency in impurity nomenclature and identifiers across the dossier",
			"Present the qualified level of each impurity with explicit cross-references to the supporting nonclinical and clinical studies",
			"If impurity characterization data has already been provided in section 3.2.S.3.2, clearly reference that section rather than duplicating content",
			"Recognize that lower-level CTD-Q headings such as 3.2.P.5.5 are not expected to contain separate individual documents or files; consolidate content appropriately within the main section narrative",
		],
	},
	{
		number: "3.2.P.5.6",
		title: "Justification of Specifications",
		input: [
			"Obtain expert opinions or scientific rationale supporting the proposed acceptance criteria and testing strategy.",
			"Gather relevant stability data from section 3.2.P.8.3, including stress study results, to support justification of stability-related specifications.",
			"Obtain data from supporting stability studies, if relevant to specification justification.",
			"Collect information on historical analytical procedures used during stability studies that may impact specification justification.",
			"Collect all relevant batch analysis data from section 3.2.P.5.4, including results from clinical, nonclinical, and stability batches used to justify acceptance criteria.",
			"Assemble literature references or compendial standards used to establish or justify specification limits.",
			"Collect any relevant regulatory correspondence or prior agency feedback related to specification setting or justification.",
			"Obtain detailed analytical data and acceptance criteria from section 3.2.P.5.1 (Specifications) to support justification.",
			"Gather information on all observed impurities from section 3.2.P.5.5, including those not included in the drug product specification.",
			"Gather summaries or detailed data from other CTD sections (e.g., stability, impurity characterization, analytical validation) that support the specification justification.",
			"Compile justification data for skip testing, including rationale, supporting studies, and risk assessments if applicable.",
			"Gather data from studies on drug product physicochemical or biological properties that evaluate the appropriateness of the acceptance criteria, as referenced in section 3.2.P.2.2.3 and ICH Q6A Decision Trees 4 (Part 3) and 7 (Part 1).",
			"Gather details of analytical procedures unique to the stability program that are relevant to the justification of specifications.",
			"Gather summarized data from other CTD sections (e.g., excipient control, analytical validation, process control) with appropriate cross-references to detailed information to support the justification of specifications.",
			"Collect statistical analysis results of stability data from section 3.2.P.8.3, along with summaries from section 3.2.P.8.1, if used to justify specifications.",
			"Obtain dissolution development data from section 3.2.P.2.2.3, including summaries and any cross-references to Module 5 studies, to support justification of the dissolution test.",
			"Prepare cross-references to detailed data in other CTD sections to avoid duplication of information.",
			"Collect analytical procedure details and validation data from sections 3.2.P.5.2 and 3.2.P.5.3 as supporting evidence for specification justification.",
			"Collect certificates of analysis or batch data for excipients that are relevant to the justification of specifications, ensuring inclusion in section 3.2.P.4.4 as supporting material for 3.2.P.5.6.",
		],
		output: [
			"Include justification for skip testing within section 3.2.P.5.6 when applicable.",
			"Ensure that all observed impurities not included in the specification are justified within this section.",
			"Ensure that section 3.2.P.5.6 is presented as a single, non-repeating section (Repeating and/or Reuse Rules: No).",
			"Follow the CTD structure and maintain one-to-one correspondence for this section heading, ensuring it appears only once in the dossier.",
			"Confirm that the section heading and content conform to the CTD hierarchy and numbering conventions (e.g., 3.2.P.5.6 Justification of Specifications).",
			"If stability-related specifications are justified, ensure that relevant stability data, stress study results, and statistical analyses are appropriately summarized and cross-referenced to sections 3.2.P.8.1 and 3.2.P.8.3.",
			"Check that the section is complete, internally consistent, and free of redundant or conflicting information.",
			"Organize the justification logically, linking each specification parameter to supporting data and rationale.",
			"Summarize supporting data from other CTD sections and provide cross-references to detailed information rather than duplicating content.",
			"Use consistent terminology and reference numbering aligned with other CTD sections (e.g., 3.2.P.5.1–3.2.P.5.5).",
			"Clearly indicate when historical analytical procedures or analytical methods unique to the stability program are relevant to the justification, and summarize them appropriately with cross-references.",
			"When justifying dissolution tests, clearly reference dissolution development data from section 3.2.P.2.2.3 and any relevant Module 5 studies.",
			"Verify that all cross-references are accurate and correspond to the correct CTD sections.",
			"Ensure the section is written in clear, scientific language suitable for regulatory review.",
			"Confirm that the justification aligns with ICH Q6A/Q6B principles for specification setting and justification.",
			"Ensure that the section includes a clear heading labeled 'Justification of Specifications' consistent with CTD terminology and formatting conventions.",
			"Provide a clear, concise justification for each test and acceptance criterion included in the specification.",
			"When summarizing data from other CTD sections, ensure that summaries are concise and supported by accurate cross-references to detailed data rather than duplicating full datasets.",
		],
	},
	{
		number: "3.2.P.6",
		title: "Reference Standards or Materials",
		input: [
			"Collect analytical test results and validation data supporting the suitability of each reference standard or material for its intended use.",
			"Gather documentation for any in-house (non-compendial) reference standards, including preparation procedures, qualification protocols, and validation reports.",
			"Collect characterization data for all reference standards, including those for the active moiety and impurities, to be included in section 3.2.P.6.",
			"Identify all reference standards cited in section 3.2.S.5 to determine which may be cross\u0011referenced rather than fully included in section 3.2.P.6.",
			"Gather detailed characterization data for each reference standard or material, including identity, purity, potency, and stability information.",
			"Obtain safety data sheets (SDS) for hazardous reference materials, if applicable.",
			"Collect literature references or scientific justification for the selection and use of specific reference standards or materials.",
			"Collect information on the source and supplier of each reference standard or material, including manufacturing details if applicable.",
			"Obtain certificates of analysis (CoA) for all reference standards or materials used in testing the drug product.",
			"Obtain regulatory documentation for any pharmacopeial reference standards (e.g., USP, EP, JP) used, including proof of compliance with pharmacopeial specifications.",
			"If the drug product is supplied with reconstitution diluent(s), gather complete reference standard information for the diluent(s) as separate drug product(s), as appropriate.",
			"Identify and gather any cross-referenced data from other CTD sections (e.g., 3.2.S.3.2) that support the characterization or qualification of reference standards.",
			"If the drug substance is already approved, obtain relevant health authority guidance or documentation to determine whether existing approval impacts the reference standards or materials requirements for section 3.2.P.6.",
			"Identify all reference standards cited in section 3.2.S.5 to determine which may be cross‑referenced rather than fully included in section 3.2.P.6.",
			"Obtain storage condition data and shelf-life information for each reference standard or material.",
			"Identify all reference standards cited in section 3.2.S.5 to determine which may be cross-referenced rather than fully included in section 3.2.P.6.",
			"Gather information on any secondary standards used, including their traceability to primary standards.",
		],
		output: [
			"Describe the qualification process for each reference standard or material, including analytical methods used and acceptance criteria.",
			"Include characterization data for each reference standard directly in section 3.2.P.6, with cross-references to other CTD sections (e.g., 3.2.S.3.2) where appropriate.",
			"Ensure compliance with applicable pharmacopeial requirements and regional regulatory expectations for reference standards.",
			"Clearly identify each reference standard or material by name, source, lot/batch number, and type (e.g., primary, secondary, pharmacopeial, in-house).",
			"Include stability information and requalification intervals for each reference standard or material.",
			"Cross-reference analytical procedures described in section 3.2.P.5 (Control of Drug Product) where the reference standards are used.",
			"Ensure that section 3.2.P.6 aligns with analytical procedures described in section 3.2.P.5.2 and validation data in section 3.2.P.5.3, maintaining consistency in reference standard usage and description.",
			"Ensure traceability of secondary standards to primary standards is documented and described.",
			"Apply the rule that only reference standards already cited in section 3.2.S.5 may be cross\u0011referenced, and all other reference standards must be fully documented within section 3.2.P.6.",
			"Present information in a structured format, typically including subsections for source, characterization, qualification, storage, and usage.",
			"Apply the rule that only reference standards already cited in section 3.2.S.5 may be cross-referenced, and all other reference standards must be fully documented within section 3.2.P.6.",
			"Apply the rule that only reference standards already cited in section 3.2.S.5 may be cross‑referenced, and all other reference standards must be fully documented within section 3.2.P.6.",
			"When summarizing data from other sections to support reference standard justification, provide clear cross-references to the detailed information rather than repeating content.",
			"Include information on all relevant reference standards, including those for the active moiety and impurities, within section 3.2.P.6.",
			"If the drug product is supplied with reconstitution diluent(s), present the 'P' information for the diluent(s) in its entirety as a separate drug product section, as appropriate.",
			"Confirm that any reference standards used exclusively for stability or batch analysis purposes are appropriately cross-referenced to sections 3.2.P.8.3 or 3.2.P.5.4, ensuring no duplication of data.",
			"If the drug substance is already approved, clearly indicate this in section 3.2.P.6 and note any reliance on existing approvals per health authority guidance.",
			"Ensure that cross-references to other sections are clearly indicated and appropriately linked to avoid duplication of data.",
			"Use consistent terminology aligned with ICH and regional regulatory guidelines when describing reference standards or materials.",
			"For pharmacopeial standards, state the compendia and monograph reference; for in-house standards, provide detailed preparation and characterization information.",
			"Verify that all reference standards or materials described are actually used in the analytical methods for the drug product.",
		],
	},
	{
		number: "3.2.P.7",
		title: "Container Closure System",
		input: [
			"Obtain manufacturer information for each container closure system, including name, address, and manufacturing site details.",
			"Gather data and supporting studies demonstrating suitability of the container closure system with respect to material choice, protection from moisture and light, compatibility (including sorption and leaching), and safety of materials of construction.",
			"Obtain regulatory documentation or certificates of compliance for container closure materials (e.g., DMF references, compendial compliance certificates).",
			"Collect brief descriptions for non-functional secondary packaging components and detailed information for functional secondary packaging components.",
			"Gather any previous regulatory correspondence or approvals related to the container closure system, if applicable.",
			"Collect detailed information on the identity and materials of construction for each primary packaging component used for the drug product.",
			"Obtain description of the container closure system(s) used for storage of the drug substance, including details on storage and shipping conditions for the drug substance.",
			"Gather test data and reports demonstrating suitability of the container closure system for the drug product (e.g., compatibility, protection, safety, and performance).",
			"Obtain specifications for each primary packaging component, including description, identification, and critical dimensions (with drawings where appropriate).",
			"Collect microbiological integrity data for sterile products demonstrating that the container closure system prevents microbial contamination.",
			"Obtain performance data demonstrating reproducibility of dose delivery when the container closure system includes a device component.",
			"Gather data supporting the suitability of the container closure system for storage, transportation (shipping), and use conditions.",
			"Collect detailed descriptions of each container closure system used for the drug product (e.g., blister packs, HDPE bottles, vials).",
			"Prepare individual documents for each container closure system type if multiple systems are used (e.g., bottles vs. blisters).",
			"Gather technical specifications for each container closure component, including materials of construction, dimensions, and performance characteristics.",
			"Collect packaging component information such as aluminum lidding, PVC laminate, or other materials used in the container closure system.",
			"Gather validation data for any non-compendial analytical methods used to test container closure components.",
			"Ensure all relevant reference standards, literature references, and comparator product packaging information are available for cross-reference.",
			"Collect stability study data that supports the integrity and compatibility of the container closure system with the drug product.",
		],
		output: [
			"Provide only a brief description for non-functional secondary packaging components, and more detailed information for functional secondary packaging components.",
			"Discuss the suitability of the container closure system with respect to material choice, protection from moisture and light, compatibility (including sorption and leaching), and safety of materials of construction.",
			"Ensure that if the 'container' keyword is used, it is applied consistently and uniquely to avoid confusion and to support regulatory navigation.",
			"Include validated non-compendial analytical methods used for testing container closure components, where applicable.",
			"Ensure that suitability information is NOT included in 3.2.P.7 and instead reference or link to section 3.2.P.2, per guidance.",
			"Use informative and descriptive document titles to differentiate multiple documents within the section (e.g., 'Description \u0005 Blister', 'HDPE Bottle \u0005 50 mL \u0005 Specification').",
			"Discuss suitability of the container closure system specifically for storage, transportation (shipping), and use conditions.",
			"Organize container closure system information under section 3.2.P.7, with each 'container' keyword value generating a separate section for each container type.",
			"Include additional or differentiating information in document titles (e.g., packaging component details such as 'Al lidding', 'PVC laminate') to clarify content.",
			"When multiple documents are included under 3.2.P.7, assign a priority number to each document to determine the order of appearance within the section.",
			"Use informative and descriptive document titles to differentiate multiple documents within the section (e.g., 'Description ‒ Blister', 'HDPE Bottle ‒ 50 mL ‒ Specification').",
			"Ensure that sterile product container closure integrity considerations are addressed when applicable.",
			"Maintain consistent naming conventions and keyword usage throughout the section to facilitate navigation and lifecycle management.",
			"Ensure that the section aligns with ICH Q6A and Q6B guidance for container closure system description and suitability discussion.",
			"Use informative and descriptive document titles to differentiate multiple documents within the section (e.g., 'Description \u0012 Blister', 'HDPE Bottle \u0012 50 mL \u0012 Specification').",
			"Ensure that all documents under 3.2.P.7 are complete, clearly labeled, and logically ordered to support regulatory review.",
			"Include specifications that cover description, identification, and critical dimensions, with drawings where appropriate.",
			"Ensure that each document clearly identifies the container closure system type and its associated specifications, manufacturer, and description.",
			"The use of the 'container' keyword in 3.2.P.7 is optional; if used, a different and unique 'container' keyword value can be applied to generate a separate section for each container type.",
			"Use informative and descriptive document titles to differentiate multiple documents within the section (e.g., 'Description \u0013 Blister', 'HDPE Bottle \u0013 50 mL \u0013 Specification').",
			"Include discussion of performance characteristics such as reproducibility of dose delivery when the container closure system includes a delivery device.",
			"Ensure that the description of container closure systems for the drug substance includes storage and shipping conditions, and cross-reference related sections (e.g., 3.2.S.6) where applicable.",
			"Use informative and descriptive document titles to differentiate multiple documents within the section (e.g., 'Description \u0003 Blister', 'HDPE Bottle \u0003 50 mL \u0003 Specification').",
			"Applicants may choose the level of granularity that best suits their business needs; all container closure information may be in one document or multiple documents.",
			"Follow Appendix E guidance on granularity: all container closure system information may be in one document or split into multiple documents depending on business needs.",
			"Consider assigning priority numbers to documents within 3.2.P.7 to control the order of appearance when multiple documents are present.",
			"Use informative and descriptive document titles to differentiate multiple documents within the section (e.g., 'Description \u0004 Blister', 'HDPE Bottle \u0004 50 mL \u0004 Specification').",
			"Use informative and descriptive document titles to differentiate multiple documents within the section (e.g., 'Description – Blister', 'HDPE Bottle – 50 mL – Specification').",
			"Provide a clear description of each container closure system, including identity of materials of construction and specifications for each primary packaging component.",
			"For a drug product containing more than one container closure system, information may be provided in its entirety, per system, or per other distinguishing information, in accordance with Appendix E.",
			"Confirm that the section accurately reflects all container closure systems used for the product and that no redundant or conflicting information is included.",
			"Use informative and descriptive document titles to differentiate multiple documents within the section (e.g., 'Description \u0007 Blister', 'HDPE Bottle \u0007 50 mL \u0007 Specification').",
			"Use informative and descriptive document titles to differentiate multiple documents within the section (e.g., 'Description \u0002 Blister', 'HDPE Bottle \u0002 50 mL \u0002 Specification').",
			"Use informative and descriptive document titles to differentiate multiple documents within the section (e.g., 'Description Blister', 'HDPE Bottle 50 mL Specification').",
			"Verify that the structure and organization of the section comply with ICH eCTD v4.0 granularity and keyword conventions.",
		],
	},
	{
		number: "3.2.P.8",
		title: "Stability",
		input: [
			"Obtain the design and justification for any reduced stability study designs (e.g., bracketing, matrixing).",
			"Collect post-approval stability protocol and stability commitment documents, if applicable.",
			"Gather any regulatory correspondence or prior approvals related to stability protocols or commitments.",
			"Collect data from constitution or dilution studies performed as part of the formal stability studies to confirm product quality through shelf-life for inclusion in section 3.2.P.8.3.",
			"Collect data from supporting stability studies that may be relevant to the drug product\u0019s stability profile for inclusion in section 3.2.P.8.3.",
			"Gather information on analytical procedures unique to the stability program.",
			"Collect the detailed statistical analysis report of the stability data, if available.",
			"Prepare the shelf-life specification for the drug product.",
			"Gather summary conclusions on storage conditions and shelf-life or retest period for inclusion in section 3.2.P.8.1.",
			"Obtain data from any supporting stability studies, if considered appropriate for inclusion.",
			"Assemble all raw stability data, including test results, time points, and storage conditions.",
			"Obtain the post-approval stability protocol and stability commitment documentation for inclusion in section 3.2.P.8.2.",
			"Gather all stability study reports for the drug product, including real-time and accelerated stability studies.",
			"Collect stress study data for the drug product, including conditions, methods, and results.",
			"Collect all relevant stability study protocols and experimental designs referenced in ICH Q1A, Q1B, and Q5C.",
			"Gather information on analytical procedures unique to the stability program for inclusion in section 3.2.P.8.3.",
			"Collect stress study data for the drug product, including conditions, methods, and results, ensuring these can be cross-referenced for analytical procedure validation as appropriate.",
			"Assemble supportive information and data for stability studies to be included in section 3.2.P.8.3.",
			"Gather results and data from forced degradation studies and stress condition studies for inclusion in section 3.2.P.8.3.",
			"Compile historical analytical procedures used to generate stability data over the course of the stability program.",
			"Collect information on the drug product storage conditions and shelf-life to be included as established conditions in section 3.2.P.8.1.",
			"Gather supportive information related to post-approval stability protocols and stability commitments for section 3.2.P.8.2.",
			"Collect information on the analytical procedures used to generate stability data and their validation reports, consistent with ICH Q2A and Q2B.",
			"Collect data from supporting stability studies that may be relevant to the drug product’s stability profile for inclusion in section 3.2.P.8.3.",
			"Gather information on any historical changes in analytical procedures used during the generation of stability data for inclusion in section 3.2.P.8.3.",
			"Collect information on in-use stability studies, including storage conditions, time points, and study conclusions.",
		],
		output: [
			"Ensure the stability summary includes types of studies conducted, protocols used, results, and conclusions on storage and shelf-life, including in‑use conditions where applicable.",
			"Include the shelf-life specification in section 3.2.P.8.1 (Stability Summary and Conclusion).",
			"Ensure that sections 3.2.P.8.2 and 3.2.P.8.3 are presented as supportive information consistent with ICH Q12 expectations.",
			"Verify that the stability section aligns with the established conditions framework, distinguishing between established conditions (e.g., shelf-life, storage conditions) and supportive information (e.g., data, protocols).",
			"Include data from supporting studies in section 3.2.P.8.3 if considered appropriate.",
			"Ensure that section 3.2.P.8.2 (Post-approval Stability Protocol and Stability Commitment) clearly presents the post-approval stability protocol and commitment in accordance with ICH Q1A and Q5C.",
			"Verify that all stability-related data and analyses are clearly presented, logically organized, and appropriately cross\u0011referenced within the CTD.",
			"Include data from supporting stability studies in section 3.2.P.8.3 if considered appropriate for the drug product.",
			"Ensure correct subdivision of content into 3.2.P.8.1 (Summary and Conclusion), 3.2.P.8.2 (Post‑approval Stability Protocol and Commitment), and 3.2.P.8.3 (Stability Data).",
			"Organize stability information either in its entirety or separated by manufacturer, stability study protocol, or other distinguishing characteristics, ensuring consistent structuring across the section.",
			"Place stress study data in section 3.2.P.8.3, with cross\u0011references to analytical procedure validation as appropriate.",
			"Ensure correct subdivision of content into 3.2.P.8.1 (Summary and Conclusion), 3.2.P.8.2 (Post-approval Stability Protocol and Commitment), and 3.2.P.8.3 (Stability Data).",
			"Apply Note 10 guidance that stability information may be provided in its entirety or organized per container closure system, manufacturer, strength, stability study protocol, and/or other distinguishing characteristics, ensuring consistent structuring and reviewer clarity.",
			"Place stress study data in section 3.2.P.8.3, with cross‑references to analytical procedure validation as appropriate.",
			"Ensure that data from constitution or dilution studies performed as part of the formal stability studies to confirm product quality through shelf-life are reported in section 3.2.P.8.3, not in 3.2.P.2.6.",
			"Confirm that no unnecessary fragmentation of stability information occurs at lower-level headings, in line with the guidance that such headings are unlikely to require separate documents.",
			"Ensure correct subdivision of content into 3.2.P.8.1 (Summary and Conclusion), 3.2.P.8.2 (Post\u0011approval Stability Protocol and Commitment), and 3.2.P.8.3 (Stability Data).",
			"Cross-reference relevant ICH guidelines (Q1A, Q1B, Q2A, Q2B, Q5C) within the stability section to demonstrate compliance with international standards.",
			"Include information on analytical procedures unique to the stability program in section 3.2.P.8.3, ensuring clarity and traceability.",
			"Include information on historical analytical procedures used to generate stability data in section 3.2.P.8.3.",
			"Place the detailed statistical analysis report in section 3.2.P.8.3 and a summary or conclusions of the statistical analysis in section 3.2.P.8.1.",
			"Ensure that stability information organization aligns with the flexibility permitted in Note 5, while maintaining clarity and traceability for reviewers.",
			"Place stress study data in section 3.2.P.8.3, with cross-references to analytical procedure validation as appropriate.",
			"Ensure that stress study data are located in section 3.2.P.8.3 and appropriately cross-referenced to analytical procedure validation, consistent with the guidance for section S.7.3.",
			"Ensure that section 3.2.P.8.3 (Stability Data) presents results of stability studies, including forced degradation and stress condition data, in an appropriate format (tabular, graphical, or narrative).",
			"Apply Note 4 guidance that lower-level headings within CTD\u0011Q for stability are unlikely to require separate individual documents or files; avoid unnecessary fragmentation.",
			"Ensure the stability summary includes types of studies conducted, protocols used, results, and conclusions on storage and shelf-life, including in\u0011use conditions where applicable.",
			"If the drug product is supplied with reconstitution diluent(s), provide the 'P' information for the diluent(s) in its entirety as separate drug product(s) where appropriate, ensuring stability data for diluents are included in the correct format.",
			"Include information on analytical procedures used to generate stability data and their validation within section 3.2.P.8.3, consistent with ICH Q2A and Q2B.",
			"Include information on any historical changes in analytical procedures used during the generation of stability data in section 3.2.P.8.3.",
			"Apply Note 4 guidance that lower-level headings within CTD-Q for stability are unlikely to require separate individual documents or files; avoid unnecessary fragmentation.",
			"Ensure that the presentation of stability data complies with ICH CTD‑Q structure and terminology requirements.",
			"Ensure that the presentation of stability data complies with ICH CTD\u0011Q structure and terminology requirements.",
			"Ensure that conclusions on storage conditions and retest period or shelf-life are clearly stated in section 3.2.P.8.1.",
			"Include validation information for analytical procedures used to generate stability data within section 3.2.P.8.3.",
			"Follow Note 5 guidance that stability information may be presented in its entirety or separated by manufacturer, stability study protocol, and/or other distinguishing characteristics, ensuring consistency and clarity.",
			"Ensure that section 3.2.P.8.1 clearly identifies the drug product storage conditions and shelf-life as established conditions.",
			"Verify that all stability-related data and analyses are clearly presented, logically organized, and appropriately cross‑referenced within the CTD.",
			"Verify that all stability‑related data and analyses are clearly presented, logically organized, and appropriately cross‑referenced within the CTD.",
			"Ensure the stability summary includes types of studies conducted, protocols used, results, and conclusions on storage and shelf-life, including in-use conditions where applicable.",
			"Verify that all stability-related data and analyses are clearly presented, logically organized, and appropriately cross-referenced within the CTD.",
			"Include information on analytical procedures unique to the stability program in section 3.2.P.8.3.",
			"Present stability study results in an appropriate format (tabular, graphical, or narrative) as required in section 3.2.P.8.3.",
			"Verify that all stability\u0011related data and analyses are clearly presented, logically organized, and appropriately cross\u0011referenced within the CTD.",
			"Ensure that the presentation of stability data complies with ICH CTD-Q structure and terminology requirements.",
			"Include the design and justification for reduced stability designs (e.g., bracketing, matrixing) in section 3.2.P.8.3 (Stability Data).",
			"Ensure that section 3.2.P.8.1 (Stability Summary and Conclusions) includes a concise summary of types of studies, protocols, results, and conclusions on storage conditions and shelf-life or retest period, consistent with ICH Q1A, Q1B, and Q5C.",
			"Apply Note 4 guidance that lower-level headings within CTD‑Q for stability are unlikely to require separate individual documents or files; avoid unnecessary fragmentation.",
		],
	},
	{
		number: "3.2.R.1.1",
		title: "Executed Production Documents",
		input: [
			"Obtain stability study data and protocols if referenced in the executed production documentation (refer to Appendix C).",
			"Ensure availability of technical specifications, manufacturing instructions, and control strategy documentation referenced in the executed production records.",
			"If applicable, obtain viral safety evaluation data for relevant manufacturing steps, ensuring cross-reference to section 3.2.A.2.",
			"Gather results from all relevant batches (e.g., clinical, nonclinical, stability), including those used to justify acceptance criteria, for inclusion in executed production documentation if referenced.",
			"Collect executed batch production records for the drug product, including master production and control records for representative commercial-scale batches.",
			"Gather any relevant regulatory correspondence or prior approvals related to manufacturing process validation or executed batch documentation.",
			"Obtain information on excipients of human or animal origin, including source details, specifications, testing performed, and viral safety data, if referenced.",
			"If the drug substance is already approved, obtain relevant health authority guidance and any associated regulatory documentation before preparing executed production documents.",
			"Collect drug product specifications, analytical procedures, validation data, batch analysis results, impurity characterisation data, and justification for specifications if referenced in executed production documentation.",
			"For drug products supplied with reconstitution diluent(s), obtain full 'P' information for the diluent(s) as separate drug product(s), including executed production records where applicable.",
			"Obtain information on the quality and control of intermediates isolated during the manufacturing process, including relevant specifications, analytical methods, and control data.",
			"Obtain executed records for each container closure system if more than one system is used, ensuring documentation is available per system or distinguishing information (refer to Appendix E).",
			"Gather process validation and/or evaluation study protocols, reports, and results for critical manufacturing steps or assays referenced in executed production documentation (e.g., sterilisation, aseptic processing, filling).",
			"Gather executed manufacturing records for each manufacturing site involved in production, including facility-specific documentation if more than one facility is used (refer to Appendix F).",
			"Collect detailed batch descriptions (batch number, manufacturing site, intended use) for all relevant batches referenced in executed production documentation.",
			"Compile any collated data from multiple batch analyses if warranted and relevant to executed production documentation.",
			"Collect specifications for all excipients used in the drug product, including analytical procedures, validation data, and justification for specifications if referenced in executed production documentation.",
			"Obtain results from any tests performed on executed batches that are not listed in the specifications, if such tests are referenced in the executed production documentation.",
			"For novel excipients referenced in executed production documentation, gather full details of manufacture, characterisation, controls, and cross-references to supporting safety data (nonclinical and/or clinical).",
			"Collect supporting in-process control data, analytical test results, and yield calculations associated with the executed production batches.",
			"Collect any expert opinions or internal QA/QC certifications verifying the accuracy and completeness of executed production records.",
			"Compile executed records for each component or excipient if multiple components or excipients are used (refer to Appendix F and Note 13).",
		],
		output: [
			"When including information on intermediates, ensure clarity on quality and control measures, and present data in alignment with ICH Q2A, Q2B, Q6A, and Q6B guidelines.",
			"If multiple facilities, components, or container closure systems are involved, organize the documents per facility, per component, or per system as applicable (refer to Appendices E and F).",
			"If including results from tests not listed in specifications, clearly identify them and present them in a consistent format within the executed production documentation.",
			"Verify that all executed records correspond to the final manufacturing process described in the dossier and reflect validated commercial-scale conditions.",
			"For submissions involving amendments or variations, ensure that the CTD structure is followed without adding unnecessary 'not applicable' pages for unused CTD headings.",
			"Ensure each executed production record is complete, legible, and includes all required signatures, dates, and batch identifiers.",
			"If viral safety evaluation data is included, ensure it is clearly cross-referenced to section 3.2.A.2 and presented in accordance with relevant ICH guidelines.",
			"When including drug product control information in executed production documentation, ensure specifications, analytical procedures, validation data, batch analyses, impurity characterisation, and justifications are clearly presented and aligned with applicable ICH guidelines.",
			"Prepare the Executed Production Documents as a distinct file under section 3.2.R.1.1 in accordance with regional guidance (Note 14).",
			"If the product is supplied with reconstitution diluent(s), ensure that the 'P' information for the diluent(s) is presented in its entirety as a separate drug product section, with executed production documentation prepared accordingly.",
			"Ensure that the file is properly paginated and labeled according to eCTD or paper submission requirements, with one file per reference if applicable.",
			"When including excipient-related information in executed production documentation, ensure specifications, analytical procedures, validation data, and justifications are clearly organized and referenced to applicable ICH guidelines.",
			"Include clear cross-references to related sections (e.g., 3.2.P.3 for manufacturing process, 3.2.P.7 for container closure, 3.2.P.8 for stability) where applicable.",
			"When stability information is included in executed production documentation, it may be presented in its entirety or organized per manufacturer, per stability study protocol, or by other distinguishing information, ensuring clarity and traceability (refer to Appendix C).",
			"If collated data from multiple batch analyses is included, present it in a clear, consolidated format with appropriate labeling and cross-references.",
			"Perform a final quality check to ensure all executed production documents are complete, accurate, and consistent with the master batch records and regulatory commitments.",
			"Maintain consistent formatting and structure across all executed records, following the CTD Module 3 conventions for document naming and numbering.",
			"Confirm compliance with regional formatting and submission standards for section 3.2.R and its subsections (Note 14).",
			"When presenting process validation or evaluation data for critical steps or assays, clearly describe the process, provide supporting documentation, and reference applicable ICH guidelines (e.g., Q6B).",
			"Do not include modules or sections that are not used for the specific amendment or variation involving executed production documents, ensuring the submission remains concise and compliant with CTD expectations.",
			"When including batch analysis data in executed production documentation, ensure that results from all relevant batches and their descriptions are clearly presented and organized.",
			"For excipients of human or animal origin, present source, specifications, testing, and viral safety data in a clear, traceable manner, with cross-references to section 3.2.A.2.",
			"For novel excipients, ensure full manufacturing, characterisation, and control details are presented in the drug substance format, with cross-references to supporting safety data in section 3.2.A.3.",
		],
	},
	{
		number: "3.2.R.1.2",
		title: "Master Production Documents",
		input: [
			"Obtain analytical procedure information and validation data for any in-process material tests performed in lieu of finished product tests, ensuring alignment with the Master Production Documents.",
			"Collect data and documentation describing any reprocessing operations included in the manufacturing process, including associated critical controls and validation data if applicable.",
			"Collect quality and control information for intermediates isolated during the process.",
			"Obtain the finalized Master Production Documents for the drug product, including the complete manufacturing instructions and batch records.",
			"Collect all standard operating procedures (SOPs) referenced in the Master Production Documents.",
			"Gather process parameter data for each step (e.g., time, temperature, pH) including expected ranges and justifications for numeric ranges for critical steps.",
			"Collect any regulatory-approved versions of the Master Production Documents from previous submissions or regulatory correspondence.",
			"Obtain equipment lists identifying type and working capacity where relevant.",
			"Gather critical process control values from relevant manufacturing batches to support numeric ranges and limits for critical process controls referenced in the Master Production Documents.",
			"Gather any study reports referenced in the Master Production Documents, ensuring that each study report is available as a complete document with text and appendices as applicable.",
			"Obtain any applicable legal authorizations or licenses required for manufacturing as referenced in the Master Production Documents.",
			"Obtain records of any approved changes to the manufacturing process that are reflected in the current Master Production Documents.",
			"Gather a manufacturing process flow diagram showing process steps, material entry points, critical steps, and points of in-process or final product controls.",
			"Gather reference standards and comparator product information if specified in the Master Production Documents.",
			"Collect narrative descriptions of the manufacturing process, including packaging, sequence of steps, scale of production, and details of novel processes or technologies.",
			"Obtain process validation and/or evaluation study descriptions, documentation, and results for critical steps or assays (e.g., sterilisation, aseptic processing, filling).",
			"Obtain details of any overages or over-fills used in the manufacturing process to ensure they are reflected in the Master Production Documents.",
			"Gather validated manufacturing formulas and bill of materials for each batch size.",
			"Collect environmental condition requirements for specific steps (e.g., low humidity for effervescent products).",
			"Gather test methods, acceptance criteria, and supporting experimental data for tests performed at critical steps.",
			"Collect statements or documentation regarding the manipulation of ruminant-derived materials in the manufacturing facility, including any risk assessments or cross-contamination prevention measures.",
			"Collect literature references cited in the Master Production Documents to ensure they can be properly listed in the table of contents.",
			"Collect detailed information on critical steps and intermediates that are controlled during manufacturing, as identified in section 3.2.P.3.3, to ensure consistency with the Master Production Documents.",
			"Obtain the batch formula including a complete list of all components of the dosage form, their amounts per batch (including overages), and references to their quality standards.",
			"Obtain technical specifications for raw materials, intermediates, and finished product as referenced in the Master Production Documents.",
			"Gather approved manufacturing process descriptions, including step-by-step instructions, equipment lists, and in-process control points.",
			"Gather information identifying all process controls, including critical process controls, as referenced in the Master Production Documents.",
			"Obtain justification and supporting data for any proposed reprocessing of materials.",
			"Collect any relevant quality agreements with contract manufacturing organizations (CMOs) if they are involved in production.",
		],
		output: [
			"State process parameters for each step (e.g., time, temperature, pH) with expected ranges; justify numeric ranges for critical steps in alignment with section 3.2.P.3.4.",
			"Cross-reference related sections of the CTD where applicable (e.g., specifications, analytical procedures) to maintain traceability.",
			"Include all mandatory elements: product name, batch size, list of raw materials with quantities, detailed manufacturing instructions, in-process controls, and packaging instructions.",
			"Include a manufacturing process flow diagram showing all process steps, material entry points, critical steps, and control points, ensuring clarity and completeness.",
			"Provide a narrative manufacturing process description that includes packaging, sequence of steps, scale of production, and additional detail for novel processes or technologies affecting product quality.",
			"Ensure the Master Production Documents are presented in a clear, logical, and sequential format covering all manufacturing steps from material preparation to final packaging.",
			"Include tests and acceptance criteria for critical steps with justification and supporting experimental data.",
			"Ensure that all documents within the 3.2.R regional section, including 3.2.R.1.2 Master Production Documents, use titling, ordering, and structuring consistent with region-specific regulatory expectations.",
			"Use consistent terminology and units of measure throughout the document to avoid ambiguity.",
			"Provide information on the quality and control of intermediates isolated during the process.",
			"Ensure that justification for any proposed reprocessing of materials is clearly presented with supporting data referenced or included.",
			"Check that all referenced SOPs, specifications, and control procedures are current and valid at the time of submission.",
			"If applicable, organize the 3.2.R.1.2 Master Production Documents using 3.2.R sub-sections in alignment with regional guidance.",
			"Include numeric ranges and limits for critical process controls supported by data from relevant manufacturing batches, ensuring traceability to validation and control data.",
			"When determining document granularity, ensure that any future lifecycle changes can be managed by replacing complete documents/files rather than partial updates.",
			"Maintain pagination, section headings, and formatting consistent with CTD Module 3 requirements.",
			"Include a statement regarding the manipulation of ruminant-derived materials in the manufacturing facility, ensuring alignment with relevant sections addressing adventitious agent safety (3.2.A.1 and 3.2.A.2).",
			"Ensure that any reprocessing steps are clearly described within the manufacturing process section of the Master Production Documents, with cross-references to critical controls and validation data where applicable.",
			"Ensure that detailed information on critical steps and intermediates controlled during manufacturing is clearly described and consistent with section 3.2.P.3.4.",
			"If any in-process material test replaces a finished product test, ensure that the analytical procedure and validation information are fully described and cross-referenced to the appropriate CTD sections (3.2.P.3.4 and 3.2.P.5.1).",
			"Identify all process controls, including critical controls, within the Master Production Documents to ensure traceability and compliance with GMP.",
			"Include any overages or over-fills explicitly in the manufacturing instructions and batch formula sections of the Master Production Documents.",
			"Verify that all instructions are detailed enough to allow reproducible manufacturing by trained personnel.",
			"Verify that all manufacturing process descriptions in the Master Production Documents align with the information provided in CTD sections 3.2.P.3.3 through 3.2.P.3.5, ensuring consistency across the dossier.",
			"Ensure that each study report referenced or included in the Master Production Documents is provided as a single document unless the report is large, in which case the text portion should be one document and appendices may be separate documents.",
			"Ensure compliance with Good Manufacturing Practice (GMP) documentation standards, including version control, authorization signatures, and effective dates.",
			"Clearly describe environmental condition requirements for specific steps where applicable.",
			"Ensure that the document reflects the currently approved manufacturing process and is consistent with other sections of the submission.",
			"Verify that documents rolled up to this level are appropriate and that multiple documents can be submitted only when justified by report size or content structure.",
			"Ensure that lower-level CTD-Q headings within section 3.2.R.1.2 do not include standalone documents or files, following regulatory guidance that these levels typically do not contain separate attachments.",
			"Ensure that literature references cited in the Master Production Documents are listed in the table of contents for traceability and compliance with CTD structure.",
			"Confirm that any process tests replacing end-product tests are clearly identified as process tests in the Master Production Documents and appropriately referenced in the product specification section.",
			"Present the document in a format acceptable to the regulatory authority (e.g., searchable PDF with bookmarks for subsections).",
			"Identify equipment by type and working capacity where relevant in the manufacturing process description.",
			"Include process validation and/or evaluation study descriptions, documentation, and results for critical steps or assays, ensuring alignment with relevant ICH guidelines.",
		],
	},
	{
		number: "3.2.R.2",
		title: "Analytical Procedures and Validation Information",
		input: [
			"Compile any regulatory correspondence or prior approvals related to analytical methods or validation approaches.",
			"Gather analytical procedures and acceptance criteria for intermediates or critical steps if these are relevant to the analytical validation information in 3.2.R.2.",
			"Collect any analytical procedures for the control of materials (e.g., starting materials, reagents, raw materials, solvents) if they are relevant to analytical validation and not already included in other sections.",
			"Ensure that any analytical procedures and validation information included in 3.2.R.2 are limited to those relevant to the drug substance and drug product quality control, and not bioanalytical methods used in clinical or nonclinical studies, which should be gathered for Modules 4 and 5 instead.",
			"Consult the relevant health authority for guidance if the drug substance is already approved, to determine whether existing analytical validation data can be referenced or abbreviated.",
			"Collect analytical procedures used for stability studies if they are relevant to the analytical validation summary.",
			"Collect reference standards and information on comparator products used in analytical validation.",
			"Obtain chromatograms and other representative analytical outputs supporting validation and method performance.",
			"Gather cross-references to analytical methods described in sections 3.2.S (Drug Substance) and 3.2.P (Drug Product) to ensure consistency.",
			"Collect all analytical procedures used to control the drug substance and drug product, including current and historical versions if relevant to data in the dossier.",
			"Obtain expert opinions or literature references supporting analytical methodology or validation approaches.",
			"Refer to Appendix C for any stability-related analytical validation information that may need to be included or cross-referenced in 3.2.R.2.",
			"Gather validation reports for each analytical procedure, including method validation data, system suitability results, and performance characteristics.",
			"Assemble technical documents such as method development reports, standard operating procedures (SOPs), and analytical method transfer documentation.",
			"Gather data tables summarizing validation parameters (accuracy, precision, linearity, specificity, detection limit, quantitation limit, robustness, etc.)",
			"Gather specifications for each quality attribute in the drug substance specification, including the associated test method and acceptance criteria, to ensure alignment with analytical validation information in 3.2.R.2.",
			"Obtain any validation information for analytical procedures used at critical steps or for intermediates if applicable to the analytical validation summary.",
			"Gather data tables summarizing validation parameters (accuracy, precision, linearity, specificity, detection limit, quantitation limit, robustness, etc.).",
			"Refer to Appendix A for any additional regional or authority-specific requirements applicable to analytical procedures and validation information.",
		],
		output: [
			"Ensure consistency between analytical procedures and specifications listed in 3.2.S.4.1 and 3.2.P.5.1.",
			"When analytical procedures relate to control of materials, intermediates, or critical steps, ensure they are cross-referenced to the appropriate CTD sections (e.g., 3.2.S.2.3, 3.2.S.2.4, 3.2.S.4.2) while summarizing validation aspects in 3.2.R.2.",
			"Acknowledge that lower-level CTD-Q headings (such as 3.2.R.2 sub-sections) are unlikely to contain individual documents or files; ensure the section is compiled as a single integrated document rather than multiple attachments.",
			"Use consistent terminology and units throughout the section to align with ICH and regional regulatory standards.",
			"Cross-reference analytical methods between drug substance and drug product sections when identical or similar methods are used, ensuring clarity on sample preparation differences.",
			"Confirm that analytical validation data supporting reprocessing operations or critical controls are clearly identified and traceable to the relevant manufacturing steps described elsewhere in the dossier.",
			"Describe analytical procedures in sufficient detail to allow replication, including sample preparation, equipment, reagents, and conditions.",
			"Ensure that acceptance criteria for intermediates or critical steps are referred to in the appropriate specifications section (e.g., 3.2.S.4.1) and that analytical procedures are referred to in the correct analytical procedures section (e.g., 3.2.S.4.2) while maintaining validation summaries in 3.2.R.2.",
			"Ensure that any stability-related analytical validation information is organized consistently with the approach described in Appendix C (e.g., by manufacturer, stability study protocol, or other distinguishing information).",
			"Ensure that analytical procedures and validation information are clearly organized and presented under section 3.2.R.2, with appropriate cross-references to 3.2.S and 3.2.P sections.",
			"Ensure that any validation information related to reprocessing or critical process controls described in 3.2.P.3.3 and 3.2.P.3.4 is appropriately cross-referenced in 3.2.R.2 if analytical validation data are included.",
			"Clearly identify which analytical procedures are used for control, stability, or other purposes, and ensure they are placed in the correct CTD sections with cross-references as needed.",
			"Include relevant chromatograms within the validation section to demonstrate method performance.",
			"Do not include bioanalytical methods and their validation reports in 3.2.R.2; instead, ensure they are placed in Module 4 (section 4.2.2.1) for nonclinical studies and Module 5 (section 5.3.1.4) for clinical studies, per CTD guidance.",
			"Ensure that section 3.2.R.2 follows regional guidance on whether to use 3.2.R or its sub-sections, per Note 14.",
			"Confirm that all validation summaries comply with applicable ICH guidelines (e.g., Q2(R2)) and regional requirements for analytical validation documentation.",
			"Ensure that for each quality attribute in the drug substance specification, the corresponding test method and acceptance criteria are clearly linked to the analytical validation information presented in 3.2.R.2.",
			"Present validation information in a structured format covering all required parameters (accuracy, precision, specificity, linearity, range, detection limit, quantitation limit, robustness).",
			"Verify that all chromatograms and validation data are properly labeled, legible, and traceable to the corresponding analytical method.",
		],
	},
	{
		number: "3.3",
		title: "Literature References",
		input: [
			"Retrieve any regulatory or technical documents that cite or rely on the literature references to ensure consistency.",
			"Collect literature references cited in the nonclinical summaries (sections 2.6.2.8, 2.6.4.11, and 2.6.6.11) to ensure consistency with Module 3.3 Literature References.",
			"Collect any literature references that support microbiology data (both in vitro and in vivo studies) included in the efficacy sections.",
			"Collect any literature references included in ICH E3 Appendices 16.1.11 (publications) and 16.1.12 (literature references) for relocation or cross-referencing to CTD Module 5.4.",
			"Prepare a compiled list of literature references to be included in the CTD Table of Contents.",
			"Obtain copies of the cited literature articles, publications, or reports for verification and archival purposes.",
			"Retrieve any literature references cited in statistical analyses or reports of analyses from more than one study (e.g., section 5.3.5.3).",
			"Gather full bibliographic details for each literature reference (author(s), title, journal, year, volume, pages, DOI if available).",
			"Collect all literature references cited in Module 4 study reports relevant to the submission.",
			"Ensure that literature references cover all relevant studies (clinical, non-clinical, in vitro, etc.) that support the application.",
			"Gather literature references that support integrated analyses of efficacy (ISE) or safety (ISS) if cited in the submission.",
		],
		output: [
			"Ensure that the Table of Contents for Module 3 includes module numbers, volume numbers, and tab identifiers as required.",
			"Verify that all literature references cited in the submission are accurately cross-referenced in the relevant CTD sections.",
			"Ensure consistent formatting and bibliographic style for all literature references.",
			"For eCTD submissions, ensure that files for publications and literature references are physically located in the Module 5.4 folder.",
			"Ensure each literature reference is presented as a separate document or appropriately grouped if applicable.",
			"Include a distinct identifier in headers or footers on every literature reference document; abbreviations of long titles are acceptable.",
			"List all literature references in the CTD tables of contents as required by Note 2.",
			"Follow the granularity guidance: typically provide a single document for each study report; if a report is large, separate into a text portion and one or more appendices.",
			"When splitting large reports, ensure the text portion is one document and appendices are separate documents, maintaining logical organization.",
			"If additional sub-numbering is used within literature reference documents, ensure subordinate headings (e.g., 3.3.1, 3.3.2) do not appear in the overall CTD Table of Contents but may be used as internal navigation or electronic bookmarks.",
			"Ensure that literature references originally located in ICH E3 Appendices 16.1.11 and 16.1.12 are placed in CTD Module 5.4, maintaining proper cross-references and consistency with the CTD organization.",
			"If a list of references is not explicitly covered in the guidance for certain summaries (e.g., nonclinical summaries 2.6.2.8, 2.6.4.11, 2.6.6.11), include a clearly labeled list of references section to ensure completeness and traceability of cited literature.",
			"In the eCTD index.xml file, include leaf elements for publications and literature references under the same heading as other study report files, with additional information included in any accompanying study tagging file.",
			"Place the list of literature references within the most appropriate location of the dossier section, and create new subsection numbers if needed to improve clarity and reviewer usability.",
			"Consider lifecycle management: choose document granularity so that when relevant information changes, complete document/file replacements can be provided.",
			"In the eCTD index.xml file, repeat the relevant leaf element under heading 5.4 Literature References to maintain correct indexing and reviewer navigation.",
			"Provide one file per literature reference in CTD section 3.3 to comply with granularity and submission structure requirements.",
			"Ensure clarity of cross-references by providing sufficient context in the text when only section numbers are used in cross strings.",
			"Allow modifications to the literature references format when needed to provide the best possible presentation and facilitate understanding by regulatory reviewers.",
			"When cross-referencing literature references in paper submissions, include only the CTD section number in the cross string to maintain brevity, but write the text so the reader can understand the section content.",
			"Paginate literature references according to the original source page numbering (journal, abstract, etc.), not with new sequential numbering.",
		],
	},
	{
		number: "4",
		title: "Non-Clinical Study Reports",
		input: [
			"Collect juvenile animal study data and prepare tabulations using the appropriate template for the type of study conducted.",
			"Gather microbiology data from both in vitro and in vivo studies if applicable to the product, for potential inclusion in the non-clinical sections.",
			"Compile all literature references cited in the non-clinical study reports for inclusion in the table of contents.",
			"Collect all non-clinical study reports relevant to the product, including pharmacology, pharmacokinetics, and toxicology studies.",
			"Ensure all study identifiers, titles, and report numbers are available for accurate listing and cross-referencing in Module 4.",
			"Ensure individual-animal data are available in the study report or as an appendix to the study report.",
			"Obtain any large study reports (e.g., carcinogenicity studies) in both text and appendix components, prepared as separate documents if necessary.",
			"For each non-clinical study report to be included in Module 4, ensure the complete study documentation is available for the specific CTD subsection (e.g., 4.2.1.1, 4.2.1.2, etc.) as indicated by 'Studies Note 1'.",
			"Ensure all supporting technical data, raw datasets, and analyses associated with the non-clinical studies are available for reference.",
			"Prepare a complete Table of Contents for Module 4 listing all non-clinical study reports and their locations in the CTD.",
			"Collect any cross-reactivity study reports (animal species cross-reactivity and human tissue cross-reactivity) relevant to monoclonal antibody development for inclusion in the appropriate non-clinical section.",
			"Gather tabulated summaries of non-clinical data, ensuring they follow the order of the Nonclinical Written Summaries and include sufficient detail for reviewer assessment.",
			"Collect any previous regulatory correspondence or approvals related to non-clinical studies if relevant to the submission.",
			"Gather all nonclinical pharmacokinetic study reports that may appear in multiple subsections (e.g., absorption, distribution, metabolism, excretion) to determine appropriate placement or cross-referencing.",
			"Gather complete study reports for each non-clinical study conducted, ensuring each report includes text and appendices as applicable.",
			"Collect any integrated analyses or statistical outputs from multiple studies that are relevant to non-clinical safety or efficacy aspects, if they are to be referenced in the non-clinical section.",
		],
		output: [
			"Follow the order of presentation given for the Nonclinical Written Summaries when preparing the Nonclinical Tabulated Summaries.",
			"Include module numbers, volume numbers, and tab dividers in all Tables of Contents for Module 4 documents.",
			"Include a distinct identifier in headers or footers on every page of each Module 4 document; abbreviations are acceptable and the full report title is not required.",
			"Place cross-reactivity studies (animal species and human tissue) in the most appropriate location within Module 4 to facilitate reviewer understanding, such as under 4.2.3.7 Other Toxicity Studies if suitable.",
			"Place the list of references for non-clinical summaries in the most appropriate location within the summary and create new subsection numbers if needed to improve clarity and reviewer understanding.",
			"Provide a single document for each non-clinical study report included in Module 4, unless the report is large (e.g., carcinogenicity study).",
			"Provide a Table of Contents for Module 4 that lists all non-clinical study reports and their locations in the CTD.",
			"Organize study reports in Module 4 according to the agreed CTD format, following the specified numbering and subheadings for sections 4.2.1 to 4.2.3.5.4.",
			"For nonclinical pharmacokinetic studies that could appear in multiple sections, either include the full study report in the first relevant section (e.g., Absorption) and cross-reference it in other sections, or include the full report in each section as appropriate.",
			"Use sub-numbering within Module 4 documents (e.g., 4.2.3.3.1, 4.2.3.3.2) as needed for navigation, but do not include these lower-level headings in the overall CTD Table of Contents.",
			"Tabulate juvenile animal study data using the template appropriate for the type of study.",
			"When referencing other sections in cross-references, include the section number in the cross string and write the surrounding text so the reader understands the section content without needing the full section name.",
			"For large study reports, submit the text portion as one document and the appendices as one or more separate documents.",
			"Applicants may modify the format of non-clinical study reports to provide the best possible presentation and facilitate understanding and evaluation by reviewers.",
			"If microbiology information is relevant to non-clinical sections, ensure it is described appropriately in addition to its placement in efficacy sections.",
			"Ensure that documents are submitted at the appropriate level of granularity, avoiding unnecessary roll-up of multiple studies into one file.",
			"Ensure individual-animal data are placed in the study report or as an appendix to the study report.",
			"Confirm that one or multiple documents can be submitted at this level, depending on study size and content.",
			"In eCTD submissions, avoid submitting duplicate files for the same nonclinical pharmacokinetic study; instead, provide references to the single file.",
			"Paginate literature references according to the original source page numbering (e.g., journal or abstract pagination).",
			"Ensure Tabulated Summaries provide sufficient detail for reviewer assessment and concise overviews of related information.",
			"Ensure that each non-clinical study report is filed in the correct CTD subsection (e.g., 4.2.1.1, 4.2.1.2, etc.) as indicated by 'Studies Note 1'.",
			"Ensure consistency in document naming and numbering to facilitate lifecycle management and document replacement.",
			"Maintain section headings for non-clinical study categories even when studies were not conducted, and provide a brief explanation for the absence of those studies.",
			"For paper CTD submissions, include a Table of Contents for Module 4; for eCTD submissions, no separate TOC entry is required for Module 4.",
			"Include bookmarks within PDF files for sub-sections below the CTD guideline numbering to facilitate reviewer navigation.",
			"Follow the suggested content and format of the Tabulated Summaries as per Appendix C examples, while optimizing presentation for the specific product.",
			"Check that all non-clinical study reports are complete, properly formatted, and compliant with CTD Module 4 submission standards.",
			"Verify that each study report is clearly identified and organized according to the CTD structure (e.g., 4.2.3.7 subsections).",
			"List all literature references in the tables of contents for Module 4.",
			"When relevant information changes during the product lifecycle, replace complete documents/files rather than partial updates.",
			"Ensure that Module 4 follows the CTD format but recognize that content may vary by region due to regional requirements or applicant preferences.",
		],
	},
	{
		number: "5.1",
		title: "Table of Contents of Module 5",
		input: [
			"Collect the official CTD numbering hierarchy for Modules 2 and 3 to ensure consistency of numbering and cross-referencing in the Module 5 Table of Contents.",
			"Obtain the official CTD/eCTD hierarchy for Module 5, including section 5.1 placement and relationship to 5.2, 5.3, and 5.4, to ensure correct ordering in the Table of Contents.",
			"Gather final titles of all clinical study reports, summaries, and appendices to be listed in the Table of Contents.",
			"Refer to Appendix A and Appendix C of the CTD guideline for any cross-referenced structural or numbering guidance that may affect the organization of Module 5 Table of Contents.",
			"Collect any regional guidance or appendices referenced for TOC structure or numbering conventions applicable to Module 5 (e.g., Appendix references for numbering or document grouping).",
			"Obtain the list of section titles and numbering conventions used in Module 3 (e.g., 3.1, 3.2.S, 3.2.P) to verify alignment and consistency in the overall CTD structure when preparing the Module 5 Table of Contents.",
			"Collect the unique short identifiers assigned to each clinical study report to ensure they are consistently used throughout Module 5, including the Table of Contents.",
			"Obtain volume numbers, module numbers, and tab identifiers for all parts of Module 5 to be included in the Table of Contents.",
			"Obtain literature references included in Module 5, with their original source pagination for accurate referencing.",
			"Gather the complete list of all clinical study reports (including identifiers) that must be individually listed in the Module 5 Table of Contents.",
			"Collect the complete list of all documents, reports, and datasets included in Module 5 (Clinical Study Reports) to be referenced in the Table of Contents.",
			"Consult the health authority for guidance if any drug substance referenced in Module 5 is already approved, to determine if cross-referencing or omission is appropriate for the Table of Contents.",
			"Collect the definition of 'document' as applied to Module 5 for both paper and electronic submissions, including pagination and tab separation rules for paper and file boundaries for eCTD.",
			"Gather the standard naming conventions for drug substance and drug product sections (e.g., 'name, manufacturer', 'name, dosage form') to ensure consistent labeling in the Table of Contents.",
			"Collect the list of all approved or proposed indications for the product to ensure indication‑specific numbering can be applied in section 5.3.5 where required.",
			"Gather information on the internal sub-numbering used within documents (if applicable) for navigation purposes, ensuring alignment with CTD numbering.",
			"Collect any abbreviations or distinct identifiers for long report titles to be used in headers/footers.",
			"Collect the full list of numerical CTD section numbers applicable to Module 5 to ensure complete inclusion in the Table of Contents.",
			"Confirm whether the submission is in paper or eCTD format, as the Table of Contents requirements differ between formats (TOC required for paper, not for eCTD).",
			"Obtain the detailed organisation structure of Clinical Study Reports and related information in Module 5 as outlined in the CTD guideline to ensure accurate TOC mapping.",
			"Gather the mapping of each clinical study (controlled, uncontrolled, efficacy, safety) to its corresponding indication to support indication‑specific organization in the 5.3.5 TOC.",
			"Gather the applicable granularity guidance for Module 5 from the CTD Granularity Document, including rules for when multiple documents/files are appropriate at a given hierarchy level.",
		],
		output: [
			"Ensure that the numbering and section titles in the Module 5 Table of Contents are consistent with the numbering and titles used in Modules 2 and 3, maintaining cross-module alignment.",
			"Ensure that lower-level headings that are unlikely to contain individual documents or files (as noted in CTD guidance) are not unnecessarily expanded in the Module 5 Table of Contents.",
			"Ensure consistent use of unique short identifiers for each clinical study report throughout Module 5, including within the Table of Contents.",
			"Do not include page numbers in the comprehensive Table of Contents for Module 1; for Module 5, there are no specific guidelines for page numbers, but ensure consistency and clarity.",
			"Apply the CTD/eCTD granularity principles to Module 5 Table of Contents: in paper submissions, each document should be a set of sequentially numbered pages separated by a tab; in eCTD, each document corresponds to a file starting at the same point as a tab in paper format.",
			"Verify that the numbering and structure of the Module 5 Table of Contents align with the CTD numbering hierarchy and regional guidance.",
			"Ensure the Module 5 Table of Contents includes all numerical items listed in the CTD guideline for Module 5.",
			"Ensure literature references are paginated according to the original source pagination when referenced in Module 5.",
			"Include module numbers, volume numbers, and tab dividers in the Table of Contents for Module 5.",
			"Ensure that Literature References for Module 5, if present, are listed in a Table of Contents specific to the literature reference section.",
			"Do not include headings in the overall Table of Contents that go below the numbering specified in the CTD guideline; lower-level numbering (e.g., 5.3.1.1, 5.3.1.2) can be used within documents for navigation but should not appear in the overall TOC.",
			"Ensure that the Table of Contents reflects the correct hierarchical indentation and structure for each section and subsection, consistent with CTD formatting conventions.",
			"Ensure consistency across all indications so sections follow the same organizational pattern when applicable.",
			"For paper submissions, ensure that a Table of Contents is included for Module 5; for eCTD submissions, no separate TOC file is required as navigation is handled electronically.",
			"Ensure that indication‑specific sub‑organization (e.g., controlled vs. uncontrolled studies per indication) is correctly reflected in the Table of Contents for section 5.3.5.",
			"Ensure that the granularity (document/file division) used in Module 5 Table of Contents is consistent throughout the life of the dossier to facilitate lifecycle management.",
			"Use the same hierarchical numbering format (e.g., 3.2.S.1, 3.2.P.1) when referencing or cross-linking to other modules in the Table of Contents to maintain consistency across the CTD.",
			"Follow the CTD/eCTD hierarchy rules for Module 5 when deciding whether to list single or multiple documents at a given section level in the Table of Contents.",
			"If any cross-referenced appendices (e.g., Appendix A or C) affect the numbering or structure of Module 5, ensure that the Table of Contents reflects these relationships accurately.",
			"Ensure the Module 5 Table of Contents continues down to at least the level of the clinical study report, identifying each clinical study report individually.",
			"Ensure that for section 5.3.5, when multiple indications exist, the CTD numbering is retained and extended with indication identifiers (e.g., 5.3.5.UTI, 5.3.5.1 UTI Controlled Studies, 5.3.5 Pneumonia).",
			"Optionally include the sections of clinical study reports (E3 structure) in the Module 5 Table of Contents or leave these sections to the TOCs within individual study reports.",
			"Do not include 'not applicable' pages or placeholder pages for unused CTD headings or modules when preparing the Module 5 Table of Contents, including for amendments or variations.",
			"Ensure that each document listed in the Table of Contents has a distinct identifier in the header/footer of every page; abbreviations of long titles are acceptable.",
			"Ensure that the Table of Contents clearly distinguishes between different study types or categories if multiple study types are included, maintaining clarity and traceability.",
			"Maintain consistent formatting and structure across the Table of Contents, ensuring clear correspondence between TOC entries and actual document titles or identifiers.",
			"Ensure that the Module 5 Table of Contents accurately reflects the 'Detailed Organisation of Clinical Study Reports and Related Information in Module 5' as specified in the CTD guideline.",
			"Present the Module 5 Table of Contents in the order described in Guideline M4E, ensuring correct placement of 5.1 before 5.2, 5.3, and 5.4.",
			"For electronic submissions, lower-level section numbers can be included as PDF bookmarks but not in the overall TOC.",
		],
	},
	{
		number: "5.2",
		title: "Tabular Listing of All Clinical Studies",
		input: [
			"Collect any additional information the applicant considers useful for inclusion in the table, such as special study notes or clarifying details.",
			"Gather study identifiers (study numbers, titles, and codes) for each clinical study.",
			"Identify any large-scale statistical outputs or integrated analyses related to the listed studies that may need to be referenced or linked to separate reports in section 5.3.5.3.",
			"Retrieve regulatory correspondence or prior submissions that confirm the inclusion or exclusion of specific studies.",
			"Collect any relevant literature references or external clinical data that support the inclusion of specific studies in the listing.",
			"Gather the sequence of studies as described in Section 5.3 to ensure the tabular listing follows the correct order or to justify any deviations.",
			"Collect a complete list of all clinical studies conducted with the investigational product, including clinical pharmacology, efficacy, safety, and bioequivalence studies.",
			"Gather information on ongoing or terminated studies to ensure completeness of the tabular listing.",
			"Obtain study reports and protocols for all clinical studies to extract key information such as study design, population, treatment arms, and duration.",
			"Gather literature references cited in relation to the clinical studies so they can be listed in the tables of contents as required.",
			"Ensure access to the clinical study database or clinical trial management system (CTMS) to verify study details and metadata.",
			"Collect summary data from each clinical study, including study type (e.g., Phase I, II, III, IV), indication, and geographic location.",
			"Obtain internal quality assurance verification that all clinical studies have been captured and cross-checked against the clinical development plan.",
			"Obtain or create a mapping document linking each study’s unique short identifier to its full study title for accurate inclusion in Section 5.2.",
			"Retrieve the information elements specified in Table 5.1 of the CTD guideline to ensure all required data fields are included in the tabular listing.",
			"Collect the unique short identifiers assigned to each clinical study to ensure consistent use across all modules.",
		],
		output: [
			"Applicants may modify the tabular format if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation by regulatory reviewers.",
			"Ensure that each study has a unique short identifier and that this identifier is used consistently across all modules, including in Section 5.2.",
			"Follow the sequence of studies as described in Section 5.3 when listing studies; if a different sequence is used, provide an explanatory note or introduction describing the rationale.",
			"Perform a final compliance check to confirm that all clinical studies referenced elsewhere in the CTD are represented in the tabular listing.",
			"Use the example format referenced in Table 5.1 as a model for structuring the tabular listing, where applicable.",
			"When referencing other sections or reports in the tabular listing, use only the section number in cross-references (cross strings) to keep them concise, and ensure the surrounding text makes the section content clear.",
			"Ensure that the tabular listing is concise, factual, and free of interpretive commentary.",
			"Ensure that the table is complete, accurate, and cross-referenced with the clinical study reports and summaries in Module 5.",
			"Prepare a single comprehensive table listing all clinical studies, organized in a clear and consistent tabular format.",
			"Use a format that facilitates regulatory review and understanding of the clinical development program.",
			"If additional information beyond Table 5.1 is included, ensure it is clearly presented and justified as useful for understanding the clinical program.",
			"When determining the level of granularity for splitting large study reports, consider that any relevant information changes during the product lifecycle will require replacement of complete documents/files.",
			"Include the type of information identified in Table 5.1 of the guideline for each study entry.",
			"Ensure that section 5.2 contains only a summary listing of all clinical studies, not the detailed listings or appendices from individual clinical study reports.",
			"Ensure that literature references are listed in the tables of contents in accordance with CTD requirements.",
			"If a study category is not applicable or no studies were conducted, retain the section heading and provide a brief explanation rather than deleting the section.",
			"Include a distinct identifier in the header or footer of each page of Section 5.2; an abbreviation is acceptable and the full study title is not required.",
			"In paper submissions, when creating cross-references (cross strings) to other sections from Section 5.2, include only the section number in the cross string to keep it concise, and write the surrounding text so that the reader understands the section content without needing the section name.",
			"Ensure that the full title of each study is included in Section 5.2, as required by CTD guidance.",
			"Maintain consistent terminology and abbreviations across all entries to align with CTD conventions.",
			"Ensure that the organization of the tabular listing supports completeness and facilitates regulatory review by aligning with the structure of Section 5.3.",
			"Ensure that any modifications to the standard format maintain clarity, completeness, and consistency with CTD structure and numbering conventions.",
			"Follow CTD formatting conventions for tables, including clear labeling, pagination, and consistent layout.",
			"When a study report is large, such as a carcinogenicity study, it may be split into multiple documents: the text portion as one document and appendices as one or more separate documents.",
			"Include footnotes or annotations where necessary to clarify study relationships, replacements, or special circumstances (e.g., terminated or ongoing studies).",
			"Ensure that the tabular listing of all clinical studies and related information is provided as a distinct section (5.2) within Module 5.",
			"Include key columns such as study identifier, title, study design, study population, indication, treatment arms, duration, and study status.",
			"Ensure that the table includes all clinical studies, regardless of whether they are pivotal, supportive, or exploratory.",
			"Verify that all study identifiers and titles match those used in other CTD sections to maintain consistency.",
		],
	},
	{
		number: "5.3.1.1",
		title: "Bioavailability (BA) Study Reports",
		input: [
			"Data on correlations between in vitro dissolution and BA, including pH effects and dissolution specifications",
			"Tabular summaries of BA studies in the format of Table 2.7.1.1, including study reference number, objective, design, treatments (dose, dosage form, route, product ID), subject demographics (number, sex, type, age mean and range), mean PK parameters (Cmax, Tmax, AUC, Cmin if applicable, T1/2, other), and study report location",
			"Study protocols and statistical analysis plans for each BA study",
			"Supportive data from Section 2.7.2 relevant to BA studies, if applicable",
			"Data on food effects on BA, including meal type and timing information",
			"Narrative summaries or abstracts describing critical design features and results of BA studies (can be derived from ICH E3 synopsis)",
			"References or electronic links to the full BA study reports for inclusion in narratives",
			"Any pharmacokinetic (PK), pharmacodynamic (PD), clinical, or in vitro dissolution data generated as part of BA studies",
			"Tabular data summarizing BA study results, including mean ratios (test/reference) for Cmax and AUC and their 90% confidence intervals or other recommended BE metrics",
			"Data on inter- and intrasubject variability for each formulation in comparative BA studies",
			"Complete datasets, including raw data, summary tables, and statistical analyses for BA studies",
			"Full study reports for dosage form proportionality studies",
			"Comparator product information (e.g., intravenous formulation, oral liquid formulation) used in BA studies",
			"Full study reports for food-effect studies",
			"Tabular summaries of in vitro dissolution studies in the format of Table 2.7.1.2, including study reference number, product ID/batch number, dosage form, test conditions (apparatus, rotation speed, medium/temperature), number of dosage units, collection times, mean % dissolved (range), and study report location",
			"Information on formulation and manufacturing changes that may affect BA or BE, including supporting PK data before and after changes",
			"Relevant literature references supporting study design or interpretation of BA results",
			"Full study reports for bioavailability (BA) studies comparing the release and systemic availability of a drug substance from a solid oral dosage form to the systemic availability of the drug substance given intravenously or as an oral liquid dosage form",
			"Comparative BA data for different dosage form strengths and clinical versus marketed formulations",
			"Regulatory correspondence or prior submission references related to BA studies, if applicable",
			"Bioanalytical and analytical method descriptions and validation reports used in BA studies (if not already included in Section 5.3.1.4)",
			"Individual study synopses for each BA study, prepared for use in all regions and consistent with the clinical study report in Module 5",
		],
		output: [
			"Include references or electronic links to the full BA study reports within the narratives",
			"Ensure that text surrounding cross-references provides sufficient context so the reader understands the referenced section content without needing the full section title",
			"Applicants may modify the format of BA study report presentation if needed to provide the best possible understanding and facilitate evaluation of results by regulatory reviewers, provided the CTD structure is maintained",
			"Include footnotes or clarifications in tables for parameter definitions (e.g., AUC_TAU, AUC_inf, Cmin applicability)",
			"If format modifications are made, ensure that they enhance clarity and comprehension without omitting required CTD elements or disrupting logical flow",
			"When cross-referencing sections in paper or electronic submissions, include at least the section number in the cross string to maintain clarity and brevity",
			"Ensure that all comparator products and formulations are clearly described in the study reports",
			"When presenting comparative BA data, include conclusions regarding BE, formulation effects, food effects, and variability",
			"Confirm that any PK studies with BA information included are correctly placed in Section 5.3.1.1 and appropriately referenced elsewhere",
			"Ensure tabular summaries of in vitro dissolution studies follow the structure of Table 2.7.1.2 with all specified columns and parameters",
			"Use consistent terminology for BA study types and endpoints (PK, PD, in vitro dissolution)",
			"Decide whether BA study information and results are best presented in tables, text, or figures to maximize clarity",
			"Cross-reference BA study reports in other sections (e.g., 5.3.1.2 for comparative BA/BE studies) when studies have multiple objectives",
			"Clearly identify and label each BA study type (e.g., IV vs oral, dosage form proportionality, food-effect)",
			"Ensure that BA/BE study reports demonstrating comparability or equivalence after formulation or manufacturing process changes are included in Module 5 as required",
			"Maintain compliance with ICH E3 structure for clinical study reports when compiling BA study reports",
			"Ensure that tables and figures are embedded in the text when they enhance readability; lengthy tables may be placed in an appendix",
			"If extensive statistical outputs or analyses related to BA studies exist, summarize key results in the main text and place detailed outputs in appendices or referenced reports to maintain readability and compliance with CTD structure",
			"Ensure that all literature references cited in BA study reports are listed in the table of contents",
			"Ensure that for generic applications, BA study reports are placed in Module 5, Section 5.3.1 'Reports of Biopharmaceutical Studies', and that comparative BA/BE study reports are placed specifically under Section 5.3.1.2",
			"Include an introduction to the tabular listing if the sequence of studies deviates from the standard order",
			"Prepare one synopsis per BA study for use in all regions, ensuring the same synopsis is included in this section and in the clinical study report in Module 5",
			"Organize BA study reports in the sequence described in Section 5.3; if a different sequence is used, note and explain it in an introduction to the tabular listing",
			"Provide an explicit explanation such as 'not applicable' or 'no study conducted' if no BA study report is available for this section",
			"Design tables to include study type, design, and results, including mean ratios (test/reference) for Cmax and AUC and their 90% confidence intervals or other BE metrics",
			"Present study reports in the standard CTD clinical study report format, including all required sections (title page, synopsis, methodology, results, discussion, appendices)",
			"Ensure that presentation of BA results allows clear identification of formulation and manufacturing change impacts on BA and BE",
			"Within each synopsis, use tables and figures as appropriate to aid clarity",
			"Provide each BA study report as a single document unless the report is unusually large, in which case the text portion should be one document and appendices may be submitted as one or more separate documents",
			"Ensure that any summaries or narratives abstracted from ICH E3 synopses are accurate and consistent with the full reports",
			"Group similar BA studies together in narratives, noting individual results and important differences among studies",
			"When choosing granularity for BA study report files, ensure that lifecycle updates can be managed by replacing complete documents rather than partial files",
			"Narrative descriptions of BA studies should be brief, similar to a journal abstract, and describe critical design features and results",
			"Ensure consistency with the tabular listing of all clinical studies, including sequencing aligned with Section 5.3",
			"Cross-reference BA study reports in other sections (e.g., 5.3.1.2) when studies have multiple objectives",
			"Ensure cross-references to related sections (e.g., 5.3.1.2 for comparative BA/BE studies) where applicable",
			"Follow the CTD Module 5 organizational structure ensuring BA study reports are placed specifically under Section 5.3.1.1",
			"Verify that all data and analyses presented are consistent with the original study reports and datasets",
			"Ensure any comparisons or analyses included in narratives focus on factual observations only, avoiding interpretation or critical analysis",
			"Ensure tabular summaries of BA studies follow the structure of Table 2.7.1.1 with all specified columns and parameters",
			"Limit synopsis length to usually up to 3 pages; for more complex or important studies, synopsis may be longer (e.g., up to 10 pages)",
			"Ensure each BA study report appears in only one section based on its primary objective",
		],
	},
	{
		number: "5.3.1.2",
		title: "Comparative BA and Bioequivalence (BE) Study reports",
		input: [
			"Prepare tabular data including mean ratios (test/reference) for Cmax and AUC and their 90% confidence intervals or other recommended BE metrics for inclusion in tables or appendices.",
			"Gather overview information on formulation development, in vitro and in vivo dosage form performance, and rationale for the comparative BA/BE study database.",
			"Obtain ICH E3 clinical study reports for comparative BA/BE studies to extract relevant summaries and data.",
			"Ensure availability of narrative descriptions (abstract-like) for each comparative BA/BE study, including critical design features and results, with references or electronic links to full reports.",
			"Gather evidence and data on food effects on bioavailability and conclusions regarding bioequivalence with respect to meal type or timing.",
			"Gather any meta-analyses or cross-study analyses involving comparative BA/BE studies where full reports are included in Module 5.",
			"Collect relevant pharmacokinetic (PK), pharmacodynamic (PD), or in vitro dissolution data used as endpoints in comparative BA/BE studies.",
			"Prepare a tabular listing of all relevant comparative BA/BE studies for inclusion in the appendix of the summary section.",
			"Gather study reports comparing the drug product used in clinical studies supporting effectiveness and the drug product used in stability batches.",
			"Collect documentation or statements regarding GCP compliance for each comparative BA/BE study.",
			"Ensure access to certificates of analysis for test and reference products used in comparative BA/BE studies.",
			"Collect summaries of analytical methods used in comparative BA/BE studies, including assay validation performance characteristics (linearity range, sensitivity, specificity) and quality control parameters (accuracy, precision).",
			"Collect data on correlations between in vitro dissolution and bioavailability, including pH effect studies and dissolution specification data.",
			"Collect bioanalytical and analytical method validation reports referenced in the comparative BA/BE study reports (from Section 5.3.1.4).",
			"Collect comparative BA data comparing clinical study formulations and to-be-marketed formulations.",
			"Gather data on inter- and intrasubject variability for each formulation in comparative BA studies.",
			"Collect any relevant pharmacodynamic (PD) or antigenicity data required to support conclusions when PK studies alone are insufficient.",
			"Obtain all associated clinical study protocols, statistical analysis plans, and raw datasets for comparative BA/BE studies.",
			"Collect data and results on the effects of formulation and manufacturing changes on in vitro dissolution and bioavailability, including any PK studies comparing pre- and post-change products.",
			"Gather study reports comparing the drug product used in clinical studies supporting effectiveness and the to-be-marketed drug product.",
			"Gather reference product information, including labeling, formulation details, and batch information for comparator products used in BE studies.",
			"Gather any pertinent animal data or product quality information that may have clinical implications for comparative BA/BE study interpretation.",
			"Compile references to guidelines or literature used in planning and conducting comparative BA/BE studies.",
			"Collect full study reports for all comparative bioavailability (BA) and bioequivalence (BE) studies comparing the rate and extent of release of the drug substance from similar drug products (e.g., tablet to tablet, tablet to capsule).",
			"Gather study reports comparing similar drug products from different manufacturers.",
			"Collect any relevant post-marketing data from other regions that pertain to comparative BA/BE performance of the product.",
			"Ensure availability of regulatory correspondence or prior approvals related to comparative BA/BE studies, if applicable.",
			"Gather comparative BA data for different dosage form strengths.",
			"Compile any expert opinions or literature references used to justify study design or interpretation of comparative BA/BE results.",
		],
		output: [
			"Include discussion of evidence regarding formulation and manufacturing changes, food effects, in vitro–in vivo correlations, dosage form strength comparisons, and variability sources.",
			"Verify that all data presented are consistent with the corresponding datasets and analytical reports.",
			"Ensure that all data presented are consistent with the corresponding datasets and analytical reports.",
			"Ensure that placement of case report forms, individual patient data listings, and literature references follows CTD Module 5 organization (case report forms in 5.3.7, literature references in 5.4) and not within Section 5.3.1.2.",
			"Provide an explicit explanation such as 'not applicable' or 'no study conducted' if no comparative BA/BE report is available for this section.",
			"Include an introduction or summary table listing all comparative BA/BE studies with identifiers, study types, and key parameters.",
			"Write narrative descriptions in a concise, abstract-like format summarizing critical design features and results, similar to a journal abstract.",
			"Identify unresolved issues related to comparative BA/BE studies, explain why they are not barriers to approval, and describe plans to resolve them.",
			"Ensure that comparative BA/BE studies are included in the Table of Contents for Module 5.",
			"Ensure that each comparative BA/BE study report is placed in Section 5.3.1.2 of the CTD.",
			"Include BE conclusions for different dosage form strengths and formulations.",
			"Check that all references to other CTD sections are accurate and properly cited.",
			"For the summary of results of individual studies, provide a tabular listing and brief narrative descriptions (abstract-like) of each comparative BA/BE study, noting critical design features and results, and grouping similar studies together while noting differences.",
			"Highlight strengths and limitations of the comparative BA/BE study program, including any important limitations such as lack of relevant comparator or missing patient population data.",
			"For eCTD submissions, avoid submitting multiple copies of the same comparative BA/BE study report; instead, provide references or hyperlinks to the single file to ensure efficient review and compliance with eCTD structure.",
			"Verify that each comparative BA/BE study appears in only one CTD section, with additional objectives addressed through cross-references.",
			"Ensure that all tabular and graphical presentations are consistent with the data and enhance clarity of the comparative BA/BE section.",
			"Ensure that the section is formatted according to CTD Module 5 standards, including pagination, section numbering, and consistent document structure.",
			"Include references or electronic links to the full study reports within the narrative text.",
			"Include an assessment of the quality of study design and performance for comparative BA/BE studies, and state GCP compliance.",
			"If results are best presented in text and figures, use tables primarily to list studies.",
			"If a study report is relevant to multiple CTD sections, include the full report in the most appropriate section (e.g., first applicable section) and provide cross-references in other relevant sections rather than duplicating the file.",
			"Summarize analytical methods with emphasis on assay validation performance characteristics and quality control parameters.",
			"Applicants may modify the format of the comparative BA/BE study report section as needed to provide the best possible presentation of information and to facilitate understanding and evaluation of results.",
			"Include references or electronic links to the full report of each comparative BA/BE study in the narratives.",
			"Explain the basis for any important or unusual aspects of prescribing information that are supported by comparative BA/BE study results.",
			"Clearly identify the type of comparison made in each study (e.g., clinical study product vs. to-be-marketed product, clinical study product vs. stability batch, or products from different manufacturers).",
			"When creating cross strings or cross-references in the document, include only the CTD section number in the cross string, while writing the accompanying text so readers can clearly understand the referenced section’s content.",
			"Design tables to include study identification, type, design, results, and BE metrics such as mean ratios (test/reference) for Cmax and AUC with 90% confidence intervals or other recommended metrics.",
			"Ensure that the Clinical Summary length (excluding attached tables) is proportionate to the information conveyed, generally within 50 to 400 pages for the entire summary document.",
			"Address evidence of the effects of formulation and manufacturing changes on in vitro dissolution and BA, and state conclusions regarding BE.",
			"Retain the current CTD numbering for Section 5.3.1.2 and clearly identify the indication in the section title when applicable (e.g., 5.3.1.2.UTI, 5.3.1.2.Pneumonia) if multiple indications are presented.",
			"Follow the recommended sub-organization for multiple indications within Section 5.3.1.2, ensuring consistent numbering and indication labeling across subsections.",
			"Incorporate a critical analysis of the comparative BA/BE study data, focusing on conclusions and implications rather than repeating detailed data from the Clinical Summary.",
			"In the comparison and analyses section, provide a factual summary of all comparative BA studies with attention to differences in results across studies, summarizing findings in both text and tables.",
			"Address any particular efficacy or safety issues encountered in comparative BA/BE studies and how they were evaluated and resolved.",
			"Ensure that each comparative BA/BE study appears in only one CTD section, with additional objectives addressed through cross-references.",
			"Provide a factual summary of all in vitro dissolution, BA, and comparative BA studies, emphasizing differences in results across studies.",
			"Summarize findings in both text and tables, referring to the appendix for detailed tabular data.",
			"Follow the sequence of study listing as described in Section 5.3; if a different sequence is used, note and explain it in an introduction to the tabular listing.",
			"Ensure that PK studies comparing pre- and post-change products are included when relevant, even if not primarily BE-focused.",
			"Ensure that comparative BA/BE studies are accurately represented in the Module 5 tabular listing, following the required sequence.",
			"Include cross-references to related sections (e.g., Section 5.3.1.1 for BA studies or Section 5.3.1.4 for analytical methods) where applicable.",
			"Embed tables and figures within the text when they enhance readability; place lengthy tables in an appendix at the end of the section.",
			"Group similar studies together in the narrative, noting individual results and important differences among them.",
			"Ensure that tables are clear, appropriately labeled, and formatted to aid clarity; applicants may choose to present results in text, tables, or figures depending on clarity.",
			"Discuss how comparative BA/BE study results support the proposed dose, target indication, and prescribing information.",
			"In the background/overview portion, provide an overall view of formulation development, dosage form performance, and rationale for the comparative BA/BE study database without including detailed individual study data.",
			"Ensure that each study report includes complete information on study design, methodology, results, and conclusions consistent with ICH CTD format for clinical study reports.",
			"Maintain consistent terminology for 'comparative bioavailability' and 'bioequivalence' throughout the section.",
			"Ensure that the placement of each comparative BA/BE study report is determined by the primary study objective.",
			"Base narrative summaries on the ICH E3 synopsis where applicable.",
			"When studies contribute to both efficacy and safety, include in the narrative description within Section 5.3.1.2 enough detail to allow the reviewer to understand the extent of exposure and how safety data were collected, while keeping detailed safety results in the appropriate safety section.",
		],
	},
	{
		number: "5.3.1.3",
		title: "In vitro-In vivo Correlation Study Reports",
		input: [
			"Gather literature references or published studies supporting the IVIVC approach and methodology.",
			"Gather all relevant in vitro study data used to establish the correlation, including dissolution profiles, assay results, and analytical method validation reports.",
			"Identify and collect only those dissolution studies that are intended to correlate with in vivo data (exclude routine QC or batch-release dissolution tests).",
			"Ensure availability of any relevant nonclinical or microbiology data if they contribute to the IVIVC justification.",
			"Obtain complete in vitro-in vivo correlation (IVIVC) study reports, including full protocols, raw data, and final analyses.",
			"Gather all relevant in vivo study data used to establish the correlation, including pharmacokinetic (PK) data, bioavailability/bioequivalence study reports, and statistical analyses.",
			"Collect any regulatory correspondence or prior submissions related to IVIVC studies for the product.",
			"Collect any modeling and simulation data, including software output files, model validation reports, and parameter estimates.",
			"Gather in vitro dissolution study reports specifically used to provide BA information or support IVIVC development (distinct from dissolution tests used solely for quality control).",
			"Obtain expert opinions or internal scientific assessments supporting the validity of the IVIVC model.",
			"Identify and collect any supportive data from CTD Section 2.7.2 that are relevant to the IVIVC study and can be incorporated into Section 5.3.1.3.",
			"Obtain comparator product information if used in the correlation studies, including reference product specifications and batch data.",
		],
		output: [
			"Include a distinct identifier (e.g., report number or abbreviated title) in the header or footer on every page of the IVIVC study report to ensure traceability and alignment with the Table of Contents entry.",
			"Use cross-referencing rather than duplicate content if the same study information would otherwise appear in multiple CTD sections, ensuring clear and correct reference links.",
			"Ensure consistent page layout and formatting across the dossier; minor layout differences between report sections and quality sections are acceptable if clarity and traceability are maintained.",
			"Organize the report to clearly describe study objectives, methodology, results, statistical analyses, and conclusions.",
			"Place references in the most appropriate locations within the IVIVC study report and create new subsection numbers if needed to improve clarity.",
			"Applicants may modify the format of IVIVC study reports if needed to provide the best possible presentation and facilitate understanding and evaluation of the results, consistent with flexibility allowed for nonclinical tabulated summaries.",
			"Ensure the sequence of study reports placed in section 5.3.1.3 follows the study listing order described for section 5.3, and if using a different sequence, explain the deviation in an introductory note or tabular listing.",
			"Ensure that any cross-references to other CTD sections use the section number in the cross string, and write the text so the reader understands the section content without needing the full section name.",
			"Ensure clarity and readability for both technical and non-technical reviewers, avoiding unnecessary jargon.",
			"Follow ICH E3 structure and content principles for clinical study reports where applicable to IVIVC studies.",
			"Ensure that all data tables, figures, and appendices are properly labeled, paginated, and referenced in the text.",
			"Verify that the report complies with 21 CFR 314.50 requirements for study report content and format.",
			"Maintain consistent terminology for in vitro and in vivo parameters throughout the document.",
			"Modify the format of the IVIVC study report as needed to provide the best possible presentation and facilitate regulatory understanding.",
			"Incorporate supportive data from Section 2.7.2 into the IVIVC study report where relevant, ensuring proper cross-referencing and integration into the narrative.",
			"If a particular study type relevant to IVIVC (e.g., certain PK or kinetic studies) was not conducted, maintain the section heading in the CTD and provide a brief explanation for its absence rather than deleting the heading.",
			"Include both in vitro and in vivo components in a logically connected manner to demonstrate the correlation.",
			"When creating cross-references within the IVIVC report, include the CTD section number (e.g., 5.3.1.3) in the cross string, and write the surrounding text so that the reader can understand the referenced content without needing the full section name.",
			"If the amount of statistical output is too large for the main body, place detailed statistical listings in an appendix or separate report, with appropriate references in section 5.3.1.3.",
			"It is acceptable to use an abbreviated title or report number in headers/footers instead of the full report title, provided the identifier clearly links to the TOC entry.",
			"Ensure that in vitro dissolution studies included in section 5.3.1.3 are only those providing BA information or used for IVIVC development, and exclude dissolution tests used solely for batch quality control.",
			"Present the IVIVC study reports in full detail in section 5.3.1.3, ensuring they are complete and self-contained.",
		],
	},
	{
		number: "5.3.1.4",
		title: "Reports of Bioanalytical and Analytical Methods for Human Studies",
		input: [
			"Obtain study protocols and analytical plans describing sample collection, handling, and analysis procedures for human studies.",
			"Obtain relevant literature references or expert opinions supporting the analytical methodology or validation approach.",
			"Gather analytical method validation reports used for quantifying drug, metabolites, or biomarkers in human biological matrices.",
			"Gather documentation required for data audit and inspection, including validation and bioanalytical report files as described in Table 1 of the guideline.",
			"Gather relevant chromatograms supporting the analytical method validation and performance data for inclusion in the section.",
			"Compile a list of all biopharmaceutical and in vitro dissolution studies in which each analytical or bioanalytical method was used, to determine whether the method needs to be included once in Section 5.3.1.4.",
			"Ensure access to all human study identifiers and cross-references to the clinical study reports where the analytical methods were applied.",
			"Collect complete bioanalytical method validation reports for all human studies, including method development, validation, and performance data.",
			"Collect information on analytical procedures used only for stability studies if they support human study data.",
			"Prepare summary information for inclusion in the CTD, including method titles, identification codes, assay types, Bioanalytical Report codes, effective dates, and associated Validation Report codes.",
			"Retrieve raw analytical data, calibration curves, chromatograms, and quality control results supporting the bioanalytical reports.",
			"Collect historical analytical procedures used to generate data included in batch analyses for human studies.",
			"Compile summary tables of all relevant Validation Reports for each analyte, including Partial Validation and Cross Validation Reports, with method identification codes, method types, reasons for new or additional validation, and details of method changes.",
			"Collect information on reference standards, internal standards, and comparator products used in the analytical methods.",
			"Collect all relevant documentation necessary for reconstructing the study as it was conducted and reported, including source data, protocols, reports, procedural and operational records, environmental records, and correspondence between involved parties.",
			"Collect documentation discussing method changes, including evolution of methods, reasons for revisions, and unique aspects.",
			"For comparative bioavailability/bioequivalence studies, gather a list of regulatory site inspections conducted over the last three years and one year post study completion, including dates and outcomes for each analytical site.",
			"Collect any unique analytical or bioanalytical method documentation specific to in vitro dissolution studies that are not already covered in biopharmaceutical study reports.",
			"Gather any regulatory correspondence or prior approvals related to analytical method validation or bioanalytical assay acceptance.",
			"Ensure availability of general and specific SOPs related to analytical method validation and record keeping.",
			"Prepare a summary table cross-referencing multiple identification codes when a method has different codes for the method, Validation Reports, and Bioanalytical Reports.",
		],
		output: [
			"Organize the content by study or by analytical method, ensuring each report is complete and traceable to the corresponding human study.",
			"Ensure that documentation format (paper or electronic) complies with data integrity principles, maintaining traceability, legibility, and accessibility.",
			"Include summary tables cross-referencing multiple identification codes when applicable to ensure traceability between methods, validation reports, and bioanalytical reports.",
			"Ensure literature references used in this section are listed appropriately in the Module 5 table of contents.",
			"Ensure that all documentation is maintained in a secure environment and is readily available for audit or inspection upon request.",
			"Ensure that detailed analytical data and validation results are presented in full reports in this section rather than summarized elsewhere.",
			"Ensure that relevant chromatograms are included in the section to support analytical method validation and performance data.",
			"Ensure the section 5.3.1.4 is clearly titled 'Reports of Bioanalytical and Analytical Methods for Human Studies' and includes all relevant reports in a structured format.",
			"Confirm that all documentation described in Table 1 (validation and bioanalytical report documentation) is included or referenced appropriately within Section 5.3.1.4.",
			"Ensure that each analytical or bioanalytical method report appears only once within Module 5; use cross-references when multiple objectives apply.",
			"When historical analytical procedures are included, clearly indicate their use in generating specific data and distinguish them from current validated methods.",
			"If no analytical or bioanalytical method reports are available for Section 5.3.1.4, maintain the section heading and provide a brief explanation for their absence rather than deleting the heading or renumbering subsequent sections.",
			"Retain the current CTD numbering structure for Section 5.3.1.4 and ensure consistency with the numbering conventions used throughout Module 5.",
			"Include cross-references to related sections (e.g., clinical study reports in 5.3.1) using section numbers in cross strings; section names may be omitted to reduce length.",
			"Provide an explicit statement such as 'not applicable' when no analytical or bioanalytical method report is available for Section 5.3.1.4.",
			"Ensure Section 5.3.1.4 is listed correctly within the Module 5 Table of Contents following CTD sequence requirements.",
			"Clearly identify and discuss any method changes, including reasons for revisions and unique aspects, within the section or accompanying summaries.",
			"For comparative BA/BE studies, include a summary of regulatory site inspections with dates and outcomes for each analytical site, as required.",
			"Ensure that summary information and tables are clearly presented and include all required elements (method titles, identification codes, assay types, report codes, effective dates, validation report codes).",
			"Ensure that the placement of reports in Section 5.3.1.4 is determined by the primary objective of the analytical or bioanalytical method documentation.",
			"Ensure that section numbering and labeling remain consistent with CTD conventions even when multiple indications or study types are presented elsewhere in Module 5.",
			"Applicants may modify the format of Section 5.3.1.4 if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation of the results by regulatory reviewers.",
			"Write the text so that the reader can easily identify the content of the referenced section even if only the section number is used in the cross string.",
			"Follow the sequence of studies and reports as defined in CTD Section 5.3 when organizing and presenting analytical method reports.",
			"Maintain contemporaneous records for all analytical and validation activities; any alterations or reprocessing of data must preserve the original record and include documented justification.",
			"Ensure consistency between the analytical methods described here and those referenced in clinical study reports and summaries.",
			"Follow CTD formatting conventions for Module 5, including pagination, consistent section numbering, and clear labeling of appendices or attachments.",
			"Verify that all reports are complete, legible, and compliant with applicable regulatory standards for analytical method validation documentation.",
			"Include each analytical or bioanalytical method and its validation only once in Section 5.3.1.4 when the same method is used in multiple studies, and provide appropriate cross-references in the individual study reports.",
			"Ensure that methods supporting biopharmaceutical studies and in vitro dissolution studies are captured when not fully presented within the individual study reports.",
			"When providing large analytical method reports with extensive appendices, ensure the main text is provided as one document and appendices as separate documents to allow easier lifecycle management and document replacement.",
			"Verify that any cross-references to appendices (e.g., case report forms, individual patient data listings, literature references) follow the CTD Module 5 organization and numbering scheme.",
		],
	},
	{
		number: "5.3.2.1",
		title: "Plasma Protein Binding Study Reports",
		input: [
			"Collect any comparative analyses or cross-study evaluations that include plasma protein binding data as part of PK characterization.",
			"Obtain validation reports for analytical methods used in the plasma protein binding studies, if applicable.",
			"Ensure that the plasma protein binding study reports are correctly listed in the Module 5 Table of Contents (Section 5.1) and Tabular Listing of All Clinical Studies (Section 5.2).",
			"Gather all raw data, datasets, and analytical results from ex vivo plasma protein binding studies.",
			"Gather data from related human biomaterial studies (e.g., permeability, hepatic metabolism, metabolic-based drug-drug interaction studies) that may support interpretation of plasma protein binding results.",
			"Obtain complete ex vivo plasma protein binding study reports conducted using human biomaterials (e.g., human albumin).",
			"Confirm that the plasma protein binding study reports are properly categorized under Section 5.3.2.1 within the overall Module 5 structure.",
			"Ensure availability of comparator/reference standards used in the plasma protein binding studies.",
			"Collect summaries or references from Module 2 sections (2.7.1, 2.7.3, 2.7.4) that provide contextual information on pharmacokinetic and pharmacodynamic rationale, if relevant to plasma protein binding interpretation.",
			"Collect study protocols and methodologies used for plasma protein binding assessments.",
			"Retrieve any relevant ethical approvals or consent documentation if human-derived materials required such approvals.",
			"Collect literature references or expert opinions supporting the design, conduct, or interpretation of plasma protein binding studies.",
			"Obtain tabular listings or summary tables of clinical pharmacology studies that include plasma protein binding data, if referenced in higher-level summaries.",
			"Gather any relevant regulatory correspondence or prior submissions related to plasma protein binding studies.",
		],
		output: [
			"Clearly identify the studies as ex vivo plasma protein binding studies using human biomaterials.",
			"Maintain alignment of the plasma protein binding study report section with the overall Module 5 hierarchy to facilitate reviewer navigation and ensure compliance with CTD structure.",
			"If plasma protein binding data contribute to PK/PD interpretation, ensure that the linkage between these data and other PK/PD studies is clearly described and cross-referenced.",
			"When summarizing or referencing plasma protein binding studies in higher-level summaries (e.g., Module 2.7.2), ensure consistency between the summary and the detailed report in Section 5.3.2.1.",
			"Provide a clear explanation such as 'not applicable' or 'no study conducted' in this section if no plasma protein binding study reports are available.",
			"Ensure the report follows the standard clinical study report format as applicable for CTD submissions.",
			"Ensure that any modifications to the standard format or placement of the study report are justified and documented to facilitate reviewer understanding.",
			"For eCTD submissions, avoid submitting multiple copies of the same plasma protein binding study report; provide references to a single file to maintain consistency and reduce redundancy.",
			"When drafting cross strings in paper submissions, balance clarity and brevity by including only the section number in the cross string while ensuring the surrounding text clearly conveys the section content for reader orientation.",
			"When creating cross-references in paper submissions, include at least the section number in the cross string; write the surrounding text so the reader can understand the section content without requiring the full section name.",
			"Confirm that the placement of the plasma protein binding study report is consistent with Module 5 organizational expectations for clarity and completeness.",
			"Recognize that including the section header in addition to the section number may improve clarity but is not required, and may be overly long; prioritize readability and usability.",
			"Verify that all data presented are consistent with source data and comply with regulatory requirements for accuracy and completeness.",
			"If the same nonclinical pharmacokinetic study (including plasma protein binding) is relevant to multiple CTD sections, include the full report in the first appropriate section (e.g., Absorption) and provide cross-references in other relevant sections instead of duplicating the file.",
			"Ensure that the table of contents and tabular listing of studies (Sections 5.1 and 5.2) reference this plasma protein binding study report in the correct sequence and location.",
			"Ensure cross-references are clear and concise to improve usability for reviewers, particularly those unfamiliar with the dossier structure.",
			"If no plasma protein binding study was conducted, retain the 5.3.2.1 section heading in the CTD and provide a brief explanation for the absence of the study rather than deleting the heading or renumbering subsequent sections.",
			"Determine placement of the plasma protein binding study report based on the primary objective of the study and document this decision clearly if any ambiguity exists.",
			"Include sufficient methodological detail to allow assessment of study design, conduct, and results.",
			"Organize the content so that the sequence of studies follows the order described in Section 5.3; if a different sequence is used, note and explain it in an introduction.",
			"Ensure that the section numbering and titles used for plasma protein binding study reports (5.3.2.1) match exactly with the CTD Module 5 structure to maintain consistency and traceability.",
			"Verify that the plasma protein binding study reports are properly indexed and hyperlinked (for eCTD) or correctly paginated (for paper CTD) according to the Module 5 Table of Contents.",
			"Applicants may modify the format of the plasma protein binding study report if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation of the results by regulatory reviewers.",
			"Cross-reference related sections (e.g., analytical methods in 5.3.1.4) where applicable.",
			"Maintain consistency of terminology and data presentation between plasma protein binding study reports and related PK/PD summaries to support coherent interpretation across modules.",
			"Ensure each plasma protein binding study report appears only once in the CTD; avoid duplication and rely on cross-referencing when a study has multiple objectives.",
			"Ensure that any overview or summary text referencing plasma protein binding studies is concise, factual, and avoids duplication of detailed study information already presented in Section 5.3.2.1.",
			"Place only ex vivo plasma protein binding study reports in this section; do not include protein binding data from PK blood/plasma studies (those go in Section 5.3.3).",
		],
	},
	{
		number: "5.3.2.2",
		title: "Reports of Hepatic Metabolism and Drug Interaction Studies",
		input: [
			"Collect all clinical study reports related to hepatic metabolism studies, including in vivo and in vitro studies assessing hepatic enzyme activity, metabolic pathways, and hepatic clearance.",
			"Obtain details on study type, method, and location in CTD (volume, section, study number) for each hepatic metabolism and drug interaction study to ensure accurate referencing.",
			"Gather all drug interaction study reports involving hepatic metabolism, including studies assessing CYP enzyme induction, inhibition, and substrate potential.",
			"Gather representative human pharmacokinetic data at the maximum recommended dose for comparison with hepatic metabolism and drug interaction study results.",
			"Prepare the full study reports for inclusion in CTD section 5.3.2.2, ensuring they are complete and finalized according to ICH E3 structure.",
			"Collect any regulatory correspondence or prior submissions related to hepatic metabolism or drug interaction findings for the product.",
			"Obtain relevant clinical pharmacology study protocols, statistical analysis plans, and datasets supporting hepatic metabolism and drug interaction evaluations.",
			"Collect reports of hepatic metabolism and metabolic drug interaction studies specifically conducted with human hepatic tissue, such as hepatocytes and/or hepatic microsomes.",
			"Ensure availability of comparator product information or reference standards used in hepatic metabolism or drug interaction studies.",
			"Gather literature references or expert opinions used to support hepatic metabolism mechanisms or drug interaction interpretations.",
			"Collect tabulated results for drug-drug interaction studies, including species differences, gender differences, dose dependency, and any special comments relevant to hepatic metabolism.",
			"Collect any bioavailability or bioequivalence study reports that demonstrate product comparability or equivalence following formulation or process changes, as these may be cross-referenced in Module 5 and relevant to hepatic metabolism or drug interaction interpretation.",
			"Retrieve analytical data and bioanalytical validation reports used to quantify drug and metabolite concentrations in hepatic metabolism and interaction studies.",
			"Ensure that any nonclinical or clinical data supporting impurity qualification that may impact hepatic metabolism or drug interaction interpretation are available for cross-reference if applicable.",
		],
		output: [
			"Ensure that all appendices, tables, and figures referenced in the reports are included and properly paginated.",
			"Ensure that the sequence in which hepatic metabolism and drug interaction studies are listed follows the sequence described in CTD Section 5.3; if a different sequence is used, note and explain this in an introduction to the tabular listing.",
			"Confirm that the content meets the requirements of 21 CFR 314.50 regarding completeness of clinical data presentation.",
			"Clearly indicate study type, method, and CTD location (volume, section, study number) in the tabulated summaries to facilitate cross-referencing.",
			"Verify that all reports are clearly labeled with study identifiers, titles, and report numbers consistent with the application’s master study list.",
			"Ensure that any cross-references to other CTD sections (e.g., 3.2.S.2.6, 3.2.P.2.2.1, or 3.2.P.2.3) are clearly identified and properly linked in the eCTD structure when applicable.",
			"Ensure the section 5.3.2.2 includes complete study reports of hepatic metabolism and drug interaction studies, not just summaries.",
			"Follow the ICH E3 (Structure and Content of Clinical Study Reports) format for each study report included in this section.",
			"Include cross-references to related sections (e.g., summaries in Module 2.7) using section numbers in cross strings; section names may be omitted to maintain brevity.",
			"Organize reports in a logical sequence, typically starting with hepatic metabolism studies followed by drug interaction studies.",
			"If applicable, combine drug-drug interaction tabulated results with absorption tables, ensuring clarity and proper labeling.",
			"When presenting tabulated results for drug-drug interaction studies, include one column for each study conducted and ensure inclusion of representative human data at the maximum recommended dose for comparison.",
			"Include other relevant pharmacokinetic routes (e.g., biliary, respiratory) in the tabulated results if such studies were performed and are relevant to hepatic metabolism or drug interaction context.",
			"For eCTD submissions, submit only a single file for each study report and use cross-referencing rather than multiple uploads.",
			"Ensure that detailed analyses too extensive for Module 2 summaries are fully presented in this section as separate reports.",
			"Allow modification of the report presentation format when necessary to facilitate reviewer understanding, as long as CTD structure is retained.",
			"Check that the section is formatted consistently with CTD Module 5 standards, including appropriate headers, pagination, and document structure.",
			"Avoid duplicating files for studies that may appear relevant to multiple CTD sections; place the full study report in the most appropriate location and provide cross-references in other sections.",
			"Maintain consistency in terminology and data presentation across all included reports to align with FDA and ICH expectations.",
			"Include cross-references in section 5.3.2.2 to any bioavailability or bioequivalence studies located elsewhere in Module 5 that demonstrate product comparability after formulation or process changes, if relevant to hepatic metabolism or drug interaction context.",
		],
	},
	{
		number: "5.3.2.3",
		title: "Reports of Studies Using Other Human Biomaterials",
		input: [
			"Justification for any reprocessing steps applied to human biomaterials or related intermediates, if applicable",
			"Information on critical steps and intermediates relevant to the preparation or control of human biomaterials, if applicable, as referenced in manufacturing process descriptions (e.g., 3.2.P.3.3)",
			"Population PK analyses and results addressing inter-individual variations due to intrinsic or extrinsic factors",
			"Data and analyses on dose-response or concentration-response (PK/PD) relationships",
			"Narrative summaries or abstracts describing critical design features and results of individual studies using human biomaterials",
			"Analytical procedures and acceptance criteria for control of materials used in the studies",
			"Technical documents describing the study protocols for studies using other human biomaterials",
			"Analytical procedures and acceptance criteria for intermediates or critical steps, if applicable to the studies",
			"Descriptions and specifications of the human biomaterials used (e.g., type of cells, tissues, proteins, source, preparation method)",
			"Clinical pharmacokinetic (PK) and pharmacodynamic (PD) study reports relevant to human biomaterial studies",
			"Tabular listings of all clinical pharmacology studies relevant to PK, PD, and PK/PD relationships",
			"Validation information for any critical processes or reprocessing steps associated with the preparation of human biomaterials",
			"Batch data for intermediates or critical steps relevant to the preparation or use of human biomaterials in the studies",
			"Detailed descriptions and specifications of starting materials, reagents, raw materials, and solvents used in the studies, including source and quality attributes",
			"Information supporting dosage selection and dose individualization in target and special populations (e.g., pediatric, geriatric, renal/hepatic impairment)",
			"Information or data on reprocessing steps relevant to the preparation or handling of human biomaterials, if applicable, as referenced in manufacturing process descriptions (e.g., 3.2.P.3.3)",
			"Ethics committee approvals or informed consent documentation if applicable to the procurement/use of human biomaterials",
			"Statements or documentation regarding manipulation of ruminant-derived materials in facilities handling human biomaterials, if applicable, to assess potential cross-contamination risks",
			"In vitro study reports using human cells, tissues, or related materials pertinent to PK processes",
			"References or electronic links to full study reports for each study summarized",
			"Data on inter- and intra-individual variability and intrinsic/extrinsic factors affecting PK and PD relationships",
			"Full study reports of studies using human biomaterials other than plasma protein binding studies or hepatic metabolism/drug interaction studies",
			"Relevant literature references supporting the choice of biomaterials or study design",
			"Human PK study data including standard parameters and variability sources",
			"Immune response data supporting dose selection, dosage schedule, and formulation for vaccine products",
			"Comparator product information if applicable to the study design",
			"Results from in vitro drug metabolism and drug-drug interaction studies and their clinical implications",
			"Data from PK studies evaluating extrapolation of foreign clinical data to new regions (per ICH E5)",
			"Validation reports for any analytical or bioanalytical methods used in the studies",
			"Analytical procedures related to adventitious agent safety evaluation for materials of biological origin, if applicable",
			"Summarized data from sections 2.7.1, 2.7.3, and 2.7.4 that provide context for PK, PD, and PK/PD development rationale",
			"Raw data, datasets, and analytical results generated from studies using other human biomaterials",
			"Regulatory correspondence or prior submission references if these studies were previously submitted or discussed with authorities",
			"Expert opinions or scientific justifications for the use of specific human biomaterials in the studies",
		],
		output: [
			"Write cross-references and cross-strings clearly so that the reader can easily identify the referenced section content even if only the section number is used",
			"If analytical procedures for control of materials are relevant to the studies in 5.3.2.3, ensure they are described in the appropriate referenced section (e.g., 3.2.S.2.3) and cross-referenced accurately",
			"If justification for reprocessing or validation information is relevant to the preparation of human biomaterials, ensure it is included in the correct referenced sections (e.g., 3.2.S.2.2, 3.2.S.2.4, 3.2.S.2.5) and cross-referenced in 5.3.2.3 as needed",
			"Use tables and text to present factual data across studies, focusing on PK, PD, and PK/PD relationships",
			"Follow the sequence of study listing as described in section 5.3; if a different sequence is used, note and explain it in an introduction to the tabular listing",
			"Provide a brief overview of clinical studies characterizing PK and PD, including PK/PD relationships and effects of intrinsic/extrinsic factors",
			"When referencing or linking to other sections, maintain consistency in section numbering and ensure that references are accurate and functional in both electronic and paper formats",
			"If batch data, analytical procedures, or acceptance criteria for intermediates or critical steps are relevant to the studies, ensure they are presented in the correct referenced sections (e.g., 3.2.S.2.4, 3.2.S.4.1, 3.2.S.4.2) and linked appropriately",
			"Applicants may modify the format and presentation of section 5.3.2.3 as needed to facilitate regulatory reviewers' understanding and evaluation of the results",
			"Highlight evidence supporting dose selection, dose intervals, and dosage instructions relevant to labeling",
			"Cross-reference related studies in other sections (e.g., nonclinical studies in Module 4) if applicable",
			"Ensure that cross-references to other CTD sections include at least the section number; inclusion of the section name is optional but can improve clarity",
			"Ensure that dose-response or concentration-response (PK/PD) studies are summarized only if not already presented in efficacy/safety sections (2.7.3 or 2.7.4)",
			"Ensure that PK studies evaluating extrapolation of foreign clinical data are clearly identified and discussed (per ICH E5)",
			"Applicants may modify the format and presentation of section 5.3.2.3 as needed to facilitate regulatory reviewers\u0019 understanding and evaluation of the results",
			"Identify and discuss any major inconsistencies in the human biomaterial, PK, or PD database",
			"Ensure that studies addressing properties outside PK (e.g., sterility, pharmacodynamics) are not included here but are placed in the appropriate CTD section",
			"Maintain clear, logical organization of reports to facilitate regulatory review",
			"When using cross-strings in paper submissions, include only the section number to minimize length, and write the surrounding text so the reader can understand the section content without requiring the section name",
			"Discuss inter- and intra-individual variability and intrinsic/extrinsic factors affecting PK and PD relationships",
			"Place all reports of studies using human biomaterials (excluding plasma protein binding and hepatic metabolism/drug interaction studies) in section 5.3.2.3",
			"Include references or electronic links to full study reports for each summarized study",
			"Ensure that detailed analyses or statistical outputs too extensive for summaries are appropriately placed in their designated sections (e.g., 5.3.5.3), and not within 5.3.2.3",
			"Maintain factual, concise, and logically structured presentation to facilitate regulatory review and comprehension",
			"Clearly identify the type of human biomaterial used in each study and its relevance to pharmacokinetic assessment",
			"If reprocessing or critical steps are described in manufacturing sections (e.g., 3.2.P.3.3), ensure that cross-references in 5.3.2.3 are accurate and consistent with those sections",
			"For vaccine products, include a summary of immune response data supporting dose, schedule, and formulation decisions",
			"Group similar studies together when appropriate, noting individual results and key differences",
			"Do not include detailed information about individual studies; only provide brief summaries or overviews",
			"Applicants may modify the format and presentation of section 5.3.2.3 as needed to facilitate regulatory reviewers’ understanding and evaluation of the results",
			"Ensure the section contains complete study reports, not just summaries",
			"If any manipulation of ruminant-derived materials or potential cross-contamination risks are relevant to human biomaterial studies, ensure that appropriate cross-references to 3.2.A.1 and 3.2.A.2 are included for completeness and regulatory traceability",
			"Begin the section with a concise overview of the human biomaterial studies conducted and their purpose in interpreting PK or PD data",
			"Ensure that summaries of individual studies are concise, similar to journal abstracts, describing key design features and critical results",
			"Use consistent terminology for human biomaterials in line with regulatory definitions (proteins, cells, tissues, related materials derived from human sources)",
			"Include comparisons between single- and multiple-dose PK studies and population PK analyses",
			"Highlight critical aspects of study design and data analysis, such as dose selection, study population, PD endpoints, and analytical approach (traditional vs. population)",
			"Include an introduction or explanatory note if the study sequence deviates from the standard order",
		],
	},
	{
		number: "5.3.3.1",
		title: "Healthy Subject PK and Initial Tolerability Study Reports",
		input: [
			"Gather data on intrinsic and extrinsic factors affecting PK and PK/PD relationships in healthy subjects (e.g., age, gender, ethnicity, food effects).",
			"Gather immune response data for vaccine products that support dose selection, dosage schedule, and formulation decisions.",
			"Gather study reports or datasets assessing dose proportionality or time‑dependent PK behavior (e.g., changes due to enzyme induction or antibody formation) in healthy subjects if these studies were performed.",
			"Retrieve any regulatory correspondence or prior approvals related to the healthy subject PK or tolerability studies.",
			"Prepare a tabular listing of all healthy subject PK and initial tolerability studies in the sequence described in Section 5.3, including study identifiers, titles, and key design features.",
			"Collect full study reports of pharmacokinetic (PK) studies conducted in healthy subjects.",
			"Collect data from in vitro studies using human biomaterials (e.g., human cells, tissues) that are pertinent to PK processes, such as permeability, protein binding, hepatic metabolism, and metabolic-based drug-drug interactions.",
			"Gather bioanalytical method validation reports and sample analysis data supporting PK results.",
			"Collect tabular listings of all clinical pharmacology studies relevant to PK and PD, including study identifiers, design features, and outcomes.",
			"Obtain datasets and statistical analyses related to PK parameters (e.g., Cmax, Tmax, AUC) from healthy subject studies.",
			"Collect literature references or comparator data if used in the interpretation of PK or tolerability results.",
			"Obtain any population PK analyses or cross-study comparisons that include healthy subject data to support variability assessments.",
			"Gather any supportive data from Section 2.7.2 that is used to supplement or contextualize healthy subject PK or tolerability study reports.",
			"Gather study reports or datasets assessing dose proportionality or time\u0011dependent PK behavior (e.g., changes due to enzyme induction or antibody formation) in healthy subjects if these studies were performed.",
			"Collect mass balance study reports conducted in healthy subjects, including excretion data in urine and/or feces when applicable.",
			"Ensure availability of signed clinical study reports (CSRs) compliant with ICH E3 format for each healthy subject PK and tolerability study.",
			"Collect full study reports of initial tolerability studies conducted in healthy subjects.",
			"Retrieve summaries or datasets of pharmacodynamic (PD) and PK/PD relationship studies in healthy subjects relevant to initial tolerability and PK characterization.",
			"Collect information on dose-response or concentration-response relationships relevant to PK/PD interpretation in healthy subjects.",
			"Collect reports or datasets of tissue distribution studies performed in healthy subjects when these were part of PK assessments (e.g., distribution into synovial fluid or cerebrospinal fluid).",
			"Collect safety and tolerability data, including adverse event listings, laboratory results, and vital sign data from healthy subject studies.",
			"Gather all associated clinical study protocols, investigator brochures, and informed consent forms for the healthy subject PK and tolerability studies.",
			"Obtain narrative summaries or abstracts of critical individual studies that provided PK, PD, or PK/PD data relevant to healthy subject studies.",
			"Obtain any relevant certificates of analysis or reference standards used in the PK studies.",
		],
		output: [
			"If no healthy subject PK or initial tolerability studies were conducted, maintain the section heading and provide a brief explanation rather than deleting the section.",
			"When creating cross-references (cross strings), include the section number and write the accompanying text so that the section content is clear without requiring the full section name.",
			"Clearly label each report with study title, study number, and type (PK or tolerability).",
			"Maintain uniform formatting across reports (font, margins, spacing) as per CTD formatting standards.",
			"Do not include detailed information about individual studies in this section; only include full study reports as required for Module 5.",
			"Maintain clear cross-referencing between the full study reports in 5.3.3.1 and the corresponding summaries or analyses in Module 2.7.2.",
			"Ensure that tissue distribution, mass balance, dose proportionality, and other specialized PK results are included in this section when these studies were performed in healthy subjects.",
			"Each study report should follow the ICH E3 structure for clinical study reports, including title page, synopsis, ethics, study design, efficacy and safety results, and appendices.",
			"Include cross-references to related sections (e.g., 2.7.2 Clinical Pharmacology Summary) where applicable.",
			"Ensure consistency of terminology and study identifiers with other CTD sections (e.g., summaries in Module 2.7).",
			"Assign each study a unique short study identifier and use it consistently throughout all modules, including Section 5.3.3.1.",
			"Ensure the tabular listing of studies follows the sequence described in Section 5.3; if a different sequence is used, note and explain this in an introduction to the tabular listing.",
			"Ensure that any references to summaries in Module 2.7 (e.g., 2.7.1, 2.7.3, 2.7.4) are accurate and consistent with the data presented in this section.",
			"Applicants may modify the format of the section if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation of the results by regulatory reviewers.",
			"Ensure that only reports of PK and initial tolerability studies in healthy subjects are included in this section (5.3.3.1).",
			"Exclude patient PK studies, intrinsic/extrinsic factor studies, or population PK studies, which belong in other subsections (5.3.3.2\u00135.3.3.5).",
			"Exclude patient PK studies, intrinsic/extrinsic factor studies, or population PK studies, which belong in other subsections (5.3.3.2–5.3.3.5).",
			"Perform a compliance check to confirm that all healthy subject PK and tolerability studies are accounted for and correctly placed in this section.",
			"Organize reports in chronological or logical order, consistent with CTD Module 5 structure.",
			"Summarize critical aspects of study design and data analysis, including dose selection, study population, and PD endpoints, where relevant to healthy subject PK and tolerability studies.",
			"Verify that all reports are complete, signed, and paginated according to regional submission requirements.",
			"Confirm that all included studies are relevant to the characterization of PK and initial tolerability in healthy subjects and exclude unrelated PD or patient studies.",
			"Ensure that the presentation of PK and tolerability data supports understanding of dose selection and variability in healthy subjects, consistent with the overall clinical pharmacology rationale.",
			"Confirm proper categorization of PK studies to avoid misplacement of intrinsic factor, extrinsic factor, or population PK studies into Section 5.3.3.1.",
			"Provide a brief overview of any human biomaterial studies that support interpretation of PK or PD data, noting their relevance to healthy subject PK studies.",
			"Ensure that study numbering and placement within Section 5.3.3.1 complies with the ICH CTD Granularity Document.",
		],
	},
	{
		number: "5.3.3.2",
		title: "Patient PK and Initial Tolerability Study Reports",
		input: [
			"Full clinical study reports for patient pharmacokinetics (PK) studies, including protocols, statistical analysis plans, and final reports",
			"Ethics committee/institutional review board approvals for the studies",
			"Full clinical study reports for initial tolerability studies in patients, including safety data, adverse event listings, and investigator assessments",
			"Bioanalytical data supporting PK results, including calibration curves, QC results, and assay performance metrics",
			"Cross-reference information identifying where related analyses or summaries are located in other CTD sections (e.g., Module 2 summaries or other Module 5 reports)",
			"Reference literature or comparator product data if used to contextualize PK or tolerability findings",
			"Demographic and baseline characteristic data for study participants",
			"Any integrated analyses or statistical outputs related to patient PK or tolerability data that are too extensive for inclusion in Module 2 summaries, to be placed in Module 5.3.3.2 as separate reports",
			"Relevant regulatory correspondence or approvals related to the conduct of the PK and tolerability studies",
			"All relevant PK datasets, including concentration-time data, individual subject data, and summary tables",
			"Informed consent forms used in the studies",
			"Analytical method validation reports for PK assays used in the studies",
			"Full reports of PK and initial tolerability studies conducted in patients, ensuring they are distinct from healthy subject PK/tolerability studies and placed in the correct section",
			"Dose administration records and compliance data for PK and tolerability studies",
		],
		output: [
			"Ensure clear cross-referencing to related studies or data in other CTD sections where applicable",
			"Follow the principle of providing one file per reference or per study report to maintain clarity and traceability in the submission",
			"For paper CTD submissions, include a table of contents (TOC) for Module 4; for eCTD submissions, no TOC entry is required for Module 4",
			"Ensure that each study report is placed under the correct CTD section number and labeled consistently with the CTD structure",
			"When integrated analyses or statistical outputs are too extensive for inclusion in summary documents, present them in a separate report placed in the appropriate Module 5 section",
			"Refer to relevant appendices or health authority guidance when clarification is needed on document inclusion or structure, ensuring consistency with CTD conventions",
			"Format of the section can be modified if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation of the results",
			"Retain current CTD numbering for the section and clearly identify indications when more than one indication is applicable",
			"Include all necessary tables, figures, and listings in a manner that supports comprehension of PK and tolerability results",
			"Ensure that lower-level CTD headings (e.g., sub-subsections) do not contain unnecessary or individual files unless specifically required for clarity or completeness",
			"Ensure that only PK and initial tolerability study reports conducted in patients are included in this section, and that reports for healthy subjects or other PK study types are placed in their respective sections",
			"For eCTD submissions, do not submit multiple identical files; instead, provide references to the single file location",
			"Ensure that lower-level CTD headings do not contain unnecessary or individual files unless specifically required for clarity or completeness",
			"For eCTD submissions, ensure that only one file per reference is provided; avoid duplication of identical files across sections",
			"In cross-references or cross strings, include at least the section number; including the section header is optional but can improve clarity",
			"Maintain consistency with CTD-Q structural principles, ensuring that the section organization aligns with the overall CTD hierarchy even if no individual files are present at lower levels",
			"Ensure that the presentation of results allows for straightforward evaluation by reviewers, avoiding unnecessary complexity or redundancy",
			"When integrated analyses or statistical outputs are too extensive for inclusion in summary documents, present them in a separate report placed in the appropriate Module 5 section (e.g., 5.3.3.2 for patient PK and tolerability studies)",
			"Organize content to facilitate the best possible understanding by regulatory reviewers, using logical sequencing and clear headings",
			"Ensure that each study report is placed under the correct CTD section number (e.g., 5.3.3.2 for patient PK and tolerability studies) and labeled consistently with the CTD structure",
			"If a study report is relevant to multiple sections, place the full report in the first appropriate section and cross-reference it in other sections rather than duplicating it",
			"Write text so that readers can easily understand the content of the referenced section even if only the section number is provided in the cross string",
		],
	},
	{
		number: "5.3.3.3",
		title: "Intrinsic Factor PK Study Reports",
		input: [
			"Ensure availability of any statistical listings or appendices that support the intrinsic factor PK analyses, especially if detailed outputs are too extensive for inclusion in Module 2 summaries.",
			"Collect demographic and clinical data related to intrinsic factors including age, gender, race, weight, height, disease state, genetic polymorphism, and organ dysfunction.",
			"Collect any bioavailability or bioequivalence study reports that demonstrate product comparability or equivalence following formulation or process changes, as these may provide relevant PK data for intrinsic factor evaluation.",
			"Collect complete reports of pharmacokinetic (PK) studies specifically designed to assess the effects of intrinsic factors on systemic exposure to the drug.",
			"Obtain cross-references or summaries from Module 3 sections (e.g., 3.2.S.2.6, 3.2.P.2.2.1, 3.2.P.2.3) if intrinsic factor PK data are linked to manufacturing or formulation changes.",
			"Collect any integrated analyses or summary tables that combine intrinsic factor PK data across multiple studies, if such analyses are referenced in Module 2 summaries or ISS/ISE documents.",
			"Obtain datasets and statistical analyses describing PK parameters such as Cmax, AUC, clearance, and accumulation for intrinsic factor subgroups.",
			"Gather study protocols, investigator brochures, and final clinical study reports for intrinsic factor PK studies.",
			"Ensure availability of any prior PK data from healthy subject or patient studies (Sections 5.3.3.1 and 5.3.3.2) that serve as baseline or comparative data for intrinsic factor analyses.",
			"Retrieve analytical data and bioanalytical method validation reports used to measure drug and metabolite concentrations in plasma, urine, or other relevant matrices.",
			"Collect any regulatory correspondence or prior agency feedback related to intrinsic factor PK evaluations.",
			"Ensure inclusion of any mass balance or dose proportionality data if these were influenced by intrinsic factors.",
			"Gather relevant literature references or expert opinions supporting the interpretation of intrinsic factor effects on PK.",
		],
		output: [
			"Include clear cross-references to related PK studies in Sections 5.3.3.1 and 5.3.3.2 when baseline or comparative data are used.",
			"Organize the section by intrinsic factor type (e.g., age, gender, race, organ impairment, genetic polymorphism) to ensure clarity and traceability.",
			"If integrated analyses or summaries of intrinsic factor PK data are too extensive for inclusion in Module 2, ensure that detailed reports are placed in Section 5.3.3.3 with appropriate cross-references from Module 2.",
			"Verify that all intrinsic factor PK studies are correctly categorized and not mixed with extrinsic factor studies (which belong in Section 5.3.3.4).",
			"When intrinsic factor PK data are derived from bioavailability or bioequivalence studies conducted to demonstrate comparability after formulation or process changes, ensure that these reports are properly cross-referenced from relevant quality sections (e.g., 3.2.S.2.6, 3.2.P.2.2.1, 3.2.P.2.3) and clearly identified in Section 5.3.3.3.",
			"If no intrinsic factor PK studies have been conducted, maintain the Section 5.3.3.3 heading and provide a brief explanation for their absence rather than deleting the heading or renumbering subsequent sections.",
			"Applicants may modify the format of Section 5.3.3.3 if needed to provide the best possible presentation of the information and to facilitate the understanding and evaluation of the results, provided CTD structure is maintained.",
			"Ensure that tables and figures summarizing PK results by intrinsic factor subgroup are clearly labeled and formatted consistently.",
			"Ensure consistent terminology and units for PK parameters (e.g., Cmax, AUC, clearance) across all reports.",
			"Confirm that all data presented are traceable to validated analytical methods and verified datasets.",
			"Each study report should follow the standard clinical study report format as per ICH E3, including synopsis, objectives, methods, results, and conclusions.",
			"When cross-referencing other CTD sections, include the section number in the cross string and ensure the surrounding text makes the section content clear, to improve clarity and maintain concise references.",
			"Maintain compliance with CTD Module 5 formatting standards, including pagination, section numbering, and electronic submission file structure.",
			"Provide a brief summary or contextual note in Section 5.3.3.3 when intrinsic factor PK data are linked to manufacturing or formulation changes, ensuring traceability between quality and clinical modules.",
			"Ensure that the level of detail in Section 5.3.3.3 aligns with the expectations for detailed study reports rather than summary-level information, consistent with FDA and ICH E3 guidance.",
			"If no intrinsic factor PK studies have been conducted, maintain the Section 5.3.3.3 heading in the CTD and provide a brief explanation for their absence rather than deleting the heading or renumbering subsequent sections.",
			"Place all reports of PK studies assessing intrinsic factors in Section 5.3.3.3 of Module 5.",
		],
	},
	{
		number: "5.3.3.4",
		title: "Extrinsic Factor PK Study Reports",
		input: [
			"Prepare an explanatory note or introduction if the sequence of extrinsic factor PK studies deviates from the standard order described in Section 5.3.",
			"Gather data from PK studies evaluating extrinsic factors such as drug\u0013drug interactions, diet, smoking, and alcohol use.",
			"Gather data from PK studies evaluating extrinsic factors such as drug–drug interactions, diet, smoking, and alcohol use.",
			"Obtain regulatory correspondence or prior submissions related to extrinsic factor PK studies, if available.",
			"Collect statistical analyses and summary tables showing PK parameters (Cmax, AUC, clearance, half-life, accumulation) under different extrinsic factor conditions.",
			"Obtain clinical study protocols and final reports for extrinsic factor PK studies, including methodology, subject demographics, dosing regimens, and sampling schedules.",
			"Collect any tabular listings of clinical studies as required for Section 5.3, ensuring extrinsic factor PK studies are listed in the correct sequence.",
			"Collect full study reports of pharmacokinetic (PK) studies specifically designed to assess the effects of extrinsic factors on systemic drug exposure.",
			"Ensure availability of comparator product information if extrinsic factor studies involve drug\u0013drug interaction with marketed products.",
			"Ensure availability of comparator product information if extrinsic factor studies involve drug–drug interaction with marketed products.",
			"Compile PK datasets including plasma concentration–time data, urine/feces excretion data (if relevant), and metabolite concentration data related to extrinsic factor influence.",
			"Collect literature references or expert opinions supporting the design, conduct, or interpretation of extrinsic factor PK studies.",
			"Compile PK datasets including plasma concentration\u0013time data, urine/feces excretion data (if relevant), and metabolite concentration data related to extrinsic factor influence.",
			"Gather any relevant bioanalytical method validation reports used for PK sample analysis in extrinsic factor studies.",
		],
		output: [
			"Ensure that only PK study reports assessing extrinsic factors are included in Section 5.3.3.4 and that reports related to intrinsic factors, healthy/patient PK, population PK, PD, or efficacy/safety studies are excluded from this section.",
			"Include interpretation of the impact of the extrinsic factor on systemic exposure and clinical relevance.",
			"Present PK results with appropriate tables and figures showing parameter estimates (Cmax, AUC, clearance, half-life, accumulation) for each extrinsic factor condition.",
			"Describe study objectives, design, population, dosing regimen, sampling schedule, and analytical methods in a structured format consistent with ICH CTD requirements.",
			"If a tabular listing of studies is included, ensure it follows the standard sequence and includes any additional useful information as appropriate.",
			"Ensure that cross-references to other CTD sections are written so the reader can easily identify the referenced section’s content without needing the full section title.",
			"Ensure that the sequence of extrinsic factor PK study reports follows the overall sequence described in Section 5.3; if a different sequence is used, include an explanatory note or introduction describing and justifying the deviation.",
			"Ensure that cross-references to other CTD sections are written so that the reader can easily identify the referenced section’s content without needing the full section title.",
			"Verify that all data presented are consistent with source datasets and statistical analyses.",
			"Organize content logically: introduction, methods, results, discussion, and conclusions, with cross-references to related sections if needed.",
			"Place all reports of PK studies assessing effects of extrinsic factors in Section 5.3.3.4 of the CTD.",
			"Ensure compliance with CTD formatting standards for Module 5, including pagination, section numbering, and consistent headings.",
			"In paper submissions, include only the CTD section number (e.g., 5.3.3.4) in cross strings rather than the full section name to maintain brevity while ensuring clarity through surrounding text.",
			"Clearly identify the extrinsic factor(s) studied (e.g., specific interacting drug, dietary component, smoking status, alcohol consumption) in the report title or introduction.",
			"When including cross-references within Section 5.3.3.4, use the CTD section number only in cross strings, and write surrounding text so the reader can understand the referenced section content.",
			"Applicants may modify the format of Section 5.3.3.4 if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation of the results.",
			"Ensure terminology is consistent with ICH E5 definitions of extrinsic factors.",
		],
	},
	{
		number: "5.3.3.5",
		title: "Population PK Study Reports",
		input: [
			"Obtain datasets containing sparse PK concentration data from relevant clinical studies.",
			"Prepare an explanatory note or introduction if the sequence of population PK study reports deviates from the standard order described in Section 5.3.",
			"Collect demographic, dosing, and covariate data (e.g., age, gender, weight, organ function, concomitant medications) used in the population PK analysis.",
			"Gather comparative data between single-dose and repeated-dose PK studies relevant to population PK analyses.",
			"Collect the tabular listing of clinical studies to ensure the population PK study reports are sequenced consistently with Section 5.3.",
			"Collect evidence supporting dose selection and dose individualisation in the target and special populations (e.g., paediatric, geriatric, renal or hepatic impairment).",
			"Prepare tabular summaries or figures for population PK studies suitable for inclusion in an appendix, following the example format of Table 2.7.2.1.",
			"Obtain relevant literature references or external data used to support model assumptions or parameterization.",
			"Collect summary tables and figures showing model diagnostics, goodness-of-fit plots, and predictive checks.",
			"Ensure availability of software validation documentation for population PK modeling tools (e.g., NONMEM, Monolix, Phoenix NLME).",
			"Collect data and analyses addressing inter-individual variability in PK or PD due to intrinsic or extrinsic factors.",
			"Gather any regulatory correspondence or prior feedback related to population PK analyses or modeling approaches.",
			"Ensure inclusion of any bridging or supportive analyses linking population PK results to exposure-response or dose justification sections.",
			"Ensure availability of complete population PK study reports specifically based on sparse samples obtained in clinical trials, including both efficacy and safety trials, for placement in Section 5.3.3.5.",
			"Gather clinical trial protocols and statistical analysis plans that describe the population PK sampling strategy and modeling approach.",
			"Retrieve model development documentation, including model selection rationale, parameter estimates, and model validation results.",
			"Collect final study reports of population pharmacokinetic (PK) analyses conducted using sparse sampling data obtained from clinical trials, including efficacy and safety trials.",
			"Obtain results of dose-response or concentration-response analyses that support dosage selection and justification.",
			"Gather data from PK studies evaluating extrapolation of foreign clinical data to the new region (e.g., ICH E5 bridging studies) if relevant to population PK interpretation.",
			"Prepare an explanation such as 'not applicable' or 'no study conducted' if no population PK study report is available for Section 5.3.3.5.",
		],
		output: [
			"When creating cross-references to Section 5.3.3.5, include only the section number (e.g., \b5.3.3.5\u0019) in the cross string to maintain clarity and brevity.",
			"Ensure that reports are clearly identified as population PK analyses based on sparse sampling from clinical trials.",
			"Place all population PK study reports in Section 5.3.3.5 of the CTD.",
			"Include discussion of inter-individual variability in PK or PD due to intrinsic or extrinsic factors as part of the population PK analysis presentation.",
			"Applicants may create new subsection numbers within Section 5.3.3.5 if needed to improve clarity and organization for regulatory reviewers.",
			"When creating cross-references to Section 5.3.3.5, include only the section number (e.g., \u00185.3.3.5\u0019) in the cross string to maintain clarity and brevity.",
			"Use consistent terminology and units for pharmacokinetic parameters across all reports.",
			"If applicable, include summaries of PK studies evaluating extrapolation of foreign clinical data to the new region, ensuring clear presentation of similarity analyses between regions or races.",
			"Applicants may modify the format of Section 5.3.3.5 to provide the best possible presentation of population PK information and facilitate understanding and evaluation by regulatory reviewers.",
			"When creating cross-references in paper submissions, include only the section number (e.g., '5.3.3.5') in the cross string and ensure accompanying text clearly identifies the content so the reader can easily locate the relevant report.",
			"If no population PK study report is available for Section 5.3.3.5, include a clear statement such as 'not applicable' or 'no study conducted' in that section.",
			"Ensure that any tables or figures related to population PK studies are embedded in the text when they enhance readability, or placed in an appendix if lengthy, following the example tabular format (e.g., Table 2.7.2.1).",
			"When creating cross-references in paper submissions, it is recommended to include only the section number in the cross string and write the accompanying text so the reader will also know the section content, thereby reducing length while maintaining clarity.",
			"Summarise comparisons between single-dose and repeated-dose PK findings where relevant to population PK interpretation.",
			"Ensure accompanying text in cross-references clearly identifies the content (e.g., population PK study identification) so the reader can easily locate the relevant report.",
			"Structure each report to include objectives, study design, data sources, modeling methods, results, and conclusions.",
			"Cross-reference related sections (e.g., 5.3.3.3 and 5.3.3.4) if intrinsic or extrinsic factors were evaluated within the population PK analysis.",
			"Verify that all reports are complete, signed, and dated, and that any appendices (e.g., datasets, code listings) are properly referenced and organized.",
			"Include clear descriptions of the modeling approach, assumptions, covariate analyses, and validation procedures.",
			"When creating cross-references to Section 5.3.3.5, include only the section number (e.g., \u001175.3.3.5\u00119) in the cross string to maintain clarity and brevity.",
			"Highlight evidence supporting dose selection and dose individualisation in the target and special populations within the population PK study reports.",
			"When creating cross-references to Section 5.3.3.5, include only the section number (e.g., ‘5.3.3.5’) in the cross string to maintain clarity and brevity.",
			"If additional information is included in the tabular listing or introduction, ensure it is clearly labeled and consistent with the structure of Section 5.3.",
			"Ensure each study report appears in only one section of the CTD; if the study has multiple objectives, cross-reference it in other relevant sections without duplicating the full report.",
			"Include graphical representations (e.g., diagnostic plots, predictive checks) to support model adequacy and interpretation.",
			"Ensure each study report appears in only one section of the CTD; if the study has multiple objectives, use cross-references in other relevant sections without duplicating the full report.",
			"When creating cross-references to Section 5.3.3.5, include only the section number (e.g., \b5.3.3.5\t) in the cross string to maintain clarity and brevity.",
			"When creating cross-references to Section 5.3.3.5, include only the section number (e.g., '5.3.3.5') in the cross string to maintain clarity and brevity.",
			"Ensure that tabular and graphical summaries of population PK results are clearly labeled, legible, and consistent with the CTD presentation standards.",
			"Ensure compliance with ICH CTD format and numbering conventions for section 5.3.3.5.",
			"Present results in a logical sequence, including parameter estimates, variability components, and covariate effects.",
			"Ensure that the sequence of population PK study reports follows the overall sequence described in Section 5.3; if a different sequence is used, include an explanatory introduction noting and justifying the deviation.",
			"Confirm that only reports of population PK studies based on sparse samples from clinical trials, including efficacy and safety trials, are included in Section 5.3.3.5, and that unrelated PK or PD study reports are placed in their appropriate sections.",
		],
	},
	{
		number: "5.3.4.1",
		title: "Healthy Subject PD and PK/PD Study Reports",
		input: [
			"Collect references or electronic links to the full reports of each study summarized in the narratives.",
			"Collect any concentration\u0013response study reports in healthy subjects that include both PK and PD data.",
			"Obtain any modeling and simulation reports used to evaluate PK/PD relationships in healthy subjects.",
			"Retrieve any short-term PD study reports in healthy subjects that are not intended to demonstrate efficacy or safety.",
			"Collect tabular listings of all clinical pharmacology studies relevant to PK, PD, and PK/PD relationships.",
			"Gather any literature references or external data sources used to support interpretation of PD or PK/PD results in healthy subjects.",
			"Retrieve summaries or references to data presented in CTD sections 2.7.1, 2.7.3, and 2.7.4 that provide context for PK, PD, and PK/PD development rationale.",
			"For vaccine products, collect immune response data that support dose selection, dosage schedule, and formulation of the final product.",
			"Collect any concentration–response study reports in healthy subjects that include both PK and PD data.",
			"Gather results from population PK analyses and studies comparing single versus repeated-dose PK in healthy subjects.",
			"Gather dose-finding study reports conducted in healthy subjects where PD and/or PK/PD data were collected.",
			"Prepare an explanation such as 'not applicable' or 'no study conducted' if no report or information is available for Section 5.3.4.1.",
			"Prepare an introductory note or explanation if the sequence of studies in Section 5.3.4.1 differs from the standard order described in Section 5.3.",
			"Gather brief narrative summaries (similar to abstracts) describing design features and critical results of each PK, PD, or PK/PD study in healthy subjects.",
			"Obtain full study reports of pharmacokinetic/pharmacodynamic (PK/PD) studies conducted in healthy subjects with non-therapeutic objectives.",
			"Obtain full study reports of pharmacodynamic (PD) studies conducted in healthy subjects with non-therapeutic objectives.",
			"Gather data on dose-response or concentration-response (PK/PD) studies with pharmacodynamic endpoints conducted in healthy subjects.",
			"Collect data on inter- and intra-individual variability and intrinsic/extrinsic factors affecting PK and PK/PD relationships in healthy subjects.",
			"Collect data supporting dose selection, dose intervals, and dosage instructions relevant to PK/PD findings in healthy subjects.",
			"Collect the tabular listing of all clinical studies to ensure that the sequence of studies in Section 5.3.4.1 aligns with the overall sequence described in Section 5.3.",
			"Collect relevant protocols, amendments, and final study reports for each included study.",
			"Gather data from studies of permeability (e.g., intestinal absorption, blood-brain barrier passage), protein binding, hepatic metabolism, and metabolism-based drug-drug interactions relevant to PK interpretation.",
			"Ensure that the studies collected are not part of efficacy or safety demonstration (those belong in section 5.3.5).",
			"Collect any human biomaterial study reports (e.g., studies using human cells, tissues, or related materials) that are pertinent to pharmacokinetic processes.",
			"Gather associated datasets, tables, and statistical analyses from the PD and PK/PD studies in healthy subjects.",
		],
		output: [
			"Exclude any PD or PK/PD studies in healthy subjects that are part of efficacy or safety demonstration; these should be placed in section 5.3.5.",
			"Ensure that the presentation highlights evidence supporting dose selection, dose intervals, and dosage instructions relevant to healthy subject data.",
			"Follow the overview of human biomaterial studies with a concise summary of clinical studies characterizing PK and PD, including PK/PD relationships in healthy subjects.",
			"Ensure that cross-references are written in a way that guides the reader to the correct study type and section without requiring excessively long section names.",
			"Confirm that any tabular listings or summaries of studies are consistent with the overall clinical study table in Section 5.3.",
			"Ensure that the order of studies listed in Section 5.3.4.1 follows the overall sequence described in Section 5.3; if a different sequence is used, provide an explanation in an introductory note.",
			"Group similar studies together in the narrative, noting individual results and key differences.",
			"Organize reports clearly to distinguish them from patient PD/PK-PD studies (section 5.3.4.2) and from efficacy/safety studies (section 5.3.5).",
			"Ensure that the section structure and content align with CTD conventions for summarizing PK/PD data, including appropriate cross-references to related sections (e.g., 2.7.1, 2.7.3, 2.7.4).",
			"When creating cross‑references (cross strings), include only the section number to reduce length, but write the surrounding text so the reader can clearly understand the referenced section content.",
			"Applicants may create new subsection numbers within Section 5.3.4.1 if doing so facilitates clearer presentation and understanding by regulatory reviewers.",
			"Place only PD and/or PK/PD study reports with non-therapeutic objectives in healthy subjects in this section.",
			"Ensure that cross‑references are written in a way that guides the reader to the correct study type and section without requiring excessively long section names.",
			"Verify that all terminology is consistent with regulatory definitions for PD, PK, and PK/PD studies.",
			"If no study report is available for Section 5.3.4.1, include an explicit statement such as 'not applicable' or 'no study conducted'.",
			"Verify that cross-references to other sections (e.g., 5.3.1 for BA/BE studies or 5.3.3 for PK studies) are accurate and consistent with CTD structure.",
			"Maintain compliance with CTD Module 5 formatting and submission requirements, including pagination, section numbering, and electronic submission standards.",
			"Ensure internal consistency of data presentation, including alignment of text, tables, and figures.",
			"Discuss inter- and intra-individual variability and intrinsic/extrinsic factors affecting PK and PK/PD relationships.",
			"Ensure that any format modifications or new subsections maintain logical flow and consistency with CTD Module 5 numbering conventions.",
			"Maintain consistency between summarized data and the full reports referenced in other CTD sections.",
			"Ensure that narrative descriptions of individual studies are concise (similar to journal abstracts) and include critical design features and results.",
			"When creating cross-references (cross strings), include only the section number to reduce length, but write the surrounding text so the reader can clearly understand the referenced section content.",
			"Do not include detailed information about individual studies; provide only brief overviews or summaries.",
			"Ensure that cross\u0011references are written in a way that guides the reader to the correct study type and section without requiring excessively long section names.",
			"Begin the section with a brief overview of human biomaterial studies conducted to aid interpretation of PK or PD data.",
			"Cross-reference related studies in other sections where applicable, without duplicating full reports.",
			"Applicants may modify the format of Section 5.3.4.1 if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation of the results.",
			"Ensure that summaries of dose-response or concentration-response (PK/PD) studies are included only if they are not used as primary evidence of efficacy or safety.",
			"Clearly identify the study type (PD, PK/PD, dose-finding, concentration–response) and confirm that the study population is healthy subjects.",
			"When cross-referencing study reports within Section 5.3.4.1 or to other sections, provide clear references to the original file or location rather than duplicating files, especially in eCTD submissions.",
			"Ensure that each report is complete and follows the ICH E3 structure for clinical study reports where applicable.",
			"Highlight critical aspects of study design and data analysis, such as dose selection, study population, intrinsic/extrinsic factors, PD endpoints, and analytical approach (traditional or population-based).",
			"Clearly identify the study type (PD, PK/PD, dose-finding, concentration\u0013response) and confirm that the study population is healthy subjects.",
			"Use tables and text to present data across studies factually, focusing on PK, PD, and PK/PD relationships and variability.",
			"When creating cross\u0011references (cross strings), include only the section number to reduce length, but write the surrounding text so the reader can clearly understand the referenced section content.",
			"Identify and discuss any major inconsistencies in the PK, PD, or human biomaterial database relevant to healthy subject studies.",
			"If a study has multiple objectives, cross-reference it in the relevant sections without duplicating the full report.",
			"Include references or electronic links to full study reports within the narrative summaries.",
			"Include sufficient detail in the report to describe study objectives, design, methods, results, and conclusions relevant to PD and PK/PD endpoints.",
			"Ensure that each study report appears in only one section of Module 5, determined by the primary objective of the study.",
		],
	},
	{
		number: "5.3.4.2",
		title: "Patient PD and PK/PD Study Reports",
		input: [
			"Ensure that the tabular listing of patient PD and PK/PD studies aligns with the overall Module 5 structure as outlined in the CTD Table of Contents.",
			"Collect data on biomarkers, surrogate markers, or clinical endpoints evaluated in patient PD and PK/PD studies.",
			"Include literature references or external data sources used to support interpretation of PD or PK/PD findings in patients.",
			"Prepare a tabular listing of all included patient PD and PK/PD studies following the sequence described in Section 5.3, including study identifiers, titles, and key parameters.",
			"Confirm that studies included in this section are not primarily designed for efficacy or safety demonstration (those belong in Section 5.3.5).",
			"Obtain any expert opinions or internal review summaries interpreting PD or PK/PD results in patients.",
			"Retrieve any modeling or simulation data used to evaluate PK/PD relationships in patients.",
			"Ensure availability of clinical study identifiers, titles, and summaries for all included patient PD and PK/PD studies.",
			"Obtain datasets and analyses showing the relationship between dose, plasma concentration, and pharmacodynamic effects in patients.",
			"Collect full study reports of pharmacodynamic (PD) and pharmacokinetic/pharmacodynamic (PK/PD) studies conducted in patients.",
			"Cross-check that all patient PD and PK/PD study reports correspond to the correct section (5.3.4.2) in the Module 5 Table of Contents to maintain consistency with the CTD structure.",
			"Gather study protocols, investigator brochures, and statistical analysis plans for each patient PD or PK/PD study.",
			"Collect data on biomarkers, surrogate markers, or clinical endpoints evaluated in patient PD or PK/PD studies.",
			"If a different sequence from Section 5.3 is used in the tabular listing, prepare an explanatory introduction justifying the alternative order.",
			"Gather any relevant regulatory correspondence or prior submissions related to patient PD or PK/PD studies.",
		],
		output: [
			"Ensure adherence to CTD principles for organizing study reports to support consistent preparation and review of the dossier.",
			"Ensure that the section title '5.3.4.2 Patient PD and PK/PD Study Reports' is used exactly as listed in the CTD Table of Contents to maintain consistency across the dossier.",
			"Applicants may modify the format of Section 5.3.4.2 if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation of the results, provided CTD principles are maintained.",
			"Avoid including long section names in cross strings to maintain brevity and clarity in paper submissions.",
			"If no patient PD or PK/PD studies are available, include an explicit statement such as 'not applicable' or 'no study conducted' in this section.",
			"Verify that all included reports are complete, legible, and formatted according to regional CTD submission standards (e.g., PDF or eCTD format).",
			"Ensure that cross-references are written in a way that helps the reader locate the referenced study report (e.g., by including study number and section number in the text).",
			"When preparing cross-references in paper submissions, include only the section number (e.g., 5.3.4.2) in the cross string, and write the surrounding text so that the reader can easily identify the referenced section content.",
			"Do not include studies whose primary objective is to demonstrate efficacy or safety; such studies should be placed in Section 5.3.5.",
			"Ensure the tabular listing is complete, accurate, and includes all relevant patient PD and PK/PD studies with consistent formatting.",
			"Confirm that the section numbering, titles, and subheadings conform to CTD conventions.",
			"Check that all data summaries, tables, and figures are properly labeled and referenced within the text.",
			"Ensure that only PD and/or PK/PD study reports conducted in patients are included in this section.",
			"Ensure that each study report appears only once within Module 5, with cross-referencing used appropriately if multiple objectives apply.",
			"Verify that the numbering and placement of this section correspond precisely to the CTD Module 5 Table of Contents structure.",
			"When using cross strings (cross-references) in paper submissions, include only the section number in the cross string while ensuring the surrounding text makes the referenced content clear.",
			"Maintain clear distinction between PD-only and PK/PD combined studies within the section.",
			"Maintain alignment between the organization of Section 5.3.4.2 and the overall CTD Module 5 hierarchy to facilitate regulatory review and navigation.",
			"Ensure that the section is logically organized, with studies presented in a clear sequence (e.g., by study type, objective, or patient population).",
			"Ensure that placement of each study report in Section 5.3.4.2 is based on the primary objective of the study, consistent with CTD organization rules.",
			"Ensure cross-referencing to related sections (e.g., 5.3.4.1 for healthy subject PD/PK-PD studies) is accurate and consistent.",
			"Organize study reports clearly and consistently, following the CTD Module 5 structure under Section 5.3.4.2.",
			"Perform a compliance check to ensure that all included studies meet the definition of PD or PK/PD studies in patients as per ICH guidelines.",
			"If no patient PD or PK/PD studies are conducted, retain the Section 5.3.4.2 heading in the CTD and provide a brief explanation for the absence of studies rather than deleting the heading or renumbering subsequent sections.",
			"Use consistent terminology for pharmacodynamic parameters, PK/PD modeling terms, and patient population descriptions.",
			"List studies in the tabular listing in the sequence described in Section 5.3; if a different sequence is used, clearly note and explain the deviation in an introductory statement.",
			"Each study report should follow the ICH E3 format for clinical study reports, including title page, synopsis, methodology, results, and conclusions.",
		],
	},
	{
		number: "5.3.5.1",
		title: "Study Reports of Controlled Clinical Studies Pertinent to the Claimed Indication",
		input: [
			"Case report forms (CRFs) or relevant excerpts for controlled clinical studies, if required by regulation or agreed with the reviewing division.",
			"Explanatory statement such as 'not applicable' or 'no study conducted' when no controlled clinical study report is available for the claimed indication.",
			"Literature references supporting the design, conduct, or interpretation of the controlled clinical studies pertinent to the claimed indication.",
			"Any appendices referenced in the clinical study reports, including patient narratives, listings, and supplementary tables.",
			"Tabular listing entry for each controlled clinical study pertinent to the claimed indication, including the type of information identified in Table 5.1 of the guideline.",
			"Published controlled clinical study reports where only limited or no further data are available to the sponsor.",
			"Regulatory correspondence or agreements with the reviewing division regarding the scope and content of controlled clinical study reports.",
			"Integrated analyses of all relevant efficacy and safety data from the controlled clinical studies, not just summaries.",
			"Protocols and protocol amendments for each controlled clinical study pertinent to the claimed indication.",
			"Datasets required by the region for controlled clinical studies pertinent to the claimed indication, organized according to regional guidance.",
			"Supportive data from Section 2.7.2 (Summary of Clinical Efficacy) that are relevant to the controlled clinical studies pertinent to the claimed indication, for incorporation or cross-reference as appropriate.",
			"Statistical analysis plans and complete statistical datasets for each controlled clinical study pertinent to the claimed indication.",
			"Full clinical study reports for all controlled clinical studies pertinent to the claimed indication, prepared in accordance with ICH E3 (Structure and Content of Clinical Study Reports).",
			"Clinical efficacy study reports for studies in other indications that provide support for efficacy in the proposed indication.",
			"Controlled safety study reports, including those conducted in conditions not part of the claimed indication, when they contribute relevant safety evidence.",
			"Pharmacodynamic study reports that contribute to evidence of efficacy for the claimed indication.",
		],
		output: [
			"Ensure that the sequence of controlled clinical studies in the tabular listing (Module 5.2) follows the sequence described in Section 5.3; if a different sequence is used, note and explain it in an introduction to the tabular listing.",
			"Ensure that the section contains detailed, integrated analyses of all relevant data from controlled clinical studies pertinent to the claimed indication, rather than brief summaries.",
			"If a study supports multiple indications, place its full report in the most appropriate Section 5.3.5 and cross-reference it in the others as needed.",
			"Include controlled safety studies, even those in conditions not part of the application, within Section 5.3.5.1.",
			"Ensure that all tables, figures, and listings are clearly labeled and referenced within the text of the reports.",
			"Sequence controlled clinical studies by type of control within Section 5.3.5.1, in the following required order: placebo control, no-treatment control, dose‑response without placebo, active control without placebo, external/historical control.",
			"Ensure that the identifier used in headers/footers corresponds to the title entry in the CTD table of contents for traceability.",
			"For eCTD submissions, place files for publications and literature references in the Module 5.4 folder; in the index.xml file, include leaf elements for these under the same heading as other study report files with additional information in the study tagging file, and optionally repeat the leaf element under 5.4 heading.",
			"Apply the same indication-specific numbering scheme consistently across all subsection levels within 5.3.5 when multiple indications are included.",
			"Ensure that the exact CTD section title 'Study Reports of Controlled Clinical Studies Pertinent to the Claimed Indication' is used to match the official Module 5 table of contents.",
			"Verify that all referenced appendices and supplementary materials are included and correctly linked.",
			"Follow the structure and content principles of ICH E3 when compiling individual study reports.",
			"Provide an explanation such as 'not applicable' or 'no study conducted' in section 5.3.5.1 when no controlled clinical study report is available for the claimed indication.",
			"Verify that the placement of the controlled clinical study reports follows the CTD Module 5 hierarchy as shown in the official table of contents (5.3 > 5.3.5 > 5.3.5.1).",
			"Incorporate or cross-reference supportive data from Section 2.7.2 (Summary of Clinical Efficacy) where relevant to the controlled clinical studies, ensuring consistency between Modules 2 and 5.",
			"Maintain consistency in terminology, units, and data presentation formats across all study reports in the section.",
			"When creating cross-references (cross strings) in paper submissions, include only the CTD section number (e.g., 5.3.5.1) in the cross string to minimize length, and ensure the surrounding text clearly identifies the referenced content.",
			"Include sufficient detail in the reports to meet the requirements of 21 CFR 314.50 for clinical data submission.",
			"If the integrated analysis is too extensive for inclusion in Module 2 summaries, ensure that the full details are presented in the study reports in this section.",
			"Apply the same indication‑specific numbering scheme consistently across all subsection levels within 5.3.5 when multiple indications are included.",
			"Within each control type, organize studies by treatment duration when relevant to assessment of drug effect.",
			"Ensure that literature references cited in controlled study reports are placed in Module 5.4, following CTD organizational rules, with proper cross-referencing from section 5.3.5.",
			"Apply the same indication\u0011specific numbering scheme consistently across all subsection levels within 5.3.5 when multiple indications are included.",
			"Ensure that cross-references to controlled clinical study reports in section 5.3.5.1 are written in a way that helps the reader locate the referenced study report easily (e.g., by mentioning the study type or indication in the text).",
			"Retain the CTD numbering in section 5.3.5 with explicit identification of each indication (e.g., 5.3.5.UTI, 5.3.5.1 UTI Controlled Studies, 5.3.5.2 UTI Uncontrolled Studies; similarly for other indications).",
			"For paper submissions, place publications and literature references in Module 5.4.",
			"Ensure that case report forms and individual patient data listings referenced in study reports are placed in their designated CTD locations (Module 5.3.7) rather than within section 5.3.5, while cross-referencing them appropriately.",
			"Present completely reported studies (ICH E3 full reports) before abbreviated reports; published reports with limited or no additional data should be placed last.",
			"Ensure that case report forms and individual patient data listings referenced in study reports are placed in their designated CTD locations (Module 5.3.7) rather than within section 5.3.5, while cross‑referencing them appropriately.",
			"Confirm that all cross-references within section 5.3.5.1 correctly point to the appropriate CTD section numbers and that numbering is consistent throughout the submission.",
			"Organize the reports in a logical sequence, typically by study type, design, and chronological order, to facilitate review.",
			"Ensure that studies in other indications that support efficacy for the proposed indication are included in Section 5.3.5.1.",
			"Include a distinct identifier (e.g., study number or abbreviated title) in the header or footer on every page of each controlled clinical study report; the full title is not required.",
			"Include pharmacodynamic studies that contribute to evidence of efficacy within Section 5.3.5.1.",
			"Place each controlled clinical study report in only one CTD section, determined by the primary objective of the study; if multiple objectives exist, cross-reference in other relevant sections.",
			"Maintain consistent page layout and header/footer conventions across all clinical study reports within Section 5.3.5.1, even if different from those used in Quality sections.",
			"For paper submissions, place case report forms and individual patient data listings in Module 5.3.7, identified by study.",
			"Ensure compliance with applicable FDA and ICH formatting requirements for Module 5 submissions, including pagination, section numbering, and document labeling.",
			"Ensure that literature references cited in controlled study reports are placed in Module 5.4, following CTD organizational rules, with proper cross\u0011referencing from section 5.3.5.",
			"When creating cross-references (cross strings) in paper submissions, include only the CTD section number (e.g., 5.3.5.1) in the cross string to minimize length, but ensure the surrounding text clearly identifies the referenced content so the reader understands the section context.",
			"Ensure that case report forms and individual patient data listings referenced in study reports are placed in their designated CTD locations (Module 5.3.7) rather than within section 5.3.5, while cross\u0011referencing them appropriately.",
			"If a study supports multiple indications, place its full report in the most appropriate Section 5.3.5 and cross\u0011reference it in the others as needed.",
			"Ensure that literature references cited in controlled study reports are placed in Module 5.4, following CTD organizational rules, with proper cross‑referencing from section 5.3.5.",
			"For eCTD submissions, organize PDF files for case report forms and individual patient data listings by study in the Module 5.3.7 folder; in the index.xml file, include leaf elements for these under the same heading as other study report files with additional information in the study tagging file, and optionally repeat the leaf element under 5.3.7 heading.",
			"Do not organize studies based on the chronological order in which they were conducted; place them according to control type regardless of timing.",
			"Use a unique short study identifier consistently across Modules 2 and 5 when referencing clinical study reports, ensuring uniform citation throughout the application.",
			"Use clear cross-referencing to related sections (e.g., Module 2 summaries), including at least the section number in cross strings; write the surrounding text so the reader understands the section content.",
			"If a study supports multiple indications, place its full report in the most appropriate Section 5.3.5 and cross‑reference it in the others as needed.",
			"Organize datasets, if required by the region, according to applicable regional guidance.",
			"Sequence controlled clinical studies by type of control within Section 5.3.5.1, in the following required order: placebo control, no-treatment control, dose-response without placebo, active control without placebo, external/historical control.",
			"Maintain a separate Section 5.3.5 for each indication when multiple therapeutic indications are included in the application.",
			"Sequence controlled clinical studies by type of control within Section 5.3.5.1, in the following required order: placebo control, no-treatment control, dose\u0011response without placebo, active control without placebo, external/historical control.",
		],
	},
	{
		number: "5.3.5.2",
		title: "Study Reports of Uncontrolled Clinical Studies",
		input: [
			"Ensure access to statistical analyses, datasets, and summary tables generated from uncontrolled clinical studies.",
			"Verify that all uncontrolled clinical studies included are properly identified with study numbers and titles for cross-referencing.",
			"Gather supporting clinical data from uncontrolled studies, including patient demographics, efficacy outcomes, safety data, and adverse event listings.",
			"Obtain any relevant regulatory correspondence or prior submissions referencing uncontrolled clinical studies.",
			"Gather literature references cited in relation to uncontrolled clinical studies to ensure they can be listed in the tables of contents as required.",
			"Gather case report forms (CRFs) for uncontrolled clinical studies, ensuring they are available for placement in Module 5.3.7 as per CTD organization.",
			"Collect individual patient data listings for uncontrolled clinical studies for placement in Module 5.3.7.",
			"Collect any expert opinions or literature references used to support interpretation of uncontrolled study results.",
			"Collect full study reports for all uncontrolled clinical studies conducted for the product, including protocols, investigator brochures, and final clinical study reports.",
			"Obtain publications and literature references relevant to uncontrolled clinical studies for placement in Module 5.4.",
			"Collect published reports of uncontrolled clinical studies where only limited or no further data are available to the sponsor, for placement at the end of Section 5.3.5.2.",
			"Ensure that the tabular listing of all clinical studies (Section 5.2) includes the uncontrolled clinical studies that will be detailed in Section 5.3.5.2, to maintain consistency across modules.",
			"Ensure that the Clinical Overview (Module 2.5) and Clinical Summary (Module 2.7) reference and align with the uncontrolled clinical study reports included in Section 5.3.5.2.",
			"Identify and retrieve any supportive data from Section 2.7.2 that are relevant to uncontrolled clinical studies for incorporation into Section 5.3.5.2.",
			"Confirm that the Table of Contents of Module 5 (Section 5.1) correctly lists Section 5.3.5.2 as 'Study Reports of Uncontrolled Clinical Studies' with accurate pagination and document references.",
		],
		output: [
			"For each uncontrolled clinical study report, typically provide a single document; if the report is large, submit the text portion as one document and the appendices as one or more separate documents.",
			"Maintain section headings even if certain uncontrolled clinical studies were not conducted, and provide a brief explanation for their absence rather than deleting the heading or renumbering subsequent sections.",
			"Ensure that only noteworthy findings from uncontrolled clinical studies are tabulated or summarized, focusing on statistically significant or otherwise clinically meaningful results.",
			"Ensure that each uncontrolled clinical study report submitted in Module 5.3.5.2 is provided as multiple documents when appropriate, including a synopsis, main body, and appendices organized per ICH E3.",
			"Ensure literature references related to uncontrolled clinical studies are listed in the tables of contents, in compliance with CTD requirements.",
			"When determining document granularity for uncontrolled study reports, consider future lifecycle needs, ensuring complete documents/files can be easily replaced if updated.",
			"Applicants may modify the format of Section 5.3.5.2 as needed to provide the best possible presentation and to facilitate understanding and evaluation of uncontrolled clinical study results.",
			"If the uncontrolled clinical study report is large, ensure that the text portion is provided as one document and the appendices as one or more separate documents.",
			"Follow recommended CTD table formats for clarity and consistency, but modify as needed to best present uncontrolled clinical study data and facilitate understanding by reviewers.",
			"Maintain consistency between the Clinical Overview, Clinical Summary, and Section 5.3.5.2 in terms of study numbering, titles, and conclusions to facilitate regulatory review.",
			"Verify that cross-references are accurate and direct the reader correctly to the uncontrolled clinical study reports in section 5.3.5.2.",
			"Ensure that the level of detail in uncontrolled study reports aligns with ICH E3 expectations for full versus abbreviated reports.",
			"Ensure that each uncontrolled clinical study report appears in only one section of the CTD, with placement determined by the primary objective of the study.",
			"When determining the level of document granularity for uncontrolled clinical study reports, consider lifecycle management so that complete documents/files can be replaced when relevant information changes.",
			"Ensure that each uncontrolled clinical study report is placed in CTD section 5.3.5.2.",
			"Within Section 5.3.5.2, categorize uncontrolled studies by whether the report is complete or abbreviated, with complete reports presented first.",
			"When a study serving multiple objectives is not placed in Section 5.3.5.2, ensure that proper cross-referencing to Section 5.3.5.2 is included where applicable.",
			"Maintain consistent terminology and section numbering throughout the submission to ensure clarity and regulatory compliance.",
			"When cross-referencing uncontrolled clinical studies within the dossier text, include only the section number (e.g., 5.3.5.2) in the cross string to maintain brevity.",
			"Incorporate relevant supportive data from Section 2.7.2 into Section 5.3.5.2 where it strengthens the presentation of uncontrolled clinical study results, ensuring proper cross-referencing.",
			"Use clear and consistent study identifiers (e.g., study numbers) when referring to uncontrolled clinical studies.",
			"Place published uncontrolled study reports with limited or no additional data at the end of Section 5.3.5.2.",
			"Organize studies in Section 5.3.5 by design, ensuring uncontrolled clinical studies are clearly separated from controlled studies.",
			"Ensure that the presentation of uncontrolled clinical study reports in Section 5.3.5.2 supports the Clinical Overview (Module 2.5) by providing factual data that can be referenced for benefit-risk evaluation.",
			"Ensure that literature references cited in relation to uncontrolled clinical studies are listed in the table of contents, per CTD requirements.",
			"Retain the current CTD numbering for section 5.3.5.2 and include identification of the indication (e.g., '5.3.5.2. UTI Uncontrolled studies', '5.3.5.2. Pneumonia Uncontrolled studies') when there is more than one indication.",
			"Provide an explanation such as 'not applicable' or 'no study conducted' if no uncontrolled study report or related information is available for Section 5.3.5.2.",
			"Follow the recommended organization for multiple indications by grouping uncontrolled studies under each indication within section 5.3.5.2.",
			"Write the surrounding text so that the reader can easily understand the content of the referenced section without needing the full section title.",
			"Ensure that Section 5.3.5.2 is properly listed and paginated in the Table of Contents of Module 5, maintaining alignment with the CTD structure.",
			"Confirm that the organization of Section 5.3.5.2 follows the CTD sequence under 'Reports of Efficacy and Safety Studies' and is clearly distinguished from Sections 5.3.5.1, 5.3.5.3, and 5.3.5.4.",
			"Ensure that case report forms and individual patient data listings for uncontrolled studies are referenced and located in Module 5.3.7, and that literature references are located in Module 5.4, in compliance with CTD organization.",
			"If analytical methods or data collection approaches changed during development, include explanatory footnotes or annotations in relevant tables to clarify applicability of data to the final analysis.",
		],
	},
	{
		number: "5.3.5.3",
		title: "Reports of Analyses of Data from More than One Study",
		input: [
			"Compile any pooled data tables, listings, and figures generated from the combined analysis of multiple studies.",
			"Retrieve any regulatory correspondence or prior submissions that define or agree upon the scope and methodology of the integrated analysis.",
			"Ensure access to raw and derived datasets used in the integrated analysis for verification and traceability.",
			"Obtain final clinical study reports and associated statistical analysis plans for each study included in the integrated analysis.",
			"Gather information on all relevant indications covered by the integrated analysis to ensure correct identification and labeling in section numbering (e.g., UTI, Pneumonia).",
			"Obtain the full title of each study from the Tabular Listing of All Clinical Studies (Section 5.2) for accurate referencing.",
			"Collect all supplementary analyses conducted in addition to the main and sensitivity analyses that provide additional insights into treatment effects.",
			"Gather any exploratory analyses, datasets, and outputs relevant to exploratory objectives, including any post hoc or hypothesis-generating analyses.",
			"Collect any case report forms (CRFs) relevant to the integrated analysis for placement in Module 5.3.7 as per CTD organization.",
			"Gather all relevant publications and literature references cited in the integrated analysis for placement in Module 5.4.",
			"Collect detailed descriptions of statistical models, hypotheses, and analytical methods used for each exploratory objective within the integrated analysis.",
			"Gather detailed statistical outputs and datasets from multiple studies that are too extensive to be included in the Clinical Summary (Module 2.7).",
			"Collect individual patient data listings relevant to the integrated analysis for placement in Module 5.3.7 as per CTD organization.",
			"Assign a unique short identifier to each clinical study included in the integrated analysis and ensure it is used consistently throughout the application.",
			"Obtain documentation or confirmation from study statisticians regarding whether exploratory objectives exist; if none, prepare a statement of 'Not applicable'.",
			"Collect detailed descriptions of statistical models, hypotheses, and methods of analysis used for each secondary objective included in the integrated analysis.",
			"Collect all relevant integrated analyses of data from more than one clinical study, including efficacy and/or safety analyses as applicable.",
			"Collect any relevant expert statistical or clinical interpretations that support the integrated analysis conclusions.",
			"Gather datasets, outputs, and statistical summaries specific to supplementary analyses for each secondary objective.",
			"Gather the list of all secondary objectives from the relevant clinical protocols to ensure proper mapping and numbering in the integrated analysis report.",
		],
		output: [
			"If no exploratory objectives exist, include a statement 'Not applicable' under section 10.6 as required by conformance rules.",
			"Verify that exploratory analyses are clearly distinguished from secondary and supplementary analyses within section 5.3.5.3.",
			"If the details of the analysis are too extensive for inclusion in the Clinical Summary (Module 2.7), prepare a separate, standalone report for section 5.3.5.3.",
			"Maintain consistency between the Table of Contents and the section numbering for exploratory analyses (10.6) to ensure traceability.",
			"Ensure that each clinical study included in the integrated analysis is cited using its unique short identifier consistently throughout all modules of the application.",
			"Use cross\u0011references to related sections (e.g., Module 2 summaries, individual study reports in Module 5) where appropriate.",
			"Ensure that the heading 'Analyses Associated with Exploratory Objective(s)' is labeled as required and conforms to controlled terminology (Value: 'Analyses of Exploratory Endpoint(s)').",
			"Ensure compliance with 21 CFR 314.50 requirements if applicable, verifying that the content meets regulatory expectations for integrated analyses.",
			"Organize section 5.3.5.3 consistently for each indication, following the recommended CTD structure for multiple indications (e.g., indication-specific subsections for controlled and uncontrolled studies where applicable).",
			"Use cross‑references to related sections (e.g., Module 2 summaries, individual study reports in Module 5) where appropriate.",
			"Ensure that each secondary objective and its associated statistical analysis method are clearly labeled and uniquely numbered to maintain traceability and alignment with the protocol.",
			"Ensure that any literature references cited in section 5.3.5.3 are included in the application's master table of contents as required by CTD guidelines.",
			"Structure the report to clearly present integrated analyses from more than one study, ensuring logical flow and clarity for the reviewing authority.",
			"Retain the current CTD numbering for section 5.3.5.3 and include identification of the indication in the section title/numbering (e.g., 5.3.5.3.UTI, 5.3.5.3.Pneumonia) when more than one indication is covered.",
			"Maintain one-to-one correspondence between each secondary objective and its supplementary analysis subsection.",
			"Ensure that the 'Supplementary Analysis' subsection is included conditionally\u0014only when supplementary analyses are conducted for a secondary objective.",
			"Follow the controlled terminology and heading conventions specified for statistical analysis methods, ensuring consistent use of section titles and numbering.",
			"In paper submissions, include only the section number (5.3.5.3) in cross strings to reduce length, but write the text so the reader understands the section content.",
			"Under section 10.6, describe the statistical model, hypothesis, and methods of analysis for each exploratory objective within the integrated analysis.",
			"Ensure that the 'Supplementary Analysis' subsection follows the same structural and formatting conventions as other level 4 subsections (e.g., Statistical Analysis Method, Sensitivity Analysis).",
			"Repeat the 'Statistical Analysis Method' subsection for each secondary objective as required, maintaining one-to-one correspondence between objectives and analysis descriptions.",
			"Ensure that case report forms and individual patient data listings referenced in section 5.3.5.3 are located in Module 5.3.7, and that literature references are located in Module 5.4, in compliance with CTD organization.",
			"Repeat the 'Supplementary Analysis' subsection for each secondary objective as a series of level 4 sections (10.5.X.1 through 10.5.X.5) following the controlled numbering convention.",
			"Include a Level 4 heading titled 'Statistical Analysis Method' (10.5.X.1) under each secondary objective section to describe the statistical model, hypothesis, and analytical methods used.",
			"Verify that all supplementary analyses are properly cross-referenced to the corresponding secondary objective and analysis hierarchy in the Table of Contents.",
			"Ensure that the 'Supplementary Analysis' subsection is included conditionally—only when supplementary analyses are conducted for a secondary objective.",
			"Use cross-references to related sections (e.g., Module 2 summaries, individual study reports in Module 5) where appropriate.",
			"If exploratory objectives exist, create additional subsections as needed to describe analyses for each exploratory objective, maintaining one-to-one correspondence with the protocol hierarchy.",
			"When describing analyses associated with secondary objectives, create repeatable subsections for each objective, using sequential numbering (e.g., 10.5.1, 10.5.2, etc.) to maintain consistency with the protocol hierarchy.",
			"Ensure that supplementary analysis text describes analyses conducted in addition to main and sensitivity analyses, focusing on additional insights into treatment effects.",
			"Include a Level 4 heading titled 'Supplementary Analysis' (10.5.X.5) under each secondary objective section when applicable.",
			"Follow applicable FDA and ICH guidance (e.g., ISS/ISE structure, ICH E3 principles) for organizing and presenting integrated analyses.",
			"Ensure the report contains sufficient methodological detail, statistical results, and interpretation to allow independent assessment.",
			"Ensure that section 10.6 follows the same formatting and structural conventions as other analysis sections (e.g., level 4 subsections for each objective).",
			"Use cross references to related sections (e.g., Module 2 summaries, individual study reports in Module 5) where appropriate.",
			"When citing studies in section 5.3.5.3, use the full study title as provided in the Tabular Listing of All Clinical Studies (Section 5.2) for clarity and traceability.",
			"Include a Level 3 heading titled 'Analyses Associated with Exploratory Objective(s)' (10.6) following the controlled terminology and numbering convention.",
			"Ensure the completed integrated analysis report is placed in section 5.3.5.3 as required by CTD organization.",
		],
	},
	{
		number: "5.3.5.4",
		title: "Other Clinical Study Reports",
		input: [
			"Collect individual patient data listings for the studies in section 5.3.5.4, ensuring they are available for placement in Module 5.3.7 as per CTD organization.",
			"Collect any relevant regulatory correspondence or prior submissions that clarify placement of microbiology or other special clinical studies in this section.",
			"Collect datasets associated with the studies in section 5.3.5.4 if required by the region, ensuring they are organized according to applicable regional guidance.",
			"Obtain any supporting data, tables, and analyses associated with the microbiology studies to ensure completeness of the reports.",
			"Collect any case report forms (CRFs) relevant to the studies included in section 5.3.5.4, ensuring they are available for placement in Module 5.3.7 as per CTD organization.",
			"Gather any expert opinions or literature references that support the interpretation of microbiology or other special clinical study results.",
			"Ensure availability of integrated analyses or appendices that may be referenced from Module 2 summaries but require detailed reporting in Module 5.",
			"Collect all clinical study reports that do not fit into other predefined CTD categories (e.g., pharmacokinetic, pharmacodynamic, efficacy, or safety studies) for inclusion in section 5.3.5.4.",
			"Gather any publications and literature references cited in the reports for section 5.3.5.4, ensuring they are available for placement in Module 5.4.",
			"Gather microbiology study reports, including both in vitro and in vivo microbiology studies, as these are explicitly required to be filed in section 5.3.5.4.",
		],
		output: [
			"Confirm that all reports are formatted consistently with CTD Module 5 standards, including pagination, section numbering, and labeling.",
			"Ensure that microbiology study reports (both in vitro and in vivo) are placed in section 5.3.5.4 under 'Other Clinical Study Reports' as per CTD Efficacy (M4E) guidance.",
			"Ensure that literature references cited in study reports are listed in the module\u0019s table of contents, consistent with Note 2.",
			"Organize the reports in a clear and logical manner, separating different study types (e.g., in vitro vs. in vivo) and ensuring each report is complete and self-contained.",
			"Retain the current CTD numbering for section 5.3.5.4 and clearly identify the indication(s) in the section headings when there is more than one indication, following the example format provided in CTD Efficacy (M4E) Q&A.",
			"Ensure that appendices for study reports in section 5.3.5.4 are organized in accordance with ICH E3 appendix structure requirements.",
			"Ensure that the organization of section 5.3.5.4 follows the recommended structure for multiple indications, grouping studies under each indication with appropriate sub-numbering consistent with CTD conventions.",
			"Applicants may modify the format of section 5.3.5.4 reports if needed to provide the best possible presentation of the information and to facilitate understanding and evaluation of the results by regulatory reviewers.",
			"Ensure literature references cited in study reports are listed in the module\u0019s table of contents, consistent with Note 2.",
			"Ensure that literature references cited in study reports are listed in the module’s table of contents, consistent with Note 2.",
			"Ensure that the placement of each study report in section 5.3.5.4 is determined strictly by the primary study objective, consistent with CTD Module 5 organizational rules.",
			"Ensure that each study report in section 5.3.5.4 is submitted as multiple documents (a synopsis, a main body, and appendices) in accordance with ICH E3, unless the applicant chooses to consolidate into a single document for small reports.",
			"Ensure that any modifications to the standard CTD format for section 5.3.5.4 are justified by improved clarity or comprehension for reviewers, maintaining consistency with CTD numbering and structure.",
			"Ensure that literature references cited in section 5.3.5.4 study reports are listed in the Module 5 table of contents where required (e.g., paper CTD submissions).",
			"When no study report exists for a subsection of 5.3.5.4, include a brief explanation such as 'not applicable' or 'no study conducted' to maintain completeness and transparency.",
			"Choose document granularity with consideration that updates during the product lifecycle may require replacement of entire documents.",
			"Include appropriate cross-references to related summaries in Module 2.7 (Clinical Summary) to maintain traceability between summary and detailed reports.",
			"Follow the structure and content principles outlined in ICH E3 (Structure and Content of Clinical Study Reports) when compiling the reports.",
			"For paper submissions, place publications and literature references in Module 5.4.",
			"Verify that the level of detail provided in this section complements, but does not duplicate, the information summarized in Module 2.",
			"Ensure compliance with 21 CFR 314.50 requirements for clinical data presentation if applicable to the submission.",
			"Ensure that each study report appears in only one CTD section, with additional objectives cross‑referenced appropriately.",
			"If a study report is large, ensure the text portion is provided as one document and the appendices as one or more separate documents.",
			"Ensure that one document is provided per study report unless the report is unusually large, in which case the text should remain one document and appendices may be separated, avoiding inappropriate 'roll\u0011up' of multiple studies into a single document.",
			"Ensure literature references cited in study reports are listed in the module’s table of contents, consistent with Note 2.",
			"Ensure cross-references in text maintain clarity for readers by including the section number in parentheses and writing the surrounding text so the reader understands the context without needing the full section name.",
			"For eCTD submissions, organize PDF files for case report forms and individual patient data listings by study in the Module 5.3.7 folder, and in the index.xml file include leaf elements for these under the same heading as other study report files with additional information in the study tagging file; optionally repeat the leaf element under heading 5.3.7.",
			"Ensure that case report forms and individual patient data listings are located in Module 5.3.7 and that literature references are located in Module 5.4, in compliance with CTD organization requirements.",
			"For paper submissions, place case report forms and individual patient data listings in Module 5.3.7, identified by study.",
			"Ensure datasets, if required by the region, are organized according to applicable regional guidance.",
			"When creating cross-references or cross strings in paper submissions, include only the section number (e.g., 5.3.5.4) to maintain clarity and brevity, while ensuring the text contextually identifies the section content.",
			"Ensure that one document is provided per study report unless the report is unusually large, in which case the text should remain one document and appendices may be separated, avoiding inappropriate 'roll‑up' of multiple studies into a single document.",
			"For eCTD submissions, place publications and literature references in the Module 5.4 folder, and in the index.xml file include leaf elements for these under the same heading as other study report files with additional information in the study tagging file; optionally repeat the leaf element under heading 5.4.",
			"Include a distinct identifier in headers or footers on every page of each study report; the identifier may be an abbreviated title rather than the full report title.",
			"Ensure consistency with the overall Module 5 organizational structure, including alignment with the Module 5 Table of Contents requirements.",
		],
	},
	{
		number: "5.3.6",
		title: "Reports of Post-Marketing Experience if Available",
		input: [
			"Collect all available post-marketing experience reports related to the product, including safety and efficacy data gathered after marketing authorization.",
			"Gather literature references describing post-marketing experience, including published case reports, epidemiological studies, and meta-analyses.",
			"Obtain expert opinions or safety assessments related to post-marketing findings.",
			"Obtain adverse event reports, pharmacovigilance data, and safety signal detection analyses from post-marketing monitoring systems.",
			"Gather regulatory documents such as post-marketing surveillance reports submitted to health authorities, periodic safety update reports (PSURs), and any regulatory correspondence regarding post-marketing safety or efficacy.",
			"Compile any relevant comparator product post-marketing data if used for contextual safety/efficacy assessment.",
			"Collect post-marketing study reports, including Phase IV clinical trial reports, observational studies, and registry data if available.",
			"Gather regulatory documents such as post-marketing surveillance reports submitted to health authorities, periodic safety update reports (PSURS), and any regulatory correspondence regarding post-marketing safety or efficacy.",
		],
		output: [
			"Verify that datasets required by regional guidance are not placed in section 5.3.6 and are instead organized according to the applicable regional requirements.",
			"Ensure that case report forms and individual patient data listings referenced in section 5.3.6 are located in Module 5.3.7 for both paper and eCTD submissions.",
			"For eCTD submissions, ensure that leaf elements for literature references are included under the same heading as other study report files in the index.xml, with optional repetition under the 5.4 heading.",
			"Ensure that literature references cited in section 5.3.6 are located in Module 5.4 for both paper and eCTD submissions.",
			"Maintain section headings for all CTD sections, including section 5.3.6, even if no post-marketing experience data are available, and provide a brief explanation stating that such studies or data were not conducted or are not applicable.",
			"Applicants may adapt the presentation format of section 5.3.6 to best facilitate understanding and evaluation, consistent with CTD flexibility principles outlined for other sections.",
			"Applicants may adapt or modify the presentation format of section 5.3.6 to best facilitate understanding and evaluation, consistent with CTD flexibility principles, provided the changes facilitate understanding and evaluation of post-marketing experience by regulatory reviewers.",
			"Applicants may modify the presentation format of section 5.3.6 if needed, provided the changes facilitate understanding and evaluation of post\u0011marketing experience by regulatory reviewers.",
			"Maintain clarity and ease of navigation for the reader by ensuring cross-references are accurate and correspond to the correct section number.",
			"Ensure that any cross-references to section 5.3.6 in the submission text include only the section number in the cross string (e.g., '(5.3.6)') to maintain brevity.",
			"Confirm that any references to supporting materials such as case report forms, individual patient data listings, or literature references are correctly placed in their designated CTD modules (e.g., 5.3.7 for case report forms and individual patient data listings, 5.4 for literature references) and not duplicated within section 5.3.6.",
			"Applicants may modify the presentation format of section 5.3.6 if needed, provided the changes facilitate understanding and evaluation of post‑marketing experience by regulatory reviewers.",
			"Ensure compliance with CTD structure by placing the post-marketing experience report in section 5.3.6 and not in other sections unless otherwise justified.",
			"Applicants may modify the presentation format of section 5.3.6 if needed, provided the changes facilitate understanding and evaluation of post-marketing experience by regulatory reviewers.",
			"Ensure that any modifications to the section 5.3.6 format preserve the integrity of CTD numbering and do not result in renumbering or deletion of standard headings.",
			"Ensure that section 5.3.6 follows the same organizational logic as other efficacy and safety report sections (e.g., 5.3.5) when multiple indications are presented, maintaining clear separation and labeling by indication.",
			"Verify that all post-marketing experience data presented are clearly organized and appropriately linked to the relevant CTD section.",
			"Retain the current CTD numbering structure when organizing section 5.3.6, and if multiple indications exist, identify each indication clearly under the same numbering system (e.g., 5.3.6.UTI, 5.3.6.Pneumonia) to maintain consistency with CTD conventions.",
			"When referencing specific post-marketing studies or reports, provide enough descriptive context in the text to guide the reader to the correct section (e.g., mention the type of study or safety finding).",
			"Write the surrounding text so that the reader can understand the content of section 5.3.6 without including the full section title in the cross string.",
			"For eCTD submissions, ensure that leaf elements for case report forms and individual patient data listings are included under the same heading as other study report files in the index.xml, with additional information provided via the study tagging file, and optionally repeated under the 5.3.7 heading.",
		],
	},
	{
		number: "5.3.7",
		title: "Case Reports Forms and Individual Patient Listings",
		input: [
			"If applicable, gather any detailed statistical outputs or listings related to CRFs and patient data that are too extensive for inclusion in summary documents, ensuring they are prepared as separate reports for placement in the appropriate CTD section.",
			"Obtain any datasets required by the regional authority for inclusion with the CRFs and patient listings.",
			"Ensure that all CRFs and patient listings correspond to the studies reported in Module 5.3.",
			"Verify that all study identifiers and titles match those used in the clinical study reports and other parts of Module 5.",
			"Collect all case report forms (CRFs) for each clinical study included in the submission.",
			"Verify that the full title of each study corresponding to the CRFs and patient listings is available in the Tabular Listing of All Clinical Studies (Section 5.2) for cross-referencing.",
			"Ensure that each clinical study included in the CRFs and patient listings has a unique short identifier that is used consistently throughout the application, including in the Clinical Overview, Clinical Summary, and Module 5.3.7.",
			"Confirm that all CRFs and patient listings are complete, legible, and finalized prior to submission.",
			"Gather individual patient data listings for each clinical study, organized by study.",
		],
		output: [
			"Include additional information for CRFs and patient listings in any accompanying study tagging file as required.",
			"When creating cross-references in text for paper submissions, include only the section number in the cross string to keep it concise, but ensure the surrounding sentence provides enough context so the reader understands the section content (e.g., reference the study type or indication along with the section number).",
			"In headers or footers of each document in Module 5.3.7, include a distinct identifier; this does not need to be the full title from the TOC entry—an abbreviation is acceptable to improve usability and reduce length.",
			"For eCTD submissions, provide case report forms and individual patient data listings as PDF files organized by study in the Module 5.3.7 folder.",
			"Verify that file naming conventions, folder structure, and XML indexing comply with eCTD technical specifications.",
			"If sub-numbering is used within documents placed in Module 5.3.7 (e.g., internal navigation within long CRF listings), ensure that these lower-level headings do not appear in the overall CTD Table of Contents but may appear as PDF bookmarks.",
			"Ensure datasets, if required by the region, are organized according to regional guidance and linked appropriately to the corresponding studies.",
			"Include a distinct identifier in headers or footers of all Module 5.3.7 documents; an abbreviation of the full TOC title is acceptable.",
			"Ensure that the study identifiers used in Module 5.3.7 match those listed in the Tabular Listing of All Clinical Studies (Section 5.2) to maintain consistency and facilitate cross-referencing.",
			"In eCTD, include leaf elements for CRFs and individual patient data listings under the same heading as other study report files in the index.xml file.",
			"Optionally, repeat the leaf element under the heading 5.3.7 Case Report Forms and Individual Patient Data Listings in the eCTD index.xml.",
			"Ensure that case report forms originally located in Appendix 16.3 and individual patient data listings originally located in Appendix 16.4 of ICH E3–compliant clinical study reports are relocated or referenced appropriately in CTD Module 5.3.7 according to CTD organizational requirements.",
			"Confirm that all CRFs and patient listings are properly cross-referenced to their respective study reports within Module 5.",
			"For paper submissions, when creating cross-references (cross strings) to section 5.3.7, include only the section number in the cross string to reduce length, but write the surrounding text so the reader understands the section content.",
			"Use a consistent short study identifier across all modules (including Module 5.3.7) when referencing CRFs and patient listings to maintain traceability and alignment with the Clinical Overview and Clinical Summary.",
			"For paper submissions, place case report forms and individual patient data listings in Module 5.3.7, organized and identified by study.",
			"Ensure that module numbers, volume numbers, and tab identifiers are included in any applicable Table of Contents entries related to Module 5.3.7 materials.",
		],
	},
]
